Engineering of a thermostable alcohol dehydrogenase towards imine reduction by Nethercott, Alanna Mary
1	
	
Department	of	Chemical	and	
Environmental	Engineering 	
	
 
 
 
	
	
	
ENGINEERING	OF	A	THERMOSTABLE	
ALCOHOL	DEHYDROGENASE	TOWARDS	
IMINE	REDUCTION	
	
	
	
	
	
Alanna	Mary	Nethercott	
	
	
	
	
	
A	thesis	submitted	to	the	University	of	Nottingham	
for	the	degree	of	Doctor	of	Philosophy	
	
	
September	2017
i	
	
Acknowledgements	
Firstly,	I	would	like	to	express	my	heartfelt	gratitude	to	my	supervisor	Dr.	Anca	Pordea	
for	 the	 constant	 support	 throughout	 my	 studies	 and	 research,	 for	 her	 patience,	
motivation,	and	vast	knowledge.	Her	guidance	has	helped	me	 immensely	 in	all	my	
time	at	Nottingham	University	and	the	writing	of	this	thesis.	None	of	it	would	not	have	
been	possible	without	her	and	I	could	not	have	wished	for	a	better	supervisor.	
Besides	my	supervisor	I	would	like	to	thank	Steve,	Rachel,	Christof,	Gill	and	Anna	for	
all	their	help	and	encouragement	at	the	beginning	and	throughout.	I	would	also	like	
to	thank	the	Pordea	group:	Lei,	Jaicy,	Tim,	Camille	and	Mattias	for	all	their	boosts	of	
confidence,	knowledge	sharing	especially	with	regards	to	the	chemical	synthesis	and	
for	the	many	laughs	inside	and	outside	of	the	lab.	
I	would	also	like	to	thank	all	the	wider	BECT	group	especially	Luca,	Joe	and	Andy	for	
showing	me	the	ropes	and	sharing	all	their	knowledge	and	experience	in	the	beginning	
and	throughout.	In	addition	to	the	lab	technicians,	Sam,	Amy	and	Rachel	for	their	help	
in	preparing	media,	glassware,	etc.	A	huge	thank	you	goes	to	Doerte	for	all	her	help	
experimentally	 and	performing	parts	 of	 the	work	 carried	out	 in	 sections	4.1.6	 and	
4.2.2.	
Another	thank	you	goes	to	my	lovely	Coates	ladies	Maria	and	Lois	who	have	shared	in	
this	PhD	experience	and	to	my	housemates,	Charlotte	and	Angela	for	keeping	me	sane	
and	for	their	friendship.	Also,	my	PhD	bffs	Athina	and	Juliana	who	I’ve	have	shared	
many	a	laugh	and	plenty	of	tears	with	during	this	whole	PhD	experience.	
To	my	friends	at	home,	Carrie,	Stacey,	Amy	and	Rachael	for	their	encouragement	and	
support	especially	during	the	write	up	period.	
A	massive	thank	you	goes	to	my	wonderful	parents	for	putting	up	with	me	during	the	
write	up	period	and	the	rest	of	my	family	especially	my	brother	and	sisters	for	their	
ii	
	
constant	support	throughout.	The	furbabies	of	the	family	also	have	to	be	thanked	for	
keeping	me	company	in	the	solace	of	writing	up.	
Finally,	a	huge	thank	you	to	Barry	for	sticking	with	me	over	the	past	four	stressful	years	
with	no	doubts	of	my	capability	and	for	taking	me	out	of	the	world	of	results	when	it	
got	a	bit	too	much.		
I	am	forever	grateful	to	all	who	I	have	met	and	shared	in	this	unforgettable	experience	
with,	you	have	all	made	it	truly	special.	
	
	
	
	
	
	
	
	
	
	
	
	
iii	
	
Abstract	
The	enantioselective	reduction	of	carbon-nitrogen	double	bonds	is	a	powerful	tool	for	
accessing	 chiral	 secondary	 amines.	 These	 are	 important	 building	 blocks	 in	 the	
production	of	many	high-added	 value	 chemicals,	with	 an	 estimated	 40-45	%	of	 all	
pharmaceuticals	and	20	%	of	agrochemicals	containing	a	chiral	amine	intermediate.	
However,	most	of	their	current	methods	of	manufacture	are	inefficient	and	wasteful.	
As	a	 consequence,	 there	 is	 an	 interest	 to	develop	better	 synthetic	 routes	 to	 chiral	
amines	based	on	the	use	of	catalytic	technologies	and	of	atom	efficient	reagents.	One	
approach	is	with	the	use	of	enzymes,	due	to	their	high	activities	and	selectivities,	mild	
reaction	conditions	and	their	renewable	origin.	The	enzymatic	reduction	of	imines	is	
a	relatively	recent	area	of	research,	and	the	known	imine	reductases	(IREDs)	have	low	
activities	and	limited	substrate	scope.	The	research	presented	here	investigates	new	
routes	to	make	 imine	reduction	biocatalysts,	whereby	an	alcohol	dehydrogenase	 is	
used	as	a	starting	point	to	engineer	reaction	promiscuity.	These	enzymes	catalyse	the	
reduction	 of	 a	 similar	 functionality,	 the	 carbon-oxygen	 double	 bond.	 The	mode	 of	
substrate	activation	differs	between	the	two	enzymes:	a	Brønsted	acid	is	used	in	imine	
reductases,	while	a	zinc(II)	Lewis	acid	is	used	in	alcohol	dehydrogenases.		
The	well-characterised	thermostable	alcohol	dehydrogenase	from	Thermus	sp.	ATN1	
(TADH)	was	selected,	due	to	its	broad	substrate	range	and	stability.	Docking	studies	
with	selected	imines	suggested	that	these	substrates	could	be	accommodated	in	the	
hydrophobic	binding	pocket.	Both	 imines	 and	amines	were	 shown	 to	act	 as	mixed	
inhibitors	of	the	native	TADH	activity,	and	it	was	suggested	that	inhibition	occurred	
due	 to	 binding	 elsewhere	 in	 the	 active	 site.	 Three	 approaches	 were	 investigated	
towards	the	engineering	the	TADH	active	site	to	avoid	inhibition	and	promote	imine	
activation,	based	on	both	genetic	and	chemical	modifications.		
First,	 sixteen	 zinc-devoid	 TADH	 mutants	 containing	 aspartic	 acid	 or	 tyrosine	 at	
selected	positions	within	the	active	site	were	created,	in	an	effort	to	mimic	the	key	
features	found	in	existing	imine	IREDs.	Whilst	ketone	reduction	activity	was	abolished	
in	these	mutants,	no	imine	reduction	activity	could	be	restored.	Second,	a	chemical	
modification	 approach	 was	 proposed,	 involving	 the	 replacement	 of	 the	 catalytic	
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zinc(II)	ion	by	a	rhodium(I),	which	is	known	to	activate	imines	in	synthetic	catalysts.	
Zinc	was	successfully	removed	from	the	active	site	to	yield	apo-TADH,	as	shown	by	the	
absence	of	catalytic	activity.	Rhodium(I)	was	observed	to	non-selectively	bind	to	apo-
TADH	and	to	restore	a	small	degree	of	native	activity,	however	no	 imine	reduction	
activity	was	observed.	Finally,	a	novel	iridium(III)	complex	containing	a	nicotinamide-
functionalised	 N-heterocyclic	 carbene	 ligand	 was	 designed	 and	 synthesised.	 This	
complex	was	capable	of	performing	transfer	hydrogenation	of	an	aromatic	ketone	and	
an	aromatic	imine,	in	both	organic	and	aqueous	conditions.	An	increased	activity	was	
observed	for	the	imine	compared	to	the	ketone	in	aqueous	media	employing	sodium	
formate	as	the	hydride	source.	Inhibition	studies	showed	that	the	Ir-catalyst	acted	as	
a	mixed	inhibitor	for	TADH,	suggesting	that	interactions	with	the	protein	do	not	occur	
at	the	co-factor	binding	site.		
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Chapter	1 Literature	review		
1.1 Imine	reduction	as	a	tool	for	chiral	amine	synthesis		
1.1.1 Background	
Chiral	 amines	 are	 important	 constituents	 of	 many	 bioactive	 compounds,	 such	 as	
natural	products,	pharmaceuticals	and	agrochemicals.	They	also	have	notable	use	as	
ligands	in	transition	metal	catalysis	or	as	chiral	organocatalysts,	as	well	as	resolving	
agents	 for	 the	separation	of	enantiomers	via	diastereomeric	 salt	 formation.1	 It	has	
been	 estimated	 that	 approximately	 40-45	 %	 of	 pharmaceuticals	 and	 20	 %	 of	
agrochemicals	 contain	 a	 chiral	 amine	 functionality.2-5	 A	 selection	 of	 commercially	
relevant	compounds	containing	chiral	amines	is	shown	in	Figure	1.1.	
	
Figure	1.1.	Selection	of	commercially	relevant	bioactive	compounds	containing	chiral	amines.	
Current	industrial	methods	to	produce	enantiomerically	pure	chiral	amines	are	largely	
dependent	upon	the	resolution	of	racemates.6	With	a	maximum	attainable	yield	of				
50	%,	the	kinetic	resolution	route	is	inefficient	in	terms	of	atom	economy,	especially	
if	 the	 desired	 racemate	 requires	 a	 multistep	 synthesis.	 Consequently,	 continued	
N
H
H
N
HO
OH
Ethambutol
N
H
O
O
O
S
O O
NH2
Tamsulosin
NCl
O
O
NNH
NHHO
O
O
HHH
H
NHO
NF3C
CF3
H
O
O
H
N
OH
N
H
O
N
HN
O
O
O
N N
O
N
H
O
OH
O
N
Repaglinide
Tubulosine
Rivastigmine
(S)-Metolchlor
Lopinavir Lariam
NCl
O
O
(S)-Metolachlor
8	
	
substantial	effort	has	gone	into	the	development	of	more	efficient	methods	for	the	
synthesis	of	chiral	amines.7	A	particularly	efficient	route	 is	 the	reduction	of	 imines,	
which	 in	 turn	can	be	prepared	 from	the	corresponding	ketones	 (Figure	1.2).	When	
imine	formation	and	reduction	occur	sequentially	in	one	pot,	the	reaction	is	referred	
to	 as	 reductive	 amination.	 Importantly,	 these	 reactions	 give	 access	 to	 secondary	
amines.		
	
Figure	1.2.	General	reaction	scheme	for	indirect	reductive	amination	for	the	synthesis	of	chiral	amines	
including	the	enantioselective	imine	reduction	step.		
Furthermore,	the	reductive	amination	highlighted	in	Figure	1.2	 is	performed	with	a	
primary	 amine	 reacting	with	 the	 carbonyl	 group	 of	 the	 ketone.	 However,	 when	 a	
secondary	 amine	 is	 used,	 the	 reaction	 yields	 an	 iminium	 ion	 intermediate.	 This	
charged	species	can	further	tautomerise	to	the	corresponding	enamine,	 if	an	acidic	
proton	is	available	in	the	a-position	of	the	ketone	/	iminium	functionality	(Figure	1.3).	
	
Figure	 1.3.	 Acid-catalysed	 nucleophilic	 reaction	 of	 a	 ketone	with	 a	 secondary	 amine	 highlighting	
enamine	formation.		
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Traditional	 methods	 for	 secondary	 amine	 synthesis	 via	 this	 route	 are	 energy-
consuming,	 not	 very	 efficient	 and	 generate	 waste.	 As	 a	 consequence,	 there	 is	 an	
interest	to	develop	better	routes	for	the	reduction	of	carbon-nitrogen	double	bonds	
(C=N),	 based	 on	 the	 use	 of	 catalytic	 technologies	 and	 of	 atom	 efficient	 reagents.	
During	a	roundtable	discussion	of	 international	pharmaceutical	companies	 in	2005,	
this	reaction	was	highlighted	as	one	of	the	key	research	areas	needing	improvement	
by	the	incorporation	of	‘green	chemistry’	principles.8		
The	development	of	efficient	processes	towards	enantioselective	imine	reduction	has	
been	 slow,	 compared	 to	 the	 numerous	 reduction	 methods	 of	 their	 carbonyl	
counterparts.	 Nonetheless,	 important	 advances	 were	 made	 in	 the	 early	 2000’s	
towards	 the	 development	 of	 practical	 approaches,	 largely	 based	 upon	 synthetic	
transition-metal	catalysts	for	the	reduction	of	imines	using	various	sources	of	hydride.		
1.1.2 Synthetic	catalysts	for	imine	reduction		
1.1.2.1 Metal	catalysts	for	imine	hydrogenation	and	transfer	hydrogenation		
Early	 efforts	 to	 asymmetrically	 reduce	 imines	 focused	 on	 the	 development	 of	
transition	 metal	 catalysts	 for	 asymmetric	 hydrogenation.	 The	 majority	 of	
hydrogenation	catalysts	generally	consist	of	a	transition	metal	ion	in	a	low	oxidation	
state,	attached	to	a	chiral	ligand.	The	metal	controls	the	reactivity	whilst	the	ligand	is	
responsible	for	introducing	selectivity	into	the	final	product.	The	hydrogen	atoms	are	
accessed	 from	 either	molecular	 hydrogen	 (a	 reaction	 known	 as	 hydrogenation)	 or	
from	 an	 organic	 hydrogen	 source	 (Figure	 1.4),	 such	 as	 2-propanol,	 formic	 acid	 or	
Hantzsch	 esters	 (referred	 to	 as	 transfer	 hydrogenation).	 The	 latter	 structure	 is	 an	
analogue	of	the	biological	hydride	source	nicotinamide	adenine	dinucleotide	(NADH),	
used	as	a	cofactor	by	enzymes	performing	reductions	in	nature.		
	
Figure	1.4.	Hydride	sources	used	with	transition	metal	catalysts.	
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The	first	catalytic	example	of	asymmetric	hydrogenation	of	 imines	was	reported	by	
Levi	et	al.	in	1975,	using	the	rhodium-diphosphine	catalyst	Rh-DIOP	(Figure	1.5)	and	
molecular	hydrogen.	Although	the	optical	purity	was	relatively	low	(22	%	ee),	this	work	
demonstrated	the	use	of	a	chemical	complex	based	on	a	transition	metal	as	a	new	
route	to	enantiomerically	enriched	chiral	amines.9		
	
Figure	1.5.	Asymmetric	imine	reduction	with	the	Rh(DIOP)	catalyst.9		
Significantly	higher	enantioselectivities	 (60-70	%	ee)	were	obtained	a	decade	 later,	
using	a	range	of	other	chiral	rhodium-based	diphosphine	ligand	complexes.10	Bakos	et	
al.	 reported	 the	 asymmetric	 hydrogenation	of	N-benzyl	 imines	 in	 a	 biphasic	water	
ethyl	 acetate	 mixture,	 with	 a	 rhodium	 complex	 of	 the	 sulfonated	 2,4-
bis(diphenylphosphino)pentane	(BDPP)	ligand	(Figure	1.6).11	
	
Figure	1.6.	Asymmetric	imine	reduction	in	biphasic	conditions	with	Rh-BDPPS.	
Current	existing	catalysts	for	imine	hydrogenation	most	commonly	consist	of	rhodium,	
ruthenium,	iridium	or	palladium	complexes.12	Amongst	these,	iridium-based	catalysts	
with	bidentate	phosphorous	ligands	are	the	most	efficient.	For	example,	the	iridium	
based	 complex	 Ir-xyliphos	 is	 employed	 in	 the	 industrial	 process	 for	 the	
11	
	
enantioselective	 reduction	of	 the	 imine	precursor	of	 the	herbicide	 (S)-Metolachlor,	
commercially	known	as	Dual	Mangum®	(Figure	1.7).13		
	
Figure	 1.7.	 Asymmetric	 imine	 hydrogenation	 using	 Ir-xyliphos,	 applied	 to	 the	 synthesis	 of	 (S)-
metolachlor.	Modified	from	Blaser	et	al.	(1999).13	
A	major	breakthrough	came	in	1996,	when	Noyori,	Ikariya	and	co-workers	reported	
the	first	chiral	Ru(II)	complex	for	the	asymmetric	transfer	hydrogenation	of	various	
imines	 with	 high	 enantioselectivities	 (77-97	 %	 ee).	 The	 same	 authors	 had	 initially	
developed	 these	 complexes	 for	 the	 transfer	 hydrogenation	 of	 ketones.	 The	 piano-
stool	 p-complex,	 [Ru(p-cymene)	 (TsDPEN)Cl],	 contained	 p-cymene	 as	 the	 capping	
arene	and	the	N-tosylated	1,2-diphenyl	ethylene	diamine	(TsDPEN)	as	the	chiral	
	
Figure	1.8.	Asymmetric	transfer	hydrogenation	of	selected	imines	using	the	Noyori-Ikariya	catalyst.	
Modified	from	Wang	et	al.	(2011).14	
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ligand.	 Instead	 of	 hydrogen,	 the	 formic	 acid-triethylamine	 mixture	 was	 used	 as	
hydride	source	(Figure	1.8).14	
Since	 the	 discovery	 of	 the	 Ru-aminosulfonamide	 complexes	 for	 imine	 transfer	
hydrogenation,	a	variety	of	ligands	and	metal	complexes	have	been	developed	for	the	
reduction	of	a	range	of	substrates.12	The	most	successful	catalytic	systems	are	based	
on	half-sandwich	p-complexes	of	Ru(II),	Rh(III)	and	Ir(III),	with	a	capping	arene	(usually	
p-cymene)	or	cyclopentadienyl	ligand	(Cp	or	Cp*).	The	best	chiral	ligands	are	bidentate	
monotosylated	 1,2-diamines	 or	 1,2-amino	 alcohols.	 An	 additional	 ligand,	 usually	 a	
halide,	occupies	the	fourth	coordination	site,	and	is	displaced	during	catalysis	to	allow	
formation	of	the	active	hydride	species	(Figure	1.9).	
	
Figure	 1.9.	 General	 structures	 of	 half-sandwich	 Ru(II),	 Rh(III)	 and	 Ir(III)	 p-complexes	 for	 the	
asymmetric	transfer	hydrogenation	of	ketones	and	imines.	
The	most	 common	 hydride	 sources	 are	 the	 azeotropic	mixture	 of	 formic	 acid	 and	
triethylamine	(HCOOH	/	Et3N)15	and	alcohols	such	as	isopropanol	(iPrOH).16	Aqueous	
sodium	 formate	 (HCOONa)	 can	also	be	used,	 for	 reactions	 taking	place	 in	water.17	
When	isopropanol	is	used,	a	base	such	as	potassium	hydroxide	is	necessary	to	activate	
the	complex,	and	the	hydride	transfer	is	reversible.18,19	However,	asymmetric	transfer	
hydrogenation	of	imines	does	not	proceed	when	isopropanol	is	used	as	the	hydride	
souce	with	Noyori’s	catalyst.20	When	formate	is	used	in	an	open	system,	the	reaction	
proceeds	in	an	irreversible	manner,	due	to	the	formation	and	continuous	elimination	
of	gaseous	CO2.15,21	
In	addition	to	the	bidentate	ligands	described	above,	N-heterocyclic	carbenes	(NHCs)	
have	 been	 reported	 to	 promote	 reduction	 of	 imines.	 Efficient	 catalysts	 include	
complexes	 of	 NHCs	 with	 Ru(II)-arene	 and	 Rh(III)	 /	 Ir(III)-cyclopentadienyl,	 but	 also	
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Rh(I)-	and	Ir(I)	complexes,	bearing	diene	ligands	such	as	cyclooctadiene	(COD)	(Figure	
1.10).22-23	Most	catalysts	are	based	on	Ir	and	Ru,	with	less	examples	available	for	Rh.	
Generally,	catalysts	that	perform	imine	transfer	hydrogenation	would	also	be	active	
for	 the	 reduction	 of	 imines.	 Few	 examples	 are	 found	 in	 aqueous	 solutions,	 and	
isopropanol	is	the	most	commonly	used	hydride	donor,	in	the	presence	of	a	base,	such	
as	KOH.	For	example,	N-benzyl-substituted	NHCs	based	on	benzimidazole	were	shown	
to	promote	imine	transfer	hydrogenation	in	>99	%	yields	when	complexed	to	Ir(I),24	
while	Ir(III)	and	Ru(II)	complexes	with	4-acetylbenzyl-NHCs	were	active	in	both	ketone	
and	imine	reduction.25	
	
Figure	1.10.	Metal	complexes	of	NHCs	for	imine	reduction.		
1.1.2.2 Mechanism	of	imine	transfer	hydrogenation	
The	general	mechanism	 for	 the	metal-catalysed	 reduction	of	 carbonyls	 and	 imines	
involves	 formation	 of	 the	 metal	 hydride,	 followed	 by	 its	 transfer	 to	 the	
substrate.18,26,27	The	mechanisms	of	ketone	and	imine	reduction	are	very	similar	and	
metal	complexes	used	for	this	catalysis	are	generally	quite	similar	too.	The	full	catalytic	
cycle	 is	 shown	 in	 Figure	 1.11	 for	 the	 reduction	 of	 aromatic	 imines	 using	 [Ru(p-
cymene)(R,R-TsDPEN)Cl]	complex.	The	catalyst	precursor	A	first	eliminates	HCl	to	form	
the	16	e-	catalytic	species	B.	Hydride	transfer	from	the	donor	leads	to	the	18	e-	Ru-
hydride	complex	C,	which	in	turn	transfers	the	hydride	to	the	substrate,	to	re-form	the	
16	e-	complex	B.	
General structures: 
Examples: 
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Figure	1.11.	Catalytic	cycle	for	the	transfer	hydrogenation	of	imines	by	[Ru(p-cymene)(R,R-TsDPEN)Cl]	
with	formate	as	hydrogen	donor.		
The	mechanism	of	transfer	hydrogenation	is	classified	depending	on	the	role	played	
by	the	substrate:	coordination	of	the	substrate	to	the	metal	centre	is	characterised	as	
inner	sphere,	whereas	no	direct	coordination	of	the	substrate	to	the	metal	centre	is	
characterised	as	outer	 sphere.28	 In	both	pathways	 the	metal	hydride	 is	 transferred	
onto	the	sp2-carbon,	which	is	activated	differently	depending	on	the	mechanism.		
In	 the	 inner	 sphere	mechanism,	 the	metal	 centre	 acts	 as	 a	 Lewis	 acid,	with	 imine	
activation	occurring	by	coordination	to	the	metal	centre	via	a	vacant	coordination	site,	
followed	by	protonation	of	the	heteroatom	by	the	protic	solvent.	In	the	outer	sphere	
mechanism,	 the	 hydride	 and	 proton	 are	 transferred	 in	 a	 concerted	 polarised	 or	
stepwise	 fashion,	 upon	 activation	 of	 the	 heteroatom	 by	 hydrogen	 bonding	 or	 by	
protonation	(Figure	1.12).29	When	the	proton	is	acquired	from	a	ligand	in	the	metal	
complex,	as	exemplified	in	Figure	1.11,	the	outer	sphere	mechanism	is	referred	to	as	
bifunctional	catalysis,	a	term	coined	by	Noyori.30	The	substrate	is	activated	through	
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hydrogen	bonding	with	the	ligand,	a	six	membered	transition	state	occurs	between	
the	complex	and	the	substrate,	allowing	both	proton	and	hydride	transfer	to	occur	in	
a	concerted	fashion.18,26		
	
Figure	 1.12.	 Asymmetric	 imine	 reduction	 via	 inner	 and	 outer	 sphere	mechanisms.	Modified	 from	
Wang	et	al.	(2011).14		
In	other	studies,	Bäckvall	and	co-workers	suggested	that	that	the	 imine	only	reacts	
with	the	metal	hydride	complex	in	the	presence	of	acid,	which	protonates	the	imine	
to	yield	an	 iminium	 ion,	which	 is	 then	reduced	to	the	corresponding	amine	 (Figure	
1.13).31	Others	have	also	confirmed	this	ionic	mechanism.32,33	Norton	clearly	defined	
this	 mechanism	 for	 the	 asymmetric	 hydrogenation	 of	 iminium	 salts	 with	 Ru-
diphosphine	catalysts.34,35	
	
Figure	1.13.	Proposed	ionic	mechanism	for	imine	reduction.	Modified	from	Wang	et	al.	(2011).14	
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1.1.2.3 Imine	transfer	hydrogenation	in	aqueous	solvents		
Several	 examples	 of	 aqueous-phase	 transfer	 hydrogenation	 reactions	 have	 been	
reported.17,36-39	Generally,	water-soluble	catalysts	contain	 ligands	with	sulfonic	acid	
functionalities	 and	 sodium	 formate	 is	 employed	 as	 the	 hydrogen	 source.	 The	 low	
solubility	of	the	substrates	in	the	reaction	mixture	does	not	seem	to	affect	the	yields.36	
The	 pH	 has	 a	 critical	 influence	 on	 rate	 and	 enantioselectivity	 as	 highlighted	 in	
investigations	 by	 both	 Ogo	 et.	 al.40	 and	 Wu	 et.	 al.41	 In	 contrast	 to	 ketones,	 an	
important	issue	for	aqueous	imine	reduction	is	the	hydrolysis	of	imines	in	water,	to	
form	 the	 corresponding	 carbonyl	 and	 amine	 precursors.	 The	 use	 of	 cyclic	 imines	
minimises	 this	problem.42	Some	acyclic	 imines	derived	 from	aryl	ketones	have	also	
been	successfully	used	in	aqueous	systems.	
Xiao	 and	 co-workers	 found	 that	 the	 reduction	 of	 quinolines	 by	 the	
[(Cp*)Rh(TsDPEN)Cl]	catalyst	was	strongly	dependent	on	the	pH,	with	the	maximum	
conversion	obtained	at	pH	5.33	The	suggested	explanation	is	that	a	compromised	pH	
had	to	be	achieved,	where	the	protonated	quinoline	(pKa	5.4)	and	the	formate	(pKa	
3.6)	species	were	sufficient	for	the	reaction	to	occur.		
Catalysts	based	on	Ru,	Rh	and	Ir-	aminosulfonamide	complexes	have	all	shown	to	be	
active	in	the	aqueous	transfer	hydrogenation	of	imines.17,39,42	(Figure	1.14)		
	
Figure	1.14.	Aqueous	transfer	hydrogenation	of	imines.	
For	example,	Deng	and	co-workers	reported	a	range	of	chiral	water-soluble	catalysts	
for	 the	 asymmetric	 transfer	 hydrogenation	 of	 both	 ketones	 and	 imines	 using																					
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N-aminosulfonated	ligands	bearing	solubilising	groups	such	as	sulfonate	(guanidinium,	
or	amines).17		
1.1.2.4 Bioinspired	imine	transfer	hydrogenation		
A	 biologically	 inspired	 approach	 to	 imine	 reduction	 was	 recently	 reported,	 which	
utilises	a	rhodium	complex	tethered	to	Hantszch	ester.	Hantszch	esters	are	commonly	
used	 in	 transfer	 hydrogenation	 as	 mimics	 of	 the	 biological	 NAD(P)H	 cofactor.43-46			
Colbran	and	co-workers	developed	this	bio-inspired	metal	complex	as	an	active	site	
mimic	of	alcohol	dehydrogenase	for	imine	reduction.47	The	basic	mechanism	involved	
imine	 activation	by	 direct	 coordination	 to	 the	metal	 centre	 acting	 as	 a	 Lewis	 acid,	
hydride	 transfer	 from	 the	 tethered	 dihydropyridine	 ligand,	 followed	 by	 proton	
transfer	 from	 the	 formate	proton	 source	 (Figure	 1.15).	 The	 complex	produced	 the	
corresponding	amines	in	excellent	yields	(>90	%)	from	simple	aldimines	and	ketimines	
in	air.	Additionally,	reduction	of	the	pyridinium	ligand	to	dihydropyridine	was	possible	
via	the	rhodium	hydride	(Rh-H)	complex.	This	is	an	example	of	how	modern	chemistry	
is	moving	towards	“greener”	synthesis	with	assistance	from	Nature.		
	
Figure	1.15.	Proposed	mechanism	of	 imine	transfer	hydrogenation	using	 the	bioinspired	Hantzsch	
pyridine	tethered	rhodium	catalyst.	Reproduced	from	McSkimming	et	al.	(2013).47		
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Despite	 the	 successful	 progress	 of	 metal	 catalysts	 for	 the	 asymmetric	 transfer	
hydrogenation	of	imines	in	aqueous	conditions	there	are	still	some	limitations,	such	
as	the	use	of	enantiomerically	pure	ligands	that	require	a	long	and	difficult	synthesis.	
The	metal	centre	is	also	quite	expensive	and	can	be	susceptible	to	deactivation	from	
any	nitrogen	or	sulphur	containing	compounds	within	the	reaction.	Thus,	efforts	are	
still	being	made	towards	the	development	of	efficient	processes	for	imine	reduction	
as	a	way	to	access	enantiopure	amines.	
1.1.3 Biocatalysts	for	imine	reduction		
1.1.3.1 Background	and	early	developments		
The	potential	of	enzymes	as	“green	catalysts”	has	been	increasingly	recognised	and	
exploited	in	the	past	20	years.	As	a	consequence,	much	research	has	focused	on	the	
discovery	 and	 development	 of	 biocatalysts	 capable	 of	 enantioselective	 imine	
reduction,	 as	 a	 direct	 approach	 to	 chiral	 amines.	 Until	 recently,	 this	 reaction	 was	
assumed	to	be	absent	from	nature’s	enzymatic	toolbox.	Currently,	various	enzymatic	
routes	exist	 for	 the	synthesis	of	optically	active	primary	amines,	 such	as	 (dynamic)	
kinetic	 resolution	 using	 hydrolases,	 asymmetric	 synthesis	 using	 amine	
dehydrogenases	 and	 deracemisation	 using	monoamine	 oxidase.48	 Transaminases49	
and	ammonium	lyases50	have	recently	found	applications	in	industry	for	the	synthesis	
of	optically	active	primary	amines.		
On	the	other	hand,	the	enzymatic	routes	towards	chiral	secondary	or	tertiary	amine	
derivatives	are	less	common.	For	example,	few	transaminases	can	produce	secondary	
amines	with	smart	substrate	selection	when	coupled	with	chemical	catalysts.51	Thus,	
efforts	 into	 the	 search	 and	 development	 of	 biocatalysts	 for	 asymmetric	 imine	
reduction	 have	 been	 emerging.	 At	 the	 beginning	 of	 this	 thesis,	 the	 number	 of	
published	examples	of	enzymes	exhibiting	 imine	reductase52	activity	was	 limited	to	
Candida	 parapsilosis	 (ATCC	 7330),53	 Pseudomonas54-56	 and	 Streptomyces	 sp;52,57,58	
strains	 reported	 to	possess	 this	activity.	 Since	 these	 initial	 reports,	much	work	has	
gone	 into	the	discovery	and	development	of	 imine	reductases	and	the	number	has	
been	 increasing	 over	 the	 past	 few	 years,	 along	 with	 an	 understanding	 of	 their	
characteristics	and	mechanism.	
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Candida	parapsilosis	ATCC	7330,	a	fungal	species	from	the	yeast	family	originally	used	
as	 a	 biocatalyst	 for	 the	 asymmetric	 reduction	 of	 α-	 and	 β-	 keto	 esters59-60	 was	
investigated	for	asymmetric	 imine	reduction,	due	to	the	chemical	analogy	between	
ketones	 and	 imines.	 The	 functional	 groups	 (C=O)	 and	 (C=N)	 of	 these	 compounds	
display	similar	chemical	reactivities,	due	to	their	similarity	in	size	and	the	availability	
of	lone	electron	pairs.	Indeed,	resting	/	living	Candida	cells	were	found	to	reduce	aryl	
imines	to	the	corresponding	(R)-amines	with	good	yields	and	high	enantioselectivities	
(Figure	1.16).53	However,	low	reaction	rates	were	observed	with	these	systems.		
	
Figure	1.16.	Imine	reduction	using	Candida	parapsilosis	ATCC	7330.	Modified	from	Vaijayanthi	et	al.	
(2008).53	
Li	 et	 al.	 demonstrated	 the	 use	 of	 a	 dynamic	 combinatorial	 screen	 as	 a	 versatile	
approach	 for	 the	 discovery	 of	 imine	 reductase	 activity.61	 They	 used	whole	 cells	 of	
Acetobacterium	woodii,	an	anaerobic	bacterium	which	reduces	C=C	double	bonds	as	
part	 of	 a	 respiratory	 process,	 to	 reduce	 aldimines,	 formed	 in	 situ	 from	 the	
corresponding	amines	and	aldehydes.	The	products	were	obtained	in	low	quantities,	
and	the	enzymes	responsible	for	this	reaction	were	not	identified.	
Enzymes	 from	 Pseudomonas	 putida	 ATCC	 1263355	 and	 Pseudomonas	 syringe	 pv.	
tomato56	 were	 also	 observed	 to	 possess	 imine	 reductase	 activity	 towards																										
Δ1-piperidine-2-carboxylate	 and	 Δ1-pyrroline-2-carboxylate,	 producing	 the	
corresponding	 (S)-amines	 in	 the	 presence	 of	 NADPH	 as	 the	 cofactor	 (Figure	 1.16).	
These	 Pseudomonas	 enzymes	 have	 been	 classed	 as	 NADPH-dependent	
oxidoreductases	belonging	to	a	new	family	of	malate	/	lactate	dehydrogenases	(MDH	
/	LDH).	The	family	retains	no	sequence	homology	to	conventional	MDH	/	LDHs,	and	
the	main	difference	was	observed	in	the	NADPH-binding	site62,63	therefore	displaying	
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different	 activities.64-66	 However,	 yields	 and	 optical	 purities	 of	 the	 corresponding	
amines	were	not	reported.	
	
Figure	1.17.	Imine	reduction	using	Pseudomonas	strains.56	
Streptomyces	sp.	was	another	strain	reported	to	possess	imine	reductase	activity	by	
Mitsukura	 et	 al.	 in	 2010,	 and	 has	 been	 extensively	 studied	 ever	 since.57	 Five	
Streptomyces	sp.	based	strains	were	reported	to	display	asymmetric	imine	reduction	
activity	with	2-methyl-1-pyrroline	as	substrate	(Figure	1.18).	Streptomyces	sp.	GF3587	
produced	the	corresponding	(R)-enantiomer	with	an	optical	purity	of	99	%	ee,	while	
Streptomyces	sp.	GF3546	produced	the	(S)-enantiomer,	with	81	%	ee.		
	
Figure	1.18.	Imine	reduction	using	Streptomyces	strains.57		
1.1.3.2 Imine	reductases	and	their	applications		
Following	the	successful	results	described	above	with	the	Streptomyces	strains,	the	
same	 research	 group	 purified	 and	 characterised	 the	 corresponding	 enzymes	
responsible	 for	 the	 imine	 reduction	 activity,	 which	 were	 found	 to	 be	 NADPH-
dependent.67	The	(R)-imine	reductase	((R)-IRED)	from	Streptomyces	sp.	GF3587	was	
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only	 active	with	 2-methyl-1-pyrroline,67	whereas	 the	 (S)-imine	 reductase	 ((S)-IRED)	
Streptomyces	sp.	GF3546	displayed	a	broader	substrate	specificity	(Figure	1.19a).52		
Turner	and	collaborators	extended	this	investigation	into	(S)-IRED	from	Streptomyces	
sp.	GF3546,	 	 reporting	 the	acceptance	of	 six	and	seven	membered	cyclic	 imines	as	
substrates.68	However,	reported	kcat	values	(maximum	number	of	substrate	molecules	
converted	to	product	per	enzyme	molecule	per	second)	were	relatively	low	(10-1-10-3	
s-1).	In	addition,	when	incorporated	into	an	E.coli	whole	cell	biocatalyst	supplemented	
with	glucose	to	aid	cofactor	recycling,	this	(S)-IRED	was	shown	to	enantioselectively	
catalyse	 the	 reduction	 of	 a	 range	 of	 substituted	 dihydroisoquinolines	 and	 1-
substituted	dihydro-β-carbolines	with	excellent	ee	values	(>98	%,	Figure	1.19b).68		
Another	 example	 of	 a	 tailor-made	whole	 cell	 catalyst	was	 designed	more	 recently	
using	 imine	 reductase	 from	 Streptomyces	 viridochromogenes,	 alongside	 glucose	
dehydrogenase	from	Bacillus	subtilis,	for	in	situ	cofactor	regeneration.	The	system	was	
incorporated	and	expressed	in	E.coli,	and	was	shown	to	effectively	reduce	the	model	
substrate	 1-methyl-3,4-dihydroisoquinoline	 at	 high	 substrate	 concentrations	 (100	
mM)	with	 high	 conversion	 and	 excellent	 enantioselectivity	 (>99	%	 ee).	 This	was	 a	
promising	 result	 towards	 any	 future	 whole-cell	 enantioselective	 imine	 reduction	
processes.	
Grogan	 and	 co-workers	 reported	 a	 protein	 homologous	 to	 the	 Streptomyces	 sp.	
GF3587	(R)-IRED,	named	Q1EQE0	from	Streptomyces	kanamyceticus.58	This	enzyme	
showed	(R)-selective	imine	reduction	activity	towards	the	monocyclic	imine,	2-methyl-
1-pyrroline	 as	 well	 as	 towards	 some	 dihydroisoquinoline	 derivatives	 such	 as	 3,4-
dihydroisoquinoline,	including	an	iminium	ion	(Figure	1.19c).58	This	was	also	the	first	
structurally	characterised	IRED.	
Following	 from	 the	 successful	 isolation	 and	 application	of	 IRED	 from	Streptomyces	
strains,	 efforts	 have	multiplied	 to	 find	 new	members	 of	 this	 enzyme	 family	 using	
bioinformatics	tools.	At	present,	with	the	aid	of	recently	established	Imine	Reductase	
Engineering	Database	(www.ired.biocatnet.de)	more	than	30	IREDs	have	been		
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Figure	1.19.	Substrate	range	and	application	scope	of	IREDs	from	Streptomyces	strains.52,58,68		
identified	for	enantioselective	reductions	of	various	cyclic	imines.	They	are	split	into	
two	superfamilies,	 (R)-IRED	and	 (S)-IRED,	based	upon	their	stereopreference.	Some	
examples	 of	 IREDs	 from	 different	 organisms,	 identified	 by	 screening	 of	 the	 IRED	
database,	are	briefly	discussed	next.	
The	 substrate	 spectrum	 was	 expanded	 with	 the	 discovery	 of	 the	 (S)-IRED	 from	
Amycolatopsis	 orientalis	 (AoIRED),	 which	 could	 reduce	 5-,	 6-	 and	 7-membered	
monocyclic	 imines,	 in	 addition	 to	 isoquinolines	 and	 a	 few	 iminium	 ion	 substrates	
(Figure	1.20a).69	Lenz	et.	al.	reported	the	identification	and	isolation	of	(S)-IRED	from	
Panenibacillus	elgii	(PeIRED)	and	of	the	(R)-IRED	from	Streptosporangium	roseum	DSM	
43021	(SrIRED),70	which	were	specific	for	their	substrates:	PeIRED	displayed	a	specific	
activity	 of	 0.24	 U	 /	 mg	 with	 3,4-dihydroisoquinoline,	 whereas	 SrIRED	 displayed	 a	
specific	activity	of	2.58	U	/	mg	with	2-methyl-1-pyrroline	(Figure	1.20b).	These	results	
confirmed	 the	 relatively	 low	 activities	 seen	 with	 the	 previously	 discussed	 IREDs									
N
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(0.1-3	U	/	mg),	as	well	as	the	lower	activities	of	(S)-IREDs	compared	to	their	(R)-IRED	
counterparts.		
On	the	other	hand,	Li	et.	al.	report	(S)-IRED	identified	from	Stackebrandtia	nassauensis	
(SnIRED),71	which	performed	the	reduction	of	1-methyl-3,4-dihydroisoquinoline	with	
a	catalytic	activity	that	was	25-	to	1400-fold	greater	compared	to	previous	IREDs.	A	
range	of	dihydroisoquinolines	containing	relatively	bulky	substituents	at	the	1	position	
were	 reduced	 with	 moderate	 to	 excellent	 enantioselectivities	 (up	 to	 99	 %	 ee),	
depending	on	the	a-carbon	substituent	(Figure	1.20c).71	
1.1.3.3 Characterisation	and	mechanism	of	IREDs		
All	 IREDs	 characterised	 so	 far	 are	 NADPH-dependent	 and	 do	 not	 contain	 catalytic	
metal	ions.	The	majority	of	the	IREDs	discovered	are	of	bacterial	origin.	Their	size	and	
complexity	ranges	from	21	kDa	observed	for	small	monomeric	proteins	to	370	kDa	for	
the	large	homodecamers.	They	are	diverse	in	their	structure	and	no	restricted	fold	for	
imine	reductase	activity	has	been	identified.	Nevertheless,	the	majority	of	IREDs	share	
the	same	overall	architecture:	they	are	homodimeric	proteins	with	one	molecule	of	
NADPH	bound	 to	 each	 subunit.	 Their	 natural	 function	 is	 unknown,	 and	 their	 large	
active	 site	 suggests	 accommodation	 of	 larger	 natural	 substrates	 than	 the	 small	
hydrophobic	imines	investigated	so	far.	This	is	supported	by	the	low	catalytic	activities	
observed	with	these	substrates.		
Analysis	of	the	IRED	sequences	identified	two	specific	regions,	consisting	of	a	highly	
conserved	co-factor	binding	site	and	a	specific	active	site	motif,	relating	to	a	primarily	
hydrophobic	 substrate-binding	 cleft.72	 The	 conservation	 analysis	 also	 revealed	 two	
clusters,	depending	on	the	catalytic	protic	residues.	Generally,	(R)-IREDs	are	observed	
in	 the	 larger	 cluster,	 possessing	 a	 conserved	 aspartate,	while	 known	 (S)-IREDs	 are	
members	 of	 the	 smaller	 cluster,	 with	 a	 conserved	 tyrosine.	 These	 residues	 are	
responsible	for	catalysis,	as	demonstrated	by	loss	of	activity	when	mutated	to	alanine.	
However,	the	discovery	of	non-protic	residues	Asn	and	Phe	in	this	position	have	also	
shown	to	be	active	IREDs.69,73	
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Figure	 1.20.	 Substrate	 scope	 of	 asymmetric	 imine	 reduction	 with	 different	 IREDs	 identified	 by	
screening	of	the	IRED	database.	a)	AoIRED	b)	PeIRED	and	SrIRED	c)	SnIRED	highlighting	activities	and	
enantioselectivities.		
The	 IRED	mechanism	and	the	type	and	role	of	 the	catalytic	 residues	are	still	under	
debate.	The	basis	of	the	mechanism74	involves	the	enzymes	ability	to	bind	both	the	
cofactor	 and	 substrate	 in	 a	 suitable	 coordination	 for	 hydride	 transfer,	 and	 the	
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presence	of	an	active	site	residue	with	a	role	in	proton	transfer.	It	is	unclear	which	of	
hydride	or	proton	transfer	occurs	first,	and	two	approaches	have	been	highlighted:				
1)	formation	of	an	iminium	ion	through	protonation	of	the	imine,	followed	by	hydride	
transfer	forming	the	nascent	amine;	or	2)	concerted	transfer	of	hydride	and	proton.	
These	mechanisms	are	similar	to	the	bifunctional	and	ionic	mechanisms	described	in	
Section	 1.1.2.2	 with	 the	 synthetic	 catalysts,	 except	 that	 in	 the	 case	 of	 the	 IREDs	
hydride	delivery	is	not	mediated	by	a	metal.	
The	first	structurally	characterised	IRED	was	reported	by	Grogan	and	co-workers	and	
was	the	(R)-selective	Q1EQE0	from	Streptomyces	kanamyceticus.58	Three	reductases	
that	 were	 structurally	 similar	 to	 this	 IRED	 were	 identified	 from	 the	 analysis:		
dihydrofolate	reductase	(DHFR)	and	Irp3	from	Yersinia	enterocolitica, both	exhibiting	
imine	 reduction	 activity	 towards	 their	 natural	 substrates,	 and	 hydroxyisobutyrate	
dehydrogenase	 (HiBDH),	which	was	a	ketoreductase	 identified	by	 searching	 similar	
structures	via	the	DALI	server.75	DHFR	is	believed	to	transfer	a	proton	from	a	water	
molecule	to	the	imine	substrate,	thus	forming	an	iminium	ion,	which	is	reduced	to	an	
amine	via	hydride	transfer.76	On	the	other	hand,	Irp3	is	believed	to	first	transfer	the	
hydride	and	then	the	proton,	from	either	a	His	or	Tyr	residue.		Hydride	transfer	prior	
to	 protonation	 seems	 unlikely	 due	 to	 the	 high	 basicity	 of	 the	 resulting	 amide	
intermediate.	In	HiBDH,	Lys165	in	the	active	sites	provides	the	proton	to	the	nascent	
hydroxyl	 group.	 Superimposition	 of	 the	 Q1EQE0	 structure	 with	 HiBDH	 identified	
Asp187	at	the	place	of	the	lysine.	Genetic	modification	of	this	residue	to	asparagine	
and	alanine	resulted	 in	a	 loss	of	activity.	From	this,	the	suggested	IRED	mechanism	
involved	 imine	 protonation	 by	 Asp187,	 whose	 pKa	 is	 most	 likely	 lowered	 by	 the	
hydrophobic	residues	Leu191	and	Leu137.	The	resulting	iminium	ion	is	stabilised	by	
the	predominately	negatively	 charged	active	 site	 (Figure	1.21).58	 In	 support	 of	 this	
mechanism,	recent	theoretical	activation	energies	calculated	by	Lenz	et.	al.	suggested	
that	the	protonation	of	imines	occurred	prior	to	hydride	transfer,	as	the	iminium	ions	
were	demonstrated	to	be	more	reactive	than	the	corresponding	imines.74		
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Figure	1.21.	a)	Suggested	mechanism	of	Q1EQE0	 IRED.	Modified	 from	Schrittwieser	et	al.	 (2015);77								
b)	Active	site	of	Q1EQE0,	with	the	suggested	catalytic	residue	Asp187	highlighted	as	yellow	sticks.	
The	 AoIRED	 structure	 co-crystallised	 with	 NADPH	 and	 the	 corresponding	 amine	
product	 1-methyl-1,2,3,4-tetrahydrosioquinoline	 was	 also	 reported	 (Figure	 1.22),	
providing	the	first	insights	into	the	possible	substrate-binding	site	and	interaction	with	
active	site	residues.	The	binding	position	of	the	(R)-amine	product	shows	the	nitrogen	
atom	within	a	4.4	Å	distance	of	the	active	site	Tyr179	residue,	and	the	chiral	carbon	
within	3.5	Å	of	the	C4	atom	of	NADPH,	which	delivers	the	hydride. 
	
Figure	1.22.	 Structure	of	Amycolatopsis	orientalis,	AoIRED	co-crystallised	with	model	 substrate	1-
methyl-1,2,3,4-tetrahydrosioquinoline	and	NADPH.	Reproduced	from	Aleku	et	al.	(2016)69	(A)	and	(B)	
identifying	the	different	protein	monomers.	
Lenz	 et	 al.	 also	 showed	 PeIRED	 and	 SrIRED	 activity	 towards	 the	 reduction	 of	 the	
carbonyl	bond	in	2,2,2-trifluoroacetophenone.74 This	demonstrated	for	the	first	time	
IRED	 reaction	 promiscuity	 towards	 the	 reduction	 of	 carbonyls	 and	 raised	 an	
interesting	question:	can	this	expansion	of	activity	be	mimicked	in	carbonyl	reductases	
(alcohol	 dehydrogenases,	 ADHs)?	 These	 enzymes	 (ADH)	 are	 well-studied	 and	
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characterised,	encompassing	a	broad	range	of	substrates,	with	the	majority	employing	
the	cheaper	NADH	cofactor.		
1.2 Alcohol	dehydrogenases		
1.2.1 Background	and	classification		
Alcohol	dehydrogenases	[ADHs,	EC	1.1.1.1]	are	a	group	of	enzymes	belonging	to	the	
oxidoreductase	 family.78	 They	 catalyse	 the	 reversible	 oxidation	 of	 alcohols	 to	 the	
corresponding	aldehydes	or	ketones,	with	the	concomitant	reduction	of	the	coenzyme	
nicotinamide	adenine	(phosphate)	NAD(P)+	cofactor	via	hydride	transfer	(Figure	1.23).		
	
Figure	1.23.	Reactions	catalysed	by	alcohol	dehydrogenase	(ADH).	
ADHs	are	present	in	many	organisms,	including	humans,	animals,	plants,	yeasts	and	
bacteria.	 In	 the	mammalian	 organisms,	 they	 facilitate	 the	 breakdown	 of	 alcohols,	
which	are	toxic	to	the	body	if	left	untreated.		Whereas	in	plants,	yeast	and	bacteria,	
the	 reverse	 reaction	 occurs,	 producing	 the	 alcohol,	 as	 part	 of	 the	 fermentation	
process.	 ADHs	 selectively	 transform	 a	 broad	 range	 of	 substrates	 including	 hemi-
acetals,	primary,	secondary	and	cyclic	alcohols.78	
Alcohol	dehydrogenases	can	be	split	into	three	classes	depending	on	their	structure	
and	amino	acid	chain	length.		
• Long	chain	dehydrogenase	/	reductases	(LDR),	approx.	700	amino	acids,	such	
as	Zymomonas	mobilis	ADH;	
• Medium	 chain	 dehydrogenase	 /	 reductase	 (MDR),	 approx.	 350-375	 amino	
acids,	such	as	horse	liver	ADH	and	yeast	ADH;		
• Short	chain	dehydrogenase	/	reductase	(SDR)	approx.	250	amino	acids,	such	as	
Drosophila	ADH.	
Many	alcohol	dehydrogenases	contain	a	zinc	 ion	in	their	active	site,	however	some	
were	 described	 to	 contain	 iron	 (Saccharomyces	 cerevisiae	 ADH),79	 magnesium	
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(Thermus	 thermophilus)	or	nickel	 (Oenococcus	oeni).80	SDRs,	 such	as	 the	ADH	from	
Drosophila,	contain	no	metal	ions.81	
1.2.1.1 Medium	chain	dehydrogenase	/	reductase	
Zinc-containing	MDRs	constitute	a	large	part	of	the	alcohol	dehydrogenase	family	and	
have	been	studied	extensively.	These	alcohol	dehydrogenases	exist	either	as	dimers	
(mammalian	ADHs)	or	tetramers	(bacterial	ADHs)	of	subunits,	as	represented	by	the	
two	most	explored	enzymes	of	this	group:	ADH	from	horse	liver	(HLADH)	and	from	
yeast.82	MDRs	 consist	 of	 a	 chain	 of	 approximately	 350	 amino	 acids	 per	monomer,	
weighing	 approximately	 40	 kDa.	 The	 monomer	 is	 divided	 into	 two	 domains:	 a	
coenzyme-binding	domain	and	a	catalytic	domain,	which	are	separated	by	a	long	deep	
cleft	in	the	protein	structure	(Figure	1.24a).83		
The	coenzyme	binding	domain	binds	either	NAD+	or	NADP+,	or	their	reduced	forms,	
depending	 on	 the	 enzyme	 and	 its	 sequence.	 In	 most	 cases	 the	 catalytic	 domain	
contains	 two	 zinc	 ions,	 one	 which	 is	 responsible	 for	 the	 catalysis	 and	 one	 that	 is	
structural.	 The	 catalytic	 zinc	 is	 coordinated	 in	 an	 approximate	 tetrahedral	
conformation	to	three	protein	ligands,	usually	one	histidine	and	two	cysteines	(Figure	
1.24b).	The	fourth	ligand	is	usually	a	water	molecule.	The	structural	zinc	interacts	with	
four	protein	ligands,	all	of	which	are	cysteines	in	all	structurally	characterised	ADHs	so	
far.84		
	
Figure	1.24.	a)	Dimeric	HLADH	structure,	co-crystallised	with	NADH	(orange	sticks),	zinc	 ions	(grey	
spheres);	b)	close	view	of	the	HLADH	active	site	showing	the	amino	acids	(green	sticks)	bound	to	the	
catalytic	zinc	(grey	sphere).	(PDB	ID	4XD2).	
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A	review	of	the	3D	structures	of	MDRs	shows	that	the	catalytic	domain	varies	slightly	
throughout	 the	 entire	 alcohol	 dehydrogenase	 family.82	 For	 example,	 the	 spacing	
between	 the	 metal	 binding	 ligands	 can	 vary,	 and	 a	 more	 significant	 variation	 is	
observed	with	the	third	ligand.	In	most	NADP(H)-dependent	dehydrogenases	the	third	
ligand	is	found	to	be	an	aspartic	acid	while	in	polyol	dehydrogenases,	this	is	replaced	
by	a	glutamic	acid.84	In	a	few	cases	the	coordination	by	the	forth	ligand	is	a	glutamic	
acid	rather	than	a	water	molecule.84,85	Only	two	structurally	described	ADHs	lack	the	
structural	 zinc,	 and	 they	 come	 from	 the	 thermophiles	Thermoanaerobacter	 brockii	
and	Thermoanaerobacter	ethanolicus.86	
1.2.1.2 Short	chain	dehydrogenases	/	reductases		
Short	chain	reductases	(SDRs)	are	distinct	from	the	MDRs	due	to	their	lack	of	metal	
ion	and	shorter	chain	length.87	This	enzyme	family	includes	representatives	from	all	
domains	of	life,	from	primitive	bacteria	to	higher	eukaryotes.88	The	most	studied	SDR	
is	Drosophila	ADH	 coming	 from	 an	 insect	 species.	 The	 chain	 length	 of	 SDRs	 varies	
between	250	and	300	amino	acids,	and,	like	MDRs,	they	also	have	a	cofactor-binding	
site	 and	 a	 substrate-binding	 site.	 The	 substrate	 binding	 cleft	 determines	 substrate	
selectivity,	however	across	the	family	there	is	a	considerable	variation	in	the	structure	
of	this	site,	leading	to	variation	in	their	substrate	scope.	On	the	other	hand,	active	site	
residues	are	similar,	and	consist	of	a	highly	conserved	tyrosine	in	close	proximity	to	
Lys,	Ser	and	Asn	residues,	presenting	an	active	tri-	/	tet-	rad	capable	of	performing	
acid/base	catalysis.89	This	mechanism	is	in	contrast	to	the	MDR	substrate	activation	
by	zinc(II)	(disscussed	later).	
1.2.2 Mechanism	of	zinc-dependent	alcohol	dehydrogenases		
HLADH	was	generally	used	as	 the	model	 for	 the	enzymatic	mechanism,	which	was	
suggested	based	on	crystallography,	kinetic	and	spectroscopic	 studies.	The	hydride	
transfer	 reaction	 can	 occur	 reversibly	 between	 the	 carbon	 bound	 to	 the	 alcohol	 /	
carbonyl	functionality	of	the	substrate	and	the	pyridinium	ring	of	NAD+	in	its	reduced	
/	oxidised	form.	In	the	oxidation	direction,	two	hydrogen	atoms	are	removed	from	the	
alcohol	one	of	which	is	released	as	a	proton	and	the	other	transferred	as	a	hydride	to	
NAD+,	reducing	it	to	NADH.		
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The	NAD+	binds	to	the	coenzyme	binding	site	transforming	the	enzyme	into	an	active	
species,	as	a	result	of	a	conformational	change	in	the	enzyme	structure,	during	which	
the	nicotinamide	 ring	moves	deeper	 into	 the	 active	 site	 and	 the	 substrate	binding	
pocket	is	formed	(Figure	1.25).	Substrate	binding	occurs	by	coordination	of	the	oxygen	
to	the	catalytic	zinc	acting	as	a	Lewis	acid,	and	displacement	of	a	water	molecule.	In	
the	 oxidative	 direction,	 the	 zinc	 draws	 electrons	 from	 the	 oxygen	 and	 facilitates	
proton	release,	aided	by	hydrogen	bonding	with	 the	enzyme.	The	proton	 from	the	
alcohol	function	is	involved	in	H-bonding	with	residue	Ser48.	As	shown	in	Figure	1.26,	
this	proton	is	removed	via	a	proton	relay	system	between	the	alcohol,	the	2’-hydroxyl	
group	of	the	nicotinamide	ribose,	and	residues	Ser48	and	His51.83		
	
Figure	1.25.	Structure	of	HLADH	monomer	co-crystallised	with	pentafluorobenzyl	bromide.	Catalytic	
and	structural	zinc	ions	are	represented	in	grey,	cofactor	NAD+	in	green	and	pentafluorobenzyl	bromide	
in	 yellow,	 representing	 the	 substrate.	 The	 metal	 binding	 residues	 are	 highlighted	 in	 red	 and	 the	
substrate	 pocket	 residues	 are	 highlighted	 in	 dark	 blue,	 purple	 and	 grey.	Modelled	 on	HLADH	 (PDB	
1HLD).		
After	deprotonation	of	the	alcohol	and	formation	of	the	negatively	charged	alkoxide	
ion,	a	hydride	is	transferred	from	the	alcohol	to	the	C4	position	on	the	nicotinamide	
ring,	 consequently	 forming	 the	 corresponding	 carbonyl	 and	NADH.	 The	 carbonyl	 is	
released,	followed	by	release	of	NADH.	NADH	binding	to	the	enzyme	is	stronger	than	
NAD+	binding,	and	the	NADH	release	 is	classed	as	 the	rate	determining	step	 in	 the	
alcohol	oxidation.90	In	the	reverse	reaction	of	carbonyl	reduction,	coordination	of	the	
oxygen	 to	 the	 catalytic	 zinc(II)	 increases	 the	 electrophilicity	 on	 the	 α-carbon	 and	
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facilitates	the	hydride	transfer	from	the	NADH.	This	is	then	followed	by	proton	relay	
from	a	water	molecule	to	the	carbonyl,	resulting	in	the	corresponding	alcohol.	
	
Figure	1.26.	Proposed	HLADH	mechanism	illustrating	the	proton	relay	system.	Modified	from	Eklund	
et	al.	(1982)91	and	Choonseok	et	al.	(2013).92		
Whilst	this	mechanism	is	generally	accepted	for	HLADH,	certain	authors	suggested	a	
different	mechanism	for	some	bacterial	ADHs,	such	as	the	thermostable	TbADH	from	
Thermoanaerobacter	brockii.86	Based	on	data	obtained	by	X-ray	absorption,	circular	
dichroism	(CD),	fluorescence	spectroscopy,	structural	analysis	and	modelling	studies	
of	 the	 ternary	 complex	 TbADH-NADP+-DMSO	 (as	 ketone	 mimic),	 the	 zinc	 ion	 was	
suggested	to	be	pentacoordinated	during	hydride	transfer,	with	the	water	molecule	
acting	as	the	fifth	ligand,	instead	of	being	displaced	by	the	substrate.93	The	absence	of	
a	 proton	 relay	 system	 was	 also	 suggested	 in	 the	 TbADH	 mechanism,	 and	 was	
supported	by	the	lack	of	hydrogen	bonds	between	Ser37	and	His42	(corresponding	to	
residues	 Ser48	 and	 His51	 in	 HLADH)	 to	 the	 2’-hydroxyl	 group	 of	 the	 nicotinamide	
ribose,	observed	from	the	crystal	structure.	
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Depending	on	the	ADH	hydride	transfer	takes	place	from	NAD(P)H	to	the	re-face	of	
the	ketone	producing	the	(S)-alcohol	(referred	to	as	Prelog’s	rule);	or	to	the	si-face,	
delivering	 the	 (R)-alcohol	 (following	 the	 anti-Prelog’s	 rule).	 In	 addition	 to	 the	
stereospecific	approach	of	the	substrate,	the	hydride	transfer	to	/	from	NAD(P)H	is	
also	 stereospecific:	 some	dehydrogenases	 specifically	 transfer	 the	pro-R	 hydrogen,	
while	other	transfer	the	pro-S	hydrogen	at	position	4	of	the	NAD(P)H	nicotinamide	
ring.	 A	 number	 of	 reasons	 have	been	proposed	 for	 this	 stereospecificity.94	 From	a	
structural	standpoint,	to	accommodate	both	the	nicotinamide	ring	and	the	substrate	
in	the	pocket,	the	enzyme	binds	the	cofactor	in	a	particular	conformation,	in	which	
the	amide	group	is	away	from	the	pocket.	 	For	example,	HLADH	exclusively	follows	
Prelog’s	rule,	resulting	in	a	predictable	stereochemical	outcome	for	the	substrate	in	
which	the	pro-R	hydride	is	transferred	from	the	NADH	coenzyme	to	the	re-face	of	the	
carbonyl	group	resulting	in	the	(S)-alcohol	(Figure	1.27).	
	
Figure	1.27.	HLADH	following	Prelog’s	rule,	resulting	in	the	corresponding	(S)-alcohol.	The	si-face	of	
the	ketone	is	shown,	as	well	as	the	pro-R	and	pro-S	hydride	in	NADH.		
1.2.3 Applications	of	selected	zinc-dependent	alcohol	dehydrogenases		
There	is	considerable	interest	in	the	use	of	ADHs	in	the	food,	pharmaceutical,	and	fine	
chemicals	industries	for	the	production	of	aldehydes,	ketones,	and	particularly	chiral	
alcohols.	 After	 hydrolases,	 ADHs	 are	 the	 most	 widespread	 enzymes	 in	 organic	
synthesis.95	A	range	of	ADHs	are	commercially	available,	and	taken	together	they	have	
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a	 broad	 substrate	 range,	 including	 aldehydes,	 acyclic,	 bicyclic,	 aromatic	 and	
unsaturated	ketones,	as	well	as	diketones	and	oxo-esters	(Figure	1.28).96		
	
Figure	1.28.	 Illustration	of	 the	 substrate	 range	of	a	 range	of	 common	ADHs.	Modified	 from	Faber	
(2011).96		
Horse	liver	ADH	reduces	a	wide	range	of	substrates	with	good	to	excellent	enantio-	
and	 regio-selectivities,	 including	 cyclic	 and	 bicyclic	 ketones	 of	 medium	 size	 (4-9	
membered),	 diketones	 and	 organometallic	 compounds97,98	 (Figure	 1.29a-b).	
Molecules	 larger	 than	 decalines	 (>10	 membered	 bicyclic	 rings)	 are	 not	 as	 readily	
accepted	as	 substrates.99	While	O-	 and	S-	 containing	heterocyclic	 ketones	 are	well	
tolerated	by	HLADH,	the	presence	of	amines	(for	example	in	N-heterocyclic	ketones)	
inhibits	 the	 reaction,	 presumably	 due	 to	 the	 strong	binding	of	 the	nitrogen	 to	 the	
catalytic	zinc.100	HLADH	also	catalyses	the	oxidation	of	racemic	primary	and	secondary	
alcohols,	and	is	particularly	useful	for	the	oxidation	of	polyols	and	diols	to	ultimately	
yield	chiral	lactones	(Figure	1.29c).101		
On	the	other	hand,	acyclic	ketones	and	secondary	alcohols	are	not	good	substrates	
for	HLADH.	Other	commercial	enzymes	such	as	TbADH	are	used	as	catalysts	for	the	
oxidation	/	reduction	of	these	substrates.	Interest	in	TbADH	for	biocatalysis	is	due	to	
its	high	thermostability	(up	to	85	oC)	and	high	tolerance	for	organic	solvents.102	It	is	
particularly	effective	for	the	oxidation	of	medium	chain	aliphatic	secondary	alcohols	
and	the	reduction	of	the	corresponding	acyclic	ketones	with	excellent	selectivities.103	
High	optical	purities	have	been	observed	for	ω-haloalkyl-,	methyl-	or	trifluoromethyl	
ketones	with	heterocyclic	 substituents,104,105	whereas	α,β-unsaturated	ketones	and	
ketones	 with	 both	 substituents	 larger	 than	 an	 ethyl	 group	 are	 not	 accepted	 as	
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substrates.96	 TbADH	 has	 also	 been	 employed	 in	 the	 synthesis	 of	 bioactive	
compounds.106	
	
Figure	1.29.	Examples	of	reduction	and	oxidation	reactions	performed	with	HLADH.96,98,101		
Interestingly,	TbADH	exhibits	a	substrate	size-induced	reversal	of	enantioselectivity:	
when	the	substrate	is	small,	i.e.	methyl	ethyl,	methyl	isopropyl	or	methyl	cyclopropyl	
ketones,	reduction	follows	the	anti-Prelog	rule	with	the	hydride	attacking	the	si-face	
of	the	carbonyl	resulting	in	the	corresponding	(R)-alcohol.	However,	when	the	ketones	
are	larger	in	size,	TbADH	follows	Prelog’s	rule	with	the	hydride	attacking	the	re-face	
of	 the	carbonyl	 resulting	 in	 the	 (S)-alcohol.	 Some	examples	of	 substrates	and	 their	
alcohol	configuration	are	shown	in	Figure	1.30.96		
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Figure	1.30.	 Enantioselectivity	 for	 TbADH	on	 selected	 substrates;	 aswitch	of	 the	ketone	 reduction	
catalysed	by	TbADH.	Modified	from	Keinan	et	al.	(1986).106	
As	demonstrated	with	TbADH,	the	application	of	robust	biocatalysts,	in	terms	of	heat	
and	solvent	tolerability	commonly	displayed	by	thermostable	enzymes,	is	desired	in	
many	 industrial	 processes.	 Whilst	 mesophilic	 ADHs	 such	 as	 HLADH	 have	 found	
application	 in	 biotransformations,	 these	 enzymes	 have	 been	 shown	 to	 undergo	
conformational	changes	affecting	their	activity	under	thermal	stress.107	On	the	other	
hand,	the	substrate	scope	of	TbADH	is	limited	compared	to,	for	example,	HLADH.	A	
zinc-dependent	 thermostable	 enzyme	 from	 Thermus	 sp.	 ATN1	 raised	 considerable	
interest,	due	to	its	 large	substrate	scope,	thermal	and	organic	solvent	tolerance,	as	
well	 as	 compatibility	 with	 inorganic	 rhodium-based	 catalysts	 for	 cofactor	
regeneration.108,109		
1.2.4 Alcohol	dehydrogenase	from	Thermus	sp.	ATN1	(TADH)		
Zinc-dependent	ADH	from	Thermus	sp.	ATN1	was	initially	reported	in	2001110	and	was	
shown	 to	be	highly	 thermostable	 (up	 to	90	 oC).108	 The	enzyme	was	expressed	and	
purified	 from	 E.	 coli	 and	 displayed	 a	 broad	 substrate	 range,	 including	 alcohols	
(primary,	 secondary	 and	 cyclic),	 aldehydes	 and	 ketones	 (acyclic	 and	 cyclic),	with	 a	
preference	 for	 primary	 alcohols	 and	 their	 corresponding	 aldehydes.	 Excellent	
activities	 towards	 cyclohexanone	 and	 its	 derivatives	 (Figure	 1.31)	 have	 also	 been	
observed.109	TADH	exclusively	 follows	Prelog’s	 rule,	catalysing	the	 formation	of	 (S)-
alcohols.		
R1 R2
O
R1 R2 R1 R2
OH OHTbADH
NADPH
(R)-alcohol (S)-alcohol
or
Prochiral
ketone
R1= CH3; R2= CH(CH3)2, C2H5, 
cyclo-C3H5
[R1= CF3; R2= Ph]a
[R1= Cl-CH2-; R2= CH2-CO2Et]a
R1= CH3; R2= n-C3H7, C=CH, 
CH2-CH(CH3)2, (CH2)3-Cl,        
n-C5H11, (CH2)5-Cl
R1= C2H5; R2= n-C3H7,           
(CH2)2-CO2Me, (CH2)5-Cl
R1= n-C3H7; R2= n-C3H7
44-94 % ee 79-99 % ee
36	
	
	
Figure	 1.31.	 Substrate	 scope	 of	 TADH	 as	 reported	 by	 Höllrigl	 et.	 al.	 (2008).109	 a)	 In	 the	 oxidative	
direction	displaying	the	relative	activity	as	a	percentage	of	cyclohexanol	(100	%,	20.8	U	/	mg);	b)	In	the	
reductive	direction	displaying	the	relative	activity	as	a	percentage	of	cyclohexanone	(100	%,	15.1	U	/	
mg).	
TADH	was	 also	 shown	 to	 exhibit	 tolerance	 towards	water-miscible	 and	 immiscible	
organic	solvents.	Octane	and	hexane	(50	%	v	/	v)	were	shown	to	act	as	substrate	/	
product	sinks	in	two	phase	systems,	while	acetone	could	be	used	both	as	sacrificial	
substrate	 in	 regeneration	 systems,	 or	 as	 a	 solubiliser	 to	 increase	 substrate	
availability.109		
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Hollmann	 and	 co-workers	 studied	 the	 interaction	 between	 TADH	 and	 the	
[Cp*Rh(bpy)(H2O)]2+	 catalyst,	which	 can	be	used	 for	 cofactor	 regeneration.111	 They	
found	that	TADH	could	bind	up	to	4	equivalents	of	 the	catalyst	without	detectable	
decrease	in	catalytic	activity	and	stability,	whilst	higher	molar	ratios	led	to	inactivation	
of	the	enzyme.		
The	crystal	 structure	of	TADH	was	 recently	 solved	 (PDB	 ID	4CPD),	and	 showed	 the	
occurrence	of	the	catalytic	and	structural	zinc-binding	sites.	Similar	to	other	bacterial	
ADHs,	 such	 as	 TbADH,	 the	 catalytic	 zinc	 is	 bound	 in	 a	 tetrahedral	 coordination	 to	
Cys38,	His59	and	Asp152,	as	well	as	a	water	molecule	as	the	fourth	ligand.	While	the	
structural	zinc	ion	is	bound	by	four	cysteines	at	positions	89,	92,	95	and	103.	TADH	is	
a	homotetrameric	structure	(subunits	A-D),	each	monomer	containing	347	residues,	
which	can	also	be	observed	as	two	dimers	due	to	the	close	association	of	A	with	B	and	
C	 with	 D.	 There	 are	 numerous	 interactions	 between	 subunits,	 along	 with	 a	 high	
number	of	prolines	and	condensed	surface	loops	in	its	structure,	which	are	all	features	
attributed	 to	 increased	 thermostability,	 as	 is	 seen	with	 TADH	displaying	 activity	 in	
temperatures	up	to	90	oC	and	in	some	organic	solvents.109		
1.2.5 Use	of	NADH	mimics	with	alcohol	dehydrogenases		
To	avoid	the	use	of	expensive	cofactors	in	biocatalysis,	cofactor	regeneration	systems	
have	 been	 developed.112-114	 In	 a	 different	 approach,	 mimics	 of	 the	 nicotinamide	
cofactors	 have	 been	 synthesised,	 and	 their	 use	 was	 demonstrated	 with	 certain	
NAD(P)H-dependent	reductases.		
Fish	 and	 co-workers	 reported	 the	 use	 of	 1-benzylnicotinamide	 9r	 and	 of	 β-
nicotinamide-5’-ribose	methyl	phosphate	10r	 (Figure	1.32)	 instead	of	NADH	during	
reduction	of	ketones	by	HLADH.115	These	structures	 led	to	high	enantioselectivities	
and	conversions	of	the	selected	ketone	substrates,	in	combination	with	HLADH	and	a	
chemical	 regeneration	 system	based	on	a	 rhodium-bipyridine	complex	and	 sodium	
formate	.	
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Figure	1.32.	Use	of	NADH	mimics	for	the	HLADH-catalysed	reduction	of	ketones.		9r	and	10r	refer	to	
the	reduced	for	of	NAD+	mimics	9	and	10	discussed	in	section	4.4.2.	
The	results	obtained	with	the	NADH	mimics	were	similar	to	the	results	with	the	natural	
cofactor.	Thus,	the	authors	suggested	that	the	binding	of	the	mimics	to	ADH,	resulting	
in	production	of	 the	desired	 chiral	 alcohol,	was	 similar	even	 in	 the	absence	of	 the	
adenosine,	pyrophosphate	or	ribose	functions	of	NADH.	Any	doubts	that	activity	was	
due	 to	 residual	 binding	 and	 recycling	 of	 NADH	were	 dismissed	 in	 a	 recent	 report,	
displaying	thoroughly	performed	controls,116	showing	that	only	racemic	alcohol	was	
detected	in	the	absence	of	reduced	analogues	9r	and	10r.	
Hollmann	 and	 co-workers	 also	 used	 compound	 9r	 and	 its	 derivatives	 as	 synthetic	
nicotinamide	 cofactors	 for	 enoate	 reductases,	 which	 depend	 on	 both	 FMN	 and	
NADH.116		
1.2.6 Exchange	of	zinc	for	other	metals	in	alcohol	dehydrogenases	
Successful	metal	exchange	was	reported	for	two	metal-dependent	ADHs:	HLADH	and	
TbADH.	 Metals	 other	 than	 Zn	 were	 used	 as	 spectroscopic	 probes	 instead	 of	 the	
spectroscopically	“invisible”	Zn(II)	ion,	as	well	as	to	investigate	their	influence	on	the	
kinetics	of	the	catalytic	mechanism.	The	catalytic	zinc(II)	ion	of	HLADH	was	replaced	
with	a	series	of	first	row	transition	metals,	and	the	resulting	properties	of	the	enzyme	
were	 examined.	 These	 metals	 include	 Co(II),117	 Ni(II),118	 Cu(I)	 and	 (II),119	 Fe(II),120	
Mn,121	as	well	as	a	second	row	transition	metal,	Cd(II).	Bogin	et	al.	reported	the	effects	
of	 exchanging	 the	 zinc	 ion	 for	 V(III),	Mn(II),	 Co(II),	 Cu(II)	 and	 Cd(II)	 on	 the	 TbADH	
structure	and	enzymatic	properties.122	
X-ray	 crystallographic	 studies	 of	 HLADH	 variants	 substituted	 with	 Co,	 Ni	 and	 Cd	
showed	that	the	overall	active	site	and	protein	structure	were	essentially	preserved,	
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maintaining	a	tetrahedral,	or	in	the	case	of	the	cadmium(II)	ion,	a	distorted	tetrahedral	
geometry	with	 the	 binding	 ligands,	 Cys46,	His67,	 Cys174	 and	 a	water	molecule.123	
Some	of	the	original	catalytic	activity	was	also	maintained	when	ethanol	was	used	as	
substrate.	 Substrate	 binding	 and	 activation	 investigations	 with	 trans-4-(N,N-
dimethylamino)cinnamaldehyde	 (DACA)	 revealed	 that	both	 the	dissociation	 rate	of	
DACA	and	the	hydride	transfer	rate	constant	were	correlated	with	the	expected	Lewis	
acidities	 of	 investigated	 metals,	 in	 the	 order	 Co(II)	 >	 Ni(II)	 ≥	 Zn(II)	 >>	 Cd(II).	 This	
indicated	 that	 the	 different	 catalytic	 behaviours	 observed	were	 a	 reflection	 of	 the	
different	 chemical	 properties	 of	 the	 metal	 ion	 introduced	 at	 the	 active	 site,	
emphasising	its	importance	on	the	kinetics	of	catalysis.	
In	support	of	the	above	conclusion,	replacement	of	the	zinc	ion	in	TbADH	with	Mn(II)	
and	 Co(II)	 resulted	 in	 enhanced	 activity	 (245	 %	 and	 130	 %	 of	 the	 initial	 activity,	
respectively),	 whilst	 replacement	 with	 Cd(II),	 Cu(II)	 and	 V(III)	 resulted	 in	 reduced	
activity	(20	%	for	Cd	and	<5	%	of	the	initial	activity	for	Cu	and	V).	These	results	were	
explained	by	 the	 Lewis	 acidity	 of	 the	metals	 in	 the	 tetrahedral	 coordination.124	 To	
further	understand	the	increase	in	native	activity,	the	authors	investigated	the	local	
structure	and	electronics	at	the	catalytic	cobalt	site	using	X-ray	absorption	(XAS)	and	
quantum	chemical	calculations.	The	data	provided	was	consistent	with	an	octahedral	
coordination	at	 the	metal	 active	 site	 in	Co-TbADH,	with	 the	 two	additional	 ligands	
believed	to	be	water	molecules.	Using	DMSO	as	a	substrate	model,	it	was	found	that	
the	coordination	number	remained	as	six	when	the	substrate	analogue	was	bound,	
with	 a	 small	 variation	 in	 the	 bond	 lengths	 between	 the	 zinc	 site	 with	 bound	 and	
unbound	 substrate	 (Figure	1.33).	 This	 change	 in	bond	 length	may	 result	 in	a	 slight	
conformational	 change	 upon	 substrate	 binding,	 resulting	 in	 a	 more	 favourable	
position	 for	 catalysis.	 It	 was	 suggested	 that	 the	 higher	 coordination	 number	 was	
directly	 correlated	with	 the	 higher	 reactivity	 seen	with	 Co-TbADH.	 This	 hypothesis	
could	also	explain	the	increased	activity	seen	with	Mn-TbADH,	as	manganese	tends	to	
coordinate	octahedrally	in	proteins.		
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Figure	 1.33.	 Hypothesised	 geometry	 of	 the	 catalytic	 metal	 site	 in	 Co-TbADH.	 Reproduced	 from	
Kleifield	et	al.	(2004).124	
Furthermore,	 the	 same	 group	 also	 suggested	 oxidation	 to	 Co3+	 due	 to	 the	
accumulation	of	additional	positive	charge	from	the	octahedral	coordination	at	the	
catalytic	site	DMSO	was	found	to	induce	a	distinct	change	in	the	catalytic	zinc	charge	
in	 native	 TbADH,	 which	 correlated	 to	 the	 formation	 of	 a	 pentacoordinated	
intermediate	 during	 catalysis.	Whereas	 in	 Co-TbADH,	DMSO	binding	 did	 not	 cause	
such	 changes,93	 suggesting	 it	 remained	 in	 an	 octahedral	 coordination	 throughout	
catalysis,	 displacing	 one	 of	 the	 ligands	 rather	 than	 adding	 as	 an	 extra	 ligand,	 as	
observed	 with	 Zn-TbADH.	 It	 has	 been	 proposed	 by	 this	 group	 that	 the	 additional	
positive	charge	found	with	cobalt	substitution	stabilised	the	catalytic	transition	state	
and	consequently	lowered	the	barrier	for	catalysis.117,125		
1.3 Enzyme	engineering	for	promiscuous	reactivity		
1.3.1 Background		
Enzymes	are	of	great	interest	for	applications	in	industrial	chemical	transformations,	
due	to	their	high	selectivity	and	efficiency	under	mild	reaction	conditions.	However,	
they	are	usually	limited	to	their	natural	substrates,	or	variations	of	these.	Promiscuous	
reactivities	are	rare,	in	which	transformations	that	are	completely	different	from	the	
native	 reactivity	 are	 catalysed	by	 enzymes.126	 Protein	 engineering	methods	 can	be	
applied	to	expand	the	reactivity	scope	of	existing	biocatalysts.	
	
His59
9	
Substrate	
H2O	
H2O	
	
	
	
	
Cis37
Asp150
9	
	 His59	
41	
	
Some	 enzymes	 naturally	 display	 reaction	 promiscuity.	 For	 example,	 Candida	
antarctica	lipase	B	(CALB)	has	been	observed	to	catalyse	an	array	of	transformations,	
in	 addition	 to	 its	 native	 hydrolysis	 and	 transacylation	 reactions.	 These	 additional	
reactivities	 include	 aldol	 additions,	 conjugate	 additions,	 epoxidations,	 Mannich	
reactions	and	Markovnikov	additions	which	proceed	through	different	transition	state	
geometries	and	reaction	mechanisms.		
In	contrast	to	altering	the	reactions	conditions	to	coax	reaction	promiscuity,	a	lot	of	
effort	has	gone	into	the	re-design	of	enzymes	to	induce	new	or	promiscuous	activities.	
This	 was	 accelerated	 by	 the	 tremendous	 advances	 in	 molecular	 biology,	
bioinformatics,	computational	modelling	and	protein	engineering	observed	in	the	past	
two	 decades.	 Genetic	modification	 at	 enzymatic	 active	 sites	 can	 be	 performed	 by	
rational	 design	 or	 directed	 evolution,	 to	 allow	 acceptance	 of	 new	 substrates	 and	
consequently	new	reactivities.	For	example,	replacement	of	an	active	site	alanine	with	
a	histidine	in	human	glutathione	transferase	(hGST	A1-1,	EC	2.5.1.18)	transformed	a	
transferase	into	a	hydrolase.127,128		
The	approach	highlighted	above	relies	on	an	existing	protein	scaffold,	suitable	for	the	
re-design	exclusively	by	genetic	modifications.	A	different	method	 involves	a	 semi-
synthetic	enzyme	design,	by	attachment	of	a	synthetic	transition	metal	catalyst	into	a	
protein	 scaffold,	 affording	 novel	 reactivities.	 These	 hybrid	 catalysts	 are	 known	 as	
artificial	metalloenzymes.		
1.3.2 Artificial	metalloenzymes		
1.3.2.1 General	features	
The	creation	of	artificial	metalloenzymes	(AMs)	has	emerged	in	the	past	decade	as	a	
hybrid	 of	 homogeneous	 and	 enzymatic	 catalytic	 approaches,129-131	 encompassing	
advantages	of	 the	 traditional	methods	 thus,	merging	 “the	best	 of	 both	worlds.”132	
They	rely	on	 the	 incorporation	of	a	catalytic	metal	complex	 into	a	macromolecular	
host,	such	as	a	protein.129	The	protein	host	acts	as	a	chiral	scaffold	and	is	therefore	
responsible	 for	 inducing	high	enantioselectivity	and	 for	allowing	 the	reaction	 to	be	
carried	 out	 in	 aqueous	 solution.	 The	metal	 catalyst	 determines	 the	 reactivity	 and	
reaction	 scope,	 allowing	 performance	 of	 non-natural	 reactions	 in	 a	 protein	 host.	
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Another	 benefit	 is	 the	 ease	 of	 modification	 of	 these	 artificial	 metalloenzymes	 by	
chemical	 (spacers,	 ligands,	 etc.)	 or	 genetic	 means	 (rational	 design	 or	 directed	
evolution)	approaches,	thus	allowing	the	AMs	to	be	rapidly	optimised	for	a	particular	
reaction.	
One	of	the	first	artificial	metalloenzymes	was	developed	by	Whitesides	and	Wilson	in	
the	late	1970s.133	They	performed	asymmetric	hydrogenation	of	alkenes	with	a	hybrid	
catalyst	 based	on	 a	 biotinylated	 rhodium	 complex	 incorporated	 into	 avidin	 (Figure	
1.34).	
	
Figure	 1.34	 Asymmetric	 hydrogenation	 of	 functionalised	 alkenes	 using	 Whitesides	 biotin-avidin	
system.133		
Whilst	organic	cofactors	have	been	introduced	into	protein	scaffolds	as	catalysts,134		
the	introduction	of	metal	complexes	has	proved	to	be	the	most	successful.	This	is	due	
to	the	reactivities	associated	with	transition	metals,	which	can	be	honed	with	change	
in	oxidation	states,	ligands,	geometrical	structures	or	change	in	metal	ion.	However,	
this	approach	is	limited	by	the	number	and	location	of	binding	sites	available	to	bind	
a	metal	complex	inside	a	protein.	Nevertheless,	it	is	possible	to	create	artificial	binding	
sites,	using	chemical	or	genetic	protein	modifications	to	introduce	non-natural	amino	
acids	or	completely	artificial	ligands	at	desired	positions.135-138		
Metal	catalysts	can	be	attached	to	the	protein	via	three	different	modes	of	anchoring:	
dative,	 covalent	 or	 non-covalent	 (supramolecular).	 Dative	 anchoring	 is	 the	 direct	
coordination	of	the	metal	to	amino	acid	side	chains,	and	usually	implies	the	existence	
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Figure	 1.35.	 General	 design	 of	 artificial	 metalloenzymes	 illustrating	 the	 different	 anchoring	
strategies.129	a)	dative,	b)	covalent	and	c)	non-covalent.		
of	a	defined	binding	site	within	the	protein	scaffold.129	This	strategy	usually	consists	in	
the	 removal	 of	 the	 catalytic	 active	 metal	 from	 an	 existing	 metalloenzyme	 and	
replacing	 it	 with	 a	 different	 metal	 ion,	 in	 order	 to	 enhance	 current	 activity	 or	 to	
introduce	 a	 new	 reactivity	 (see	 section	 1.4.2.2).	 Covalent	 anchoring	 involves	 the	
covalent	binding	of	a	catalytic	complex	to	a	uniquely	reactive	amino	acid,	such	as	a	
cysteine,	within	the	protein	host.	For	example,	Kamer	and	co-workers	developed	a	
highly	efficient	method	for	selective-cysteine	bioconjugation	of	phosphine	ligands	for	
attachment	of	a	rhodium	phosphine	complex.139	The	non-covalent	or	supramolecular	
approach	consists	of	the	binding	of	the	metal	complex	to	the	protein	via	hydrogen	
bonding,	hydrophobic	or	electrostatic	interactions.	An	exciting	example	of	this	is	the	
incorporation	 of	metalloporphyrins	 containing	 the	 non-native	 Ir	 metal	 into	 heme-
dependent	proteins,	leading	to	the	catalysis	of	carbene	insertions	into	C-H	bonds.140	
Another	 supramolecular	 approach	 consists	 in	 linking	 a	 completely	 synthetic	metal	
complex	to	a	cofactor	with	affinity	for	the	protein	host.	The	biotin-streptavidin	system	
is	one	of	the	most	successful	examples	of	this	strategy.141-143		
1.3.2.2 Introduction	of	non-native	metals	in	existing	metal-binding	sites		
Substitution	of	an	existing	metal	by	a	non-native	one	has	been	shown	to	change	the	
reactivity	of	metalloenzymes.	One	of	the	earliest	examples	was	provided	by	Kaiser	in	
1976,	 who	 reported	 the	 oxidation	 of	 ascorbic	 acid	 using	 a	 Cu(II)	 substituted	
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carboxypeptidase	A	(Cu2+-CPA).144,145	In	2002,	Bakker	et	al.	reported	the	oxidation	of	
thioanisole	with	hydrogen	peroxide,	employing	a	 thermolysin	variant	 in	which	 zinc	
was	replaced	with	much	larger	anions	(molybdate,	selenate	or	tungstate).146	However,	
it	wasn’t	until	2006	that	metal-substituted	artificial	metalloenzymes	were	developed	
to	perform	enantioselective	reactions.	The	groups	of	Kazlauskas147	and	Soumillion148	
both	 reported	 the	 replacement	 of	 the	 native	 zinc	 with	 manganese	 in	 carbonic	
anhydrase,	 a	 metalloenzyme	 which	 catalyses	 the	 hydration	 of	 carbon	 dioxide	 to	
bicarbonate.	 The	 substitution	 for	 manganese	 transformed	 this	 enzyme	 into	 an	
enantioselective	peroxidase,	displaying	a	 similar	or	enhanced	enantioselectivity	 for	
the	epoxidation	of	styrenes	and	olefins	in	comparison	with	natural	peroxidases.		
Kazlauskas	and	co-workers	also	reported	the	successful	exchange	of	 the	active	site	
zinc	 ion	 in	 human	 carbonic	 anhydrase	 (hCA)	 for	 a	 rhodium.	 The	 exchange	 was	
performed	by	dialysis	with	a	zinc	chelator,	2,6-pyridinedicarboxylate	(dipicolinic	acid),	
resulting	in	apo-hCA	with	5-10	%	remaining	active	site	zinc,	followed	by	subsequent	
dialysis	against	a	rhodium	salt,	to	give	the	Rh-hCA	enzyme.	In	a	first	report,	the	authors	
used	[Rh(COD)2]BF4,	which	was	reported	to	avoid	protein	precipitation,	and	obtained	
hCA	containing	a	6.5-fold	excess	of	Rh.149	Both	chemical	and	genetic	modifications	
were	used	to	remove	the	binding	of	Rh	to	surface	histidines	and	greatly	reduced	the	
amount	 of	 additional	 bound	 rhodium	 to	 2.3	 and	 1.8,	 respectively.	 These	 rhodium	
carbonic	 anhydrase	 complexes	 showed	 selectively	 reduced	 cis-stilbene	 over	 trans-
stilbene.	 In	 a	 subsequent	 report,	 the	 same	 authors	 reported	 an	 improved	 Rh-hCA	
variant,	with	only	0.4	extra	Rh	equivalents,	when	[Rh(CO)2(acac)]	was	used	as	metal	
precursor.150	The	majority	of	the	rhodium	was	bound	by	three	histidines	at	the	active	
site,	assuming	a	tetrahedral	geometry,	with	a	water	molecule	as	the	fourth	ligand.	This	
Rh(I)-hCA	adduct	catalysed	the	regioselective	hydroformylation	of	styrene,	with	up	to	
8.4-fold	selectivity	for	linear	over	branched	product	(Figure	1.36).		
More	recently,	the	groups	of	Hartwig150	and	Piazzetta151	also	reported	their	studies	on	
the	incorporation	of	iridium	and	of	rhodium	into	human	carbonic	anhydrase,	and	its	
applications.	 Hartwig	 reported	 the	 characterisation	 of	 organometallic	 fragments	
bound	to	hCA,	following	treatment	of	the	apo	enzyme	lacking	three	surface	histidines	
with	[Rh(NBD)2]BF4,	[Rh(CO)2(acac)]	and	[Ir(CO)2(acac)].	NMR,	IR,	UV-Vis	and	EXAFS	
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Figure	1.36.	Regioselective	hydroformylation	of	styrene	catalysed	by	a	human	carbonic	anhydrase	II	
mutant,	incorporating	Rh(I)	catalyst.	
spectroscopy	were	used	to	characterise	the	discrete	organometallic	fragments	at	the	
metal-binding	site,	and	it	was	suggested	that	these	fragments	were	not	responsible	
for	catalysis.	On	the	other	hand,	theoretical	calculations	reported	by	Piazzetta	et	al.	
suggested	 that	 Rh(I)	 bound	 at	 the	 active	 site	 of	 hCAII	 could	 catalyse	 the	 direct	
hydrogenation	of	CO2	to	formic	acid.	
1.3.2.3 Artificial	metalloenzymes	for	enantioselective	imine	reduction		
The	best	hybrid	catalytic	systems	reported	so	 far	 for	 the	reduction	of	 imines	come	
from	the	group	of	Ward	and	co-workers.	They	initially	reported	on	biotin-streptavidin	
catalysts	 containing	 Noyori-type	 complexes	 for	 ketone	 transfer	
hydrogenation.141,152,153	 These	 were	 later	 demonstrated	 to	 be	 effective	 for	 the	
enantioselective	reduction		
	
Figure	1.37.	Artificial	metalloenzyme	based	on	biotin-streptavidin	technology	for	 imine	reduction.	
Modified	from	Duerrenberger	et	al.	(2011).154		
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of	imines.154	The	group	identified	that	a	biotinylated	iridium	piano	stool	complex	[(ɳ5-
Cp*)Ir(Biot-p-L)Cl]	 incorporated	 into	 different	 mutants	 of	 streptavidin	 at	 the	 112	
position	produced	both	the	(R)-	and	(S)-	enantiomers	of	salsolidine	(Figure	1.37),	with	
high	ee’s	(98	%	and	78	%,	respectively),	employing	formate	as	the	hydrogen	source.	
This	reaction	was	optimised	by	two	different	approaches.	The	first	consisted	of	the	
introduction	of	an	appropriately	positioned	histidine,	which	was	used	to	reinforce	the	
anchoring	of	 the	 iridium	metal	 complex	within	 the	active	 site	via	 a	dative	bond	as	
shown	in	Figure	1.38.142	Secondly,	they	investigated	the	genetic	optimisation	of	this	
system,	with	introduction	of	lipophilic	amino	acids	around	the	active	site,	resulting	in	
an	8-fold	increase	in	catalytic	efficiency	compared	with	the	wild	type	artificial	imine	
reductase.		
	
Figure	1.38.	Dual	anchoring	strategy	based	on	biotinylated	piano	stool	catalysts	 incorporated	 into	
streptavidin.	Reproduced	from	Zimbron	et	al.	(2013).142	
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Ward	and	co-workers	also	investigated	the	use	of	human	carbonic	anhydrase	II	(hCA	
II)	in	combination	with	iridium	piano-	tool	complexes	for	imine	reduction.	In	this	case,	
aryl	sulphonamide	inhibitors,	known	to	bind	with	high	affinity	to	hCA	II,	were	used	as	
anchors	 for	 the	 metal	 catalysts	 (Figure	 1.39).	 These	 presented	 lower	 turnover	
numbers	 in	contrast	 to	the	streptavidin	systems.	Nonetheless,	 incorporation	of	 the	
iridium	complex	into	the	hCA	II	provided	a	significant	improvement	in	catalytic	activity	
and	selectivity	(up	to	68	%)	in	comparison	to	the	free	catalysts,	in	which	only	racemic	
mixtures	were	available.155			
	
Figure	 1.39.	 Artificial	 imine	 transfer	 hydrogenase	 based	 on	 aryl-sulfonamide	 functionalised	 Ir-
complexes	incorporated	into	human	carbonic	anhydrase	II.	Reproduced	from	Monnard	et	al.	(2013).155	
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Chapter	2 Aim	and	objectives		
The	literature	review	highlighted	the	importance	of	the	enantioselective	reduction	of	
carbon-nitrogen	double	bonds,	as	an	efficient	route	to	chiral	secondary	amines.	The	
need	for	more	sustainable	methods	led	to	successful	recent	discoveries,	and	a	number	
of	imine	reductases	were	developed	as	efficient	biocatalysts	for	this	transformation.	
However,	their	activities	are	still	low,	and	the	substrate	scope	is	limited.		
Given	 the	 chemical	 similarity	 between	 ketone	 and	 imine	 substrates	 and	 their	
enzymatic	reduction	mechanisms,	it	is	surprising	that	no	ADHs	have	been	shown	to	
catalyse	 the	 reduction	 of	 imines.	 Several	 reasons	 can	 be	 identified	 for	 this.	 Imine	
substrates	or	 amine	products	might	 inhibit	ADHs,	 as	a	 result	of	 the	 strong	binding	
between	nitrogen	and	the	catalytic	zinc.	Imine	size	and	shape	may	also	be	an	issue,	
due	to	the	extra	substituent	bound	to	the	nitrogen	atom.	Finally,	imine	instability	in	
aqueous	 media	 may	 result	 in	 hydrolysis	 of	 the	 substrate	 being	 faster	 than	 the	
reduction.		
In	contrast	to	IREDs,	ADHs	have	a	broader	substrate	range,	many	of	them	employ	the	
cheaper	cofactor	NADH,	and	thermostable	enzymes	have	been	discovered,	which	also	
show	organic	 solvent	 tolerance.	Therefore,	 they	 represent	good	 starting	points	 for	
engineering	of	reaction	promiscuity	towards	imine	reduction.	
The	overall	aim	of	this	thesis	is	to	engineer	a	thermostable	ADH	in	order	to	introduce	
imine	reductase	activity,	by	exploring	different	modes	of	substrate	activation.	The	first	
approach	consists	of	mimicking	the	active	site	of	current	IREDs,	by	introducing	a	protic	
residue	in	place	of	the	catalytic	zinc.	The	second	approach	is	to	chemically	modify	the	
zinc-binding	site,	by	incorporating	a	Rh(I)	ion	in	place	of	the	active	site	zinc(II)	in	an	
effort	 to	 replicate	 the	 imine	 activation	mechanism	of	 chemical	 catalysts.	 The	 third	
strategy	is	to	introduce	a	synthetic	catalyst	into	the	TADH	active	site,	by	anchoring	it	
to	a	NADH	mimic,	previously	reported	to	occupy	the	NADH-binding	site	in	horse	liver	
ADH.	For	each	of	these	approaches,	the	objectives	are	outlined	below.		
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1) Genetic	engineering	of	the	TADH	active	site	for	imine	reduction	
This	 objective	 involves	 replication	 of	 the	 IRED	 active	 site	 within	 an	 ADH,	 by	
replacement	of	the	catalytic	zinc	ion	with	an	aprotic	residue	situated	within	range	of	
substrate	 interaction.	First,	the	choice	of	the	thermostable	TADH	from	Thermus	sp.	
will	 be	 justified,	 and	 reliable	methods	 for	 its	 expression	 in	E.	 coli,	 purification	 and	
enzymatic	 assay	will	 be	 developed,	 based	 on	 literature	 reports.	 The	 interaction	 of	
TADH	with	imines	will	be	characterised,	and	this	will	be	performed	by	experimental	
(inhibition	studies)	and	computational	(docking)	methods.	Based	on	the	comparison	
between	ADH	and	IRED	active	sites,	mutants	devoid	of	catalytic	zinc	and	containing	a	
protic	residue	will	be	designed,	produced	and	tested	for	IRED	activity.		
2) Replacement	of	the	catalytic	zinc	with	rhodium	in	TADH	
This	objective	involves	the	development	of	a	method	to	perform	the	replacement	of	
the	catalytic	zinc(II)	of	TADH	with	another	metal.	To	achieve	this,	studies	into	removal	
of	the	catalytic	zinc	will	be	performed,	to	create	the	apo-TADH.	Reinsertion	of	zinc(II)	
will	be	studied,	to	assess	whether	the	enzyme	can	be	reconstituted	with	full	activity	
and	metal	content.		Following	this,	reinsertion	of	other	metals,	such	as	Co(II)	and	Rh(I)	
will	 be	 tested:	 the	 first	 is	 aimed	 at	 comparing	 zinc	 exchange	 in	 TADH	 with	 other	
published	ADHs,	while	the	second	is	aimed	at	introducing	imine	reduction	activity,	in	
a	fashion	similar	to	synthetic	transition	metal	catalysts.	
3) Synthesis	of	an	artificial	metal-binding	site	for	TADH	
The	third	objective	involves	the	incorporation	into	TADH	of	a	metal-containing	catalyst	
capable	of	imine	reduction,	anchored	to	a	NAD+	analogue	with	affinity	for	the	enzyme.	
To	achieve	this,	a	transition	metal	catalyst	will	be	designed	and	synthesised,	and	its	
imine	 reduction	 activity	 will	 be	 tested	 in	 the	 presence	 and	 in	 the	 absence	 of	 the	
enzyme.	The	interaction	of	the	nicotinamide-functionalised	complex	with	TADH	will	
be	studied	by	inhibition	kinetics.	
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Chapter	3 Materials	and	Methods	
3.1 Materials	
All	chemical	reagents	unless	otherwise	stated	were	purchased	as	analytical	grade	from	
Sigma	Aldrich.	E.coli	BL21(DE3)	and	BL21(DE3)pLysS	competent	cells	and	Overnight	
Express™	Autoinduction	System	2	were	purchased	from	Novagen.	The	kits	for	protein	
concentration	assays:	Detergent	compatible	(DC)	assay	and	Bicinchoninic	acid	(BCA)	
assay	kit	were	purchased	from	Bio-Rad	Laboratories	Inc.	and	Pierce	respectively	(UK).	
NAD+,	 NADH	 and	 4-chloronicotinic	 acid	 were	 purchased	 from	 Apollo	 Scientific	 Ltd	
(UK).	 HiTrap	 Q	 Sepharose	 High	 Performance	 (5mL),	 HiLoad	 Superdex	 200	 and	
disposable	PD-10	desalting	columns	were	from	GE	Healthcare.	4-Bromonicotinic	acid	
was	purchased	 from	Key	Organics	 Ltd.	 (UK).	Water	was	purified	using	 the	Milli-Q®	
Reference	Water	Purification	System	from	Merck.	
The	pASZ2	plasmid,	harbouring	the	TADH	gene	on	a	derivative	of	the	pET11a	vector	
was	a	kind	donation	 from	Dr.	Frank	Hollmann,	Department	of	Biotechnology,	Delft	
University	 of	 Technology	 (Netherlands)	 and	 its	 construction	 was	 previously	
described.108	To	confirm	 its	 integrity,	 sequencing	was	performed	by	Eurofins	MWG	
Operon	(Germany),	results	shown	in	Appendix	1.	
3.2 Instruments		
Sterilisation	 of	 all	 media	 and	 flasks	 was	 performed	 using	 a	 Prestige	 Classic	 2100	
benchtop	autoclave	(Medstore	Medical)	at	an	operating	temperature	and	pressure	of	
121	oC	and	20	psi.	
New	Brunswick	Scientific	Innova	40	Incubator	Shakers	(Eppendorf),	Centrifuge	5810R	
(Eppendorf),	Avanti	J-26	XP	Centrifuge	(Beckman	Coulter)	and	One	Shot	Cell	Disruptor	
(Constant	Systems	Ltd.)	were	used	in	protein	expression.	
Protein	 chromatography	 was	 performed	 using	 an	 AKTA	 Fast	 Protein	 Liquid	
Chromatography	system	(GE	Healthcare)	and	monitored	by	absorbance	at	280	nm.		
Enzymatic	 activity	 was	 measured	 using	 UV	 mini-1240	 UV-VIS	 spectrophotometer	
(Shimadzu).	
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ICP-MS	 data	 was	 acquired	 on	 an	 iCAP-Q	 equipped	 with	 CCTED	 (collision	 cell	
technology	with	energy	discrimination,	Thermo-Fisher	Scientific),	with	the	help	of	Dr.	
Scott	Young	at	the	University	of	Nottingham,	Sutton	Bonington	Campus.	
NMR	spectra	were	recorded	at	298	K	using	a	Bruker	AV(III)400,	AV400,	DPX400	(400	
MHz	 1H	 frequency,	 100	 MHz	 13C	 frequency)	 or	 DPX300	 instrument	 (300	 MHz	 1H	
frequency,	 75	MHz	 13C	 frequency).	 Chemical	 shifts	 are	 quoted	 in	 parts	 per	million	
(ppm),	 referenced	 to	 the	 residual	 deuterated	 solvent	 quoted	 in	 text	 as	 internal	
standard.	 Coupling	 constants	 J	 are	 quoted	 in	 Hz.	 Multiplicity	 of	 each	 signal	 is	
designated	with	the	following	abbreviations:	s,	singlet;	d,	doublet;	t,	triplet;	q,	quartet;	
m,	multiplet;	app,	apparent;	br,	broad.	In	the	13C	spectra,	signals	corresponding	to	C,	
CH,	CH2	and	CH3	were	assigned	from	DEPT	experiments.	Mass	spectra	were	recorded	
on	a	Bruker	MicroTOF	61	mass	spectrometer	using	electrospray	ionisation	(ESI).	
3.3 Computational	techniques	
Protein	 sequences	 for	 IREDs	and	ADHs	were	obtained	 from	 the	RCSB	Protein	Data	
Bank	and	were	compared	via	sequence	alignment	performed	using	the	Clustal	Omega	
programme	 (http://www.ebi.ac.uk/Tools/msa/clustalo/).	 All	 protein	 3D	 structures	
were	extracted	from	the	RCSB	Protein	Data	Bank	(http://www.rcsb.org).		
The	proteins	used	were:		
TADH	from	Thermus	sp.	ATN1,	EC	1.1.1.1,	PDB	ID	4CPD,	(2.70	A	̊).		
IREDs:	Q1EQE0	from	Streptomyces	kanamyceticus,	EC	1.5.1,	PDB	ID	3ZHB,	(2.73	A	 ̊);	
from	Streptomyces	 sp.	GF3546	PDB	 ID	 4OQY,	 (1.90	A	 ̊);	 and	BcSIRED	 from	Bacillus	
cereus	BAG3X2,	EC	1.5.1.3,	PDB	ID	4D3D,	(1.71	A	̊).		
Superimposition	of	the	structures	was	executed	using	LigAlign,		treating	the	cofactors	
NADH	and	NADPH	as	ligands.	Automated	docking	of	organic	substrates	within	TADH	
was	performed	using	AutoDock	Vina.156	 Imines	were	prepared	using	Chemdraw	3D	
and	BIOVINA	Discovery	Visualiser.	The	appropriate	pdbqt	files	for	the	dimeric	model	
of	TADH	and	the	 ligands	were	prepared	by	using	Autodock	tools.	The	active	site	of	
TADH	was	contained	in	a	grid	size	of	28	A	̊	×	34	A	̊	×	26	A	̊	with	1	A	̊	spacing,	ce
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around	the	catalytic	centre	at	positions	23.44	A	̊	×	12.69	A	̊	×	106.06	A	̊	(corresponding	
to	 x,	 y,	 z),	 which	 was	 generated	 using	 AutoGrid	 in	 the	 Autodock	 Tools	 interface.	
Substrates	were	flexibly	docked,	while	the	protein	receptor	was	kept	rigid	performed	
by	VINA.	Results	were	visualised	using	Autodock	Vina	and	Pymol.	
3.4 Expression,	purification	and	characterisation	of	TADH	
3.4.1 General	methods	
Media	components	were	sterilised	by	autoclaving	(121	°C,	20	min,	20	psi),	or	where	
stated	in	the	text	by	filtration	(0.2	μm	filter),	and	mixed	when	cooled.	Media	solutions	
were	 prepared	 in	 deionised	water	 (dH2O)	 and	 stored	 at	 room	 temperature	 unless	
otherwise	 stated.	Where	 solid	medium	was	 required,	 agar	 (Melford;	 15	 g	 /	 L)	was	
added	to	the	medium	prior	to	autoclaving.	Antibiotics	were	prepared	as	a	1000	times	
concentrate	of	the	working	concentration:		chloramphenicol	solutions	(34	mg	/	mL)	
were	 prepared	 in	 ethanol	 (100	%)	 and	 carbenicillin	 (50	mg	 /	mL)	was	 prepared	 in	
water,	filter	sterilised	and	stored	at	-20	°C.		
E.	coli	BL21(DE3)	or	BL21(DE3)	pLysS	cells	were	transformed	with	the	pASZ2	plasmid	
according	to	the	manufacturer’s	protocol.	Unless	otherwise	stated,	transformed	E.coli	
strains	were	generally	cultured	in	lysogeny	broth	(LB),	which	contained	LB	granulated	
medium	(25	g	/	L,	referring	to	a	mixture	of	10	g	/	L	NaCl,	10	g/	L	tryptone	and	5	g	/	L	
yeast	extract),	 supplemented	with	1	%	(w	/	v)	glucose.	When	cells	were	BL21(DE3)	
pLysS,	 growth	 and	 expression	 media	 contained	 carbenicillin	 (50	 µg	 /	 mL)	 and	
chloramphenicol	 (34	 µg	 /	 mL).	 When	 cells	 were	 BL21(DE3),	 the	 antibiotic	 was	
carbenicillin	(50	µg	/	mL).	All	cultivations	were	performed	in	Erlenmeyer	flasks,	with	
nominal	 volumes	 five	 times	 the	 culture	 volume,	 unless	 when	 1	 L	 expression	 was	
performed,	when	the	total	volume	of	the	flask	was	double	(2	L).	Strains	were	routinely	
stored	as	glycerol	stocks	at	-80	°C.	Glycerol	stocks	were	prepared	by	picking	a	single	
colony	of	the	strain	and	culturing	it	overnight	in	LB	supplemented	with	the	appropriate	
antibiotic	(100	mL).		
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The	pH	of	the	buffers	was	adjusted	after	supplementation	with	the	desired	additive,	
and	was	performed	once	the	solution	reached	the	desired	temperature	(4	oC,	25	oC	or	
60	oC).	
3.4.2 	Protein	expression	
An	overnight	pre-culture	was	prepared	by	inoculating	LB	medium	(10	mL)	with	glycerol	
stocks	 (20	μL)	 and	 incubating	 overnight	 at	 30	 oC.	Overnight	 cultures	were	 used	 to	
inoculate	fresh	LB	medium	(100	mL)	to	an	OD660	of	0.1-0.2	and	the	cultures	incubated	
at	30	oC,	160	rpm	until	OD660			̃1.0.	This	second	pre-culture	was	used	to	inoculate	the	
expression	culture	 (1	L),	which	was	grown	at	30	oC,	160	rpm	to	an	OD660	=	0.6-0.8.	
Expression	 was	 induced	 with	 isopropyl	 β-D-1-thiogalactopyranoside	 (IPTG)	 (final	
concentration	generally	0.4	mM,	otherwise	the	concentration	stated	in	the	text)	and	
cells	were	grown	overnight	at	30	oC,	160	rpm	to	an	OD660	of				̃4-5.	Cells	were	harvested	
by	centrifugation	(8500	rpm,	4	oC,	20	min)	and	stored	at	-80	oC.	
When	auto-induction	medium	was	used,	a	pre-culture	(20	mL)	previously	grown	in	LB	
medium	 to	 an	 OD660	 0.5-0.6	 from	 a	 cryostock	 was	 used	 to	 inoculate	 Overnight	
Express™	Autoinductive	System	2	medium	(200	mL)	containing	carbenicillin	(50	µg	/	
mL),	to	an	OD660	0.1.	The	culture	was	grown	at	37	oC,	300	rpm	for	24	hours.	Cells	were	
harvested	by	centrifugation	(8500	rpm,	4	oC,	20	min)	and	stored	at	-80	oC.	
3.4.3 Protein	purification		
The	harvested	cell	pellet	was	resuspended	in	20	mM	Tris	buffer	(pH	7.5),	benzonase	
nuclease	(0.1	µL	/	mL)	was	added,	and	the	cells	were	lysed	by	two	passages	through	
the	One	Shot	Cell	Disrupter	 (25	kpsi).	The	resulting	sample	was	centrifuged	(12000	
rpm,	4	oC,	20	min)	and	the	supernatant	was	heated	at	the	desired	temperature	(75	or	
80	oC)	for	the	specified	time	(15	or	20	min),	to	precipitate	most	of	the	cell	proteins.	
The	sample	was	centrifuged	(12000	rpm,	4	oC,	20	min)	and	the	supernatant	containing	
TADH	was	aliquoted	and	stored	at	-20	oC	or	subjected	for	further	purification	by	either	
anion	exchange	chromatography	(AEX)	or	size	exclusion	chromatography	(SEC).	
AEX	was	performed	using	a	HiTrap	Q	Sepharose	High	Performance	column	(5	mL).	The	
column	 was	 equilibrated	 with	 20	 mM	 Tris	 buffer	 pH	 7.5,	 the	 sample	 was	 loaded												
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(1-5	mg	/	mL,	up	to	10	mL)	and	the	protein	was	eluted	with	20	mM	Tris	buffer,	pH	7.5	
using	a	linear	gradient	from	0	to	1	M	NaCl.		
SEC	was	performed	using	a	HiLoad	Superdex	200	column,	which	was	equilibrated	with	
20	mM	Tris	buffer	pH	7.5,	the	sample	was	loaded	(1-5	mg	/	mL,	3-5	mL)	and	the	protein	
was	eluted	with	20	mM	Tris	buffer,	pH	7.5.		
Fractions	containing	pure	protein	(SDS-PAGE)	were	pooled	together,	concentrated	by	
ultrafiltration	using	Vivaspin	6	 (10	 kDa	MWCO)	 centrifugal	 concentrator,	 (Sartorius	
Stedim	Biotech),	subjected	to	protein	analysis	and	stored	at	-20	oC	until	further	use.	
3.4.4 Protein	concentration	
The	protein	content	of	the	expressed	TADH	was	determined	by	the	Bradford	assay	
(Pierce).	For	all	Bradford	assays	a	standard	curve	of	bovine	serum	albumin	(BSA)	was	
constructed	using	known	concentrations	of	BSA	(0.2-1.5	or	2	mg	/	mL),	and	formation	
of	adducts	determined	at	595	nm.	All	assays	performed	in	triplicate.	
A	typical	calibration	curve	is	shown	below	for	the	Bradford	assay.	
	
Figure	3.1.	Calibration	curve	for	the	Bradford	assay		
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A	typical	calculation	of	the	protein	concentration	of	a	sample	is	given	below.		
Sample:	5x	dilution	
Sample	absorbance:	A595	=	0.24	(within	calibration	range)	
Calibration	equation:	A595	=	0.4244	x	conc.	(mg	/	mL)	+	0.0345	
	 	 	 0.24	=	0.4244	x	conc.	(mg	/	mL)	+	0.0345	
	 	 									conc.	(mg	/	mL)	=	(0.24	-	0.0345)	/	0.4244	
	 	 	 	 	 	=	0.484	mg	/	mL	
Thus,	non-diluted	sample	concentration	=	0.484	x	5	
	 	 	 	 	 							=	2.4	mg	/	mL		
3.4.5 SDS-PAGE	analysis	
SDS-PAGE	was	used	to	analyse	protein	expression	and	purity.	Cell	samples	for	analysis	
were	taken	pre-induction	and	at	intervals	stated	in	the	text	post-induction.	The	OD660	
of	the	sample	was	measured	and	samples	(1	mL)	were	harvested	by	centrifugation	
(13400	rpm,	2	min).	The	supernatant	was	discarded	and	the	cell	pellets	were	frozen		
(-20	oC)	until	required.	Cell	pellets	were	resuspended	to	an	OD660	of	0.2	in	BugBuster	
lysis	 buffer	 (Novagen).	 BugBuster	 lysis	 buffer	 was	 supplemented	 with	 benzonase	
nuclease	(0.1	µL	/	mL).	Cell	suspensions	were	 incubated	with	gentle	shaking	(room	
temperature,	15	min)	and	the	cell	debris	removed	by	centrifugation	(13400	rpm,	10	
min).	Supernatant	(20	µL)	was	transferred	to	a	fresh	tube	containing	sample	buffer	
(20	µL)	and	the	remaining	supernatant	discarded.	The	cell	debris	was	resuspended	in	
potassium	phosphate	buffer	pH	7.0	(50	µL)	and	samples	(20	µL)	transferred	to	a	fresh	
tube	containing	sample	buffer	(20	µL).	Sample	buffer	contained	Laemmli	buffer	(Bio-
Rad)	and	5	%	(v	/	v)	β-mercaptoethanol	(β-ME).	Samples	were	heated	(105	oC,	5	min)	
and	stored	on	ice	until	required.	
Running	buffer	was	Tris	/	Glycine	/	SDS	(2.5	mM	Tris,	19.2	mM	glycine,	0.01	%	SDS,	pH	
8.3)	(Bio-Rad).	Gels	were	loaded	with	denatured	protein	(15	µL)	along	with	PageRuler	
Prestained	Protein	Ladder	(5	µL),	used	as	a	marker	and	run	at	150	volts	for	50	min.	
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Gels	used	12	%	Mini-PROTEAN®	TGX™	Precast	Protein	Gels,	12-well,	20	µl.	(Bio-rad)	
Staining	of	gels	was	performed	with	EzBlue	Stain	(Bio-Rad).	
3.4.6 Standard	enzymatic	assays	
3.4.6.1 Oxidation	assays	
The	enzymatic	activity	of	TADH	was	routinely	assayed	with	substrates	1-butanol	or	
cyclohexanol.	 The	 following	 standard	 procedure	 is	 outlined	 with	 1-butanol.	 Any	
variations	in	enzyme	assay	parameters	are	highlighted	in	the	Results.		
The	reagents	and	cell	compartment	of	the	spectrometer	were	kept	at	60°C	prior	to	
assay.	The	 following	 reagents	were	added	 to	a	1	mL	cuvette:	1-butanol	 (100	mM),	
enzyme	(10	µL,	3	µg)	and	up	to	1	mL	50	mM	Glycine-NaOH	buffer,	pH	9.0,	and	the	
absorbance	was	set	to	zero.	The	reaction	was	initiated	by	addition	of	NAD+	(1	mM),	
followed	by	mixing	of	the	reagents	with	a	1	mL	pipette,	in	the	cell	compartment	(at			
60	oC).	The	increase	of	absorbance	at	340	nm,	(due	to	the	formation	of	NADH)	was	
monitored.	For	all	enzymatic	assays	the	specific	activity	was	calculated	from	the	initial	
linear	 rate	 of	 reaction	 (up	 to	 the	 initial	 300	 s).	 For	 all	 enzymatic	 assays,	 a	 control	
reaction	was	performed	replacing	the	enzyme	with	50	mM	Glycine-NaOH	buffer,	pH	
9.0	 (10	µL)	 following	NADH	absorbance	at	340	nm,	no	 increase	 in	absorbance	was	
observed.	 A	 typical	 example	 of	 NADH	 absorbance	 increase	 during	 an	 oxidative	
enzymatic	assay	is	shown	below	in	Figure	3.2.		
	
Figure	3.2.	Initial	rate	of	reaction	for	an	enzymatic	assay	in	the	oxidative	direction	monitoring	NADH	
absorbance	at	340	nm	with	1-butanol	as	the	substrate:	()	control;	(l)	100	mM	1-butanol.	
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The	 absorbance	 readings	 for	 the	 initial	 rate	 of	 reaction	 were	 converted	 to	 NADH	
concentration	(Figure	3.3)	(mol	/	L)	using	the	Beer-Lambert	 law:	A	=	εlc,	where	A	=	
absorbance	at	340	nm;	ε	=	extinction	coefficient	(L	/	(mol.cm);	l	=	path	length	(cm)	and	
c	=	concentration	(mol	/	L).	The	extinction	coefficient	for	NADH	is	6220	L	/	(mol.cm)	
and	the	path	length	was	1	cm.	The	concentration	of	NADH	was	plotted	against	time	
(seconds)	and	a	line	of	best	fit	assigned.	The	equation	of	the	line	of	best	fit	was	then	
used	to	calculate	the	enzymatic	activity	(µmol	/	min)	of	the	sample	assayed.		
	
Figure	3.3.	Initial	rate	of	reaction	of	an	enzymatic	assay	in	the	oxidative	direction	plotted	as	NADH	
concentration	against	time.	
In	the	example	shown,	the	best	fit	line	equation	is	y	=	3.02x10-7	x	+	2.79x10-6,	where	
the	gradient	of	the	line	(3.02x10-7)	is	the	initial	rate:		
v0	=	∆[NADH]	/	∆time	in	mol	L-1	s-1.	
Enzymatic	activity,	EA	(µmol	.	mL-1.min-1)	=	vo	x	106	x	10-3	x	60	=	v0	x	60	000	
Following	from	the	previous	example	the	enzymatic	activity	is	calculated	as:	
EA	=	3.02x10-7	x	60	000	=	0.01812	µmol	.	mL-1	.	min-1	=	18.1	μM	/	min	
The	specific	activity	 (µmol	min-1	mg-1	or	U	mg-1)	was	calculated	 from	the	enzymatic	
activity	(µmol	mL-1	min-1)	for	the	volume	of	the	reaction	(1	mL)	divided	by	the	total	
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mass	of	protein	 in	 the	sample	 (mg).	 	From	the	previous	example	 the	 total	mass	of	
TADH	added	was	0.003	mg,	the	specific	activity	was	calculated	as:		
SA	=	(0.01812	x	1)	/	0.003	=	6.0	U	/	mg	
3.4.6.2 Reduction	assays	
The	enzymatic	activity	of	TADH	was	routinely	assayed	with	substrates	butyraldehyde	
or	cyclohexanone.	The	following	standard	procedure	is	outlined	with	butyraldehyde.	
Any	variations	in	enzyme	assay	parameters	are	highlighted	in	the	Results.		
The	reagents	and	cell	compartment	of	the	spectrometer	were	kept	at	60	°C	prior	to	
assay.	The	following	reagents	were	added	to	a	1	mL	cuvette:	butyraldehyde	(20	mM),	
enzyme	(10	µL,	1	µg)	and	up	to	1	mL	50	mM	Bis-Tris	buffer,	pH	6.0,	and	the	absorbance	
was	set	to	zero.	The	reaction	was	initiated	by	addition	of	NADH	(0.1	mM),	followed	by	
mixing	of	the	reagents	with	a	1	mL	pipette,	in	the	cell	compartment	(at	60	oC).	The	
decrease	of	absorbance	at	340	nm,	(due	to	the	consumption	of	NADH)	was	monitored.	
For	all	enzymatic	assays	the	specific	activity	was	calculated	from	the	initial	linear	rate	
of	reaction	(up	to	the	initial	300	s).	For	all	enzymatic	assays,	a	control	reaction	was	
performed	replacing	the	enzyme	with	50	mM	Bis-Tris	buffer,	pH	6.0	(10	µL)	following	
NADH	absorbance	at	340	nm,	no	decrease	in	absorbance	was	observed.		
3.4.7 Enzyme	kinetics	and	inhibition	studies	with	different	organic	substrates	
Enzymatic	assays	were	performed	in	both	the	reductive	and	oxidative	directions	for	
both	native	activity	and	imine	reductase	activity.	Wild-type	and	other	TADH	variants	
enzymes	were	prepared	to	a	concentration	of	0.2	mg	/	mL	in	20	mM	Tris	pH	7.5.	NADH	
was	prepared	to	a	concentration	of	10	mM	in	milliQ	water.	NAD+	was	prepared	to	a	
concentration	 of	 50	 mM	 in	 milliQ	 water.	 Imine	 (2-methyl-1-pyrroline	 1,	 2,3-
dihydroisoquinoline	2)	and	ketone	(cyclohexanone)	stock	solutions	were	prepared	in	
a	concentration	of	1	M	in	acetonitrile	(or	other	organic	solvent	as	specified	in	text).	
Amine	 (2-methylpyrrolidine	 3,	 1,2,3,4	 tetrahydroisoquinoline	 4)	 and	 alcohol	
(cyclohexanol)	stock	solutions	were	prepared	at	a	concentration	of	5	M	in	acetonitrile	
(or	other	relevant	solvent,	as	specified	in	text).	To	vary	solvent	concentrations	in	the	
assay,	the	concentration	of	the	substrate	stock	in	organic	solvent	was	varied.	
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Reduction:	The	following	reagents	were	added	to	a	1	mL	cuvette;	NADH	(10	µL,	final	
conc.	0.1mM),	substrate	(20	µL,	final	conc	20	mM),	enzyme	(100	µL,	final	conc.	0.02	
mg/mL)	and	50	mM	Bis-Tris	buffer,	pH	6.0	 (to	1	mL).	The	reaction	was	 initiated	by	
addition	of	NADH	followed	by	mixing	of	the	reagents	with	a	1	mL	pipette,	in	the	cell	
compartment	 (at	 60	 oC).	 The	 decrease	 of	 absorbance	 at	 340	 nm,	 (due	 to	 the	
consumption	of	NADH)	was	monitored.	A	control	assay	was	performed,	replacing	the	
enzyme	with	50	mM	Bis-Tris	buffer,	pH	6.0	(100	µL),	no	decrease	in	NADH	absorbance	
was	observed.	
Oxidation:	The	following	reagents	were	added	to	a	1	mL	cuvette;	NAD+	(20	µL	,	1	mM),	
substrate	 (20	 µL,	 100	mM),	 enzyme	 (100	 µL,	 final	 conc.	 0.02	mg/mL)	 and	 50	mM	
Glycine-NaOH	buffer,	pH	9.0	(to	1	mL).	The	reaction	was	initiated	by	addition	of	NAD+	
followed	by	mixing	of	the	reagents	with	a	1	mL	pipette,	in	the	cell	compartment	(at		
60	oC).	The	increase	of	absorbance	at	340	nm,	(due	to	the	formation	of	NADH)	was	
monitored.	A	control	assay	was	performed,	replacing	the	enzyme	with	50	mM	Glycine-
NaOH	buffer,	pH	9.0	(10	µL),	no	increase	in	NADH	absorbance	was	observed.	
The	procedures	described	above	were	 repeated	 for	 the	Michaelis-Menten	kinetics,	
except	 that	 the	 concentration	 of	 the	 substrate	was	 varied,	 to	 reach	 the	 following	
concentrations	in	the	assay:		
Cyclohexanol:	0.5,	1,	1.5,	2,	3,	5,	7.5	and	10	mM	
Cyclohexanone:	1,	2.5,	7.5,	15,	25	and	50	mM	
The	procedures	described	for	Michaelis-Menten	kinetics	were	repeated	for	inhibition	
kinetics	with	imine	and	amines,	except	that	inhibitor	was	added	in	each	kinetics	series,	
in	the	following	concentrations:	
2-methyl-1-pyrroline	1	in	the	oxidation	assay:	10	mM,	25	mM,	50	mM	
2-methyl-pyrrolidine	2	in	the	reduction	assay:	1	mM,	5	mM,	10	mM	
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For	each	 inhibition	study	 the	resulting	values	were	used	to	plot	a	Lineweaver-Burk	
graph	in	Excel	and	GraphPad	Prism	8	was	used	to	plot	the	Michaelis-Menten	kinetics	
and	to	determine	the	kinetic	constants.		
The	 procedures	 described	 above	 were	 repeated	 for	 inhibition	 kinetics	 with	 the	
nicotinamide	ligand	21a	(0.1	mM	and	0.25	mM)	and	Ir-complex	24a	(0.05	mM	and	0.1	
mM).	The	parameters	of	the	enzymatic	assays	are	outlined	in	section	3.9.1	and	3.9.2.	
3.5 Preparation	and	characterisation	of	TADH	mutants	
All	TADH	single	and	double	mutants	were	prepared	using	the	QuikChange	Lightning	
Site-Directed	 Mutagenesis	 Kit	 (Agilent),	 and	 their	 DNA	 sequences	 confirmed	 by	
sequencing	 performed	 by	 Eurofins	 Genomics.	 Primers	 were	 designed	 using	 the	
QuikChange®	Primer	Design	Program	(Agilent)	and	purchased	from	Integrated	DNA	
Technologies.	Primer	sequences	for	each	mutation	can	be	found	in	Appendix	2.	
PCR	was	 performed	 on	 a	Mastercycler®	 personal	 (Eppendorf)	 under	 the	 following	
conditions:	1	cycle	at	95	oC	for	2	min	followed	by	18	cycles	of	95	oC	for	20	s,	60	oC	for	
10	s	and	68	oC	for	30	s,	finishing	with	a	cycle	at	68	oC	for	5	min.	
Following	successful	mutagenesis,	the	mutated	plasmids	were	then	transformed	into	
BL21(DE3)	cells	and	glycerol	stock	prepared	and	stored	at	-80	oC.	Each	of	the	mutants	
was	 then	 grown	 as	 described	 in	 section	 3.4.2.	 (LB	 media,	 37	 oC,	 200	 rpm)	 and	
expression	induced	at	30	oC	OD600	~0.8	with	IPTG	to	a	final	conc.	0.4mM.	Purification	
was	performed	by	heat	treatment	(80	oC,	20	min)	and	a	sample	taken	for	SDS-PAGE	
analysis,	 protein	 concentration	 and	 activity	 assays.	 Expression	 cultures	 were	
performed	in	250	mL	expression	volumes	for	single	mutants	and	50	mL	volumes	for	
double	mutants.	
3.5.1 Enzymatic	assays	of	mutants	
All	mutants	were	investigated	for	both	native	activity	and	imine	reductase	activity	in	
both	oxidative	and	reductive	directions	as	outlined	in	section	3.4.6.,	using	substrates	
1-butanol,	2-methylpyrrolidine	3	and	1,2,3,4-tetrahydroisoquinoline	4	in	the	oxidation	
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assays	and	butyraldehyde,	2-methylpyrroline	1	and	3,4-dihydroisoquinoline	2	 in	the	
reduction	assays.	
Oxidation:	 Stock	 solutions	 of	 amines,	 3	 and	 4	 were	 prepared	 in	 ACN	 to	 a	 final	
concentration	of	5	M.	
Table	3.1.	Enzyme	parameters	for	oxidative	assays	outlined	below.a	
	 Stock	conc.	
Vol	(µL)	
added	
control	
Vol	(µL)	
added		 Final	conc.	
Glycine-NaOH	
pH	9.0	 50	mM	 860	 860	 -	
Enzyme	 0.2	mg	/	mL	 100	 100	 0.02	mg	/	mL	
Substrateb	 5	M	in	ACN	 20	 20	 100	mM	
ACN	 -	 20	 0	 2	%	
NAD+	 50	mM	 0	 20	 1	mM	
a	Assays	 run	at	340	nm,	60	 oC	 for	5	min;	 b	1-butanol	was	added	to	a	 final	conc.	of	100	mM	with	no	
addition	of	organic	solvents.	
Reduction:	 Stock	 solutions	 of	 imine	 1	 and	 2	 were	 prepared	 in	 ACN	 to	 a	 final	
concentration	of	1	M.	
Table	3.2.	Enzyme	parameters	for	reductive	assays	outlined	below.a	
	 Stock	conc.	
Vol	(µL)	
added	
control	
Vol	(µL)	
added		 Final	conc.	
Bis-Tris	pH	6.0	 50	mM	 Up	to	1	mL	 Up	to	1	mL	 -	
Enzyme	 0.2	mg	/	mL	 10	or	100	 10	or	100	 0.002	or			0.02mg	/	mL	
Substrateb	 1	M	in	ACN	 20	 20	 20	mM	
ACN	 -	 20	 0	 2	%	
NAD+	 10	mM	 0	 10	 1	mM	
a	Assays	run	at	340	nm,	60	oC	for	5	min;	b	butyraldehyde	was	added	to	a	final	conc.	of	20	mM	with	no	
addition	of	organic	solvents.	
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Controls	performed	without	NADH	showed	that	both	3,4-dihydroisoquinoline	2	and	
the	corresponding	amine	4	have	an	absorbance	at	340	nm,	therefore	the	absorbance	
was	set	to	zero	before	addition	of	NAD(H)	to	begin	the	reactions.	
3.6 Replacement	of	zinc	with	other	metals	
3.6.1 Equipment	
Dialysis	 tubing	 (Sigma-Aldrich)	 (molecular	 cut-off	 =	 14	 kDa)	 was	 treated	 for	 the	
removal	of	traces	of	glycerol,	sulphides	and	heavy	metals.	Dialysis	tubing	was	washed	
in	 distilled	water	with	 shaking	 for	 3-4	 hours.	 This	was	 followed	by	 treatment	with								
0.3	%	w	/	v	sodium	sulphide	solution	at	80	oC	for	1	minute	and	washing	with	hot	water	
at	60	oC	for	2	minutes.		Acidification	with	0.2	%	v	/	v	sulphuric	acid	solution	was	then	
performed,	rinsing	with	hot	water	to	remove	the	acid.	Finally,	the	tubing	was	added	
to	a	1	mM	EDTA	+	2	%	w	/	v	sodium	bicarbonate	solution	with	gentle	shaking	for	4	
hours	 followed	 by	 extensive	 rinsing	 with	 Chelex100®	 treated	 milliQ.	 The	 treated	
dialysis	tubing	was	then	stored	in	Chelex100®	treated	20	%	ethanol	solution	at	4	oC,	
until	ready	for	use.	Prior	to	dialysis,	the	tubing	was	soaked	and	washed	extensively	
with	MilliQ-H2O.	All	buffers	were	treated	with	Chelex100®	(0.01	g	of	Chelex100®	for	
every	1	g	of	buffer	salt)	and	the	resulting	solution	stirred	at	room	temperature	for	one	
hour.	 The	 Chelex100®	 was	 removed	 from	 solution	 with	 Buchner	 filtration.	 All	
glassware	used	in	dialysis	were	treated	with	3	x	30	%	nitric	acid	washes	following	by	
extensive	rinsing	with	milliQ-H2O.	
3.6.2 General	procedures	
Each	 dialysis	 step	 was	 carried	 out	 at	 4	 oC	 unless	 otherwise	 stated,	 against	 three	
changes	of	buffer	(100-500	volumes),	with	3	hours	between	first	two	buffer	changes	
and	overnight	 for	 the	 final	buffer	change.	Sample	solutions	of	TADH	(1-5	mg	/	mL,						
0.8-3	mL)	were	prepared	and	loaded	into	the	pre-soaked	dialysis	tubing.	The	sample	
solutions	were	dialysed	against	 initial	 buffer	 containing	 chelators	 for	 zinc	 removal.	
After	this,	chelators	were	removed	by	dialysis	against	one	round	of	initial	buffer	(3	h)	
followed	by	two	rounds	of	final	buffer	(3	h	and	overnight),	to	yield	apo-TADH.	The	apo-
TADH	solutions	were	dialysed	against	final	buffer	containing	metal	ions	(up	to	1	mM,	
Mn+)	for	12	hours	(no	buffer	change	used	for	this	step).	Excess	Mn+	was	removed	by	
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dialysis	against	final	buffer.	Protein	concentration,	purity	and	enzymatic	activity	assays	
were	performed	on	initial	TADH,	apo-TADH	after	chelator	removal	and	metal-TADH	
after	removal	of	the	excess	metal	salt.		
Apo-TADH	after	chelator	removal,	Mn+-TADH	after	removal	of	excess	Mn+	and	control	
samples	were	centrifuged,	unless	stated	otherwise	(12,000	rpm,	4	oC,	2	min)	and	any	
protein	pellets	removed	before	sample	analysis.	Apo-,	Mn+-TADH	and	control	samples	
(250	-	500	μL)	were	analysed	by	ICP-MS,	as	detailed	in	section	3.6.10.	
A	control	sample	was	performed	for	each	dialysis:	this	was	a	TADH	sample	which	was	
kept	 at	 the	 sample	 temperature	 and	 the	 same	 conditions	 as	 the	 final	 Mn+-TADH,	
excluding	any	chelator	or	metal	addition	to	the	buffers,	for	the	entire	length	of	the	
dialysis	investigation,	before	protein	and	metal	analysis	was	performed.		
The	following	buffer	and	chelators	were	used:	
Initial	buffers:	50	mM	sodium	acetate	buffer	pH	5.5;	20	or	50	mM	MES	buffer	pH	6.0	
or	6.5;	20	mM	Tris	buffer	pH	6.5	
Chelators:	5-20	mM	dipicolinic	acid	(DA);	5-20	mM	1,10-phenanthroline	(OPA);	5-20	
mM	ethylenediaminetetraacetic	acid	(EDTA)	or	a	combination	thereof	
Final	buffers:	20	mM	MES	pH	6.5,	20	mM	Tris	pH	6.5	or	7.5	
Metals:	 Zinc(II)	 acetate	 dihydrate,	 cobalt(II)	 acetate	 tetrahydrate	 or	
Dicarbonyl(acetylacetonato)	rhodium(I).	
3.6.3 Preliminary	chelator	investigations		
Six	samples	of	TADH	(6.5	mg	/	mL,	500	μL)	were	dialysed	using	midi	dialysis	tubing	(up	
to	800	μL	total	volume)	against	500	volumes	of	buffer.	Initial	buffers:	50	mM	sodium	
acetate	pH	5.5	containing	dipicolinic	acid	(5	and	1	5mM),	1,10-phenanthroline	(5	and	
15	mM)	or	ethylenediaminetetraacetic	acid	(5	and	15	mM);	Final	buffer:	20	mM	MES	
pH	6.5;	Metal	salts:	Zinc(II)	acetate	dihydrate	(20	μM).	
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3.6.4 	Impact	of	pH	on	zinc	removal		
TADH	samples	(1.3	mg	/	mL.	2.5	mL)	were	dialysed	in	dialysis	tubing	(2.5	mL)	against	
100	volumes	of	buffer.	Initial	buffers:	50	mM	sodium	acetate	buffer	pH	5.5,	20	mM	
MES	pH	6.5	containing	1,10-phenanthroline	(5	mM),	dipicolinic	acid	(15	mM)	and	a	
combination	of	1,10-phenanthroline	(5	mM)	an	dipicolinic	acid	(20	mM);	Final	buffer:	
20	mM	MES	pH	6.5,	20	mM	Tris	pH	7.5;	Metal	salts:	Zinc(II)	acetate	dihydrate	(20	μM).	
3.6.5 Impact	of	chelator	combinations	on	zinc	removal		
TADH	samples	(1.3	mg	/	mL,	3	mL)	were	dialysed	in	dialysis	tubing	against	100	volumes	
of	 buffer.	 Initial	 buffers:	 (20	 mM)	 MES	 pH	 6.0	 or	 pH	 6.5	 containing	 1,10-
phenanthroline	 (10	mM)	 and	 a	 combination	 of	 1,10-phenanthroline	 (10	mM)	 and	
EDTA	(20	mM);	Final	buffer:	20	mM	MES	pH	6.5	or	Tris	pH	7.5;	Metal	salts:	Zinc(II)	
acetate	dihydrate	(20	μM).	
3.6.6 Impact	of	temperature	on	zinc	removal		
TADH	 (1.3	 mg	 /	 mL	 900	 uL)	 samples	 were	 dialysed	 in	 dialysis	 tubing	 against	 150	
volumes	of	buffer.	Initial	buffers:	20mM	Tris	pH	6.5	containing	a	combination	of	1,10-
phenanthroline	(10	mM)	and	EDTA	(20	mM);	Final	buffer:	20	mM	Tris	pH	7.5;	Metal	
salts:	Zinc(II)	acetate	dihydrate	(20	μM);	Temperature	throughout	dialysis:	4	oC,	room	
temp	and	60	oC.	
3.6.7 Cobalt	insertion	
TADH	(0.5	mg	/	mL,	0.5	mL)	was	dialysed	 in	dialysis	 tubing	against	100	volumes	of	
buffer.	For	cobalt	reinsertion,	the	‘apo-TADH’	created	with	treatment	of	20	mM	Tris	
pH	6.5,	4	oC	containing	combination	of	OPA	(10	mM)	and	EDTA	(20	mM)	was	then	
dialysed	against	20	mM	Tris	pH	7.5	containing	cobalt(II)	acetate	tetrahydrate	(1	mM).	
3.6.8 Metal	exchange	using	purified	secTADH	
3.6.8.1 Dialysis	procedure	
TADH	(0.60	and	0.88	mg	/	mL,	2.5	mL)	samples	were	dialysed	in	dialysis	tubing	against	
150	 volumes	 of	 buffer.	 An	 initial	 buffer	 exchange	 step	 was	 performed	 by	 dialysis	
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against	20	mM	MES	pH	6.0	for	2	h.	Dialysis	for	creation	of	Rh-TADH	was	performed	in	
degassed	buffers	under	nitrogen	during	introduction	of	rhodium.	
Initial	 buffers:	 20	 mM	MES	 pH	 6.0	 containing	 (10	 mM)	 1,10-phenanthroline	 or	 a	
combination	of	1,10-phenanthroline	(10	mM)	and	EDTA	(20mM);	Final	buffer:	20	mM	
MES	pH	6.5	(degassed	for	Rh	insertion);	Metal	salts:	Zinc(II)	acetate	dihydrate	(20	μM)	
or	Rh(acac)(CO)2	(20	μM);	Temperature	throughout	dialysis:	4	oC.	
3.6.8.2 	Gel	filtration	procedure	
Sephadex	G-25	PD-10	columns	 (2.5	mL	sample	volume)	were	equilibrated	with	 the	
appropriate	buffer	(20	mM	MES	pH	6.0	or	20	mM	MES	pH	6.5)	before	each	protein	
loading.	 The	 same	buffers	were	used	 for	 all	washes	and	buffer	exchanges.	 Sample	
concentration	 was	 performed	 after	 each	 buffer	 exchange.	 Buffer	 was	 initially	
exchanged	from	20	mM	Tris	pH	7.5	to	20	mM	MES	pH	6.0.	This	was	followed	by	direct	
treatment	of	secTADH	with	chelating	agents	(10	mM	OPA	or	10	mM	OPA	&	20	mM	
EDTA)	in	20	mM	MES	pH	6.0,	stirring	at	4	oC	for	2	h.	This	sample	was	then	subjected	
to	a	buffer	wash	with	20mM	MES	pH	6.0	and	buffer	exchange	into	20mM	MES	pH	6.5	
for	creation	of	apo-TADH.	Zn-TADH	and	Rh-TADH	were	prepared	via	direct	addition	of	
apo-TADH	to	a	solution	of	20	mM	MES	pH	6.5	containing	20	μM	zinc	acetate	stirring	
at	4	 oC	 for	2	h,	or	a	degassed	solution	of	20	mM	MES	pH	6.5	containing	of	20	μM	
Rh(acac)(CO)2,	respectively.	Samples	were	stirred	at	4	oC	under	nitrogen	for	2	h.	This	
was	followed	by	2	x	column	wash	with	20	mM	MES	pH	6.5	to	yield	the	final	Zn-TADH	
and	Rh-TADH	samples.		
The	control	was	kept	at	4	oC	throughout	and	underwent	2	x	buffer	exchanges	into	20	
mM	MES	pH	6.0	and	20	mM	MES	pH	6.5.	1	mL	samples	of	control	apo-TADH	and	Zn-	/	
Rh-TADH	were	submitted	for	analysis.	
3.6.9 	Imine	reductase	activity	
The	following	reagents	were	added	to	a	1	mL	cuvette:	NADH	(0.1	mM),	2-methyl-1-
pyrroline	(20	mM),	enzyme	(4	µg	and	20	µg)	and	up	to	1	mL	50	mM	Bis-Tris	buffer	
containing	 2	%	 v	 /	 v	ACN,	 pH	6.0.	 The	 reaction	was	 initiated	by	 addition	of	NADH	
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followed	by	mixing	of	the	reagents	with	a	1	mL	pipette,	in	the	cell	compartment	(at		
60	oC).		Absorbance	at	340	nm	was	monitored.	
3.6.10 ICP-MS	analysis	for	metal	content	
Metal	content	was	analysed	in	TADH	samples	via	multi	element	analysis	by	Inductively	
Coupled	 Plasma	 Mass	 Spectrometry	 (ICP-MS).	 TADH	 samples	 were	 centrifuged	
(12,000	rpm,	4	oC,	2	min)	and	any	insoluble	pellet	removed	to	ensure	the	sample	was	
homogeneous.	Samples	(0.5	mL,	with	>20	ppb	metal	content)	were	submitted	for	ICP-
MS	analysis.	The	samples	were	diluted	to	a	1	in	20	dilution	with	a	solvent	containing	a	
non-ionic	surfactant	in	1	%	nitric	acid	and	then	analysed	for	metal	content.	Results	are	
reported	as	gravimetric	concentrations	(µg	/	L	or	mg	/	L)	taking	into	account	the	1	in	
20	 dilution	 so	 the	 each	 value	 represents	 the	 metal	 concentration	 for	 the	 protein	
concentration	of	the	0.5	mL	sample.	To	evaluate	the	metal	:	protein	ratio	in	the	sample	
submitted,	the	protein	concentration	was	first	determined	(using	Bradford	assay	as	
outlined	in	section	3.4.4).		
The	digestion	procedure	used	by	the	ICP-MS	lab	was	compared	with	the	 literature,	
where	harsher	conditions	 for	digestion	are	usually	reported	(incubation	of	samples	
with	6	M	HNO3	at	110	oC,	6	h;	MilliQ-H2O	was	added	to	 the	samples	 for	a	1	 in	15	
dilution),	and	the	differences	were	very	small	(Table	3.3).117		
Table	3.3.	Comparison	of	ICP-MS	sample	procedures.	
Sample	 Zn	:	TADHa	ratio	 Zn	:	TADHb	ratio	
htTADH	 0.73	 0.74	
secTADH	 0.67	 0.64	
secC38A-TADH	 0.33	 0.38	
secD152A-TADH	 0.39	 0.36	
a	ICP-MS	lab	prepared	samples;	b	Acid	digestion	prepared	samples	
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3.7 	Synthesis	of	nicotinamide	NHC	functionalised	iridium	complexes	
3.7.1 General	methods	
Commercially	available	reagents	were	used	throughout,	without	purification	unless	
otherwise	 stated.	 All	 aqueous	 solutions	 were	 prepared	 using	 deionised	 water.	
Analytical	 thin	 layer	 chromatography	was	 carried	 out	 on	 aluminium	backed	 plates	
coated	with	Merck	Kieselgel	60	GF254	and	visualised	under	UV	light	at	254	and	/	or	
360	 nm.	 Chemical	 staining	was	 also	 routinely	 used,	with	 aqueous	 basic	 potassium	
permanganate.	Flash	chromatography	was	carried	out	using	Davisil	silica	60	Å,	with	
the	eluent	specified.		
All	 compounds	presented	below	were	 synthesised	 to	 a	 high	degree	of	 purity,	 (see	
Appendix	9	for	1H	and	13C	NMR	spectra	of	compounds.)	
3.7.2 Step	1	-	Preparation	of	4-	and	5-	halide	substituted	nicotinamide	precursors	
5-	and	4-Chloro-N,N-diisopropylnicotinamide	were	prepared	 from	5-bromonicotinic	
acid	 or	 4-chloronicotinic	 acid,	 respectively,	 according	 to	 a	 previously	 reported	
procedure.157		
General	procedure:	
Thionyl	chloride	(10	equivalents)	was	added	dropwise	at	room	temperature	under	N2	
to	the	solid	corresponding	nicotinic	acid	(1	equivalent).	The	resulting	suspension	was	
refluxed	for	2	h	and	the	volatiles	were	removed	in	vacuo.	The	crude	acid	chloride	was	
dissolved	in	anhydrous	CH2Cl2	(8	mL)	and	the	solution	was	added	slowly	at	0	°C	to	a	
solution	of	diisopropylamine	(100	equivalents)	in	CH2Cl2	(8	mL).	Stirring	was	continued	
overnight.	 Aqueous	 K2CO3	 (2.0	M,	 20	 mL)	 was	 added	 and	 the	 aqueous	 layer	 was	
extracted	 with	 CH2Cl2	 (3	 x	 15	mL).	 The	 combined	 organic	 extract	 was	 dried	 using	
MgSO4,	concentrated	 in	vacuo	and	the	crude	product	was	purified	by	flash	column	
chromatography	on	silica	gel.	
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5-Bromo-N,N-diisopropylnicotinamide,	16a:157		
	
The	 procedure	 described	 above	 was	 used	 with	 5-bromonicotinic	 acid	 (1.0	 g,	 4.95	
mmol),	 thionyl	 chloride	 (7.2	 mL,	 99.0	 mmol)	 and	 diisopropylamine	 (1.5	 mL,	 10.9	
mmol).	Elution	with	petroleum	ether	/	EtOAc	 (70	/	30)	afforded	fine	white	crystals	
(1.12	g,	3.93	mmol,	79	%	yield).	
1H	NMR	(300	MHz,	(CD3)2CO-d6,	298	K):	dH	(ppm)	8.69	(d,	J	=	2.3	Hz,	1H,	pyridyl-H),	
8.51	(d,	J	=	1.8	Hz,	1H,	pyridyl-H),	7.94	(t,	 J	=	2.0	Hz,	1H,	pyridyl-H),	3.73	(s,	br,	2H,	
diisopropylamine-NCH),	1.35	(s,	br,	12H,	diisopropylamine-CH3).	
13C	NMR	(100	MHz,	(CD3)2CO-d6,	298	K):	dC	(ppm)	151.3	(pyridyl-CH),	145.7	(pyridyl-
CH),	137.4	(pyridyl-C),	136.6	(pyridyl-CH)	,	121.1(pyridyl-C),	20.7	(4	x	diisopropylamine-
CH3).		
ESI+-MS:	285.1	([M+H]+,	36.9	%),	307.0	([M+Na]+,	98.2	%).	
4-Chloro-N,N-diisopropylnicotinamide,	16b:	
	
The	 procedure	 described	 above	 was	 used	 with	 4-chloronicotinic	 acid	 (1.0	 g,	 6.35	
mmol),	thionyl	chloride	(9.2	mL,	127	mmol)	and	diisopropylamine	(2.0	mL,	14.0	mmol).	
Elution	with	Petroleum	Ether	/	EtOAc	(70	/	30)	afforded	fine	white	crystals	(1.08	g,	
4.50	mmol,	71	%	yield).		
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1H	NMR	(300	MHz,	(CD3)2CO-d6,	298	K):	dH	(ppm)	8.53	(d,	J	=	5.4	Hz,	1H,	pyridyl-H),	
8.48	(d,	J	=	0.6	Hz,	1H,	pyridyl-H),	7.94	(dd,	J	=	5.4,	0.6	Hz,	1H,	pyridyl-H),	3.56-3.71	(s,	
br,	2H,	diisopropylamine-NCH),	1.55	(d,	J	=	2.6	Hz,	3H,	diisopropylamine-CH3),	1.52	(d,	
J	=	2.6	Hz,	3H,	diisopropylamine-CH3),	1.24	(d,	J	=	6.7	Hz,	3H,	diisopropylamine-CH3),	
1.16	(d,	J	=	6.7	Hz,	3H,	diisopropylamine-CH3).	
13C	NMR	 (100	MHz,	 (CD3)2CO-d6,	 298	 K):	dC	 (ppm)	 153.3	 (C=O),	 151.3	 (pyridyl-CH),	
148.3	(pyridyl-CH),	140.1	(pyridyl-C),	136.2	(pyridyl-C),	125.4	(pyridyl-CH),	46.9,	52.1		
(diisopropylamine-NCH),	20.9,	20.9,	20.8,	20.5	(diisopropylamine-CH3).	
ESI+-MS:	241.1	([M+H]+,	94.1%),	263.1	([M+Na]+,	100%),	503.2	([2M+Na]+,	53.1%).	
3.7.3 Step	2	-	Preparation	of	imidazole-substituted	nicotinamide	derivatives	by	
Ullmann	coupling	
The	following	compounds	were	prepared	according	to	a	procedure	adapted	from	the	
literature.158		
General	procedure:	
All	 manipulations	 were	 carried	 out	 using	 standard	 Schlenk	 techniques.	 The	
corresponding	 starting	material	 (1	 equivalent),	 imidazole	 (1.6	 equivalents),	 cesium	
carbonate	 (2.0	 equivalents)	 and	 copper(I)	 iodide	 (0.2	 equivalents)	 were	 mixed	 in	
deoxygenated	dimethylformamide	(8	mL)	and	heated	to	115-120	oC	under	dinitrogen	
for	 24	 h.	 After	 this	 time,	 the	 DMF	 was	 removed	 in	 vacuo	 and	 the	 crude	 product	
purified	by	flash	column	chromatography	on	silicagel.	
5-(1	H-Imidazol-1-yl)-N,N-diisopropylnicotinamide,	17a:158	
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The	procedure	described	above	was	used	with	5-bromo-N,N-diisopropylnicotinamide	
(500	mg,	1.75	mmol),	 imidazole	(192	mg,	2.81	mmol),	cesium	carbonate	(1144	mg,	
3.51	mmol)	 and	 copper(I)	 iodide	 (67	mg,	 0.35	mmol).	 Elution	with	CH2Cl2	 /	MeOH							
(95	/	5)	afforded	the	product	(323	mg,	1.19	mmol,	68	%	yield).		
1H	NMR	(300	MHz,	(CD3)2CO-d6,	298	K):	dH	(ppm)	8.93	(d,	J	=	2.6	Hz,	1H,	pyridyl-H),	
8.51	(d,	J	=	1.8	Hz,	1H,	pyridyl-H),	8.22		(m,	1H,	imidazolyl-H),	8.00	(dd,	J	=	2.6,	1.8	Hz,	
1H,	 pyridyl-H),	 7.73	 (t,	 J	 =	 1.4	 Hz,	 1H,	 imidazolyl-H),	 7.16	 (dd,	 J	 =	 1.4,	 0.9	 Hz	 1H,	
imidazolyl-H),	 3.77	 (s,	 br,	 2H,	 diisopropylamine-NCH),	 1.37	 (s,	 br,	 12H,	
diisopropylamine-CH3).	
13C	 NMR	 (100	MHz,	 (CD3)2CO-d6,	 298K):	 dC	 (ppm)	 167.4	 (C=O),	 145.5	 (pyridyl-CH),		
142.6	(pyridyl-CH),	136.6	(imidazolyl-N-C-N),	136.5	(pyridyl-C),	134.7	(pyridyl-C),	131.6	
(imidazolyl-CH),	126.0	(pyridyl-CH),	118.7	(imidazolyl-CH),	20.5	(4	x	diisopropylamine-
CH3).		
ESI+-MS:	273.2	([M+H]+,	100	%),	295.2	([M+Na]+,	12.7	%),	567.3	([2M+Na]+,	43	%).	
4-(1H-Imidazol-1-yl)-N,N-diisopropylnicotinamide	17b:	
	
The	procedure	described	above	was	used	with	4-chloro-N,N-diisopropylnicotinamide	
(150	mg,	0.62	mmol),	imidazole	(58	mg,	0.85	mmol),	cesium	carbonate	(344	mg,	1.06	
mmol)	and	copper(I)	iodide	(20	mg,	0.11	mmol).	Elution	with	CH2Cl2	/	MeOH	(95	/	5)	
gave	the	product	(104	mg,	0.38	mmol,	62	%	yield).		
1H	NMR	(300	MHz,	(CD3)2CO-d6,	298	K):	dH	(ppm)	8.72	(d,	J	=	5.4	Hz,	1H,	pyridyl-H),	
8.60	(s,	1H,	pyridyl-H),	8.02		(s,	br,	1H,	imidazolyl-H),	7.59	(s,	1H,	pyridyl-H),	7.57	(s,	
1H,	 imidazolyl-H),	7.18	(s,	br	1H,	 imidazolyl-H),	3.40-3.59	(m,	2H,	diisopropylamine-
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NCH),	 1.52,	 (d,	 J	 =	 6.8	 Hz,	 3H,	 diisopropylamine-CH3),	 1.42,	 (d,	 J	 =	 6.8	 Hz,	 3H,	
diisopropylamine-CH3),	1.05,	(d,	J	=	6.8	Hz,	3H,	diisopropylamine-CH3),	0.61	(d,	J	=	6.7	
Hz,	3H,	diisopropylamine-CH3).	
13C	NMR	 (100	MHz,	 (CD3)2CO-d6,	 298	 K):	dC	 (ppm)	 166.2	 (C=O),	 151.9	 (pyridyl-CH),	
149.6	(pyridyl-CH),	140.6	(imidazolyl-CH),	131.4	(imidazolyl-CH),	129.2	(imidazolyl-CH),	
118.7	 (pyridyl-CH),	 51.9,	 46.7,	 (diisopropylamine-NCH),	 20.8,	 20.6,	 20.0,	 19.9	
(diisopropylamine-CH3).		
ESI+-MS:	273.2	([M+H]+,	100	%),	295.2	([M+Na]+,	41.7	%),	567.3	([2M+Na]+,	9.5	%).	
5-(1H-Imidazol-1-yl)nicotinamide,	20a:	
	
The	procedure	described	above	was	used	with	5-bromonicotinamide	(500	mg,	2.49	
mmol),	imidazole	(271	mg,	3.98	mmol),	cesium	carbonate	(1621	mg,	4.97	mmol)	and	
copper(I)	iodide	(95	mg,	0.50	mmol).	Elution	with	CH2Cl2	/	MeOH	(80	/	20)	gave	the	
product	(366	mg,	1.94	mmol,	78	%	yield).	
1H	NMR	(400	MHz,	CD3OD-d4,	298	K):	dH	(ppm)	9.04	(d,	J	=	1.9	Hz,	1H,	pyridyl-H),	9.02	
(d,	J	=	2.4	Hz,	1H,	pyridyl-H),	8.49	(dd,	J	=	2.5,	1.9	Hz,	1H,	pyridyl-H),	8.32	(s,	br,	1H,	
imidazolyl-H),	7.74	(s,	br,	1H,	imidazolyl-H),	7.24	(s,	br,	1H,	imidazolyl-H).	
13C	NMR	(100	MHz,	CD3OD-d4,	298	K):	dC	(ppm)	168.7	(C=O)	,	148.3	(pyridyl-CH),	145.7	
(pyridyl-CH),	135.3	(pyridyl-C),	132.2	(pyridyl-C),	131.0	(imidazolyl-CH),	129.4	(pyridyl-
CH),	119.7	(imidazolyl-CH).		
ESI+-MS:	189.1	([M+H]+,	100	%).	
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4-(1	H-Imidazol-1-yl)nicotinic	acid,	23:	
	
The	procedure	described	above	was	used	with	4-bromonicotinic	acid	(500	mg,	2.48	
mmol),	imidazole	(2.5	eqv.,	421	mg,	6.19	mmol),	cesium	carbonate	(3.1	eqv.,	2520	mg,	
7.73	mmol)	and	copper(I)	iodide	(0.3	eqv.,	147	mg,	0.77	mmol).	Elution	with	CH2Cl2	/	
MeOH	/	Et3N	(85	/	10	/	5)	and	washing	with	DCM	gave	the	final	product	(315	mg,	1.67	
mmol,	67	%	yield).	
1H	NMR	(300	MHz,	(CD3)2SO-d6,	298	K):	dH	(ppm)	9.01	(d,	J	=	0.6	Hz,	1H,	pyridyl-H),	8.83	
(d,	J	=	5.4	Hz,	1H,	pyridyl-H),	8.01	(t,	J	=	1.1	Hz,	1H,	imidazolyl-H),	7.59	(dd,	J	=	5.4,	0.6	
Hz,	 1H,	 pyridyl-H),	 7.51	 (t,	 J	 =	 1.4	 Hz,	 1H,	 imidazolyl-H),	 7.11	 (d,	 J	 =	 1.2	 Hz,	 1H,	
imidazolyl-H).	
13C	 NMR	 (100	MHz,	 (CD3)2SO-d6,	 298	 K):	dC	 (ppm)	 165.7	 (C=O),	 153.4	 (pyridyl-CH),	
151.5	 (pyridyl-CH),	 142.6	 (pyridyl-C),	 137.4	 (imidazolyl-CH),	 129.2	 (imidazolyl-CH),	
123.0	(pyridyl-C),	120.5	(imidazolyl-CH),	120.2	(pyridyl-CH).		
ESI+-MS:	190.1	([M+H]+,	100	%),	212.0	([M+Na]+,	37.2	%).	
3.7.4 Step	 3	 –	 Preparation	 of	 benzylated	 imidazole	 substituted	 nicotinamide	
derivatives	
General	procedure:	
To	a	solution	of	imidazoyl	starting	material	(1	equivalent)	in	ACN	(5	mL)	was	added	
dropwise	benzyl	bromide	(4	equivalents).	The	resulting	reaction	mixture	was	stirred	
at	room	temp.	overnight	followed	by	heating	to	40	oC	for	a	further	24	h,	after	which	
time	a	precipitate	was	observed.	The	solution	was	allowed	to	cool	and	diethyl	ether	
N
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(10	mL)	was	added	to	further	precipitate	the	final	product.	After	filtering,	the	product	
was	washed	with	diethyl	ether	(3	×	10	mL),	to	afford	the	bromide	salt.	
1-benzyl-3-(N-benzylimidazol-1-yl)-5-(diisopropylcarbamoyl)pyridinium									
bromide,	18a:		
	
The	 procedure	 described	 above	 was	 used	 with	 5-(1	 H-imidazol-1-yl)-N,N-
diisopropylnicotinamide	 (200	 mg,	 0.73	 mmol)	 and	 benzyl	 bromide	 (0.35	 mL,	 2.93	
mmol)	affording	the	product	(274	mg,	0.45	mmol,	62	%	yield).		
1H	NMR	(300	MHz,	CD3OD-d4,	298	K):	dH	(ppm)	9.96	(dd,	J	=	2.2,	1.2	Hz,	1H,	pyridyl-H),	
9.40	(t,	J	=	1.4	Hz,	1H,	pyridyl-H),	9.09	((t,	J	=	1.7	Hz,	1H,	pyridyl-H),	8.36	(d,	J	=	2.2	Hz,	
1H,	imidazolyl-H),	7.99	(d,	J	=	2.2	Hz	,	1H,	imidazolyl-H),	7.65	–	7.69	(m,	2H,	benzyl-H),	
7.56	–	7.60	(m,	2H,	benzyl-H),	7.45	–	7.51	(m,	6H,	benzyl-H),	6.03	(s,	2H,	benzyl-CH2),	
5.62	 (s,	 2H,	 benzyl-CH2),	 3.78	 (s,	 br,	 2H,	 diisopropylamine-NCH),	 1.53	 (s,	 br,	 6H,	
diisopropylamine-CH3),	1.20	(s,	br,	6H,	diisopropylamine-CH3).		
13C	NMR	(100	MHz,	CD3OD-d4,	298	K):	dH	(ppm)	138.1	(pyridyl-CH),	134.2	(pyridyl-C),	
131.4,	130.8,	130.7,	130.6,	130.2	(2	x	benzyl-C),	125.1,	123.8	(benzyl-CH2),	67.1,	55.2	
(2	x	diisopropylamine-NCH).		
ESI+-MS:	485.3	([M2++MeO-]+,	92	%),	486.3	([M2++MeOH]2+,	32.7	%).	
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1-benzyl-4-(N-benzylimidazol-1-yl)-3-(diisopropylcarbamoyl)pyridinium								
bromide,	18b		
	
The	 procedure	 described	 above	 was	 used	 with	 4-(1	 H-imidazol-1-yl)-N,N-
diisopropylnicotinamide	(46.5	mg,	0.17	mmol)	and	benzyl	bromide	(81	µL,	0.68	mmol)	
affording	the	product,	(31	mg,	0.05	mmol,	30	%	yield).	
1H	NMR	(300	MHz,	CD3OD-d4,	298	K):	dH	(ppm)	9.84	(s,	1H,	imidazolyl-H),	9.63	(s,	1H,	
pyridyl-H),	9.47	(d,	J	=	6.5	Hz,	1H,	pyridyl-H),	8.65	(d,	J	=	6.5	Hz,	1H,	pyridyl-H),	8.09	(s,	
1H,	imidazolyl-H),	8.05	(s,	1H,	imidazolyl-H),	7.62	–	7.65	(m,	2H,	benzyl-H),	7.54	–	7.58	
(m,	2H,	benzyl-H),	7.49	–	7.51	(m,	3H,	benzyl-H),	7.45	–	7.47	(m,	3H,	benzyl-H),	6.03	(s,	
2H,	benzyl-CH2),	5.64	(s,	2H,	benzyl-CH2),	3.53	–	3.71	(m,	2H,	diisopropylamine-NCH),	
1.49,	 (d,	 J	 =	 6.8	 Hz,	 3H,	 diisopropylamine-CH3),	 1.22,	 (d,	 J	 =	 6.8	 Hz,	 3H,	
diisopropylamine-CH3),	1.09,	(d,	J	=	6.8	Hz,	3H,	diisopropylamine-CH3),	0.72	(d,	J	=	6.7	
Hz,	3H,	diisopropylamine-CH3).	
13C	NMR	(100	MHz,	CD3OD-d4,	298	K):	dH	(ppm)	131.4,	130.9,	130.8,	130.6,	130.5,	130.3	
(2	x	benzyl-C),	128.0,	125.0	(benzyl-CH2),	55.3	(2	x	diisopropylamine-NCH),	20.2	(4	x	
diisopropylamine-CH3).		
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1-benzyl-3-(N-benzylimidazol-1-yl)-5-carbamoylpyridinium	bromide,	21a:	
	
The	procedure	described	above	was	used	with	5-(1H-imidazol-1-yl)nicotinamide	(250	
mg,	1.33	mmol)	and	benzyl	bromide	(0.63	mL,	5.31	mmol)	affording	the	product,	(982	
mg,	1.85	mmol,	87	%	yield).	
1H	NMR	(400	MHz,	CD3OD-d4,	298	K):	dH	(ppm)	10.07	(t,	J	=	1.7	Hz,	1H,	pyridyl-H),	10.05	
(dd,	J	=	2.1,	1.2	Hz,	1H,	pyridyl-H),	9.68	(t,	J	=	1.3	Hz,	1H,	imidazolyl-H),	9.51	(dd,	J	=	
2.0,	1.6	Hz,	1H,	pyridyl-H),	8.40	(t,	J	=	2.0	Hz,	1H,	imidazolyl-H),	8.01	(t,	J	=	1.9	Hz	,	1H,	
imidazolyl-H),	7.68	–	7.70	(m,	2H,	benzyl-H),	7.58	–	7.61	(m,	2H,	benzyl-H),	7.49	–	7.51	
(m,	6H,	benzyl-H),	6.08	(s,	br,	2H,	benzyl-CH2),	5.64	(s,	br,	2H,	benzyl-CH2).		
13C	NMR	(100	MHz,	CD3OD-d4,	298	K):	dC	(ppm)	163.6	(C=O),	146.4	(imidazolyl-N-CH-
N),	143.1	 (pyridyl-CH),	139.6	 (pyridyl-CH),	136.9	 (pyridyl-C),	136.4	 (pyridyl-C),	134.2	
(benzyl-C),	 133.4	 (benzyl-C),	 131.4,	130.8,	130.7,	130.6,	130.3	 (2	 x	benzyl-C),	 125.2	
(imidazolyl-CH),	123.7	(imidazolyl-CH),	67.1	(benzyl-CH2),	55.2	(benzyl-CH2).	
ESI+-MS:	401.2	([M2++	MeO-]+,	100	%),	369.2	([M2+-	H+]+,	23	%),	279.1	([M+-	PhCH2]+,	
11	%).	
3.7.5 Step	4	–	Preparation	of	iridium	NHC	functionalised	complex	via	metalation	
The	 following	procedure	was	adapted	 from	 the	 reported	procedure	by	Crabtree159	
using	1-benzyl-3-(N-benzylimidazol-1-yl)-5-carbamoylpyridinium	bromide,	21a	as	the	
NHC	and	[IrCp*Cl2]2	as	the	metal	precursor.	
21a
N
O
NH2
N
N
Br
Br
Br
in ACN, 40 oC, 24 h
20a
N
O
NH2
N
N
87 %
76	
	
	
All	manipulations	were	carried	out	under	standard	Schlenk	techniques.	A	mixture	of	
21a	(75	mg,	0.14	mmol),	potassium	chloride	(71	mg,	0.95	mmol),	sodium	tert-butoxide	
(14	mg,	0.14	mmol)	and	pentamethylcyclopentadienyl	 iridium	dichloride	dimer	 (56	
mg,	 0.07	 mmol)	 was	 stirred	 in	 degassed	 MeOH	 (1.5	 mL)	 at	 reflux	 for	 16	 h.	 The	
suspension	was	filtered	through	celite	and	dried	under	vaccum.	This	solid	was	then	
purified	by	chromatography	on	silicagel	using	CH2Cl2	/	MeOH	(90	/	10)	to	afford	the	
product	(31	mg,	0.04	mmol,	28	%	yield).		
1H	NMR	(400	MHz,	CD3OD-d4,	298K):	dH	(ppm)	9.09	(d,	J	=	1.5	Hz,	1H,	pyridyl-H),	8.55	
(d,	J	=	1.5	Hz,	1H,	pyridyl-H),	8.05	(d,	J	=	2.4	Hz,	1H,	imidazolyl-H),	7.50	–	7.55	(m,	4H,	
benzyl-H),	7.44	–	7.47	(m,	3H,	benzyl-H),	7.35	–	7.37	(m,	3H,	benzyl-H),	7.19	(d,	J	=	2.3	
Hz,	1H,	imidazolyl-H),	5.70	(d,	J	=	2.3	Hz,	2H,	benzyl-CH2),	5.50	(dd,	J	=	25.7,	13.7	Hz,	
2H,	benzyl-CH2),	1.81	(s,	15H,	Cp*-CH3).	NMR	shows	some	impurities	at	low	chemical	
shift.		
13C	NMR	(100	MHz,	CD3OD-d4,	298K):	dC	(ppm)	175.5	(C=O)	,	170.7	(pyridyl-C-Ir),	167.6	
(imidazolyl-C-Ir),	151.8	(pyridyl-C),	144.0	(pyridyl-C),		139.9	(pyridyl-CH),	136.5	(benzyl-
C),	 134.9	 (benzyl-C),	 130.8,	 130.6,	 130.5,	 130.0,	 129.8,	 (2	 x	 benzyl-CH),	 124.4	
(imidazolyl-CH),	 123.7	 (pyridyl-CH),	 118.5	 (imidazolyl-CH),	 97.0	 (Cp*-C-C)	 ,	 64.5	
(benzyl-CH2),	55.5	(benzyl-CH2),	9.6	(Cp*-CH3).		
ESI+-MS:	732.2	([NHC+(IrCp*Cl)]+	6.3%).		
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3.8 Catalysis	experiments	with	Ir	complex	24a	
3.8.1 Catalysis	of	transfer	hydrogenation	in	organic	solvent	
All	solutions	were	thoroughly	degassed	and	all	manipulations	were	carried	out	under	
standard	Schlenk	techniques.	The	following	reactions	were	performed	according	to	
the	reported	procedure	by	Zhu.25	
General	Procedure	
The	 desired	 substrate,	 acetophenone,	 2-methyl-1-pyrroline	 or	 2,3-
dihydroisoquinoline,	(0.15	mmol),	NaOtBu	(1.4	mg,	0.015	mmol)	and	iridium	complex	
(1.2	mg,	0.0015	mmol)	were	added	to	a	N2	purged	vial.	This	was	followed	by	dry	iPrOH	
(0.5	mL),	the	reaction	mixture	was	then	refluxed	under	nitrogen	for	24	h.	The	resulting	
solution	was	dried	under	vacuum,	redissolved	in	CDCl3	and	analysed	by	NMR.	1H	NMR	
analysis	of	the	crude	product	showed	substrate	and	product	as	the	major	compounds,	
and	 no	 side	 products	 could	 be	 identified.	 Therefore,	 conversion	 was	 calculated	
assuming	the	alcohol	/	amine	as	the	only	products,	based	on	the	integration	of	specific	
signals	in	the	1H-NMR	spectra	as	highlighted	below.		
For	the	transfer	hydrogenation	of	acetophenone	to	1-phenylethanol,	conversion	was	
calculated	by	integration	of	the	methyl	signals	at	2.61	and	1.50	ppm,	respectively	see	
Appendix	10.	
Acetophenone:	1H	NMR	(300	MHz,	CDCl3-d,	298K):	dH	(ppm)	7.95	–	7.99	(m,	2H,	
benzyl-H	x	2),	7.54	–	7.60	(m,	1H,	benzyl-H),	7.44	–	7.50	(m,	2H,	benzyl-H	x	2),	
2.61	(s,	3H,	-COCH3).	
1-phenylethanol:	1H	NMR	(300	MHz,	CDCl3-d,	298K):	dH	(ppm)	7.32	–	7.40	(m,	
3H,	 benzyl-H	 x	 3),	 7.25	 –	 7.30	 (m,	 2H,	 benzyl-H),	 4.91	 (q,	 J	 =	 6.5	 Hz,	 1H,																							
-CHOHCH3),	1.50	(dd,	J	=	6.4,	0.5	Hz,	3H,	-CHOHCH3).		
For	 the	 transfer	 hydrogenation	 of	 3,4-dihydroquinoline	 2	 to	 1,2,3,4-
tetrahydroisoquinoline	4,	conversion	was	calculated	by	 integration	of	the	signals	at	
3.74	and	3.10	ppm,	respectively	(see	Appendix	10).	
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.		
3,4-dihydroisoquinoline:	1H	NMR	(400	MHz,	CDCl3-d,	298K):	dH	(ppm)	8.30	(s,	
1H,	phenyl-CHN),	7.36	–	7.30	(m,	1H,	phenyl-H),	7.24	–	7.28	(m,	2H,	phenyl-H	
x	2),	7.12	–	7.14	(d,	J	=	7.4	Hz,	1H,	phenyl-H),	3.74	(m,	2H,	pyridyl-CH2N),	2.73	
(m,	2H,	pyridyl-CH2).	
1,2,3,4-tetrahydroisoquinoline:	 1H	NMR	 (400	MHz,	CDCl3-d,	 298K):	dH	(ppm)	
7.03	–	7.11	(m,	3H,	phenyl-H	x	3),	6.96	–	7.99	(m,	1H,	phenyl-H),	3.98	(s,	2H,	
phenyl-CH2N),	 3.10	 (t,	 J	 =	 6.0	 Hz,	 2H,	 CH2NH),	 2.77	 (t,	 J	 =	 6.0	 Hz,	 2H,	 CH2																														
-phenyl).		
3.8.2 Catalysis	of	transfer	hydrogenation	in	buffer	at	high	substrate	concentrations	
All	solutions	were	thoroughly	degassed	and	all	manipulations	were	carried	out	under	
standard	Schlenk	techniques.	The	following	reactions	were	prepared	and	performed	
according	to	and	adapted	from	the	reported	procedure	by	Ward.154		
General	Procedure	
The	reaction	buffer	was	prepared	by	mixing	3-(N-morpholino)propane	sulfonic	acid	
(MOPS,	final	conc.	1.2	M)	and	sodium	formate	(final	conc.	3M)	in	milliQ	water.	The	pH	
was	 adjusted	 to	 pH	 8.0	 with	 NaOH.	 Substrate	 stock	 solutions	 were	 prepared	 by	
solubilising	 the	 desired	 substrate	 (acetophenone,	 2-methyl-1-pyrroline	 and	 2,3-
dihydroisoquinoline)	 in	DMF	to	a	final	concentration	of	7.5	M.	The	iridium	complex	
was	dissolved	in	DMF	to	a	final	concentration	of	0.1	M.	
Substrate	(20	µL,	final	conc.	0.3	M)	and	iridium	complex	(15	µL,	final	conc.	0.003	M)	
were	 added	 to	 a	 N2	 purged	 vial	 containing	 reaction	 buffer	 (0.5	mL).	 The	 reaction	
mixture	was	then	heated	to	55	oC	under	nitrogen	for	24	h.	After	this	time,	milliQ	water	
(1	mL)	was	added	to	the	reaction	mixture	along	with	20	%	NaOH	(0.1	mL)	to	those	vials	
containing	an	imine	substrate	and	extracted	with	CHCl3	(4	x	3	mL).	The	organic	phase	
was	then	dried	over	MgSO4,	solvent	removed	under	vacuum	and	the	crude	residue	
was	analysed	by	NMR.	
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For	the	transfer	hydrogenation	of	acetophenone	to	1-phenylethanol,	conversion	was	
calculated	 as	 above,	 by	 integration	 of	 the	 methyl	 signals	 at	 2.61	 and	 1.50	 ppm,	
respectively.		
For	 the	 transfer	hydrogenation	of	3,4-dihydroisoquinoline	2	 in	aqueous	media,	 the	
NMR	showed	presence	of	amine	only,	and	no	sign	of	degradation.		
3.8.3 Catalysis	of	transfer	hydrogenation	at	 low	substrate	concentrations	and	in	
the	presence	of	TADH	
General	procedure	
The	reaction	buffer	was	prepared	by	mixing	3-(N-morpholino)propane	sulfonic	acid	
(MOPS,	final	conc.	0.4	M)	and	sodium	formate	(final	conc.	1M)	in	milliQ	water.	The	pH	
was	 adjusted	 to	 8.0	 with	 NaOH.	 Substrate	 stock	 solutions	 were	 prepared	 by	
solubilising	 the	 desired	 substrate	 (acetophenone,	 2-methyl-1-pyrroline	 and	 2,3-
dihydroisoquinoline)	in	ACN	to	a	final	concentration	of	50	mM.	The	iridium	complex	
was	 dissolved	 in	 degassed	 milliQ	 water	 containing	 ACN	 (5	 %	 v	 /	 v)	 to	 a	 final	
concentration	of	1.25	mM.	TADH	stock	solution	was	prepared	to	a	final	concentration	
of	 0.25	mM	 in	 20	mM	 Tris	 pH	 7.5.	 NADH	was	 dissolved	 in	milliQ	water	 to	 a	 final	
concentration	of	0.25	M	to	prepare	a	NADH	stock	solution.	
Substrate	(50	µL,	final	conc.	2.5	mM),	iridium	complex	(20	µL,	final	conc.	25	µM)	TADH	
(100	µL,	final	conc.	25	µM	)	and	NADH	(10	µL),	final	conc.	2.5	mM)	were	added	to	a	N2	
purged	vial	containing	reaction	buffer	(820	µL).	The	reaction	mixture	was	then	heated	
to	55	oC	under	nitrogen	for	24	h.	After	this	time,	milliQ	water	(1	mL)	was	added	to	the	
reaction	mixture	along	with	20	%	NaOH	(0.1	mL)	to	those	vials	containing	an	imine	
substrate	and	extracted	with	CHCl3	(4	x	3	mL).	The	organic	phase	was	then	dried	over	
MgSO4,	solvent	removed	under	vacuum	and	the	crude	residue	was	analysed	by	NMR.	
Controls	were	also	performed	following	the	above	procedure,	either	without	TADH	
(replaced	by	100	µL	of	Tris	buffer)	or	without	NADH	(replaced	with	10	µL	milliQ	water).	
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3.9 Inhibition	studies	with	ligand	21a	and	Ir-complex	24a	
3.9.1 Ligand	(21a)	inhibition	studies	
The	reaction	buffer	was	prepared	by	dissolving	Bis-Tris	salts	in	milliQ	water	for	a	final	
concentration	of	50	mM.	The	pH	was	adjusted	to	6.0	with	HCl.	The	substrate	stock	was	
prepared	by	dissolving	cyclohexanone	in	milliQ	water	to	a	final	concentration	of	500	
mM.	The	ligand	was	dissolved	in	DMSO	to	a	final	concentration	of	5	and	12.5	mM.	
TADH	stock	solution	was	prepared	to	a	final	concentration	of	0.25	mM	in	20mM	Tris	
pH	7.5.	NADH	stock	solutions	were	prepared	by	dissolving	NADH	in	milliQ	water	at	
final	concentrations	of	12.5,	5,	3.75,	2.5,	1.25	and	0.5	mM	to	prepare	a	NADH	stock	
solution.	
Stock	solutions	of	ligand	21a	(20	µL,	final	conc.	0.1	or	0.25	mM),	TADH	(10	µL,	5.6	µg)	
and	NADH	(20	µL,	final	conc.	0.25,	0.1,	0.075,	0.05,	0.025,	0.01	mM)	were	added	to	50	
mM	Bis-Tris	pH	6.0	buffer	(910	µL)	and	heated	to	60	oC	for	2	min.	The	reaction	was	
started	with	the	addition	of	NADH	and	mixing.	NADH	absorbance	was	measured	at	
340	nm	over	250	seconds.	
Table	3.4.	Enzyme	assay	parameters	for	inhibition	studies	with	Ligand	21a	
	 Stock	conc.	 V	(µL)	for	control	
V	(µL)	for					
21a	 Final	conc.	
Bis-Tris	pH	6.0	 50	mM	 910	 910	 ~50	mM	
Enzyme	 0.56	mg	/	mL	 10	 10	 0.0056	mg	/	mL	
Substrate	 500	mM	 40	 40	 20	mM	
DMSO	 -	 20	 0	 2	%	
Ligand	21a	 0,	5,	12.5	mM	 0	 20	 0,	0.1,	0.25	mM	
NADH		 12.5,	5,	3.75,	2.5,	1.25,	0.5	mM	 20	 20	
0.25,	0.1,	0.075,	0.05,	
0.025,	0.01	mM	
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3.9.2 Ir	complex	(24a)	inhibition	studies	
The	reaction	buffer	was	prepared	by	dissolving	Bis-Tris	salts	in	milliQ	water	for	a	final	
concentration	of	50	mM.	The	pH	was	adjusted	to	6.0	with	HCl.	The	substrate	stock	was	
prepared	by	dissolving	cyclohexanone	in	milliQ	water	to	a	final	concentration	of	500	
mM.	The	 Ir	catalyst	was	dissolved	 in	ACN	to	 final	concentrations	of	2.5	and	5	mM.	
TADH	stock	solution	was	prepared	to	a	final	concentration	of	0.25	mM	in	20mM	Tris	
pH	7.5.	NADH	stock	solutions	were	prepared	by	dissolving	NADH	in	milliQ	water	at	
final	concentrations	of	12.5,	5,	3.75,	2.5,	1.25	and	0.5	mM	to	prepare	a	NADH	stock	
solution.	
Stock	solutions	of	Ir-complex	24a	(20	µL,	final	conc.	0.05	or	0.1	mM),	TADH	(10	µL,	5.6	
µg)	and	NADH	(20µL,	final	conc.	0.25,	0.1,	0.075,	0.05,	0.025,	0.01	mM)	were	added	
to	50	mM	Bis-Tris	pH	6.0	buffer	(880	µL)	and	heated	to	60	oC	for	2	min.	The	reaction	
was	started	with	the	addition	of	NADH	and	mixing.	NADH	absorbance	was	measured	
at	340	nm	over	250	seconds.	
Table	3.5.	Enzyme	assay	parameters	for	inhibition	studies	with	Ir	complex	24a	
	 Stock	conc.	 V	(µL)	for	control	
V	(µL)	for	
24a	 Final	conc.	
Bis-Tris	pH	6.0	 50	mM	 880	 880	 ~50	mM	
Enzyme	 0.56	mg	/	mL	 10	 10	 0.0056	mg	/	mL	
cyclohexanone	 500	mM	 40	 40	 20	mM	
ACN	 -	 50	 30	 5%	
Ir	complex	24a	 0,	2.5,	5	mM	 0	 20	 0,	0.05,	0.1	mM	
NADH	 12.5,	5,	3.75,	2.5,	1.25,	0.5	mM	 20	 20	
0.25,	0.1,	0.075,	
0.05,	0.025,	0.01	mM	
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Chapter	4 Results	and	Discussion	
4.1 Selection	and	characterisation	of	a	suitable	ADH	to	engineer	imine	reductase	
activity		
4.1.1 Introduction	and	highlights		
The	 enzymatic	 reduction	 of	 carbonyls	 is	 performed	 by	 well-described	 alcohol	
dehydrogenases	 (see	 section	 1.2).	 On	 the	 other	 hand,	 the	 enzymatic	 reduction	 of	
imines,	 which	 differ	 from	 carbonyls	 only	 by	 replacement	 of	 the	 oxygen	 with	 a	
substituted	nitrogen,	was	rarely	encountered	in	nature	until	recently;	when	the	class	
of	imine	reductases	(IREDs)	was	discovered	and	characterised.	Similar	to	ADHs,	IREDs	
depend	 on	 a	 nicotinamide	 cofactor,	 which	 transfers	 the	 hydride	 to	 the	 carbon-
nitrogen	double	bond.	Therefore,	it	was	hypothesised	that	ADHs	would	make	suitable	
starting	points	for	the	engineering	of	enzymes	with	promiscuous	reactivities,	towards	
the	transfer	of	hydrides	to	other	carbon-heteroatom	bonds	than	carbonyls.	
Since	 the	 beginning	 of	 this	 thesis,	 the	 knowledge	 and	 application	 of	 IREDs	 to	
biotransformations	have	 increased	very	 rapidly.	However,	 there	are	still	 challenges	
associated	with	IRED	application	to	organic	synthesis.	In	comparison,	ADHs	are	better	
understood	and	characterised,	which	makes	 them	very	desirable	 starting	points	 to	
engineer	new	activity.	Some	of	the	main	advantages	of	ADHs	compared	with	IREDs,	in	
terms	of	application	scope,	are	highlighted	in	Table	4.1.	
The	use	of	ADHs	to	reduce	imines	might	circumvent	some	of	the	IRED	issues,	such	as	
their	NADPH	dependence,	their	relatively	low	catalytic	efficiency	and	their	relatively	
narrow	substrate	specificity	towards	cyclic	imines.	The	aim	of	this	section	is	to	identify	
and	characterise	a	suitable	ADH	to	be	used	as	a	starting	point	for	the	development	of	
IRED	activity.	
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Table	4.1.	Comparison	of	key	traits	of	ADHs	and	IREDs	highlighting	the	advantages	of	ADHs.	
	 ADH	 IRED	
Cofactor	dependence	 NADH	and	NADPH	 Mostly	NADPH	
Thermostability	 Several	thermostable	ADHs	characterised	
No	thermostable	IRED	
characterised	so	far	
Solvent	tolerance	 Several	solvent	tolerant	ADHs	characterised	
No	solvent	tolerant	IREDs	
characterised	so	far	
Substrate	scope	
Wide	substrate	range	with	
different	structural	
architecture	
Preferred	cyclic	imines	
	
Structural	
characterisation	 Several	crystal	structures	 Three	crystal	structures	
	
Highlights	
• Thermostable	ADH	from	Thermus	sp.	ATN1	(TADH)	was	identified	as	a	starting	
point	for	the	engineering	of	promiscuity	towards	imine	reduction.	
• Literature	protocols	for	the	expression	and	purification	of	TADH	from	E.	coli	
were	 adapted,	 to	 yield	 good	 amounts	 of	 relatively	 pure	 protein	 for	 further	
studies.		
• The	kinetic	parameters	of	the	purified	TADH	were	similar	to	the	ones	reported	
in	the	literature,	although	the	specific	activity	was	consistently	lower.	
• 	The	 zinc	 content	 in	 the	 TADH	 purified	 by	 heat	 treatment	 was	 lower	 than	
expected.	Purification	by	size	exclusion	chromatography	led	to	a	protein	:	zinc	
molar	ratio	of	1	:	1.6,	closer	to	the	expected	result.	
4.1.2 Selection	 of	 TADH	 from	 Thermus	 sp.	 ATN1	 as	 starting	 point	 for	 enzyme	
engineering	
At	the	beginning	of	this	project,	few	imine	reductases	were	known	and	characterised.	
Since	then,	an	imine	reductase	database	was	created	using	bioinformatics	tools,	and	
84	
	
several	of	these	putative	IRED	sequences	were	cloned	and	characterised.	Sequence	
alignments	of	IREDs	with	either	Zn-dependent	(medium-chain)	or	non-Zn	dependent	
(short-chain)	ADHs	resulted	in	no	sequence	similarity	between	these	enzymes	(below	
20	%),	suggesting	no	evolutionary	relationship	between	the	ADH	and	IRED	scaffolds.		
In	the	absence	of	sequence	similarity,	the	criteria	listed	in	Table	4.1	above	were	used	
to	select	a	suitable	ADH	for	the	engineering	of	 imine	reductase	activity.	A	range	of	
ADHs	previously	highlighted	as	potential	biocatalysts	for	stereoselective	reductions160	
were	initially	selected	as	possible	candidates,	outlined	in	Table	4.2.	A	list	of	desired	
criteria	was	created	to	assist	in	the	selection	of	the	best	ADH	scaffold	for	introduction	
of	imine	reductase	activity:	
• Stability.	 Thermostable	 ADHs	were	 preferred,	which	 are	 usually	 tolerant	 to	
both	high	temperatures	and	organic	solvents.	Organic	solvent	use	was	thought	
to	prevent	hydrolysis	of	the	imine	substrate,	and	to	contribute	to	solubilisation	
of	hydrophobic	substrates.		
• Broad	substrate	range.	Compared	to	their	carbonyl	precursors,	imines	possess	
an	extra	 substituent	at	 the	nitrogen	atoms.	An	enzyme	with	a	promiscuous	
substrate	 spectrum	was	 hypothesised	 to	 have	 increased	 chances	 to	 accept	
non-native	imines.		
• NADH	dependence.	Use	of	NADH	as	cofactor	was	preferred,	since	 it	 is	more	
available	and	cheaper	than	NADPH.	
• Available	 crystal	 structure.	 Well	 characterised	 ADHs	 allow	 for	 better	
understanding	of	the	structure	and	mechanistic	functions,	affording	informed	
decisions	on	protein	engineering.		
• E.	 coli	 expression	 system.	 Recombinant	 expression	 in	 E.coli	 and	 easy	
purification	were	desirable	for	quick	and	easy	production	of	the	enzyme.	
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Table	 4.2.	 Comparison	 of	 desired	 criteria	 of	 potential	 ADHs	 for	 introduction	 of	 imine	 reductase	
activity.a		
	 HLADH	 ADH-A	 TbADH	 TADH	 TeSADH	 PpADH	 AdhA	
Thermostability	 O	 ü	 ü	 ü	 ü	 ü	 ü	
High	solvent	
stability	 O	 ü	 ü	 ü	 ü	 ü	 ü	
Broad	substrate	
range	 ~	 O	 O	 ü	 ü	 O	 ~	
NADH	
dependent	 ü	 ü	 O	 ü	 O	 ü	 O	
Available	crystal	
structure	 ü	 ü	 ü	 ü	 O	 O	 O	
E.	coli	expression	
system	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
a	HLADH:	from	horse	liver,	ADH-A	from	Rhodococcus	rubber,	TbADH	from	Thermoanaerobacter	brockii,	
TADH	from	Thermus	sp.	ATN1,	TeSADH	from	Thermoanaerobacter	ethanolicus,	PpADH	from	Paracoccus	
pantotrophus,	AdhA	from	Pyrococcus	furiosus.161		
One	 of	 the	 most	 studied	 ADHs	 is	 HLADH	 from	 horse	 liver.	 This	 NADH-dependent	
mesophilic	 enzyme	 accepts	 predominantly	 primary	 alcohols	 and	 aldehydes	 as	
substrates,	 although	 reduction	 of	 ketones	 was	 also	 described.	 HLADH	 was	 also	
reported	 to	 show	 some	 organic	 solvent	 tolerance.	 The	 limited	 substrate	 scope,	
thermal	stability	and	organic	solvent	 tolerance	of	HLADH	reduce	 its	applicability	 to	
organic	transformations.	In	addition,	recombinant	production	of	HLADH	from	E.	coli	
requires	 purification	 procedures	 that	 are	 not	 straightforward.	 Production	 of	 a	His-
tagged	 version	 of	 HLADH	 has	 been	 reported,	 however	 tentatives	 to	 reproducibly	
purify	this	construct	were	not	trivial	(Mattias	Basle,	unpublished	data).	
On	the	other	hand,	several	ADHs	with	 tolerance	 towards	organic	solvents	and	/	or	
possessing	 thermostability	 have	 been	 published.	 Amongst	 these,	 the	 best	
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characterised	 are	 Zn-dependent	 ADHs	 from	Rhodococcus	 ruber	DSM	 44541	 (ADH-
A),162	 Thermoanaerobacter	 brockii	 (TbADH),122	 Thermus	 sp.	 ATN1	 (TADH),163	
Thermoanaerobacter	ethanolicus	(TeSADH):164	as	well	as	non	metal-dependent	ADHs	
from	 Paracoccus	 pantotrophus	 DSM	 11072	 (PpADH)165	 and	 Pyrococcus	 furiosus	
(AdhA).161	Crystal	structures	have	also	been	published	for	the	Zn-dependent	enzymes	
excluding	TeSADH;	no	crystal	 structures	have	been	 reported	 for	either	of	 the	non-
metal	dependent	ADHs,	thus	they	were	ruled	out.	Half	of	these	enzymes,	 including	
TbADH	are	NADPH-dependent	and	were	therefore	not	considered	for	this	study.	Thus,	
leaving	 ADH-A	 from	Rhodococcus	 ruber	 and	 TADH	 from	 Thermus	 sp.,	 both	 NADH-
dependent	 thermostable	 enzymes	 as	 potential	 candidates.	 ADH-A	 is	 reported	 to	
withstand	high	solvents	concentrations,	for	example	acetone	(up	to	50	%	v	/	v)	and	2-
propanol	(80	%	v	/	v).166	TADH	is	reported	to	retain	activity	in	a	range	of	solvents	for	
example,	acetone	(10	%	v	/	v)	and	octane	(50	%	v	/	v).109	However,	ADH-A	has	a	much	
narrower	 substrate	 range	 when	 compared	 to	 TADH,	 primarily	 catalysing	 medium	
chain	secondary	alcohols	and	their	corresponding	ketones,	whilst	TADH	has	a	broad	
ketone	substrate	range	including	primary,	secondary	and	cyclic	alcohols.	Furthermore,	
TADH	has	been	used	 in	the	presence	of	chemical	catalysts	and	 in	electroenzymatic	
setups	for	cofactor	recycling	and	was	reported	to	be	recombinantly	expressed	in	E.	
coli	and	purified	by	heat.108,167	A	comparison	of	TADH	with	HLADH	shows	very	similar	
features	in	catalysis	and	in	the	substrate	binding	pocket	(Figure	4.1)	except	that	an	
aspartate	 residue	 (Asp152)	 in	 TADH	 replaces	 Cys174	 in	 HLADH.	 Therefore,	 it	 was	
hypothesised	 that	 TADH	 would	 represent	 a	 suitable	 starting	 point	 for	 active	 site	
engineering.	
One	potential	issue	with	the	use	of	the	TADH	enzyme	is	the	presence	of	five	cysteine	
residues	in	its	sequence	(see	Appendix	1).	As	mentioned	previously,	one	cysteine	is	
involved	 in	 the	 binding	 of	 the	 catalytic	 zinc(II)	 ion	 located	 in	 the	 active	 site,	 the	
remaining	four	are	bound	to	a	second	zinc(II)	ion	at	a	structural	site.	It	is	these	four	
neighboring	 cysteines	which	 could	 cause	 problems,	 if	 oxidised,	 forming	 disulphide	
bonds	with	one	another	which	can	drastically	change	the	conformation	of	the	enzyme	
and	 increase	 the	chance	of	misfolding.	Nonetheless,	 investigations	proceeded	as	 it	
was	assumed	these	cysteines,	present	in	all	structurally	characterised	ADHs	containing	
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a	structural	zinc,84	would	not	be	easily	accessible	for	oxidation	due	to	their	location	
embedded	within	the	protein	structure	and	strong	binding	to	the	structural	zinc	ion.		
	
Figure	 4.1.	 Alignment	 of	 TADH	 (PDB	 4CPD,	 green)	 and	 HLADH	 (PDB	 4XD2,	 cyan)	 active	 sites,	
highlighting	Zn-binding	amino	acids	and	 the	NADH	cofactor.	Amino	acid	numbering	 is	 from	TADH.	
Cys174	replaces	Asp152	in	TADH.		
4.1.3 Expression	of	TADH	in	E.	coli	
The	gene	for	TADH	was	obtained	from	Prof.	Frank	Hollmann	from	TU	Delft,	and	was	
already	cloned	into	the	pASZ2	plasmid,	previously	reported.	This	plasmid	carried	the	
TADH	gene	cloned	between	 the	EcoRI	and	BamHI	 restriction	 sites	of	pET11aEco	 (a	
derivative	of	pET11a,	Novagene,	carrying	an	additional	EcoRI	site	between	the	NdeI	
site	and	the	ribosome	binding	site	of	pET11a).	Gene	sequencing	confirmed	that	no	
mutations	were	present	in	the	material	received	from	the	collaborators,	and	the	gene	
sequence	is	presented	in	Appendix	1.	The	plasmid	was	transformed	into	chemically	
competent	 	 E.	 coli	 BL21(DE3)	 pLysS,	 and	 successful	 transformants	 were	 grown	 at											
37	oC	and	used	for	the	expression	of	TADH	in	LB	medium	with	IPTG	induction	at	30	oC.		
Expression	of	TADH	was	analysed	by	SDS-PAGE	of	the	soluble	and	insoluble	protein	
extracts	of	the	expression	cultures,	at	different	times	after	induction	with	IPTG.	Visual	
inspection	of	the	SDS-PAGE	showed	a	protein	band	at	37	kDa,	which	was	not	observed	
in	the	cells	before	induction	(Figure	4.2a,	lane	1	vs.	2-7).	The	first	attempt	using	the	
adapted	published	protocol	resulted	in	mostly	insoluble	TADH	(Figure	4.2a	lanes	8-9).		
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Figure	4.2.	TADH	expression	time	course	at	different	growth	temperatures:	a)	37	oC,	b)	30	oC	
E.	coli	BL21(DE3)	pLysS	pASZ2	was	grown	in	LB	supplemented	with	carbenicillin.	Protein	expression	was	
induced	at	OD600	of	~0.7	by	the	addition	of	sterile	IPTG	(1	mM	final	concentration).	The	cultures	were	
incubated	for	the	specified	time	and	temperature,	and	1	mL	samples	were	harvested	by	centrifugation.	
Samples	were	lysed	using	Bugbuster	lysis	reagent	and	the	protein	content	analysed	by	SDS-PAGE.	a)	
growth	at	37	oC,	expression	at	30	oC.	1-7:	soluble	cell	fractions	after	1:	0	h,	2:	1	h,	3:	2	h,	4:	3	h,	5:	4	h,	
6:	5	h,	7:	22	h;	8:	 insoluble	fraction	3	h,	9:	 insoluble	fraction	22	h;	b)	growth	at	30	oC,	expression	at									
30	oC,	heat	treatment	80	oC	15	min.	1:	soluble	fraction	0	h,	2-3:	soluble	fractions	18	h,	4:	soluble	fraction	
0	h	after	heat	treatment,	5-6:	soluble	fraction	18	h	after	heat	treatment,	7	&	9:	insoluble	fraction	18	h	
after	heat	treatment.	8:	insoluble	fraction	0	h	after	heat	treatment.	
89	
	
To	optimise	expression,	the	growth	temperature	was	reduced	to	30	oC,	which	resulted	
in	a	reduced	amount	of	insoluble	protein,	although	the	amount	of	soluble	TADH	was	
not	increased	(Figure	4.2b).	
The	 effect	 of	 IPTG	 concentration	 on	 TADH	 expression	 was	 also	 investigated,	 as	
Winograd	et	al.	showed	that	reduction	of	IPTG	increased	protein	solubility,	preventing	
the	formation	of	 inclusion	bodies.168	A	slight	 increase	 in	both	soluble	and	 insoluble	
protein	concentration	was	observed	by	SDS-PAGE,	when	IPTG	was	lowered	from	1	mM	
to	 0.4	 mM	 final	 concentration	 during	 induction	 (Figure	 4.3a-b,	 lanes	 3-4	 &	 7-8).	
Expression	 also	 occurred	 in	 the	 absence	 of	 IPTG,	 as	 shown	 by	 SDS-PAGE	 of	 both	
soluble	and	insoluble	fractions	(Figure	4.3a-b,	lane	6).	This	might	be	due	to	the	two	
operons	 (lac	 operon	 and	 T7	 promoter)	 present	 in	 the	 pASZ2	 plasmid,	 resulting	
inexpression	that	is	harder	to	control.	Addition	of	1	%	glucose	to	the	growth	medium	
did	not	prevent	expression	before	induction.	When	expression	was	performed	in	auto-
inductive	Terrific	Broth	(TB)	medium,	without	addition	of	IPTG,	little	expression	of	the	
desired	protein	was	observed	(Figure	4.3a-b,	lane	9).		
In	addition,	after	 induction	with	 IPTG,	 it	was	noted	that	the	expression	culture	had	
unexpectedly	high	OD600,	(5-7),	which	could	not	be	related	to	the	appearance	of	the	
sample.	When	samples	were	examined	under	the	microscope,	large	clumps	of	dead	
cells	were	observed,	which	may	relate	to	the	higher	than	expected	OD600	values.	Cell	
death	was	observed	after	induction	with	IPTG	at	1	mM,	as	well	as	during	expression	
using	the	auto-induction	TB	medium,	whilst	no	cell	death	was	observed	before	IPTG	
induction,	nor	during	induction	with	IPTG	at	0.4	mM.		
Literature	 reports	 do	 not	mention	 the	 amount	 of	 insoluble	 protein	 formed	 during	
expression.	 Growth	 of	 cells	 to	 a	 final	 OD600	 of	 9	 was	 reported	 using	 1	 mM	 IPTG	
induction,	which	was	not	reproduced	in	this	work.	A	subsequent	literature	report	by	
the	same	group	used	a	different	methodology,	based	on	expression	using	an	auto-
induction	medium	yielding	high	amounts	of	protein.	Again,	this	was	not	reproduced	
in	this	work,	using	TB	auto-induction	medium.		
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Figure	4.3.	TADH	expression	time	course	in	LB	media	with	different	concentrations	of	IPTG	at	the	
point	of	induction	compared	to	auto-induction	TB	media	:	a)	soluble	protein	fractions,	b)	insoluble	
protein	fractions.	
E.	coli	BL21(DE3)	pLysS	pASZ2	was	grown	in	LB	/	TB	supplemented	with	carbenicillin.	Protein	expression	
was	 induced	 in	 LB	 at	 OD600	 of	 0.6-0.7	 by	 the	 addition	 of	 sterile	 IPTG	 (0.4	 mM	 or	 1	 mM	 final	
concentration).	The	cultures	were	incubated	for	the	specified	time	at	30	oC,	and	1	mL	samples	were	
harvested	by	centrifugation.	Samples	were	lysed	using	Bugbuster	lysis	reagent	and	the	protein	content	
analysed	by	SDS-PAGE.	a)	soluble	fractions.	1:	0	h	in	LB,	2:	5	h	in	LB,	no	IPTG,	3:	5	h	in	LB	after	induction	
with	0.4	mM	IPTG,	4:	5	h	in	LB	after	induction	with	1	mM	IPTG,	5:	7	h	expression	in	Auto	induction	TB	
media,	6:	20	h	in	LB,	no	IPTG,	7:	20	h	in	LB	after	induction	with	0.4	mM	IPTG,	8:	20	h	in	LB	after	induction	
with	1	mM	IPTG,	9:	23	h	expression	in	Auto	induction	TB	media.		
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The	expression	studies	presented	here	suggested	the	following	optimal	conditions	for	
expression:	 cell	 growth	and	expression	at	30	 oC,	 in	 LB	medium	supplemented	with									
1	%	(w	/	v)	glucose	to	repress	basal	expression,169	and	induction	with	IPTG	at	0.4	mM	
final	concentration,	when	the	cells	reached	an	OD600	of	0.6	-	0.7.	Further	investigations	
showed	no	difference	in	protein	concentration	or	enzymatic	activity	when	a	freshly	
transformed	colony	was	used,	compared	to	a	25	%	cryostock,	and	both	these	methods	
were	used	for	expression	in	the	following	work.	
4.1.4 Purification	of	TADH	
The	first	published	work	with	TADH	suggested	a	heat	step	purification	at	80	oC	for	15	
min,	whilst	in	a	subsequent	publication,	the	heat	step	was	at	75	oC	for	20	min,	followed	
by	anion	exchange	chromatography	(AEX).	This	was	found	to	increase	the	purity	and	
specific	activity	of	TADH.	The	most	recent	paper,	published	during	the	course	of	this	
work	and	describing	the	TADH	crystal	structure,	reports	purification	by	heat	treatment	
at	80	oC	for	20	min,	followed	by	size	exclusion	chromatography.	Therefore,	the	effect	
of	the	purification	on	the	specific	activity	and	on	the	purity	of	TADH	was	investigated.	
The	purity	was	 evaluated	by	 visual	 inspection	of	 the	 SDS-PAGE,	whilst	 the	 specific	
activity	was	determined	 in	 the	oxidative	direction	 at	 60	 oC,	 using	1-butanol	 as	 the	
substrate.		
Initial	attempts	to	purify	TADH	were	performed	following	the	best	conditions	reported	
at	the	time	of	study,	which	were	by	heating	the	soluble	cell	extract	at	75	oC	for	20	min,	
followed	 by	 centrifugation	 of	 the	 precipitated	 proteins.	 SDS-PAGE	 analysis	 of	 the	
soluble	fraction	after	centrifugation	showed	a	high	degree	of	purity,	with	removal	of	
most	proteins	from	the	soluble	cell	extract,	except	for	the	desired	heat-stable	TADH	
(Figure	4.4a,	lanes	1-2).	A	good	specific	activity	(1.3	U	/	mg)	was	determined	for	the	
heat-purified	(75	oC	20	min)	TADH	,	although	this	was	lower	than	the	reported	4.7	U	/	
mg	 (80	 oC,	 15	 min).108	 Following	 the	 literature	 report,	 a	 subsequent	 AEX	
chromatography	step	was	performed	after	heating,	using	a	HiTrap	Q	Sepharose	High	
Performance	column,	resulting	in	further	purification,	as	confirmed	by	an	increased	
specific	activity	to	1.6	U	/	mg,	and	by	fainter	protein	impurity	bands	observed	by	SDS-
PAGE	(Figure	4.4a,	lane	3).	However,	this	increase	in	specific	activity	(25	%)	was	lower	
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than	 the	 reported	 one,	 which	 increased	 by	 33	 %	 after	 AEX	 treatment	 using	 a	
Sepabeads®	 EB-QA405	 column,	 (from	 15.0	 to	 20.6	 U	 /	 mg	 reported	 for	 substrate	
cyclohexanol).	This	was	most	probably	due	to	heat	loss	during	the	enzymatic	activity	
assay:	when	a	sealed	heating	block	was	used	during	the	assay,	an	increased	specific	
activity	to	6.0	U	/	mg	was	obtained	for	1-butanol.	
		
Figure	4.4.	Purification	of	TADH	by	heat	treatment	and	ion	exchange.	a)	SDS-PAGE	analysis	of	TADH	
purification.	1:	soluble	cell	extract,	obtained	after	cell	lysis	and	centrifugation	of	cell	debris,	2:	soluble	
cell	extract	after	heating	at	75	oC	for	20	min	and	centrifugation	of	the	insoluble	proteins,	3:	combined	
fractions	after	AEX	purification;	b)	AEX	chromatogram	displaying	the	UV	trace	at	280	nm	in	blue.		
Different	 temperatures	and	heating	 times	were	evaluated	 for	 the	heat	purification	
step,	due	to	the	variations	in	the	reported	methods	for	heat	purification	and	to	the	
lower	than	expected	specific	activities	obtained	during	initial	purification	attempts.	It	
was	observed	that	variations	in	both	the	temperature	and	the	time	of	heating	resulted	
in	 different	 specific	 activities.	 Hollmann	 and	 co-workers	 reported	 an	 increase	 in	
specific	 activity	 when	 the	 purification	 temperature	 increased,	 perhaps	 due	 to	
increased	folding	and	formation	of	the	quaternary	structure.	This	phenomenon	has	
previously	 been	 observed	 with	 thermostable	 proteins	 expressed	 in	 E.	 coli.	 Similar	
results	 were	 observed	 in	 this	 study	 (Table	 4.3)	 and	 the	 optimal	 heat	 purification	
conditions	were	selected	as	80	oC	for	20	min.	When	the	enzyme	was	expressed	in	TB	
auto-induction	medium,	the	specific	activity	was	lower	than	after	LB	expression,	thus	
confirming	the	choice	of	this	expression	system	as	the	optimal	one.	
	 			1	 2	 		3	
		TADH	
a)	 b)	
93	
	
After	the	heat	treatment	at	80	oC	for	20	min,	two	different	chromatography	steps	were	
compared,	 to	 assess	 whether	 TADH	 specific	 activity	 could	 be	 increased:	 anion	
exchange	(AEX)	and	size	exclusion	chromatography	(SEC).		
Table	4.3.	Effect	of	temperature	and	time	of	heating	on	the	specific	activity	of	TADH.	
Entry	 Temperature	(oC)	 Time	(min)	 Specific	activity	(U	/	mg)a	
1	 75	 15	 1.2	±	0.10	
2	 75	 20	 1.3	±	0.21	
3	 80	 20	 2.2	±	0.16	
4b	 80	 20	 1.6	±	0.10	
a	 TADH	was	 expressed	 in	 LB	medium,	 following	 induction	 with	 0.4	mM	 IPTG.	 Specific	 activity	 was	
determined	in	the	oxidative	direction	at	60	oC,	using	1-butanol	(100	mM)	as	a	substrate,	NAD+	(1	mM)	
as	 cofactor,	 in	 50	 mM	 Glycine-NaOH	 buffer	 pH	 9.0.	 b	 TADH	 was	 expressed	 in	 overnight	 express	
autoinduction	medium.	Where	error	bars	are	specified,	specific	activities	were	determined	in	triplicate,	
by	purifying	and	analysing	three	different	batches	from	the	same	cell	pellet.		
Only	a	slight	 increase	 in	activity	was	observed	when	an	additional	chromatography	
step	was	applied	(Table	4.4)	although	both	chromatograms	showed	the	removal	of	
impurities	absorbing	at	280	nm,	with	the	SEC	purified	sample	displaying	the	highest	
purity.	 Unexpectedly,	 the	 largest	 peak	 obtained	 during	 SEC	 purification	 was	 not	
representative	 of	 active	 TADH	 and	 did	 not	 show	 any	 presence	 of	 proteins	 when	
assessed	by	Bradford	assay,	despite	its	high	absorbance	at	280	nm.		
Table	4.4.		Specific	activity	of	TADH	purified	by	different	methods.	
Entry	 Purification	conditions	 Specific	activity	(U	/	mg)	
1	 80	oC	for	20	min	 2.1	
2	 80	oC	for	20	min	&	AEX	 2.3	
3	 80	oC	for	20	min	&	SEC	 2.2	
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Fractions	18-19	highlighted	in	Figure	4.5	showed	faint	protein	bands	of	similar	size	to	
TADH	when	analysed	by	SDS-PAGE,	but	exhibited	no	activity.	
	
Figure	4.5.	Comparison	of	TADH	chromatography	purification	methods.	a)	Chromatogram	of	TADH	
purification	by	 size	 exclusion	 chromatography.	 	 The	 chromatogram	 shows	 the	UV	 trace	 at	 280	nm,	
alongside	the	SDS-PAGE	analysis	of	the	collected	fractions;	b)	SDS-PAGE	comparison	of	TADH	samples	
obtained	by	three	different	purification	methods:	1:	heat;	2:	heat	&	AEX;	3:	heat	&	SEC.	
4.1.5 Determination	of	TADH	zinc	content	
The	zinc	content	of	purified	TADH	was	analysed	by	inductively	coupled	plasma	mass	
spectrometry	(ICP-MS)	and	then	compared	to	protein	concentration	determined	by	
Bradford	 assay,	 to	 calculate	 the	 ratio	 of	 TADH	 to	 zinc.	 TADH	 is	 a	 homotetrameric	
structure,	with	each	monomer	containing	two	zinc	ions:	the	catalytic	zinc(II)	found	in	
the	active	site,	and	the	structural	zinc(II).	Thus,	the	expected	TADH	:	zinc	ratio	is	1	:	2.		
Analysis	of	the	heat-purified	TADH	resulted	in	a	lower	than	expected	Zn	content,	with	
a	slightly	higher	Zn	ratio	observed	after	the	heat	step	at	a	higher	temperature	for	a	
longer	 time.	This	confirms	 that	 the	higher	purification	 temperature	might	promote	
better	 folding	 of	 the	 protein	 during	 purification.	 Further	 AEX	 purification	 did	 not	
increase	the	Zn	:	protein	ratio,	but	SEC	purification	resulted	in	an	increased	Zn	content,	
and	 suggested	 SEC	 as	 the	 optimal	 purification	 method	 (Table	 4.5).	 Nonetheless,	
purification	 by	 SEC	was	 not	 performed	 throughout	 the	 thesis,	 because	 the	 results	
above	were	obtained	after	initial	TADH	engineering	experiments	were	performed.	For	
much	of	the	following	studies	in	Section	4.3,	only	heat	purification	was	used,	which	
yielded	 high	 purity.	 The	 different	 purification	 methods	 used	 will	 be	 highlighted	
throughout.	
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Table	4.5.	Zinc	content	of	TADH	purified	by	different	methods.	
Entry	 Purification	conditions	 TADH	:	Zinc	ratioa	
1	 75	oC	for	15	min	 1.0	:	0.5	-	0.7	
2	 80	oC	for	20	min	 1.0	:	0.9	-	1.2	
3	 80	oC	for	20	min	&	AEX	 1.0	:	1.2	
4	 80	oC	for	20	min	&	SEC	 1.0	:	1.5	-	2.1	
a	Expected	TADH	:	Zinc	ratio	=	1.0	:	2.0;	where	ranges	are	observed	zinc	content	analysis	was	performed	
on	different	batches	of	TADH	purified	under	the	same	conditions.	
The	differences	in	Zn	content	depending	on	the	purification	method	were	assumed	to	
be	due	to	zinc-devoid	inactive	protein,	which	was	removed	throughout	purification.	
From	SDS-PAGE	analysis,	which	showed	high	purity	of	all	samples,	it	seemed	that	the	
majority	of	this	inactive	protein	was	inactive	TADH,	perhaps	due	to	misfolding	of	this	
thermostable	protein	expressed	in	a	mesophilic	organism.	The	ranges	of	Zn	contents	
observed	for	samples	purified	in	similar	manner	are	the	result	of	Zn	content	analysis	
of	various	enzyme	batches.	
4.1.6 Determination	of	TADH	kinetic	parameters	at	steady	state	
Kinetic	parameters	of	TADH	were	determined	according	to	methods	published	in	the	
literature,	 using	 cyclohexanol	 and	 cyclohexanone	 as	 substrates.	 Specific	 activities	
determined	for	cyclohexanol	and	cyclohexanone	were	9.9	±	0.2	and	15.9	±	0.4	U	/	mg,	
compared	to	previously	reported	(20.6	U	/	mg	for	cyclohexanol	after	AEX	purification).	
The	differences	might	come	from	slight	changes	in	the	enzymatic	assay	setup.	Steady	
state	kinetic	parameters	also	differed	slightly	from	the	reported	values,	highlighting	
the	 difficulty	 to	 reproduce	 TADH	 as	 characterised	 in	 the	 literature	 (Table	 4.6).	 For	
cyclohexanone	reduction,	the	low	solubility	of	the	substrate	hindered	the	collection	
of	a	complete	set	of	data	to	accurately	determine	Vmax.		
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Table	 4.6.	 Kinetic	 constants	 observed	 for	 cyclohexanol	 and	 cyclohexanone	 as	 compared	 to	 the	
reported	constants	found	in	the	literature.	
	 Kinetic	constants	 Reported	Value109	 Achieved	Value	
Oxidationa	 Vmax	(U	/	mg)	 20.78	±	0.55	 16.0	±	0.37	
	 KM	(mM)	 2.09	±	0.26	 1.5	±	0.11	
Reductionb	 Vmax	(U	/	mg)	 15.14	±	0.2	 7.3	±	0.11	
	 KM	(mM)	 3.68	±	0.26	 8.2	±	0.37	
a	Oxidation	was	performed	at	60	oC,	using	TADH	(3	µg),	cyclohexanol	(0.5,	1,	1.5,	2,	3,	5,	7.5	and	10	mM)	
as	substrate,	NAD+	(1	mM)	as	cofactor,	in	50	mM	Glycine-NaOH	buffer	pH	9.0;	Michaelis-Menten	plot	
is	presented	in	Appendix	3.	b	Reduction	was	performed	at	60	oC,	using	TADH	(1	µg),	cyclohexanone	(1,	
2.5,	7.5	15,	25	and	50	mM)	as	substrate,	NADH	(0.1	mM)	as	cofactor,	in	50	mM	Bis-Tris	buffer	pH	6.0;	
Michaelis-Menten	plot	is	presented	in	Appendix	4.	
4.1.7 Conclusions	
Some	issues	were	observed	with	reproducing	the	TADH	preparation	as	reported	in	the	
literature.	This	included	reproduction	of	the	high	degree	cell	growth	and	subsequent	
protein	expression	observed	in	the	literature	with	a	final	OD600	of	9	whereas	a	final	
OD600	between	3	and	5	where	generally	achieved	in	the	work	reported	here.	Initially,	
heat	loss	during	the	activity	assays	was	observed	to	be	an	issue	with	reproduction	of	
the	reported	specific	activities	(e.g.	for	1-butanol	2.2	U	/mg	compared	to	the	literature	
4.7	U	/	mg).	However,	when	this	was	resolved	the	specific	activities	were	similar	(6.0	
U	 /mg)	 to	 those	 reported	 in	 the	 literature	 for	 the	 heat-treated	 samples.	 Further	
purification	by	chromatography	methods	however	did	not	reproduce	the	 increased	
activity	observed	in	the	literature,	with	only	minor	increases	in	activity	observed.	SDS-
PAGE	analysis	did	show	the	removal	of	impurities.	Finally,	a	lower	than	expected	zinc	
content	 was	 observed	 to	 be	 an	 issue	 depending	 on	 the	 purification	 method.	 The	
literature	however	does	not	 report	quantitative	metal	analysis	 for	 comparison	 it	 is	
assumed	at	two	zinc	ions	per	monomer	of	TADH.		
Nonetheless,	an	efficient	method	for	the	expression,	purification	and	characterization	
of	TADH	was	developed,	involving	E.	coli	growth	at	30	oC,	induction	with	0.4	mM	IPTG	
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at	 30	 oC,	 heat	 purification	 at	 80	 oC	 for	 20	 min,	 followed	 by	 size	 exclusion	
chromatography.	The	resulting	TADH	showed	specific	activity	of	6.0	U	/	mg	towards	
1-butanol	 and	 11.8	 U	 /	mg	 towards	 cyclohexanol,	 steady	 state	 kinetic	 parameters	
similar	to	the	ones	reported	in	the	literature,	and	a	Zn	content	which	was	lower	than	
the	expected	1	 :	 2	 ratio	 (protein	 :	 Zn).	 This	was	probably	due	 to	unfolded	 inactive	
TADH.	
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4.2 Genetic	engineering	of	the	active	site	of	TADH	for	promiscuity	towards	imine	
reduction	
4.2.1 Introduction	and	highlights		
From	a	chemical	point	of	view,	reduction	of	ketones	and	of	imines	is	similar,	and	is	
effected	by	similar	catalysts.	However,	ADHs	have	no	cross-reactivity	towards	imines,	
whilst	IREDs	do	not	reduce	ketones.	The	aim	of	this	section	is	to	gain	understanding	
of	the	specificity	of	ADHs	/	IREDs	towards	ketones	/	imines,	respectively.	In	particular,	
to	understand	why	there	is	no	cross-reactivity,	and	to	assess	whether	cross-reactivity	
can	be	introduced	by	genetic	engineering	of	the	active	site.	
The	main	features	of	the	TADH	reductive	mechanism,	which	follows	the	mechanism	
of	all	medium-chain	(Zn-dependent)	ADHs,	involve	carbonyl	activation	by	the	catalytic	
Zn(II)	acting	as	Lewis	acid,	to	promote	hydride	transfer	from	the	NAD(P)H	cofactor,	
situated	within	4-5	Å	from	one	another	(Figure	4.6).	This	is	followed	by	protonation	of	
the	nascent	hydroxyl	by	Ser40	(TADH	numbering),	via	a	proton	relay	system.	Metal-
devoid	short-chain	reductases	activate	the	substrate	via	an	acidic	active	site	residue	
(Brønsted	 acid),	 which	 generally	 employ	 a	 tyrosine	 as	 part	 of	 a	 hydrogen	 bond	
network	tetrad	with	serine-lysine-asparagine.	Similar	to	short-chain	reductases,	IREDs	
activate	 imines	 by	 an	 aspartate	 or	 a	 tyrosine	 side-chain	 situated	 within	 a	 short	
distance	(5-8	Å)	from	the	C4	of	NADPH	(Figure	4.6).	
Whilst	the	inability	of	IREDs	to	reduce	ketones	was	systematically	tested,	the	lack	of	
activity	of	ADHs	for	imine	reduction	was	less	explored.	Kroutil’s	group	showed	some	
activity	ADHs	towards	oximes,	but	reduction	occurred	at	the	nitrogen,	rather	than	at	
the	carbon	atom,	and	the	resulting	aldimine	spontaneously	hydrolysed.170		
Several	 hypotheses	were	made	 to	 explain	 the	 specificity	 of	ADHs	 /	 IREDs	 for	 their	
respective	substrates.	In	the	case	of	IREDs,	the	acidic	Asp	/	Tyr	residue	might	not	be	
strong	enough	to	activate	the	ketone.	Indeed,	the	pKa	of	this	acidic	residue	in	short-
chain	ADHs	is	modulated	by	involvement	in	a	tetrad,	which	enables	the	proton	relay,	
whilst	 IREDs	 do	 not	 generally	 possess	 this	 hydrogen	 network.	 In	 the	 case	 of	 Zn-
dependent	ADHs,	one	hypothesis	for	lack	of	imine	reduction	activity	was	the	inhibition	
by	the	imine	substrate	or	by	the	amine	product,	as	a	result	of	strong	binding	between	
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the	nitrogen-containing	functionality	and	the	catalytic	zinc.	Additionally,	depending	
on	the	extra	substituent	bound	to	the	nitrogen	atom,	the	imines	might	not	fit	in	the	
substrate-binding	 pocket	 or	 have	 the	 correct	 orientation	within	 the	 active	 site	 for	
proton	 transfer.	 In	 particular,	 the	 cyclic	 imines	 that	 are	 generally	 used	 to	 avoid	
substrate	hydrolysis	in	water	might	not	fit	in	the	same	position	as	their	linear	ketone	
counterparts.		
	
Figure	4.6.	Comparison	of	the	active	sites	of	ADH	and	IRED.	a)	Left:	active	site	of	TADH	(PDB	4CPD),	
highlighting	the	Zn2+-binding	amino	acids;	right:	active	site	of	IRED	Q1EQE0	(PDB	3ZH8),	highlighting	the	
acidic	catalytic	residue	Asp187;	b)	Left:	ketone	activation	via	catalytic	zinc	ion	within	the	TADH	active	
site;	right:	imine	activation	via	H-bonding	within	the	IRED	active	site.	
The	aim	of	this	thesis	was	to	design	catalytic	promiscuity,	by	extending	the	substrate	
specificity	of	ADHs	from	ketones	to	imines.	To	do	this,	an	important	issue	explored	in	
this	section	was	whether	imines	could	bind	into	the	hydrophobic	substrate	pocket	in	
the	 correct	 orientation	 for	 hydride	 transfer.	 Activity	 assays	with	 relevant	 ketones,	
inhibition	 assays	 and	 docking	 studies	 were	 used	 to	 gain	 understanding	 of	 the	
interaction	 of	 imines	with	 ADHs.	 Following	 an	 active	 site	 structural	 comparison	 of	
TADH	with	IREDs,	several	mutations	were	designed	to	introduce	acidic	residues	in	the	
TADH	active	site,	in	an	attempt	to	reproduce	IRED	catalytic	features.	
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Highlights	
• TADH	 was	 demonstrated	 to	 maintain	 activity	 towards	 2-pentanone	 and	 2-
ethylbenzaldehyde,	albeit	this	was	much	reduced	compared	to	cyclohexanone.	
These	carbonyl	substrates	were	similar	in	size	to	the	corresponding	precursors	
of	cyclic	 imines,	thus	suggesting	that	 imine	substrates	could	also	fit	 into	the	
TADH	binding	pocket.	
• TADH	activity	was	inhibited	by	the	presence	of	imines	and	amines.	Inhibition	
kinetics	showed	that	2-methyl-1-pyrroline	(a	common	imine	substrate)	and	its	
reduced	amine	product	acted	as	mixed	inhibitors	of	TADH.		
• Docking	of	imines	in	the	presence	and	in	the	absence	of	cofactor	and	of	ketone	
substrate	suggested	that	both	the	substrate-binding	pocket	and	the	cofactor-
binding	pocket	could	accommodate	imines	and	amines.	
• TADH	 mutants	 devoid	 of	 catalytic	 zinc	 and	 possessing	 a	 protic	 residue	 in	
proximity	of	the	docked	imine	nitrogen	were	designed	and	produced,	but	they	
lacked	imine	reduction	activity.	
4.2.2 	TADH	activity	with	bulky	aldehydes	/	ketones	
Two	 cyclic	 imines	 and	 their	 reduced	 amine	 products	 were	 chosen	 as	 possible	
substrates	for	TADH,	as	they	were	shown	to	be	stable	under	aqueous	conditions,	and	
were	good	substrates	for	IREDs:	2-methyl-1-pyrroline	1	and	3,4-dihydroisoquinoline	
2.	 TADH	showed	no	activity	 in	either	 reduction	or	oxidation	directions	when	 these	
imines	and	their	respective	amines	were	used	as	substrates.		
	
Figure	4.7.	Imine	and	amine	compounds	used	in	this	study	to	assess	interaction	with	TADH.	
To	 assess	 whether	 the	 lack	 of	 activity	 was	 due	 to	 the	 inability	 of	 these	 substrate	
architectures	to	fit	into	the	catalytic	pocket,	investigations	into	the	activity	of	TADH	
with	a	selected	bulky	aldehyde	and	ketone	were	performed.	Selected	substrates	were	
2-pentanone	5	and	2-ethylbenzaldehyde	6,	as	well	as	 their	corresponding	alcohols.	
N
H NHN N
2-methyl-1-pyrroline 3,4-dihydroisoquinoline 2-methylpyrrolidine 1,2,3,4-tetrahydroisoquinoline
1 2 3 4
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They	were	selected	because	of	their	similar	structure	to	 imines	1	and	2,	where	the	
C=N	bond	was	 replaced	by	a	C=O	bond.	TADH	has	been	shown	 in	 the	 literature	 to	
accept	a	wide	spectrum	of	substrates,	 including	2-pentanone	and	benzaldehyde;109	
yet,	activity	with	2-ethylbenzaldehyde	6	was	not	reported.	
	
Figure	4.8.	Carbonyl	and	alcohol	compounds	used	in	this	study	to	assess	activity	with	TADH.	
Before	 activity	 of	 TADH	 with	 selected	 substrates	 could	 be	 determined,	 a	 suitable	
solvent	 had	 to	 be	 found,	 to	 allow	 substrate	 solubilisation.	 This	 was	 particularly	
important	in	the	case	of	the	bulky	aldehyde	6.	The	activity	of	TADH	was	assessed	using	
a	 range	 of	 solvents,	 at	 the	 minimal	 concentrations	 necessary	 to	 solubilise	 both	
carbonyl	and	alcohol	substrates.	
4.2.2.1 Solvent	effect	on	TADH	activity		
Literature	reported	that	TADH	maintained	activity	 in	a	range	of	water-miscible	and	
water-immiscible	solvents	up	to	10	%	(v	/	v)	and	50	%	(v	/	v),	respectively.109	In	this	
study,	 the	 effect	 of	 acetonitrile	 (ACN),	 dimethylformamide	 (DMF)	 and	 dimethyl	
sulfoxide	(DMSO)	on	TADH	activity	was	investigated	at	different	concentrations.		
Initial	 assays	 were	 performed	 using	 1-butanol	 as	 the	 standard	 substrate	 in	 the	
oxidative	direction,	using	10	%	v	/	v	solvent,	to	ensure	solubilisation	of	the	substrates	
in	 subsequent	 assays.	 DMSO	was	 observed	 to	maintain	 the	 highest	 percentage	 of	
TADH	activity,	which	was	47	%	compared	to	no	solvent	addition,	whilst	ACN	and	DMF	
inhibited	the	activity,	to	approximately	35	%	and	39	%	residual	activity,	respectively	
(Figure	4.9	and	Table	4.7,	entries	1-4).	This	is	in	contrast	with	reported	results	showing	
higher	inhibitory	effects,	with	residual	activities	of	10	%	for	DMF	and	20	%	for	DMSO	
at	10	%	v	/	v,	obtained	for	the	oxidation	of	cyclohexanol.109	When	the	substrate	was	
changed	for	cyclohexanol,	using	5	%	ACN,	the	relative	specific	activity	was	86	%	(Table	
4.7,	entry	6).	
O
O
OH
OH
pentan-2-one (2-ethylphenyl)methanol2-ethylbenzaldehyde pentan-2-ol
5 876
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Figure	4.9.	Effect	of	selected	solvents	on	the	1-butanol	oxidation	by	TADH.	Enzymatic	activity	was	
determined	in	the	oxidative	direction	at	60	oC,	using	1-butanol	(100	mM)	as	substrate,	NAD+	(1	mM)	as	
cofactor,	in	50	mM	Glycine-NAOH	buffer	pH	9	containing	the	following	solvents:	(l)	10	%	v	/	v	dH2O,				
()	10	%	v	/	v	ACN,	(¾)	10	%	v	/	v	DMF,	(¿)	10	%	v	/	v	DMSO.	The	reported	absorbances	are	averages	
of	triplicate	assays,	and	error	bars	(approx.	10	%	error,	less	than	2	%	error	for	10	%	v	/	v	dH2O)	were	
omitted	for	clarity.		
Table	4.7.	Specific	activities	of	TADH	in	the	presence	of	water-miscible	solvents.	
Entry	 Substrate	 Solvent	
Solvent							
(%	v	/	v)	
Specific	activity	
(U	/	mg)a	
Relative	specific	
activity	(%)b	
1	 1-butanol	 H2O	 10	 6.06	±	0.10	 100	
2	 1-butanol	 ACN	 10	 2.14	±	0.21	 35	
3	 1-butanol	 DMF	 10	 2.34	±	0.26	 39	
4	 1-butanol	 DMSO	 10	 2.87	±	0.29	 47	
5	 Cyclohexanol	 H2O	 5	 9.88	±	0.20	 100	
6	 Cyclohexanol	 ACN	 5	 8.46	±	0.73	 86	
a	Specific	activities	were	determined	from	the	slope	of	the	activity	plot	in	Figure	4.9	calculated	in	the	
first	250	seconds;	b	Relative	specific	activities	were	calculated	by	comparison	to	entries	1	and	5,	where	
dH2O	was	added	instead	of	organic	solvent.	
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In	 the	 reductive	 direction,	 ACN	 was	 illustrated	 to	 have	 the	 least	 effect	 on	 TADH	
activity,	with	58	%	of	the	specific	TADH	activity	maintained,	compared	to	no	solvent	
addition	(Figure	4.10	and	Table	4.8).	DMSO	and	DMF	had	a	 larger	 inhibitory	effect,	
with	42	%	and	15	%,	respectively,	of	remaining	specific	activity,	even	at	2	%	(v	/	v)	
concentration	 in	 the	 mixture.	 This	 could	 be	 explained	 by	 the	 inhibitor	 behaviour	
reported	 with	 DMF	 and	 DMSO,171	 which	 can	 act	 as	 a	 substrate	 analogue	 for	 the	
carbonyls.172,93	Further	increase	of	ACN	concentration	to	5	%	(v	/	v)	resulted	in	31	%	
residual	activity.	(Table	4.8,	entry	5).	Following	these	results,	ACN	was	selected	as	the	
solvent	of	choice	to	assess	activity	of	TADH	with	the	selected	carbonyls.	Considering	
both	substrate	solubility	requirements	and	the	effects	on	relative	activity,	5	%	(v	/	v)	
ACN	was	used	in	the	oxidative	assays,	whereas	for	the	reductive	assays	a	decreased			
2	%	(v	/	v)	ACN	was	employed.		
	
Figure	4.10.	Effect	of	selected	solvents	on	the	cyclohexanone	reduction	by	TADH.	Enzymatic	activity	
was	determined	in	the	reductive	direction	at	60	oC,	cyclohexanone	(20	mM)	as	substrate,	NADH	(0.1	
mM)	as	cofactor,	in	50	mM	Bis-Tris	buffer	pH	6.0	containing	the	following	solvents:	(l)	5	%	v	/	v	dH2O,	
(r)	5	%	v	/	v	ACN,	(p)	2	%	v	/	v	ACN,	(¾)	2	%	v	/	v	DMF,	(¿)	2	%	v	/	v	DMSO.	The	reported	absorbances	
are	averages	of	triplicate	assays,	and	error	bars	(less	than	3	%	error,	8	%	error	observed	for	2	%	v	/	v	
DMF)	were	omitted	for	clarity.	
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Table	4.8	-	Specific	activities	of	TADH	with	cyclohexanone	in	the	presence	of	water-miscible	solvents.	
Entry	 Solvent	 Solvent	ratio	(%	v	/	v)	
Specific	activity	
(U	/	mg)a	
Relative	specific	activity	
(%)b	
1	 H2O	 5	 15.9	±	0.37	 100	
2	 ACN	 2	 9.19	±	0.21	 58	
3	 DMF	 2	 2.40	±	0.19	 15	
4	 DMSO	 2	 6.59	±	0.21	 42	
5	 ACN	 5	 5.00	±	0.10	 31	
a	Specific	activities	were	determined	from	the	slope	of	the	activity	plot	in	Figure	4.10,	calculated	in	the	
first	250	seconds;	b	Relative	specific	activities	were	calculated	by	comparison	to	entry	1,	where	dH2O	
was	added	instead	of	organic	solvent.	
4.2.2.2 TADH	activity	with	substrates	5-8		
The	activities	of	TADH	for	the	oxidation	of	substrates	7	and	8	was	assayed	using	5	%	
ACN	which	was	 shown	 to	have	 little	 (>15	%)	 effect	 on	 the	oxidation	 reaction,	 and	
resulted	 in	 45	%	 and	 1	 %	 remaining	 activity,	 respectively,	 when	 compared	 to	 the	
activity	 obtained	 with	 cyclohexanol	 under	 the	 same	 conditions	 (Table	 4.9,	 entries										
1-3).	Similarly,	reduction	of	5	and	6	yielded	5	%	and	4	%	relative	activity	compared	to	
cyclohexanone,	 respectively	 (Table	 4.9,	 entries	 4-6).	 Previous	 literature	 reported	
relative	specific	activities	of	85	%	and	6	%	for	2-pentanol	oxidation	and	2-pentanone	
reduction,	 respectively,	 but	 these	 results	 were	 obtained	 in	 the	 absence	 of	 added	
organic	solvent.		
The	use	of	2-ethylbenzaldehyde	6	has	not	yet	been	reported	as	a	substrate	for	TADH,	
however	an	 increase	of	 relative	 specific	 activity	was	 reported	with	benzylaldehyde	
(154	%	compared	to	cyclohexanone).	The	explanation	for	the	low	activities	might	be	
the	presence	of	the	bulky	ethyl	group	in	the	2	position,	which	might	sterically	interfere	
in	 the	active	site.	This	effect	was	previously	observed	with	2-methylcyclohexanone			
(46	 %	 residual	 activity)	 and	 2-decalone	 (28	 %).	 The	 decrease	 in	 activity	 with	 2-
pentanone	and	2-pentanol	was	probably	due	to	the	addition	of	5	%	v	/	v	ACN.	
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Table	4.9.	Specific	activities	of	TADH	with	selected	bulky	alcohols	and	the	corresponding	ketone	/	
aldehyde,	relative	to	cyclohexan	–ol	/	-one.	
Entry	 Substrate	 Specific	activity								(U	/	mg)a	
Relative	specific	
activity	(%)b	
1	 cyclohexanol	 11.5	±	0.55	 100	
2	 2-pentanol	 5.13	±	0.19	 45	
3	 2-ethylbenzyl	alcohol	 0.12	±	0.007	 1	
4	 cyclohexanone	 9.19	±	0.21	 100	
5	 2-pentanone	 0.46	±	0.004	 5	
6	 2-ethylbenzaldehyde	 0.35	±	0.26	 4	
a	Specific	activities	were	determined	from	the	slope	calculated	in	the	first	250	seconds	of	enzymatic	
activity	plots:	in	the	oxidative	direction	at	60	oC,	substrate	(100	mM),	NAD+	(1	mM)	in	50	mM	Gylcine-
NaOH	buffer	pH	9.0	containing	5	%	(v	/	v)	ACN;	in	the	reductive	direction	at	60	oC,	substrate	(20	mM),	
NADH	(0.1	mM)	in	50	mM	Bis-Tris	buffer	pH	6.0	containing	2	%	(v	/	v)	ACN.	b	Relative	specific	activities	
were	calculated	by	comparison	to	cyclohexanol	in	entries	1-3	and	cyclohexanone	in	entries	4-6,	where	
dH2O	was	added	instead	of	solvent.		
The	results	presented	above	showed	that	TADH	could	accept	bulky	aldehyde	/	ketone	
substrates,	albeit	with	much	reduced	activity	compared	to	cyclohexanone.	Therefore,	
it	was	hypothesised	that	the	cyclic	imine	substrates	1	and	2	could,	in	principle,	fit	into	
the	TADH	binding	pocket	and	act	as	substrates	for	imine	reduction.		
4.2.3 	Inhibition	of	TADH	by	imine	and	amine	compounds	
While	the	results	presented	above	showed	that	structures	similar	to	5	and	6	could	fit	
into	 the	 TADH	 binding	 pocket,	 no	 activity	 was	 observed	 in	 either	 reduction	 or	
oxidation	directions	when	the	corresponding	imines	(1	and	2)	or	the	respective	amines	
(3	and	4)	were	used	as	substrates.	To	further	confirm	whether	these	compounds	could	
access	 the	 substrate-binding	 pocket,	 their	 inhibitory	 effect	 on	 the	 reduction	 of	
cyclohexanone	and	on	the	oxidation	of	cyclohexanol	was	investigated.		
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4.2.3.1 Preliminary	inhibition	experiments	
Imines	 were	 added	 to	 cyclohexanone	 reduction	 activity	 assays,	 in	 equal	
concentrations	 to	 the	 substrate	 (20	 mM).	 The	 results	 showed	 that	 3,4-
dihydroisoquinoline	2	completely	inhibited	cyclohexanone	reduction,	while	2-methyl-
1-pyrroline	1	only	slightly	decreased	the	activity	(Figure	4.11).	When	the	concentration	
of	 1	was	 increased	 to	 50	 mM,	 an	 increased	 inhibition	 was	 observed.	 This	 result	
suggested	 that	 the	 five-membered	 ring	 might	 be	 too	 small	 and	 perhaps	 not	
hydrophobic	enough	to	strongly	bind	to	the	substrate	pocket	with	the	same	affinity	as	
the	cyclohexanone	substrate.		
	
Figure	4.11.	Inhibitory	effect	of	imines	1	and	2	on	cyclohexanone	reduction.	NADH	absorbance	was	
monitored	at	340	nm	in	the	reductive	direction	at	60	oC,	cyclohexanone	(20	mM)	as	substrate,	NADH	
(0.1	mM)	as	cofactor,	in	50mM	Bis-Tris	buffer	pH	6.0	containing	2	%	v	/	v	ACN	with:	(l)	control	-	No	
imine,	(p)	20	mM	3,4-dihydroisoquinoline,	2	(¾)	20	mM	2-methyl-1-pyrroline,	1	(¿)	50	mM	2-methyl-
1-pyrroline,	1.	The	reported	absorbances	are	averages	of	triplicate	assays,	and	error	bars	(less	than	2	%	
error	for	control	and	20	mM,	1	whereas	50	mM	1	and	20	mM	2	had	a	higher	error	percentage	8	%	of	
and	15	%	error,	respectively)	were	omitted	for	clarity.		
On	 the	 other	 hand,	 when	 amines	 3	 and	 4	were	 added	 to	 cyclohexanol	 oxidation	
activity	assays,	complete	inhibition	was	observed	with	both	amines	(Figure	4.12).	Even	
when	the	concentration	of	3	was	decreased	to	a	fifth	of	the	substrate	concentration	
(20	mM	 vs.	 100	mM),	 activity	 was	 not	 observed.	 This	 suggested	 that	 competitive	
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inhibition	 by	 this	 amine	 was	 less	 likely,	 as	 a	 very	 strong	 binding	 of	 the	 amine	
compound	to	the	TADH	active	site	seemed	to	occur.	
	
Figure	4.12.	 Inhibitory	effect	of	amines	3	and	4	on	cyclohexanol	oxidation.	NADH	absorbance	was	
monitored	at	340	nm	in	the	oxidative	direction	at	60	oC,	cyclohexanol	(100	mM)	as	substrate,	NAD+	(1	
mM)	as	cofactor,	in	50	mM	Glycine-NaOH	buffer	pH	9.0	containing	5	%	v	/	v	ACN	with:	(l)	control	-	No	
amine,	 (p)	 100	mM	1,2,3,4-tetraisoquinoline,	4	 (¾)	 100	mM	2-methylpyrrolidine,	3	 (¿)	 20	mM	2-
methylpyrrolidine,	3.	The	reported	absorbances	are	averages	of	triplicate	assays,	and	error	bars	(less	
than	2	%	error)	were	omitted	for	clarity.	
Overall,	 these	 results	 suggested	 that	 imines	and	 their	 reduced	amine	 counterparts	
could	act	as	inhibitors	of	TADH.	Imine	1	showed	a	dependence	of	the	inhibition	on	its	
concentration,	whilst	imine	2	and	both	amines	showed	complete	inhibition	under	the	
conditions	 tested.	 To	 gain	 a	 better	 understanding	of	 the	 type	of	 inhibition,	 kinetic	
studies	were	performed,	 in	the	presence	of	different	concentrations	of	2-methyl-1-
pyrroline	1	and	2-methyl-1-pyrrolidine	3	as	inhibitors.	These	inhibitors	were	chosen	
because	 the	 corresponding	 imine	 showed	 a	 variation	 in	 the	 inhibitory	 effect	 at	
concentrations	similar	to	the	substrate,	rather	than	the	complete	inhibition	observed	
with	2	and	4	at	low	concentrations.		
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4.2.3.2 Determination	 of	 kinetic	 constants	 of	 inhibition	 with	 imine	 and	 amine	
inhibitors	
Michaelis-Menten	 kinetics	 was	 determined	 for	 cyclohexanone	 reduction	 in	 the	
presence	 of	 10	 mM,	 25	 mM	 and	 50	 mM	 of	 1,	 and	 the	 results	 are	 presented	 as	
Lineweaver-Burk	plots	(Figure	4.13,	see	Appendix	5	for	Michaelis-Menten	plots).		
	
Figure	 4.13.	 Lineweaver-Burk	 plot	 illustrating	 the	 inhibitory	 effect	 of	 2-methyl-1-pyrroline	 (1)	 on	
cyclohexanone	reduction.	Specific	activities	were	calculated	from	the	enzymatic	activities	determined	
in	the	reductive	direction	at	60	oC,	using	TADH	(1	µg),	cyclohexanone	(1,	2.5,	5,	7.5,	10,	15,	25,	50	mM)	
as	substrate,	NADH	(0.1	mM)	as	cofactor,	in	50	mM	Bis-Tris	buffer	pH	6.0	containing	2	%	v	/	v	ACN	with	
2-methyl-1-pyrroline,	1	as	inhibitor	at	concentration:	(l)	0	mM	,	()	10	mM,	(¾)	25	mM,	(¿)	50mM.	
The	data	 shown	represents	averages	of	 triplicate	assays	 (error	bars	are	presented	 in	 the	Michaelis-
Menten	plot	in	Appendix	5.)		
Enzyme	activity	(Vmax)	was	found	to	decrease	with	increasing	inhibitor	concentration,	
whereas	KM	seemed	to	slightly	 increase	(Table	4.10).	These	results	suggest	a	mixed	
inhibition,	in	which	the	inhibitor	can	bind	to	both	the	free	enzyme	and	to	the	enzyme-
substrate	complex,	at	a	 site	which	 is	different	 from	the	substrate-binding	site.	The	
increase	in	KM	suggests	that	the	binding	of	the	free	enzyme	is	preferred.	The	decrease	
in	 Vmax	 suggests	 that	 the	 enzyme	 becomes	 inactive	 upon	 inhibitor	 binding.	 For	
example,	 the	 inhibitor	might	bind	 to	 the	active	 site	 Zn,	 but	without	occupying	 the	
substrate-binding	 pocket.	 Binding	 at	 the	 place	 of	 the	 nicotinamide	 ring	 cannot	 be	
excluded.	 In	 the	 absence	 of	 structural	 information	 on	 inhibitor	 binding,	 these	
hypotheses	cannot	be	confirmed.	
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Table	 4.10.	 Kinetic	 constants	 determined	 for	 cyclohexanone	 in	 the	 presence	 of	 different	
concentrations	of	2-methyl-1-pyrroline	(1)	as	inhibitor.	
Inhibitor	concentration	
(mM)	
Vmax	
(U	/	mg)	
KM	
(mM)	
0	 6.87	±	0.27	 25.06	±	1.57	
10	 6.73	±	0.40	 27.69	±	3.37	
25	 4.40	±	0.22	 30.09	±	2.90	
50	 1.79	±	0.21	 39.91	±	8.24	
Reduction	assays	were	performed	at	60	oC,	using	TADH	(1	µg),	cyclohexanone	(1,	2.5,	7.5	15,	25	and	50	
mM)	as	substrate,	NADH	(0.1	mM)	as	cofactor,	and	2-methyl-1-pyrroline	1	as	inhibitor,	in	50	mM	Bis-
Tris	buffer	pH	6.0	containing	2	%	v	/	v	ACN.	Michaelis-Menten	plot	is	presented	in	Appendix	5.		
Preliminary	investigations	outlined	in	Figure	4.11	and	Figure	4.12	suggested	that	the	
amine	3	had	different	inhibition	characteristics	compared	to	its	imine	counterpart.	For	
example,	it	took	as	little	as	a	fifth	of	amine	concentration	compared	to	substrate	to	
inhibit	TADH	activity,	which	might	be	the	result	of	strong	binding	of	the	amine	to	the	
catalytic	 zinc,	 as	 a	 consequence	 of	 the	 more	 nucleophilic	 character	 of	 the	 amine	
nitrogen	compared	to	the	imine.	To	investigate	this	further,	Michaelis-Menten	kinetics	
was	determined	for	cyclohexanone	reduction	in	the	presence	of	1	mM,	5	mM	and	10	
mM	of	3,	and	 the	 results	are	presented	as	Lineweaver-Burk	plots	 (Figure	4.14,	 see	
Appendix	6	for	Michaelis-Menten	plots).			
The	 analysis	 of	 the	 results	 again	 suggests	 that	 2-methyl-1-pyrrolidine	3	acted	 as	 a	
mixed	inhibitor.	Enzyme	activity	(Vmax)	was	found	to	decrease	with	increasing	inhibitor	
concentration,	whereas	this	time	KM	seemed	to	slightly	decrease	(Table	4.11).	In	this	
case,	 the	 slight	decrease	 in	KM	 suggests	an	 increase	 in	 the	apparent	affinity	of	 the	
enzyme	 for	 the	 substrate,	 meaning	 that	 the	 inhibitor	 favours	 the	 binding	 of	 the	
enzyme-substrate	 complex.	 Again,	 the	 decrease	 in	 Vmax	 suggests	 that	 the	 enzyme	
becomes	 inactive	 upon	 inhibitor	 binding,	 and	 this	might	 be	 due	 to	 binding	 of	 the	
amine	to	the	catalytic	zinc,	alongside	the	substrate.	
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Figure	 4.14.	 Lineweaver-Burk	 plot	 illustrating	 the	 inhibitory	 effect	 of	 2-methylpyrrolidine	 (3)	 on	
cyclohexanol	oxidation.	Specific	activities	were	calculated	from	the	enzymatic	activities	determined	in	
the	oxidative	direction	at	60	oC,	using	TADH	(3	µg),	cyclohexanol	(0.5,	1,	2,	4,	8,	12	mM)	as	substrate,	
NAD+	 (1	mM)	as	 cofactor,	 in	 50	mM	Glycine-NaOH	buffer	 pH	9.0	 containing	5	%	 v	 /	 v	ACN	with	2-
methylpyrrolidine,	3	as	inhibitor	at	concentration:	(l)	0	mM	,	()	1	mM,	(¾)	5	mM,	(¿)	10	mM.	
The	 results	 of	 the	 inhibition	 studies	 confirmed	 binding	 of	 the	 imine	 and	 amine	
compounds	to	TADH,	followed	by	inactivation	of	the	enzyme.	
Table	4.11.	Kinetic	constants	determined	for	cyclohexanol	in	the	presence	of	different	concentrations	
of	2-methylpyrrolidine	(3)	as	inhibitor.	
Inhibitor	concentration	
(mM)	
Vmax	
(U	/	mg)	
KM	
(mM)	
0	 6.60	±	0.10	 2.16	±	0.10	
1	 5.45	±	0.05	 2.27	±	0.05	
5	 2.73	±	0.24	 1.50	±	0.46	
10	 1.74	±	0.12	 1.47	±	0.35	
Oxidation	assays	were	performed	at	60	oC,	using	TADH	(3	µg)	cyclohexanol	(0.5,	1,	2,	4,	8,	12	mM)	as	
substrate,	NAD+	(1	mM)	as	cofactor,	and	2-methyl-1-pyrrolidine	3	as	inhibitor,	in	50	mM	Glycine-NaOH	
buffer	pH	9.0	containing	5	%	ACN;	Michaelis-Menten	plot	is	presented	in	Appendix	6.	
They	also	suggested	that	inhibitor	binding	to	TADH	occurs	at	a	different	site	from	the	
substrate	(mixed	inhibition	was	observed).	Although	binding	of	the	inhibitors	to	the	
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catalytic	Zn(II)	 seems	plausible,	 the	 inhibition	mechanism	cannot	be	determined	at	
this	stage.	To	gain	further	insight	into	the	interaction	of	imines	and	amines	with	the	
active	site	of	TADH,	and	in	the	absence	of	structural	information	of	inhibitors	bound	
to	 the	enzyme,	docking	 studies	were	performed	starting	 from	 the	published	TADH	
crystal	structure.	
4.2.4 Docking	of	imines	into	the	TADH	catalytic	site	
Small	organic	molecules	can	be	easily	docked	into	enzyme	hydrophobic	pockets	using	
Autodock	Vina.156	During	this	docking	method,	the	protein	scaffold	is	maintained	rigid,	
whilst	 rotatable	bonds	 can	be	defined	within	 the	 small	organic	molecule	using	 the	
Autodock	Vina	software.	This	methodology	gives	a	good	indication	whether	an	organic	
compound	can	fit	into	a	particular	binding	pocket,	and	can	also	provide	an	insight	into	
which	orientation	of	the	ligand	would	provide	better	binding.		
The	crystal	structure	of	TADH	(PDB	4CPD),	containing	the	NADH	cofactor,	was	used	for	
the	docking.	First,	to	assess	whether	the	docking	methodology	developed	here	was	
suitable,	 the	 1-phenylacetone	 substrate	 was	 docked	 inside	 the	 protein	 scaffold,	
following	the	parameters	previously	outlined	by	Man	et	al.163	Figure	4.15	shows	a	very	
similar	 substrate	 orientation	 was	 obtained,	 thus	 confirming	 that	 the	 docking	
procedure	used	here	was	suitable	for	further	application	to	other	organic	compounds.		
	
Figure	 4.15.	Model	 of	 1-phenylacetone	 docked	within	 the	 TADH	 active	 site	 using	Autodock	Vina.											
1-Phenylacetone	represented	in	ball	and	stick	format	(carbon	atoms	shown	in	grey	and	bonds	yellow);	
distances	of	the	carbonyl	oxygen	to	the	catalytic	zinc	 ion	and	serine	40	residue	are	highlighted	with	
dashed	lines	(grey,	illustrating	distances	of	2.8	Å	and	2.9	Å	respectively);	a)	Model	taken	from	Man	et	
al.;163	b)	Reproduction	of	model	a)	within	this	study.			
NADH 
a)	 b)	
Zn 
His59 
Phe85 
Val10 Leu292 
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Ser40 
Asp152 `Cys3
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Using	 a	 similar	 procedure,	 imines	 1	 and	 2	 were	 successfully	 docked	 into	 the	
hydrophobic	substrate	pocket	of	TADH	with	the	bound	cofactor	(Figure	4.16).	The	best	
poses	 (lowest	 binding	 energies)	 were	 obtained	 when	 the	 imines	 occupied	 the	
substrate-binding	pocket,	in	similar	orientations	to	the	ketone	substrate	(Figure	4.15).	
The	 unsaturated	 carbon	 atom	 was	 positioned	 within	 an	 approximate	 4.0-4.5	 Å	
distance	from	the	nicotinamide	C4,	and	within	3	Å	distance	from	the	Ser40	hydroxyl	
group	(Figure	4.16)	and	these	distances	were	almost	identical	to	those	observed	for	
2-phenylacetone	(Figure	4.15)	which	were	4.3	and	2.9	Å,	respectively.	These	results	
were	intriguing,	given	that	 inhibition	studies	suggested	binding	of	the	inhibitor	at	a	
site	which	is	different	from	the	substrate.	Further	docking	studies	were	performed,	
where	 the	 substrate-binding	 pocket	 was	 occupied	 with	 the	 previously	 docked	 1-
phenylacetone.	Whilst	these	docking	studies	cannot	be	used	to	analyse	any	complex	
equilibria	taking	place	in	the	advent	of	reversible	inhibition,	they	do	suggest	plausible	
binding	orientations	of	the	inhibitor	in	the	active	site.		
	
Figure	4.16.	TADH	(PDB	4CPD)	active	site	with	model	imine	substrates	2-methyl-1-pyrroline	(1)	and	
3,4-dihydroisoquinoline	(2)	docked	using	Autodock	vina.	Distances	to	Ser40	and	C4	of	NADH	(orange	
sticks)	 shown	via	dashed	 lines	 (grey)	a)	2-methyl-1-pyrroline	 (pink	 sticks)	b)	3,4-dihydroisoquinoline	
(cyan	sticks).		
Docking	in	the	presence	of	the	model	ketone	showed	the	lowest	energy	imine	binding	
orientations	 to	 occur	 at	 different	 positions	 in	 the	 substrate-binding	 pocket	 (Figure	
4.17).		This	seemed	plausible,	due	to	the	large	hydrophobic	pocket	present	in	TADH.	
In	these	conformations,	interaction	of	the	imine	with	zinc	was	not	observed.		
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Figure	4.17.	TADH	(PDB	4CPD)	active	site	(surface)	with	model	imine	inhibitors	2-methyl-1-pyrroline	
(1)	 and	 3,4-dihydroisoquinoline	 (3)	 docked	 in	 the	 presence	 of	 substrate	 1-phenylacetone	 (green	
sticks).	a)	2-methyl-1-pyrroline	(pink	sticks);	b)	3,4-dihydroisoquinoline	(cyan	sticks).	Cofactor	shown	in	
orange	sticks	and	catalytic	zinc	ion	as	a	grey	sphere.	
These	 results	 can	 be	 used	 to	 provide	 an	 explanation	 for	 the	 experimental	 results	
observed	previously:	binding	of	the	imines	at	a	secondary	hydrophobic	binding	site,	
which	might	prevent	the	reaction	from	occurring.	
A	 third	 docking	 was	 performed,	 where	 imines	 1	 and	 2	 were	 docked	 in	 the	 TADH	
structure,	 from	 which	 the	 NADH	 cofactor	 was	 manually	 removed.	 Binding	 at	 the	
cofactor	 binding-site	 would	 explain	 the	 decreased	 activity	 observed	 during	 the	
inhibition	 studies,	 and	 could	 also	 influence	 substrate	 binding,	 thus	 explaining	 the	
variation	 in	 KM.	 Imine	 1	 docked	 outside	 the	 nicotinamide-binding	 pocket	 within	 a								
5.0	Å	radius	and	the	correct	orientation	 towards	 the	catalytic	zinc,	 thus	suggesting	
that	 interference	with	cofactor	binding	does	not	occur.	On	the	other	hand,	 imine	2	
occupied	the	nicotinamide	space,	therefore	suggesting	that	interference	with	cofactor	
binding	is	a	plausible	route	for	inhibition	in	this	case	(Figure	4.18).	
The	combined	results	from	docking	and	inhibition	studies	suggested	that	the	binding	
of	 imines	 and	 amines	 was	 possible	 in	 the	 proximity	 of	 the	 substrate-binding	 site.	
However,	the	activation	mechanism	that	gives	activity	with	ketones	and	alcohols	 is	
not	suitable	for	the	activation	of	imines	and	amines.	“Poisoning”	of	the	catalytic	zinc	
by	imine	/	amine	binding	could	not	be	overruled.	Thus,	a	different	substrate	activation	
must	be	envisaged,	if	imines	are	to	act	as	TADH	substrates.	Inspired	by	the	recently	
published	 IRED	catalytic	mechanism,	 it	was	decided	to	engineer	the	TADH	catalytic	
site	and	to	replace	the	Zn	activation	by	an	activation	based	on	an	acidic	residue.	
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Figure	4.18.	TADH	(PDB	4CPD)	active	site	with	model	imine	inhibitors	2-methyl-1-pyrroline	(1)	and	
3,4-dihydroisoquinoline	 (3)	docked	 in	 the	absence	of	NADH	cofactor.	a)	2-methyl-1-pyrroline	 (pink	
sticks)	b)	3,4-dihydroisoquinoline	(cyan	sticks).	The	superimposed	cofactor	structure	is	shown	in	orange	
sticks.	
4.2.5 Design	of	an	IRED	activation	mechanism	within	TADH	
Inspection	of	recently	published	(R)-	and	the	(S)-IRED	crystal	structures	showed	that	
the	distance	between	the	hydride	delivery	site,	i.e.	the	C4	of	the	nicotinamide	ring	and	
the	H-bond	donor	functionality	of	 the	enzyme	(Asp	or	Tyr	oxygen	atom)	was	5-8	Å	
(Figure	4.19)	 In	TADH,	the	distance	between	the	C4	of	NADH	and	the	activating	Zn	
atom	in	TADH	is	4.7	Å,	while	between	the	C4	and	the	Ser40	oxygen	atom,	responsible	
for	the	proton	relay,	is	4.6	Å.	It	was	hypothesised	that	proton	donor	residues	(Brønsted	
acids)	could	be	introduced	as	“activators”	at	the	place	of	the	Zn	Lewis	acid	in	TADH,	
provided	they	would	be	in	a	range	suitable	for	activation	of	the	carbon-heteroatom	
bond.	In	order	to	attempt	reproduction	of	the	IRED	activation	mechanism	in	TADH,	
residues	that	were	at	a	suitable	distance	from	the	C4	hydride	delivery	point	in	TADH	
were	 identified,	and	suitable	mutations	were	designed,	 to	 introduce	H-bond	donor	
residues	at	these	positions.		
In	order	to	compare	their	arrangement	around	the	hydride	delivery	site,	the	TADH	and	
IRED	crystal	structures	were	aligned	based	on	the	cofactors,	using	the	ligand-based	
active	site	alignment	tool	in	PyMol,	LigAlign.173	This	tool	allowed	the	alignment	of	the	
bound	cofactors,	treated	as	rigid	 ligands,	and	comparison	of	the	interactions	 in	the	
two	active	sites,	such	as	the	position	of	the	substrate-activating	functionality	and	of	
the	substrate-binding	pocket,	relative	to	the	bound	cofactor.	
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Figure	4.19.	Active	sites	of	(R)-	and	(S)-IRED	crystal	structures.	The	distance	between	the	substrate	
activation	site	(protic	residue)	and	the	hydride	delivery	site,	C4	of	NADPH,	is	highlighted	(grey	dashed	
line).	a)	 (R)-selective	Q2EQE0	 from	Streptomyces	kanamyceticus	 (PDB	3ZHB,	yellow	cartoon);	b)	 (S)-
selective	IRED	from	Streptomyces	sp.	GF3546	strain	(PDB	4OQY,	cyan	cartoon).	
The	two	(S)-selective	IREDs	for	which	crystal	structures	were	available	at	the	time	of	
this	 work	 (PDB	 4OQY	 and	 PDB	 4D3F)	 gave	 very	 similar	 results,	 thus	 only	 one	 is	
presented	here.		
	
Figure	4.20.	Superimposed	crystal	structures	of	IRED	and	TADH	using	LigAlign.	TADH	(PDB	4CPD)	is	
shown	as	green	cartoon.	a)	(R)-selective	IRED	Q2EQE0	(yellow	cartoon,	PDB	3ZHB);	b)	(S)-selective	IRED	
from	Streptomyces	GF3546	(cyan	cartoon,	PDB	4OQY).	
Inspection	of	 the	 superimposed	 structures	 (Figure	4.20)	 showed	 little	 resemblance	
between	 the	 quaternary	 arrangements	 of	 the	 two	 enzymes.	 This	 outcome	 was	
expected,	due	to	the	small	sequence	identity	(<20	%)	showed	by	the	alignment	of	the	
respective	sequences.	Upon	closer	inspection	of	the	NADH	/	NADPH	alignment,	whilst	
the	majority	of	the	co-factor	ligands	align,	the	opposite	face	of	the	nicotinamide	ring	
b)	a)	
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is	 presented	 in	 the	 IRED	 active	 site,	 i.e.	 the	 pro-S	 hydride	 is	 offered	 to	 the	 imine	
whereas	in	TADH	the	pro-R	is	offered	to	the	ketone	(Figure	4.21).	As	a	result	of	this	
when	aligned,	the	substrate	pockets	are	presented	opposite	one	another,	making	it	
difficult	to	compare	a	position	within	TADH	for	introduction	of	a	protic	residue	similar	
to	that	found	in	IREDs.		
	
Figure	4.21.	Close	view	of	the	active	sites	of	TADH	(green	cartoon),	superimposed	with	(R)-	and	(S)-
IREDs	using	LigAlign.	The	distance	(Å)	between	the	substrate-activating	functionality	(Zn	ion	or	protic	
residue)	and	the	hydride	delivery	site	(C4	of	NAD(P)H)	is	highlighted	for	both	TADH	and	IRED.	The	Zn	
ion	is	represented	as	grey	sphere,	and	the	TADH-bound	NADH	is	represented	as	orange	sticks.	a)	(R)-
selective	IRED	Q2EQE0	(yellow	cartoon,	PDB	3ZHB),	with	the	distance	shown	between	Asp187	(yellow	
sticks)	 and	 the	 C4	 of	 NADPH	 (yellow	 sticks);	 b)	 (S)-selective	 IRED	 from	 Streptomyces	 GF3546	 (cyan	
cartoon,	 PDB	 4OQY),	with	 the	 distance	 shown	 between	 Tyr169	 (cyan	 sticks)	 and	 the	 C4	 of	 NADPH	
(yellow	sticks).	
Sixteen	residues	within	a	radius	of	8	Å	from	the	C4	of	the	TADH-bound	NADH	cofactor	
were	highlighted:	Cys38,	Ser40,	His59,	Phe85,	His86,	Asp152,	Ile153,	Ser155,	Thr156,	
Val180,	Val266,	Gly267,	Val268,	Leu292,	Ala293	and	Val295	(Figure	4.22)	Out	of	these,	
certain	residues	(Ile153,	Ser155,	Thr156,	Val180,	Val266,	Gly267,	Ala293	and	Val295)	
were	present	on	 the	opposite	side	of	NADH	from	the	substrate,	and	 therefore	not	
available	for	interaction	during	catalysis.	Further	visual	inspection	showed	that	Leu292	
was	in	close	proximity	to	the	amide	functional	group	of	NADH,	and	could	therefore	
interfere	with	cofactor	binding.	In	His86,	the	distance	from	the	NADH	C4	to	the	N-H	
available	for	hydrogen	binding	was	9.4	Å,	and	was	considered	too	far	from	interaction.	
Therefore,	 these	 positions	 were	 considered	 not	 suitable	 for	 introducing	 substrate	
activating	functionalities.		
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Figure	4.22.	TADH	active	site	highlighting	the	residues	(green	sticks)	within	8.0	Å	of	the	C4	position	
of	NADH	(orange	sticks).	
Six	 possible	 sites	 remained	 available	 for	mutagenesis:	 Cys38,	 Ser40,	 His59,	 Phe85,	
Asp152	 and	 Val268	 (Figure	 4.23a).	 In	 addition,	 a	 seventh	 residue,	 Val108,	 was	
identified	by	Man	et	al.	to	be	involved	in	the	formation	of	the	immediate	cavity	around	
the	substrate.163	Although	0.6	Å	further	away	from	the	C4	NADH	than	the	selected				
8.0	Å	range,	model	docking	with	1-phenylacetone	displays	the	distance	between	the	
substrate	and	point	of	activation	as	5.3	Å.	Thus,	this	residue	was	also	selected	(Figure	
4.23b).	 In	 addition	 to	 this,	 the	 furthest	 residue	 of	 the	 seven	 selected	 was	 Val268	
identified	at	6.5	Å	from	the	model	substrate	and	the	shortest	distance	was	observed	
with	Ser40	at	2.9	Å	highlighted	 in	Figure	4.23b).	The	remaining	residues	all	 resided	
within	a	5.0	Å	distance.	
The	amino	acids	highlighted	above	were	selected	 for	mutagenesis	 to	both	tyrosine	
(pKa	 10.5)	 and	 aspartic	 acid	 (pKa	 3.9),	 which	 are	 the	 two	 main	 functionalities	
responsible	 for	 substrate	 activation	 in	 IREDs.	 Before	 creating	 the	 desired	 mutant	
library,	 the	 catalytic	 zinc	 ion	 had	 to	 be	 completely	 removed,	 in	 order	 to	 avoid	 its	
interference	with	the	imine	substrate,	resulting	in	inhibition	of	the	reaction.	All	three	
amino	 acids	 from	 the	 zinc	 binding	 site	 were	 present	 in	 the	 above	 selection	 for	
mutagenesis	into	a	proton	donor,	and	their	mutation	was	likely	to	result	in	less	affinity	
for	zinc.	However,	to	ensure	complete	zinc	removal,	the	three	binding	residues	were	
separately	mutated	to	alanine,	which	was	previously	shown	to	prevent	zinc	binding	in	
ADH.			
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Figure	4.23.	TADH	active	site	highlighting	residues	(green	sticks)	selected	for	mutagenesis	studies.	
Catalytic	 zinc	 ion	 represented	with	 a	 grey	 sphere	 and	NADH	with	 orange	 sticks;	 a)	 Six	 remaining	
residues	 highlighted	 as	 possible	 candidates	 for	 mutagenesis.	 b)	 Model	 substrate,	 1-Phenylacetone	
(yellow	 sticks)	 docked	 into	 TADH	 active	 site	 using	 Autodock	 Vina.	 The	 distances	 of	 the	 closest	 and	
farthest	away	of	the	six	residues	to	the	oxygen	of	the	ketone	is	highlighted	with	grey	dashed	lines.	A	
seventh	 residue,	Val108	has	also	been	highlighted	 for	mutagenesis	with	 the	distance	 to	 the	ketone	
illustrated	by	a	grey	dashed	line.	
TADH	with	the	selected	imines	1	and	2	modelled	in	the	zinc	free	active	site	is	illustrated	
in	Figure	4.24.	The	removal	of	catalytic	zinc	also	ensures	the	imine	substrates	have	
access	to	the	zinc	binding	residues	once	mutated,	as	these	are	promising	candidates	
for	introduction	of	protic	residues	due	to	their	positions	within	the	active	site.		
	
4.2.6 Active	site	engineering	of	TADH	
4.2.6.1 Mutagenesis	of	the	metal-binding	amino	acids	
The	 three	 single	mutants	 of	 TADH	 (C38A,	H59A	 and	D152A)	were	 created	 by	 site-
directed	mutagenesis.	 They	 were	 expressed	 and	 purified	 from	 250	mL	 expression	
Figure	 4.24.	 Model	 of	 TADH	 ‘zinc	 free’	 active	
with	2-methyl-1-pyrroline	(pink	sticks)	and	3,4-	
dihydroisoquinoline	 (cyan	 sticks)	 docked	 using	
Autodock	vina.	The	selected	residues	to	undergo	
mutagenesis	 are	 represented	 with	 green	 sticks	
and	NADH	in	orange	sticks.	
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cultures	using	the	previously	developed	procedure	for	the	preparation	of	wild-type	
(WT)	 TADH.	 The	 presence	 of	 zinc	 in	 the	 active	 site	was	 investigated	 by	 enzymatic	
activity	assays	using	1-butanol	as	the	substrate.	Given	the	catalytic	role	of	the	zinc	in	
substrate	activation,	it	was	hypothesised	that	any	loss	in	activity	could	be	correlated	
to	a	loss	in	catalytic	zinc	ion.		
SDS-PAGE	 and	 protein	 concentration	 analyses	 of	 the	 heat-purified	 TADH	 mutants	
from	 soluble	 cell	 extract	 showed	 that	 the	 zinc-devoid	mutants	 were	 expressed	 in	
lower	yields	than	the	wild-type	TADH	(Figure	4.25	and	Table	4.12).	This	result	may	be	
due	to	less	protein	being	folded	as	soluble	protein	in	the	absence	of	zinc.		
																																 	
The	specific	activity	of	all	alanine	mutants	decreased	from	4.6	U	/	mg	in	WT	TADH	to	
~0.06	U	/	mg	(<1	%),	supporting	the	fact	that	the	catalytic	zinc	was	no	longer	bound	
(Table	4.12).		The	C38A	mutant	was	selected	for	further	single	point	mutagenesis	for	
introduction	of	the	desired	protic	residue	Asp	/	Tyr.	This	was	due	to	the	slightly	higher	
expression	concentrations	compared	to	the	other	two	mutants.	
	
	
	
Figure	 4.25.	 SDS-PAGE	 of	
heat-purified	 TADH	 and	
single	mutants.	1:	WT	TADH;	
2:	C38A,	3:	H59A,	4:	D152A.	
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Table	4.12	-	Enzyme	content	and	activity	following	expression	of	TADH	WT	and	mutants.a	
Entry	 TADH	Sample	 Protein	Content	(mg)	
Specific	activity	
(U	/	mg)	
Relative	Specific	
Activity	(%)	
1	 WT	 5.95	 4.64	 100	
2	 D152A	 2.38	 0.06	 1	
3	 H59A	 2.31	 0.06	 1	
4	 C38A	 2.75	 0.05	 1	
a	WT	and	mutant	TADH	was	expressed	in	250	mL	cultures	in	LB	medium,	following	induction	with	0.4	
mM	IPTG,	as	described	in	Section	3.1.	The	protein	was	purified	by	heating	at	80	oC	for	20	min.	Protein	
content	 of	 the	 soluble	 fraction	 was	 determined	 by	 Bradford	 assay,	 after	 heat-purification	 and	
centrifugation.	Specific	activity	was	determined	in	the	oxidative	direction	at	60	oC,	using	1-butanol	(100	
mM)	as	a	substrate,	NAD+	(1	mM)	as	cofactor,	in	50	mM	Glycine-NaOH	buffer	pH	9.0.	Relative	specific	
activity	is	given	compared	to	WT	TADH.		
4.2.6.2 Preparation	and	assay	of	the	designed	mutants	
The	 residues	 selected	 for	 changing	 to	 tyrosine	 and	 aspartate	 were	 Ser40,	 His59,	
Phe85,	 Asp152,	 Val108	 and	 Val268.	 All	 corresponding	 variants	 were	 designed	 to	
contain	the	initial	single	mutation	C38A	for	zinc	removal.	Given	that	aspartic	acid	is	
already	present	at	position	152,	 this	 resulted	 in	11	double	mutants	and	one	single	
mutant	as	TADH	variants.	To	introduce	both	tyrosine	and	aspartic	acid	at	position	38,	
two	double	mutants	were	created	from	the	single	mutated	D152A	protein.	The	13	new	
mutants	were	created	by	site-directed	mutagenesis.	They	were	expressed	and	purified	
alongside	the	three	single	mutants	C38A,	H59A	and	D152A,	from	50	mL	expression	
cultures	using	the	previously	developed	procedure	for	the	preparation	of	wild-type	
(WT)	TADH.	As	previously	observed	for	the	single	mutants,	all	mutants	containing	the	
acidic	residues	were	expressed	 in	yields	that	were	25-75	%	 lower	compared	to	the	
wild-type.		
The	expression	levels	were	considered	sufficient	for	the	purpose	of	this	investigation,	
and	were	not	optimised	further.	
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Figure	 4.26.	 Expression	 yields	 of	mutant	 and	wild-type	 TADH	presented	 as	 protein	 concentration	
(mg/mL)	in	lysis	buffer	8	mL.		
Each	 of	 the	 16	 mutants	 were	 investigated	 for	 IRED	 activity	 in	 the	 reduction	 and	
oxidation	directions	using	2-methyl-1-pyrroline	1	and	3,4-dihydroisoquinoline	2,	and	
their	 corresponding	 amines	 as	 substrates.	No	 activity	was	observed	 for	 any	of	 the	
mutants.	 Their	 activity	 was	 also	 assayed	 using	 cyclohexanone,	 but	 again	
unsuccessfully,	the	mutations	resulted	in	a	loss	of	native	activity.	The	presence	of	a	
hydrogen	donor	at	the	place	of	zinc	in	the	active	site	was	not	sufficient	to	promote	
catalysis.	This	might	be	due	to	inappropriate	positioning	of	the	H-donor	residue	for	
the	H-bond	to	form,	or	to	a	non-suitable	pKa	of	the	H-donor,	necessary	to	activate	the	
substrate.	
Furthermore,	it	is	extremely	difficult	to	predict	the	orientation	of	the	mutated	amino	
acids	within	the	active	site,	and	how	or	if	this	orientation	will	affect	the	structure	and	
activity	of	the	enzyme,	despite	visual	or	predictive	aids.	 Investigations	 into	the	pKa	
and	ionisation	of	the	key	residues	are	required,	before	a	definitive	suggestion	as	to	
why	these	mutants	lack	imine	reductase	activity	can	be	put	forward.	Since	a	complete	
lack	 of	 activity	was	 observed	 in	 all	mutants,	 no	 further	 effort	was	 invested	 in	 this	
approach.	
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4.2.7 Conclusions		
A	 robust	 method	 was	 developed,	 which	 allowed	 TADH	 activity	 assay	 with	 bulky	
insoluble	substrates,	in	the	presence	of	acetonitrile	as	water-miscible	co-solvent.	The	
presence	of	the	acetonitrile	reduced	TADH	activity	to	30-60	%	of	the	initial	activity,	
depending	on	the	reaction	and	on	the	co-solvent	concentration.	In	order	to	assess	the	
ability	 of	 TADH	 to	 accept	 the	 common	 5-membered	 or	 6-membered	 cyclic	 imine	
architecture	into	the	substrate-binding	pocket,	the	activity	of	TADH	was	determined	
with	two	carbonyl	substrates,	2-pentanone	and	2-ethylbenzaldehyde,	and	with	their	
corresponding	 reduced	 alcohols.	 These	 substrates	 were	 chosen	 because	 their	
structures	 were	 similar	 to	 the	 ones	 of	 common	 cyclic	 imine	 substrates	 used	 with	
IREDs.	TADH	showed	activity	with	both	these	substrate	architectures,	albeit	a	greatly	
reduced	 activity	 was	 observed	 with	 2-ethylbenzaldehyde	 (4	 %	 remaining	 activity	
compared	to	cyclohexanone),	and	 less	 than	half	 remaining	activity	with	2-pentanol	
(compared	 to	 cyclohexanol).	 Nonetheless,	 these	 results	 demonstrated	 that	
architectures	similar	to	the	cyclic	imine	substrates	could	fit	into	the	active	site.	
Two	cyclic	imines	and	their	reduced	amine	counterparts	were	tested	as	inhibitors	of	
TADH	 in	 the	 reductive	 and	 oxidative	 directions,	 respectively.	 TADH	 activity	 was	
completely	 inhibited	 by	 both	 3,4-dihydroisoquinoline	 2	 and	 its	 corresponding								
amine	4,	when	used	 in	the	same	concentration	as	the	substrate.	 Inhibition	kinetics	
were	determined	with	the	5-membered	imine	1	and	the	reduced	amine	3,	and	showed	
that	 both	 these	 compounds	 behaved	 as	 mixed	 inhibitors	 of	 TADH.	 This	 result	
suggested	 that	 imine	 and	 amine	 inhibitors	 occupy	 a	 different	 location	 from	 the	
substrate-binding	site,	but	their	binding	prevents	the	reaction	to	occur.	For	example,	
as	illustrated	with	the	docking	studies	they	might	bind	at	the	place	of	NADH,	and	/	or	
bind	elsewhere	 in	 the	 substrate	pocket.	 The	amine	 compound	was	 shown	 to	have	
inhibitory	effect	at	 lower	concentrations	compared	 to	 the	 imine,	 thus	suggesting	a	
possible	interaction	with	the	catalytic	zinc.	
The	combined	inhibition	and	docking	results	suggested	that	imines	could	in	principle	
be	 accepted	 into	 the	 TADH	 active	 site,	 but	 that	 possible	 binding	 elsewhere	 in	 the	
active	site	might	prevent	their	turnover.	
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Mutations	 in	 the	 active	 site	 were	 designed	 to	 remove	 the	 catalytic	 zinc,	 and	 to	
introduce	protic	residues	aspartate	or	tyrosine	in	the	proximity	of	the	carbon-nitrogen	
bond.	A	total	of	14	TADH	variants	were	created	with	these	features,	in	which	Zn	was	
removed	by	mutation	of	zinc-binding	Cys38	to	alanine.	Removal	of	zinc	was	confirmed	
by	lack	of	activity	towards	alcohol	oxidation.	The	TADH	variants	containing	Asp	or	Tyr	
at	positions	38,	40,	59,	85,	108,	152	and	268	were	successfully	expressed	and	purified.	
No	activity	was	observed	for	either	imine	reduction	or	amine	oxidation.	Despite	the	
mechanistic	similarity	of	ketone	and	imine	reduction	and	structural	resemblance	of	
the	carbonyl	and	 imine	bond,	 it	 seems	 the	differences	 in	 their	 chemical	properties	
dictate	 their	 reactivity.	 For	 example,	 the	 reduction	 potential	 of	 an	 imine	 is	 less	
negative	 than	 that	 of	 a	 carbonyl	 group	 and	 thus	 imines	 have	 a	 higher	 tendency	
towards	reduction.	This	in	conjugation	with	the	relative	pKa	values	of	imines	(~24)	and	
ketones	(~20)	and	their	reduced	counterparts	amines	(~35)	and	alcohols	(~17)	may	
explain,	alongside	the	high	basicity	of	the	nitrogen	within	imines	/	amines,	why	IREDs	
use	Brønsted	rather	than	Lewis	acid	activation.	Another	point	to	note,	 is	that	while	
imines	 and	 ketones	 can	 react	 in	 a	 similar	 fashion,	 for	 example,	 under	 nucleophilic	
attack	the	conditions	under	which	they	react	differ.	Imines	usually	require	a	stronger	
nucleophile	or	more	forceful	conditions	due	to	the	differences	in	electronegativity	of	
oxygen	 and	 nitrogen,	 the	 double	 bond	 in	 imines	 is	 less	 polarised	 and	 thus	 less	
electrophilic.	 Considering	 this	 along	 with	 the	 results	 present	 within,	 it	 was	
hypothesised	that	the	active	site	of	TADH	was	not	suited	for	the	redesign	of	catalytic	
promiscuity	by	site-directed	genetic	engineering.	An	alternative	approach	was	to	take	
advantage	of	the	existing	metal-binding	site,	by	using	it	as	a	way	to	introduce	a	non-
native	metal	centre,	more	suited	to	the	reduction	of	imines.	
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4.3 Replacement	of	the	catalytic	zinc	with	rhodium	in	TADH	
4.3.1 Introduction	and	highlights	
In	addition	to	the	recent	discoveries	of	natural	IREDs,	efforts	also	yielded	the	creation	
of	artificial	metalloenzymes	capable	of	imine	reduction	via	the	incorporation	of	non-
native,	 chemical	 complexes	 within	 protein	 scaffolds.174,175	 This	 approach	 relied	 on	
building	artificial	metal	binding	sites,	by	using	a	linker	to	connect	the	metal-binding	
ligand	to	the	protein	(see	Section	1.3.2.3).	The	flexibility	of	the	linker-ligand	construct	
resulted	 in	 less	 control	 over	 the	 exact	 positioning	 of	 the	 metal.	 An	 alternative	
approach	 consists	 in	 the	 direct	metal	 incorporation	 within	 native	 binding	 sites,	 in	
which	 amino	 acids	 form	 the	 first	 coordination	 sphere	 of	 the	metal	 and	 ensure	 its	
precise	 localisation.176	This	method	generally	exploits	 the	catalytic	properties	of	an	
existing	metalloenzyme,	such	as	its	substrate-binding	site,	and	changes	its	reactivity	
by	introducing	non-native	metals	at	the	place	of	existing	catalytic	metal	 ions.	Using	
this	 method,	 Kazlauskas	 and	 co-workers	 prepared	 rhodium(I)-containing	 carbonic	
anhydrases	 for	 the	 hydrogenation	 of	 olefins	 and	 hydroformylation	 of	 styrene	 and	
reduction	of	CO2.149,177	An	artificial	metalloenzyme	for	imine	reduction	has	yet	to	be	
created	via	this	approach	and	our	attempts	are	investigated	in	this	section.	
In	the	previous	section,	TADH	was	shown	to	accept	imines	in	the	active	site,	and	it	was	
hypothesised	 that	 their	 inhibitory	 effect	 was	 due	 to	 binding	 to	 the	 catalytic	 zinc.	
However,	replacement	of	the	zinc	(Lewis	acid)	with	a	Brønsted	acid	failed	to	produce	
an	IRED.	The	aim	within	this	chapter	is	to	replace	the	catalytic	zinc	ion	in	TADH	with	a	
metal	ion	known	to	activate	imines	when	part	of	synthetic	catalysts,	and	to	investigate	
its	 effect	 on	 the	 activity.	 Literature	 precedents	 exist,	 where	 dihydropyridine	
derivatives	were	used	to	reduce	imines.	The	starting	point	of	the	work	presented	here	
was	a	report	showing	hydride	transfer	from	a	Hantzsch	ester	to	an	imine	substrate,	
activated	by	a	rhodium	catalyst	(Figure	4.27).47		
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Figure	4.27.	Imine	reduction	by	a	bioinspired	rhodium	catalyst	tethered	to	a	Hantzsch	ester.	The	imine	
is	activated	by	binding	to	rhodium,	whilst	hydride	is	delivered	by	the	tethered	dihydropyridine.	
Previous	 studies	 reported	 that	 zinc	 can	 be	 replaced	 by	 other	metals	 in	 ADHs	 (see	
Section	1.2.6).	 Crystallographic	 studies	 of	 Co-,	 Ni-	 and	 Cd-HLADH	 showed	 that	 the	
overall	 protein	 structure	 and	 the	 active	 site	 tetrahedral	 geometry	were	 essentially	
preserved.	Substrate	binding	and	hydride	transfer	rates	were	shown	to	be	positively	
correlated	with	the	Lewis	acidities	of	the	metals.123,178	In	TbADH,	studies	of	the	Co-
substituted	enzyme	indicated	an	octahedral	coordination	of	the	metal,	with	the	two	
additional	ligands	believed	to	be	water	molecules.124	The	higher	coordination	number	
was	suggested	to	be	responsible	for	the	increased	activity	observed	with	this	enzyme.	
Taken	together,	these	investigations	illustrate	the	connection	between	metal	charge,	
Lewis	acid	strength,	coordination	geometry	and	metalloenzyme	catalysis,	and	indicate	
that	metals	with	different	coordination	geometries	can	be	accommodated	 into	the	
ADH	binding	site	and	can	modulate	 its	catalytic	behaviour.	 It	 should	be	noted	 that	
none	 of	 the	 reconstituted	 ADHs	 mentioned	 above	 were	 investigated	 for	 novel	
reactivities.	Moreover,	no	examples	were	published,	where	late	transition	metals	such	
as	Ru,	Rh,	Ir	were	introduced	within	ADH.		
Additionally,	 encouraging	 reports	 were	 published,	 where	 rhodium(I)	 was	 used	 to	
replace	 zinc(II)	 in	 human	 carbonic	 anhydrase	 (see	 Section	 1.3.2.2).149,177	 Zinc(II)	
removal	 was	 performed	 by	 dialysis	 against	 a	 chelating	 agent,	 such	 as	 2,6-
pyridinedicarboxylate,	and	 rhodium	was	 inserted	 into	 the	 resulting	apo	enzyme	by	
dialysis	against	a	Rh(I)	salt.	Unspecific	binding	of	rhodium	to	surface	histidines	was	
observed,	 and	 diminished	 when	 the	 histidines	 were	 mutated	 or	 chemically	
inactivated.	This	work	demonstrated	the	exciting	possibilities	 to	 introduce	catalytic	
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promiscuity	 in	 metalloenzymes,	 by	 exchanging	 native	 with	 non-biological	 metals,	
which	are	not	readily	available	to	enzymes	in	nature.	
This	 section	 outlines	 the	 attempts	 to	 replace	 the	 catalytic	 zinc	 ion	 in	 TADH	 with	
rhodium,	in	an	effort	to	introduce	imine	reductase	activity	into	TADH.	Several	samples	
of	 TADH	were	 used	 throughout	 this	work,	which	were	 prepared	 using	 the	 various	
purification	methods	described	in	Chapter	4.1.	Initially,	heat-treated	(80	oC	for	20	min)	
samples	of	TADH	(htTADH)	were	considered	from	SDS-PAGE	to	be	relatively	pure	to	
perform	zinc	replacement	and	subsequent	analysis.	The	low	zinc	content	obtained	by	
ICP-MS	suggested	that	further	purification	was	necessary,	to	remove	any	protein	that	
might	 not	 contain	 zinc	 and	 thus	 might	 not	 be	 properly	 folded.	 Size	 exclusion	
chromatography	was	used	as	the	purification	method163	and	the	resulting	secTADH	
displayed	 an	 increased	 zinc	 occupancy	 confirmed	 by	 ICP-MS,	 despite	 only	 a	 small	
increase	 in	specific	activity	compared	to	htTADH	(Table	4.13,	All	work	presented	 in	
sections	4.3.2	to	4.3.4	was	performed	with	htTADH,	while	in	sections	4.3.5	and	4.3.6,	
secTADH	was	employed.)		
Table	4.13.	TADH	samples	used	in	Chapter	4.3	for	metal	exchange	investigations.	
Samplea	 TADH	:	Zn	molar	ratiob	
htTADH	 1.0	:	0.5	-	0.9	
secTADH	 1.0	:	1.5	-	2.1	
a	htTADH	 was	 purified	 by	 heat	 treatment	 only	 (80	 oC	 for	 20	 min),	 secTADH	 was	 purified	 by	 heat	
treatment	and	size	exclusion	chromatography;	b	The	ranges	of	TADH	:	Zn	molar	ratio	are	given	based	
on	the	results	of	different	ICP-MS	analyses	of	different	samples.	The	expected	TADH	:	Zn	molar	ratio	is	
1.0	:	2.0.	TADH	samples	were	expressed	and	purified	as	described	in	Chapter	4.1.		
Despite	 the	 low	 zinc(II)	 content	 for	 htTADH	 these	 samples	 were	 subjected	 to	
preliminary	zinc	removal	investigations.	The	low	zinc(II)	content	was	not	an	issue	as	
the	initial	criteria	for	success	was	recovery	of	native	activity,	after	zinc	removal	(loss	
of	 activity.)	As	 the	 recovery	of	 activity	 is	only	possible	as	 a	 result	of	 reinsertion	of	
zinc(II)	 at	 the	 active	 site	 (responsible	 for	 catalysis).	 Enzymatic	 activity	 assays	were	
employed	in	the	analysis.	
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Highlights	
• Dialysis	of	TADH	against	a	mixture	of	1,10-phenanthroline	(OPA,	10	mM)	and	
EDTA	(20	mM)	at	pH	6.0	or	6.5	and	at	4	oC	resulted	in	almost	complete	removal	
of	the	specific	activity,	and	a	partial	loss	of	zinc	up	to	50	%.	These	results	were	
consistent	with	removal	of	the	catalytic	zinc,	to	create	apo-TADH.	
• Reinsertion	of	zinc	into	apo-TADH	was	successfully	achieved	by	dialysis	against	
a	Zn-containing	buffer,	as	demonstrated	by	the	recovery	of	the	specific	activity	
and	of	the	zinc(II)	content.	However,	replicates	yielded	variable	results,	and	a	
considerable	amount	of	protein	was	lost.	
• Successful	insertion	of	cobalt(II)	into	apo-TADH	yielded	Co-TADH,	with	82	%	of	
the	 initial	specific	activity	and	with	a	cobalt	occupancy	 lower	than	expected	
(65	%).	
• Insertion	of	Rh+(acac)	into	apo-TADH	resulted	in	a	protein	containing	2.6-fold	
excess	of	Rh,	probably	due	to	unspecific	binding.	The	protein	was	shown	to	
retain	activity,	but	it	cannot	be	contributed	solely	to	Rh	binding	as	residual	zinc	
was	 also	 inserted.	 No	 imine	 reduction	 activity	 could	 be	 obtained	 by	 this	
method.	
4.3.2 Preliminary	chelator	investigations	
Despite	metal	exchange	having	not	previously	been	performed	with	TADH,	methods	
were	 developed	 for	metal	 exchange	 in	 both	HLADH1,16	 and	 TbADH6,9	 and	 included	
removal	 of	 zinc	 with	 1,10-phenanthroline	 (OPA),	 2,6-pyridinedicarboxylate	 or	
dipicolinic	acid	(DA),	ethylenediaminetetraacetic	acid	(EDTA)	and/or	mixtures	of	these	
chelators	in	a	range	of	concentrations,	up	to	20	mM.	The	main	method	reported	for	
metal	 exchange	 was	 dialysis	 and	 thus	 has	 been	 chosen	 for	 investigations	 of	 zinc	
removal	and	metal	reinsertion	in	TADH,	as	shown	in	Figure	4.28.	
The	main	challenge	of	this	work	is	the	presence	of	both	a	catalytic	and	a	structural	zinc	
in	 the	 protein	 structure.	 The	 removal	 of	 catalytic	 zinc	 only	would	 result	 in	 exactly										
50	%	zinc	loss,	which	was	the	target	for	apo-TADH.	Given	the	similarities	between	the	
TbADH	 and	 TADH	 catalytic	 zinc-binding	 sites,	 it	 was	 hypothesised	 that	 complete	
removal	of	catalytic	zinc	in	TADH	was	possible	using	similar	methods	to	TbADH.122,124	
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Figure	4.28.	General	outline	of	the	dialysis	method	for	zinc	removal	and	metal	re-insertion	in	TADH.	
Additionally,	 a	 previous	 report	 showed	 that	 in	 the	 absence	 of	 structural	 zinc,	 a	
disulphide	 bond	 could	 maintain	 the	 protein	 structure	 in	 the	 ADH	 from	 the	
hyperthermophilic	Aeropyrum	pernix.179	Previous	studies	with	HLADH	suggested	that	
the	catalytic	zinc	was	fast	exchanging,	whilst	the	structural	zinc	was	more	inert.117	The	
tetrahedral	coordination	of	the	structural	zinc	was	thought	to	hinder	the	approach	of	
the	chelating	ligand.	On	the	other	hand,	most	studies	with	HLADH	were	performed	on	
a	crystallised	form	of	the	enzyme,	which	was	though	to	favour	specific	removal	of	the	
catalytic	zinc.117,120		
In	the	case	of	the	TADH	studies	reported	here,	a	crystallised	form	of	the	enzyme	was	
not	available,	and	all	studies	were	performed	in	solution.	Therefore,	the	hypothesis	
was	 that	 successful	 removal	 of	 all	 catalytic	 zinc	 would	 result	 in	 complete	 loss	 of	
catalytic	activity,	and	a	loss	of	≥50	%	of	the	initial	amount	of	zinc.		
The	 three	 chelating	 agents	 identified	 from	 the	 literature	 were	 investigated	 at	
concentrations	5	mM	and	15	mM	for	the	removal	of	zinc	and	creation	of	apo-TADH.	
The	 removal	 was	 performed	 in	mini	 dialysis	 tubes	 (800	 μL),	 using	 a	 concentrated	
sample	of	TADH	(6.5	mg	/	ml;	175	µM),	which	was	dialysed	against	50	mM	sodium	
acetate	buffer	at	pH	5.5,	containing	the	chosen	chelator	in	the	chosen	concentration,	
as	described	in	the	experimental	section.	After	three	rounds	of	dialysis,	the	sample	
was	purified	from	excess	chelators	by	dialysis	against	20	mM	MES	buffer	at	pH	6.5.	
Removal	 of	 zinc	was	 assayed	 by	 determining	 the	 specific	 enzymatic	 activity	 in	 the	
oxidative	direction	with	1-butanol	as	substrate.	Additionally,	the	protein	:	zinc	molar	
ratio	was	estimated	from	protein	concentration	(determined	by	the	Bradford	assay)	
and	zinc	concentration	(determined	by	ICP-MS).		
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To	assess	the	ability	of	apo-TADH	to	re-form	a	metal-containing	active	site,	zinc	was	
added	to	apo-TADH	by	dialysis	against	Zn2+-containing	MES	buffer	(20	mM,	pH	6.5,	
containing	20	µM	Zn2+),	 to	 reconstitute	Zn-TADH.	After	 removal	of	excess	zinc,	 the	
specific	 activity	 and	 the	 zinc	 content	 of	 the	 resulting	 protein	 were	 assayed	 as	
described	above.	A	control	experiment	was	performed,	to	assess	the	stability	of	TADH	
under	 prolonged	dialysis,	 including	 the	 effect	 of	 the	 dialysis	 in	 the	 absence	 of	 the	
chelators	on	zinc	removal.	The	control	showed	22	%	loss	in	protein	concentration,	0	%	
loss	 in	Zn	content	and	14	%	 loss	 in	activity,	 compared	 to	 the	non-dialysed	sample,	
suggesting	that	the	impact	of	dialysis	on	TADH	was	not	a	major	issue.		
The	analysis	of	the	apo-TADH	samples	showed	that	four	dialysis	conditions	resulted	in	
relevant	loss	of	activity	(>30	%),	and	that	the	maximum	activity	loss	was	65	%,	using	
15	mM	DA	(Table	4.14,	entry	7).	Treatment	with	5	mM	OPA	decreased	both	activity	
and	Zn	content	to	~75	%,	although,	intriguingly,	the	result	was	not	reproduced	when	
the	OPA	concentration	was	increased	to	15	mM	(Table	4.14,	entries	1	and	3).	Similarly,	
the	use	of	5	mM	EDTA	decreased	both	activity	and	Zn	content	to	~55	%,	whilst	an	
increase	 in	 EDTA	 concentration	 was	 less	 effective	 (Table	 4.14,	 entries	 9	 and	 11).	
Dialysis	 against	 5	 mM	 DA	 had	 no	 effect	 on	 the	 activity,	 however	 when	 the	
concentration	of	DA	was	increased	to	15	mM,	both	specific	activity	and	Zn	content	
were	decreased	(Table	4.14,	entries	5	vs.	7).	It	is	worth	noting	that	Zn	removal	was	not	
correlated	with	the	percentage	of	activity	loss.	For	example,	if	only	the	catalytic	zinc	
was	removed,	as	 initially	hypothesised,	then	a	50	%	loss	of	zinc	should	result	 in	no	
activity,	whereas	35	%	activity	was	still	observed	in	the	case	where	15	mM	DA	was	
used	as	chelator.		Generally,	the	zinc	content	was	lower	than	expected	compared	to	
the	remaining	specific	activity,	suggesting	that	perhaps	some	of	the	structural	zinc	was	
lost.	
Examination	of	the	data	for	zinc	reinsertion,	showed	that	activity	was	fully	restored	
when	5	mM	OPA	and	15	mM	DA	were	used	 to	prepare	 the	apo-TADH,	and	 the	Zn	
content	also	increased,	equal	or	above	the	initial	value	(Table	4.14,	entries	2	and	8).	
On	the	other	hand,	no	activity	was	restored	when	EDTA	was	used	as	chelator,	despite	
zinc	 content	almost	doubling	 for	5	mM	EDTA,	 compared	 to	apo-TADH	 (Table	4.14,	
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entry	10).	This	result	suggested	that	loss	in	specific	activity	when	EDTA	was	used	was	
not	 related	 to	 the	 creation	 of	 apo-TADH	 but	 rather	 to	 a	 different	mechanism	 for	
activity	removal,	such	as	irreversible	binding	of	EDTA	to	the	active	site.	
Table	4.14.	Preliminary	investigations	of	zinc	removal	and	re-insertion	into	TADH.a		
Entry	 Chelator	conditions	
TADH	
sample	
Protein	
conc.	(%)	
Specific	
activity	(%)	
Zn	content	
(%)b	
	 Control	 htTADH	 5.1	mg	/	mL	 1.3	U	/	mg	 Protein	:	Zn	1	:	0.79	
1	 5	mM	OPA	 Apo-TADH	 40	 71	 75	
2	 5	mM	OPA	 Zn-TADH	 75	 96	 126	
3	 15	mM	OPA	 Apo-TADH	 33	 100	 110	
4	 15	mM	OPA	 Zn-TADH	 92	 73	 95	
5	 5	mM	DA	 Apo-TADH	 95	 100	 116	
6	 5	mM	DA	 Zn-TADH	 100	 89	 106	
7	 15	mM	DA	 Apo-TADH	 100	 35	 51	
8	 15	mM	DA	 Zn-TADH	 91	 98	 96	
9	 5	mM	EDTA	 Apo-TADH	 100	 55	 59	
10	 5	mM	EDTA	 Zn-TADH	 60	 58	 111	
11	 15	mM	EDTA	 Apo-TADH	 73	 79	 73	
12	 15	mM	EDTA	 Zn-TADH	 83	 68	 71	
a	 Apo-TADH	 was	 prepared	 by	 dialysing	 htTADH	 against	 50	 mM	 sodium	 acetate	 pH	 5.5	 containing	
chelating	agents;	excess	chelators	were	removed	by	dialysis	against	20	mM	MES	pH	6.5.	Zn-TADH	was	
prepared	by	dialysing	apo-TADH	against	20	mM	MES	pH	6.5	containing	20	μM	zinc	acetate;	excess	zinc	
was	removed	by	dialysis	against	20	mM	MES	pH	6.5.	All	dialyses	were	performed	at	4	oC.	The	control	
sample	was	htTADH	dialysed	against	20	mM	MES	pH	6.5	at	4	 oC	 throughout	 the	experiment	 (96	h).	
Experiments	were	performed	in	mini	dialysis	tubes	(800	µL),	using	250	mL	dialysis	buffer	for	a	total	of	
3	samples	each.		Percentages	are	given	compared	to	the	control.	Samples	were	analysed	directly	after	
dialysis;	b	Expected	(100	%)	zinc	occupancy	is	1.0	:	2.0	(protein	:	Zn	molar	ratio),	the	control	had	only					
40	%	of	the	expected	zinc	occupancy.			
Protein	precipitation	was	not	observed	by	eye	in	the	mini-dialysis	tubes	and	thus	the	
protein	concentration	for	all	of	the	above	samples	was	determined	on	the	sample	as	
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a	whole,	which	may	have	been	heterogeneous,	hence	introducing	possible	error	into	
the	results.	Little	protein	loss	was	observed	with	EDTA	and	DA	as	chelators.	On	the	
other	 hand,	 significant	 loss	 in	 protein	 concentration	 was	 observed	 upon	 OPA	
treatment,	although	encouragingly	some	protein	was	recovered	upon	zinc	reinsertion.	
These	 results	 indicated	 that	 zinc	 could	 be	 partially	 removed	using	 5	mM	OPA	 and									
15	mM	DA	as	chelators.	The	Zn	content	was	lower	than	expected	compared	to	the	
remaining	specific	activity,	suggesting	that	perhaps	some	of	the	structural	zinc	was	
removed.	However,	upon	zinc	reinsertion,	both	protein	content	and	activity	seemed	
to	 be	 reinstated,	 hence	 suggesting	 the	 possibility	 to	 perform	 a	 metal	 exchange.	
Optimisation	of	these	results	were	necessary,	before	inserting	a	different	metal	into	
TADH.	
4.3.3 Investigations	into	factors	affecting	zinc	removal		
Initial	zinc	removal	studies	were	performed	at	pH	5.5,	following	literature	examples.	
To	 optimise	 preliminary	 results,	 different	 pH,	 chelator	 concentrations	 and	
combinations,	 as	 well	 as	 temperature	 conditions	 were	 tested.	 Zinc	 reinsertion	
experiments	were	systematically	performed	with	all	apo-TADH	samples,	to	determine	
if	 the	 enzymes	 could	 be	 reactivated	 or	 if	 loss	 of	 activity	was	 a	 sign	 of	 irreversible	
denaturation.		
4.3.3.1 Impact	of	pH	on	zinc	removal		
When	 the	 initial	 promising	 experiments,	 using	 OPA	 and	 DA	 as	 chelators,	 were	
repeated	on	a	 larger	 scale	using	a	more	diluted	protein	 sample	 (1.3	mg	/	mL),	 the	
results	obtained	for	Zn	removal	and	reinsertion	were	not	entirely	reproducible	(Table	
4.15,	entries	1-4).		In	particular,	removal	of	zinc	using	15	mM	DA	resulted	in	a	higher	
specific	 activity,	 but	 also	 in	 significant	 protein	 loss,	 between	 50-60	 %,	 which	 was	
observed	 in	 the	 dialysis	 tubing	 within	 the	 first	 3	 hours.	 Some	 protein	 could	 be	
resolubilised	 upon	 reinsertion	 of	 zinc,	 but	 the	 specific	 activity	 did	 not	 increase,	
suggesting	that	the	resolubilised	protein	was	inactive.	When	a	combination	of	5	mM	
OPA	and	15	mM	DA	was	used,	a	greater	 loss	 in	activity	was	observed	compared	to	
individual	chelators	(27	%	remaining	activity,	compared	to	61	and	74	%	for	the	single	
chelators),	whilst	the	remaining	zinc	content	was	similar	(~50	%).	However,	a	great	
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amount	 of	 precipitation	 was	 observed,	 which	 could	 not	 be	 recovered	 after	 zinc	
reinsertion	(Table	4.15,	entries	5-6).		
It	was	 suspected	 that	 protein	 precipitation	was	 caused	 by	 the	 large	 pH	 difference	
between	the	initial	TADH	sample	prepared	in	20	mM	Tris	buffer	at	pH	7.5,	and	the	zinc	
removal	buffer	50	mM	sodium	acetate	at	pH	5.5.	Therefore,	zinc	removal	was	also	
investigated	at	pH	6.5.	This	reduced	the	loss	of	protein	content	dramatically,	to	10-20	
%	 loss	 (Table	 4.15,	 entries	 7	 and	 9).	Whilst	 little	 reduction	 in	 specific	 activity	was	
observed	under	these	conditions	with	OPA,	the	use	of	DA	at	pH	6.5	on	the	larger	scale	
yielded	encouraging	results,	with	~65	%	activity	 loss	and	~50	%	zinc	 loss,	similar	to	
previous	small	scale	experiments	at	pH	5.5.	The	zinc	content	could	be	restored	upon	
reinsertion,	although	no	protein	resolubilisation	was	observed	(Table	4.15	entry	10).	
In	combination	with	the	fact	that	only	70	%	of	activity	could	be	restored,	this	result	
may	suggest	removal	of	some	structural	zinc	ions,	thus	causing	protein	to	precipitate	
beyond	the	point	of	repair	with	zinc	insertion.	
An	additional	experiment	was	performed	at	pH	6.0,	where	the	concentration	of	OPA	
was	 increased	 to	 10	 mM	 in	 an	 attempt	 to	 increase	 the	 removal	 of	 activity.	
Encouragingly,	this	resulted	in	~80	%	loss	of	activity	and	~50	%	removal	of	zinc.	The	
loss	in	protein	under	these	conditions	was	close	to	50	%,	however	over	half	of	this	was	
resolubilised	at	the	zinc	reinsertion	stage	(Table	4.16	entries	1-2).	Based	on	literature	
precedents	 on	 Zn	 removal	 in	 TbADH,	 which	 showed	 successful	 removal	 using	 a	
combination	of	OPA	and	EDTA	as	chelators,122	this	combination	of	chelators	was	also	
assessed,	both	at	pH	6.0	and	at	pH	6.5.	The	result	was	an	encouraging	almost	complete	
removal	of	specific	activity,	correlated	with	almost	halved	zinc	content	(62	%	instead	
of	50	%),	with	little	protein	precipitation	observed	at	pH	6.0	(Table	4.16,	entries	3-4).	
At	 pH	 6.5,	 zinc	 removal	 between	 38-58	 %	was	 observed	 and	 specific	 activity	 was	
almost	totally	removed,	once	again	suggesting	removal	of	catalytic	zinc	(Table	4.16,	
entries	5-6).	However,	large	differences	were	obtained	between	replicates,	suggesting	
the	 low	 reproducibility	of	 these	experiments.	 From	these	 results,	 it	was	concluded	
that	protein	concentration	during	removal	experiments	had	a	non-negligible	effect	on	
the	outcome	of	removal	and	reinsertion	experiments.	
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Table	4.15.	Impact	of	pH	on	zinc	removal	and	re-insertion	into	TADH,	using	DA	and	OPA	chelators.a	
Entry	 Chelator	 TADH	sample	
pH	of	
dialysis	
buffer	
Protein	
conc.	(%)	
Specific	
activity	
(%)	
Zn	content	
(%)b	
1	 5	mM	OPA	 Apo-TADH	 5.5	 20	 74	 50	
2	 5	mM	OPA	 Zn-TADH	 6.5	 70	 69	 129	
3	 15	mM	DA	 Apo-TADH	 5.5	 47	 61	 59	
4	 15	mM	DA	 Zn-TADH	 6.5	 70	 61	 105	
5	 5	mM	OPA	+	15	mM	DA	 Apo-TADH	 5.5	 33	 27	 55	
6	 5	mM	OPA	+	15	mM	DA	 Zn-TADH	 6.5	 49	 51	 105	
7	 5	mM	OPA	 Apo-TADH	 6.5	 91	 89	 63	
8	 5	mM	OPA	 Zn-TADH	 7.5	 94	 95	 141	
9	 15	mM	DA	 Apo-TADH	 6.5	 82	 34	 52	
10	 15	mM	DA	 Zn-TADH	 7.5	 75	 68	 112	
a	Apo-TADH	was	prepared	by	dialysing	htTADH	against	50	mM	sodium	acetate	(pH	5.5)	or	MES	(pH	6.5)	
containing	chelating	agents;	excess	chelators	were	removed	by	dialysis	against	50	mM	MES	pH	6.5.	Zn-
TADH	was	prepared	by	dialysing	apo-TADH	against	50	mM	MES	(pH.6.5)	or	Tris	(pH	7.5)	containing	20	
μM	zinc	acetate;	excess	zinc	was	removed	by	dialysis	against	50	mM	MES	(pH.6.5)	or	Tris	(pH	7.5).	All	
dialyses	 were	 performed	 at	 4	 oC.	 The	 control	 sample	 htTADH	was	 at	 kept	 at	 4	 oC	 throughout	 the	
experiment	(96	h).	The	control	showed	98	%	protein	concentration,	62	%	specific	activity	and	100	%	
zinc	 compared	 to	 the	 non-dialysed	 protein	 at	 the	 beginning	 of	 the	 experiment.	 Experiments	 were	
performed	on	a	scale	of	2.5	mL	sample.		Percentages	are	given	compared	to	the	control.	Samples	were	
analysed	directly	after	dialysis;	 b	Expected	 zinc	occupancy	 is	1.0	 :	 2.0	 (protein	 :	 Zn	molar	 ratio),	 the	
control	had	only	40	%	of	the	expected	zinc	occupancy.			
Additionally,	 the	 pH	 of	 the	 buffer	 seemed	 to	 influence	 the	 amount	 of	 protein	
precipitation,	with	the	higher	pH	resulting	in	more	protein	being	recovered.	On	the	
other	hand,	 the	pH	seemed	to	have	 little	 influence	on	 the	 removal	of	 zinc:	 for	 the	
samples	where	the	protein	was	recovered	with	little	loss,	similar	removal	was	seen	at	
similar	pH	conditions	(see	Table	4.15	entry	3	and	Table	4.16	entry	9.)		
134	
	
Table	4.16.	Impact	of	chelator	combinations	on	zinc	removal	and	reinsertion	into	TADH.a	
Entry	 Chelator	 TADH	sample	
pH	of	
dialysis	
buffer	
Protein	
conc.	
(%)	
Specific	
activity	
(%)	
Zn	
content	
(%)b	
1	 10	mM	OPA	 Apo-TADH	 6.0	 54	 19	 47	
2	 10	mM	OPA	 Zn-TADH	 6.5	 85	 91	 113	
3	 10	mM	OPA	+	20	mM	EDTA	 Apo-TADH	 6.0	 78	 2	 62	
4	 10	mM	OPA	+	20	mM	EDTA	 Zn-TADH	 6.5	 80	 100	 137	
5	 10	mM	OPA	+	20	mM	EDTA	 Apo-TADH	 6.5	 51-69	 3-7	 38-58	
6b	 10	mM	OPA	+	20	mM	EDTA	 Zn-TADH	 7.5	 45-62	 89-153	 163-217	
a	 Apo-TADH	was	 prepared	 by	 dialysing	 htTADH	 against	 20	mM	MES	 at	 the	 specified	 pH	 containing	
chelating	agents;	excess	chelators	were	removed	by	dialysis	against	20	mM	MES	pH	6.5	(as	specified	at	
the	apo	stage).	Zn-TADH	was	prepared	by	dialysing	apo-TADH	against	20	mM	MES	pH	6.5	or	Tris	pH	7.5	
containing	20	μM	zinc	acetate;	excess	zinc	was	removed	by	dialysis	against	20	mM	MES	pH	6.5	or	Tris	
pH	7.5	as	specified.	All	dialyses	were	performed	at	4	oC.	The	control	sample	was	htTADH	dialysed	against	
chelator-free	 buffer	 at	 the	 appropriate	 pH	 at	 4	 oC	 throughout	 the	 experiment	 (96	 h).	 The	 control	
showed	95	%	protein	concentration,	90	%	specific	activity	and	100	%	zinc;	b	The	control	showed	97	%	
protein	concentration,	95	%	specific	activity	and	100	%	zinc;	compared	to	the	non-dialysed	protein	at	
the	beginning	of	the	experiment.		Experiments	were	performed	on	a	scale	of	3	mL	sample.		Percentages	
are	 given	 compared	 to	 the	 control.	 Analyses	 of	 protein	 concentration,	 specific	 activity	 and	 Zn	
concentration	were	performed	after	centrifugation	of	the	samples;	b	Expected	zinc	occupancy	is	1.0	:	
2.0	(protein	:	Zn	molar	ratio),	the	control	had	only	40	%	of	the	expected	zinc	occupancy.		
To	 differentiate	 between	 protein	 loss	 as	 a	 result	 of	 pH	 and	 protein	 loss	 due	 to	
treatment	 with	 chelating	 agents,	 occurrence	 of	 protein	 precipitation	 was	 visually	
inspected	after	dialysis	of	the	protein	in	buffers	at	pH	5.5,	6.0	and	6.5.	Precipitate	was	
observed	 after	 3	 h	 dialysis	 in	 50	 mM	 sodium	 acetate	 buffer	 at	 pH	 5.5;	 a	 slight	
precipitation	was	observed	after	36	h	dialysis	in	20	mM	MES	buffer	at	pH	6.0;	whilst	
no	precipitation	was	observed	after	36	h	dialysis	in	20	mM	MES	buffer	at	pH	6.5.	The	
samples	were	centrifuged	after	36	h	and	visually	assessed	considering	any	visible	cell	
pellets.	The	sample	at	pH	6.5	contained	a	minimal	cell	pellet,	thus	further	suggesting	
that	removal	and	reinsertion	of	zinc	should	be	performed	at	a	pH	equal	or	above	6.5.		
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To	 account	 for	 any	 protein	 precipitate	 formed	 during	 dialysis	 and	 to	 ensure	 that	
analyses	 were	 performed	 on	 soluble	 protein,	 which	 was	 likely	 to	 remain	 folded,	
dialysis	 experiments	were	 repeated	with	 individual	 chelators	 at	 pH	 6.5.	 Instead	 of	
directly	 analysing	 samples	 after	 dialysis,	 centrifugation	 was	 performed	 and	 any	
insoluble	pellet	was	removed.	This	also	meant	that	no	resolubilisation	of	the	protein	
could	be	achieved.	With	5	mM	OPA,	some	differences	were	observed	compared	to	the	
non-centrifuged	 samples,	 but	 they	 were	 difficult	 to	 explain	 and	 might	 be	 due	 to	
experimental	error.	Little	protein	loss	was	observed	upon	Zn	removal,	but	activity	loss	
was	observed	despite	no	removal	of	zinc	(Table	4.17,	entries	1-2).	When	15	mM	DA	
was	used,	the	results	were	similar	to	the	non-centrifuged	samples	(Table	4.15	entries	
3-4).	 In	 the	 following	work,	 samples	were	 centrifuged,	 to	 account	 for	 protein	 loss	
during	dialysis.	
Table	4.17.	Effect	of	sample	centrifugation	on	zinc	removal	and	re-insertion	results.a	
Entry	 Chelator	 TADH	sample	
Protein	
conc.	
(%)	
Specific	
activity	
(%)	
Zn	
content	
(%)b	
1	 5	mM	OPA	 Apo-TADH	 98	 50	 100	
2	 5	mM	OPA	 Zn-TADH	 99	 68	 118	
3	 15	mM	DA	 Apo-TADH	 75	 49	 51	
4	 15	mM	DA	 Zn-TADH	 48	 72	 137	
a	 Apo-TADH	was	 prepared	 by	 dialysing	 htTADH	 against	 20	mM	MES	 at	 pH	 6.5	 containing	 chelating	
agents;	excess	chelators	were	removed	by	dialysis	against	20	mM	MES	at	pH	6.5.	Zn-TADH	was	prepared	
by	dialysing	apo-TADH	against	20	mM	Tris	at	pH	7.5	containing	20	μM	zinc	acetate;	excess	zinc	was	
removed	by	dialysis	against	20	mM	Tris	at	pH	7.5.	All	dialyses	were	performed	at	4	 oC.	The	control	
sample	was	htTADH	dialysed	against	chelator-free	20	mM	MES	buffer	at	pH	6.5	at	4	oC	throughout	the	
experiment	(96	h).	The	control	showed	63	%	protein	concentration,	83	%	specific	activity	and	100	%	
zinc	 compared	 to	 the	 non-dialysed	 protein	 at	 the	 beginning	 of	 the	 experiment.	 	 Experiments	were	
performed	on	a	scale	of	0.9	mL	sample.		Percentages	are	given	compared	to	the	control.	Analyses	of	
protein	concentration,	specific	activity	and	Zn	concentration	were	performed	after	centrifugation	of	
the	samples;	b	Expected	zinc	occupancy	is	1.0	:	2.0	(protein	:	Zn	molar	ratio),	the	control	had	only	40	%	
of	the	expected	zinc	occupancy.	
The	results	presented	in	this	section	showed	that	the	best	conditions	to	perform	the	
removal	 of	 zinc	 from	 TADH	 were	 achieved	 at	 pH	 6.0	 and	 6.5,	 where	 protein	
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precipitation	was	minimal.	When	a	combination	of	10	mM	OPA	with	20	mM	EDTA	
were	used	as	chelators,	almost	all	specific	activity	was	lost,	and	ICP-MS	indicated	loss	
of	about	half	the	zinc	content,	consistent	with	removal	of	catalytic	zinc.	Similar	results	
were	 obtained	when	 10	mM	OPA	was	 used,	 although	 less	 activity	 was	 lost.	Most	
activity	could	be	restored	upon	reinsertion,	although	the	Zn	content	was	higher	than	
expected.	However,	results	displayed	large	errors	when	replicates	were	performed.		
4.3.3.2	Impact	of	temperature	on	zinc	removal	
All	previous	dialysis	methods	were	performed	at	4	oC.	At	this	temperature,	TADH	was	
hypothesised	to	be	more	rigid.	It	was	hypothesised	that	an	increased	flexibility	might	
increase	zinc	removal.	TADH	is	a	thermophilic	ADH	operating	at	high	temperatures	(up	
to	 90	 oC),	 and	 was	 therefore	 deemed	 to	 be	 stable	 enough	 to	 perform	 dialysis	 at	
increased	temperatures.	The	chelator	combination	of	10	mM	OPA	and	20	mM	EDTA	
was	chosen,	because	it	was	shown	to	successfully	remove	all	activity,	which	could	also	
be	entirely	restored	upon	zinc	reinsertion.	These	conditions	were	investigated	for	zinc	
removal	 at	 both	 room	 temperature	 and	60	 oC.	 Room	 temperature	was	 chosen	 for	
easier	handling	 resulting	 in	operation	on	a	 lab	bench	 rather	 than	 restricted	 to	 the	
available	space	in	the	cold	cabinet.	60	oC	was	selected	as	is	the	temperature	at	which	
all	TADH	enzymatic	assays	were	performed.		
Investigations	into	zinc	removal	and	reinsertion	by	dialysis	at	different	temperatures	
showed	similar	results	to	the	experiments	performed	at	4	oC.	Protein	precipitate	still	
occurred	 in	all	cases	and	 little	resolubilisation	could	be	seen,	 in	particular	at	60	oC.	
Similar	to	previous	results	at	4	oC,	the	zinc	concentration	obtained	after	reinsertion	
was	much	 higher	 than	 expected.	 This	 could	 be	 due	 to	 zinc	 binding	 at	 pre-existing	
available	catalytic	binding	sites	within	the	holo-TADH.	However,	 it	was	unclear	why	
such	binding	was	not	observed	with	other	chelators.	To	investigate	this	hypothesis,	a	
control	was	performed	by	treating	wild	type	TADH	with	zinc	(20	μM)	via	dialysis	at	pH	
7.5	and	4	oC	for	12	hours,	followed	by	extensive	dialysis	to	remove	any	excess	zinc	
before	enzymatic	and	metal	content	analysis.	The	specific	activity	and	 ICP-MS	data	
both	showed	a	10	%	loss	after	dialysis	with	zinc,	thus	demonstrating	no	binding	of	zinc	
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to	 unspecific	 binding	 sites.	 Another	 explanation	 was	 an	 experimental	 error	 in	 the	
assessment	of	protein	concentration,	perhaps	due	to	aggregation	of	the	protein.	
Table	4.18.	Effect	of	temperature	on	zinc	removal	and	re-insertion	results.a	
Entry	 Temperature	conditions	
TADH	
sample	
Protein	
conc.	
(%)	
Specific	
activity	
(%)	
Zn	
content	
(%)b	
1	 Room	temperaturec	 Apo-TADH	 51-72	 5-16	 27-74	
2	 Room	temperaturec	 Zn-TADH	 62-89	 80-188	 59-392	
3	 60	oC	 Apo-TADH	 29	 25	 57	
4	 60	oC	 Zn-TADH	 32	 121	 293	
a	Apo-TADH	was	prepared	by	dialysing	htTADH	against	20	mM	MES	at	pH	6.5	containing	10	mM	OPA	
and	20	mM	EDTA;	excess	chelators	were	removed	by	dialysis	against	20	mM	MES	at	pH	6.5.	Zn-TADH	
was	prepared	by	dialysing	apo-TADH	against	20	mM	Tris	at	pH	7.5	containing	20	μM	zinc	acetate;	excess	
zinc	was	removed	by	dialysis	against	20	mM	Tris	at	pH	7.5.	The	control	sample	was	htTADH	kept	at	the	
the	desired	temperature	throughout	the	experiment	(96	h).	Experiments	were	performed	on	a	scale	of	
1.5	mL	 sample.	 	Percentages	are	given	compared	 to	 the	control.	Analyses	of	protein	 concentration,	
specific	activity	and	Zn	concentration	were	performed	after	centrifugation	of	the	samples;	b	Expected	
zinc	occupancy	is	1.0	:	2.0	(protein	:	Zn	molar	ratio),	the	control	had	only	50	%	of	the	expected	zinc	
occupancy;	c	These	conditions	were	repeated	with	three	samples.	
4.3.4 Cobalt	insertion	into	apo-TADH	
Given	the	encouraging	results	obtained	with	the	OPA	/	EDTA	combination	in	section	
4.3.3,	the	insertion	of	a	non-native	metal	into	apo-TADH	was	assessed.	Cobalt(II)	was	
chosen	 as	 it	 was	 a	 good	 starting	 point	 for	metal	 exchange	 investigations	 and	 has	
previously	been	exchanged	for	the	catalytic	zinc	ion	in	both	HLADH	and	TbADH.122,180	
The	use	of	cobalt	would	also	give	the	option	to	maintain	and	assess	the	activity	for	
ketone	reduction.		
The	experiments	were	performed	starting	with	a	heat	purified	htTADH	with	1.2	U	/	
mg	specific	activity	and	24	%	of	the	metal	binding	sites	occupied	(protein	:	zinc	ratio		
1	:	0.47,	 instead	of	1	:	2,	which	would	represent	100	%	occupancy).	Apo-TADH	was	
prepared	by	treatment	with	10	mM	OPA	and	20	mM	EDTA,	at	pH	6.5	and	4	°C,	resulting	
in	3	%	residual	specific	activity	and	72	%	remaining	zinc,	compared	to	the	initial	sample	
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(protein	:	zinc	ratio	1	:	0.34),	as	shown	in	Table	4.19	and	Figure	4.29.	Reinsertion	of	
cobalt	into	the	apo-protein	by	dialysis	against	a	buffer	containing	1	mM	Co(II)	lead	to	
an	 increase	of	 the	 specific	 activity	 to	0.98	U	 /	mg,	which	 represented	82	%	of	 the	
specific	activity	in	the	original	htTADH,	before	zinc	removal	(Figure	4.29).	
	
	
	
	
	
ICP-MS	analysis	showed	an	 increased	cobalt	content,	as	well	as	a	slight	 increase	 in	
zinc,	 which	might	 come	 from	 contamination	 (Table	 4.19).	 SDS-PAGE	 shows	 highly	
purified	protein	samples	throughout	with	minor	loss	at	apo	stage	(~19%)	and	in	total	
(~37%)	at	the	end	of	the	metal	exchange	(Figure	4.29).		
	
Figure	4.29.	Comparison	of	enzymatic	activity	assays	of	htTADH	(l),	apo-TADH	()	and	Co-TADH	(¾)	
with	1-butanol.	
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Figure	 4.29.	 SDS-PAGE	 of	 protein	
samples	 throughout	 metal	 exchange.	
Protein	 samples	 purified	 via	 heat	
treatment	 (80	 oC,	20	min)	and	 sent	 for	
protein	 concentration	 analysis.	 Protein	
loss	at	apo	 stage	14	%;	37	%	 loss	with	
cobalt	addition.	
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Table	4.19.	Results	of	ICP-MS	analysis	of	htTADH,	apo-TADH	and	Co-TADH.	
TADH	sample	 TADH	:	Zn	:	Co	molar	ratioa	
htTADH	 1.0	:	0.47	:	0.01	
Apo-TADH	 1.0	:	0.34	:	0.00	
Co-TADH	 1.0	:	0.40	:	0.65	
a	The	expected	TADH	:	metal	molar	ratio	is	1.0	:	2.0.		
Although	 the	 reconstituted	 protein	 possessed	 double	 the	metal	 content	 from	 the	
original	 starting	 sample,	 it	 was	 still	 almost	 50	 %	 less	 than	 the	 expected	 amount,	
indicating	the	presence	of	inactive	protein.	However,	the	recovered	82	%	activity	was	
due	to	the	Co(II)	binding	at	the	active	site,	given	the	lack	of	activity	before	Co	addition.	
To	ascertain	that	all	cobalt	insertion	occurred	at	the	active	site,	wild	type	htTADH	was	
dialysed	 against	 a	 cobalt(II)	 solution	 under	 the	 same	 buffer	 and	 temperature	
conditions	 as	 used	 for	 the	 metal	 exchange	 procedure.	 Whilst	 the	 specific	 activity	
remained	the	same,	the	protein	:	cobalt	ratio	increased	to	1	:	0.29.	This	data,	however	
was	obtained	using	a	different	sample	of	TADH,	with	an	increased	zinc	content.	Whilst	
the	protein	:	cobalt	ratios	cannot	be	directly	compared	between	these	two	samples,	
it	 can	 be	 concluded	 that	 some	 unspecific	 binding	 of	 cobalt	 to	 TADH	 might	 have	
occurred,	implying	that	only	a	percentage	of	the	cobalt	inserted	into	the	apo-TADH	
was	actually	present	in	the	active	site.		
Table	4.20.	Specific	activities	and	cobalt	contents	of	htTADH	before	and	after	dialysis	against	a	Co-
containing	buffer	solution.	
Sample	 Specific	activity	(U	/	mg)	
TADH	:	Zn	:	Co	a	
molar	ratio	
htTADH	 1.2	 1	:	0.97	:	0.01	
htTADH	+	1	mM	Co2+	 1.2	 1	:	1.0	:	0.29	
																						a	Expected	TADH	:	metal	ratio	=	1.0	:	2.0		
In	conclusion,	successful	reinsertion	of	a	non-native	metal	into	TADH	was	achieved,	
and	 activity	 recovery	 was	 obtained.	 However,	 all	 the	 results	 presented	 above,	
particularly	 for	 zinc	 reinsertion,	 showed	 inconsistencies	 between	 protein	
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concentration	 and	 metal	 content,	 and	 their	 correlation	 with	 specific	 activity	 was	
difficult	to	interpret.	The	work	presented	so	far	was	performed	using	TADH	samples	
that	were	heat	purified	(htTADH)	and	showed	a	reduced	(50	%)	zinc	content	to	begin	
with.	This	may	have	been	a	contributing	factor	to	the	irreproducible	results	and	the	
lack	 of	 correlation	 between	 data.	 As	 shown	 in	 Chapter	 4.1,	 further	 purification	 of	
TADH	by	size	exclusion	chromatography	(secTADH)	resulted	in	protein	:	zinc	contents	
closer	to	the	expected	1.0	:	2.0	ratio.	Hence,	the	next	step	focused	on	confirming	the	
Zn	removal	and	reinsertion	conditions	using	secTADH,	prior	to	replacing	the	catalytic	
zinc	within	TADH	with	rhodium.	
4.3.5 Zinc	removal	and	reinsertion	into	purified	secTADH	
Removal	 and	 reinsertion	 of	 zinc	 into	 the	 secTADH	 purified	 by	 size	 exclusion	
chromatography	were	 performed	 using	 the	 best	 conditions	 determined	 in	 Section	
4.3.3,	using	htTADH.	Chelators	OPA	and	a	combination	of	OPA	and	EDTA	were	used	at	
pH	6.0,	which	showed	most	activity	and	zinc	removal.	Metal	insertion	was	performed	
using	20	mM	MES	buffer	at	pH	6.5,	containing	20	µM	Zn.	
4.3.5.1 Zinc	removal	and	reinsertion	into	secTADH	by	dialysis	
Initial	 experiments	 followed	 the	 same	 dialysis	 procedure	 employed	 for	 htTADH.	
Promisingly,	the	precipitation	issues,	previously	observed	during	zinc	removal,	were	
not	observed	in	any	of	the	cases	with	secTADH,	and	almost	all	protein	was	recovered.	
Treatment	of	secTADH	with	10	mM	OPA	resulted	in	44	%	retained	activity	and	38	%	
remaining	Zn;	activity	was	restored	to	72	%,	whilst	zinc	contained	was	recovered	to	
slightly	more	than	the	initial	content.	When	the	10	mM	OPA	+	20	mM	EDTA	was	used	
as	chelating	agent,	74	%	of	the	specific	activity	was	retained,	although	50	%	of	the	zinc	
was	 lost.	 Whilst	 the	 general	 trends	 and	 the	 zinc	 loss	 were	 similar	 to	 the	 results	
obtained	with	htTADH,	the	specific	activities	of	the	apo-TADH	samples	obtained	from	
secTADH	were	much	higher	than	the	ones	obtained	previously.		
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Table	4.21.	Zinc	removal	and	reinsertion	into	secTADH	by	dialysis.a	
Entry	 Chelator	conditions	
TADH	
sample	
Protein	
conc.	(%)	
Specific	
activity	(%)	
Zn	content	
(%)	
	 Controlb	 secTADH	 0.34	mg	/	mL	 8.3	U	/	mg	 Protein	:	Zn	1	:	1.6	
1	 10	mM	OPA	 Apo-TADH	 100	 44	 38	
2	 10	mM	OPA	 Zn-TADH	 n.d.	 72	 113	
3	 10	mM	OPA	+	20	mM	EDTA	 Apo-TADH	 94	 74	 50	
4	 10	mM	OPA	+	20	mM	EDTA	 Zn-TADH	 89	 96	 169	
	 Controlc	 secTADH	 0.58	mg	/	mL	 4.4	U	/	mg	 Protein	:	Zn	1	:	1.5	
5	 10	mM	OPA	+	20	mM	EDTA	 Apo-TADH	 92	 1	 13	
6	 10	mM	OPA	+	20	mM	EDTA	 Zn-TADH	 62	 42	 93	
a	Apo-TADH	was	prepared	by	dialysing	secTADH	against	20	mM	MES	pH	6.0	containing	chelating	agents;	
excess	 chelators	were	 removed	 by	 dialysis	 against	 20	mM	MES	 pH	 6.5.	 Zn-TADH	was	 prepared	 by	
dialysing	apo-TADH	against	20	mM	MES	pH	6.5	containing	20	μM	zinc	acetate;	excess	zinc	was	removed	
by	dialysis	against	20	mM	MES	pH	6.5.	All	dialyses	were	performed	at	4	oC.	The	control	sample	was	
secTADH	dialysed	against	20	mM	MES	pH	6.5	at	4	oC	throughout	the	experiment	(96	h).	b	The	control	
showed	57	%	protein	concentration,	91	%	specific	activity	and	94	%	zinc	compared;	c	The	control	showed	
66	%	protein	concentration,	76	%	specific	activity	and	no	loss	in	zinc	content;	compared	to	the	non-
dialysed	protein	at	the	beginning	of	the	experiment.	Experiments	were	performed	on	a	scale	of	2.5	mL	
sample.	 	Percentages	are	given	compared	to	the	control.	Analyses	of	protein	concentration,	specific	
activity	and	Zn	concentration	were	performed	after	centrifugation	of	the	samples.		
To	assess	reproducibility,	zinc	removal	and	reinsertion	using	the	OPA	+	EDTA	mixture	
was	 repeated	 using	 a	 newly	 prepared	 batch	 of	 TADH	 prepared	 under	 the	 same	
conditions	as	highlighted	in	section	3.4,	purifying	via	heat	treatment	(80	oC,	20	min)	
and	size	exclusion	chromatography,	with	slightly	different	characteristics.	This	time,	
the	 expected	 almost	 complete	 loss	 of	 specific	 activity	was	 observed	 (1	%	 residual	
activity),	however	much	of	the	zinc	seemed	to	be	lost	as	well,	indicating	removal	of	
the	structural	zinc.	This	was	also	suggested	by	only	a	partial	restoration	of	catalytic	
activity	 to	 42	%,	 in	 contrast	 to	 the	 full	 activity	 restoration	 observed	with	 previous	
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samples.	Despite	this	assumed	removal	of	a	proportion	of	structural	zinc	ions,	only	a	
minor	amount	of	protein	was	lost	(<10%),	and	the	lost	zinc	was	93	%	recovered	after	
reinsertion.		
These	 results	 suggested	 that	 the	dialysis	method	applied	 for	 zinc	 removal	was	not	
reproducible,	and	might	have	promoted	the	removal	of	structural	zinc.	The	removal	
of	 the	 zinc	 was	 never	 complete,	 even	 when	 specific	 activity	 was	 fully	 abolished,	
suggesting	that	one	of	the	zinc-binding	sites	were	more	stable.	Throughout	this	work,	
based	 on	 previous	 reports,	 it	 was	 hypothesised	 that	 the	 structural	 zinc	was	more	
stable.	The	results	obtained	so	far	showed	that	the	catalytic	zinc	was	at	least	partially	
removed	and	re-inserted	using	the	dialysis	method.	
On	the	other	hand,	the	dialysis	method	was	quite	lengthy,	requiring	four	days	for	the	
metal	 removal	 and	 reinsertion,	with	 loss	 in	protein	 stability	during	 this	 time	when	
stored	at	4	oC.	Protein	precipitate	was	observed	in	the	control	with	a	total	protein	loss	
of	 35-45	 %,	 while	 the	 loss	 in	 activity	 over	 this	 period	 was	 10-25	 %.	 Thus,	 metal	
exchange	of	TADH	was	investigated	by	direct	contact	with	the	chelator,	followed	by	
removal	of	the	excess	using	gel	filtration.		
4.3.5.2.	Zinc	removal	and	reinsertion	into	secTADH	by	gel	filtration	
The	use	of	gel	filtration	for	removal	and	reinsertion	of	zinc	is	a	much	shorter	process	
and	can	be	performed	in	6-8	hours.	Prior	examples	of	chromatography	use	for	metal	
exchange	 were	 published	 by	 Maret	 et	 al.	 for	 cobalt	 substitution	 in	 HLADH.117	
Additionally,	others	have	also	reported	Rh	insertion	into	apo	carbonic	anhydrase	by	
direct	 treatment	with	 the	metal	 salt,	 followed	by	gel	 filtration.	This	procedure	was	
adapted	to	TADH.	
In	brief,	a	sample	of	TADH	in	20	mM	MES	buffer	at	pH	6.0	was	treated	directly	with	
the	chelating	agent	with	stirring	for	2	hours,	before	excess	chelator	was	removed	by	
gel	 filtration	using	PD-10	desalting	columns,	as	described	by	the	manufacturer	(see	
Materials	and	Methods	section	3.1).	Excess	zinc	was	then	added	to	apo-TADH	and	the	
mixture	was	stirred	for	2	hours	again	before	exchange	into	fresh	buffer	20	mM	MES	
pH	6.5	by	gel	 filtration,	 resulting	 in	Zn-TADH.	A	control	was	performed	with	buffer	
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exchange	into	20	mM	MES	pH	6.0	at	the	beginning	of	the	experiment,	followed	by	a	
second	buffer	exchange	into	20	mM	pH	6.5	at	the	end	of	the	experiment,	whilst	stored	
at	4	oC	in	between.	The	control	showed	no	significant	protein	loss,	however	less	than	
50	%	activity	was	recovered.		
Table	4.22.	Zinc	removal	and	reinsertion	into	secTADH	by	gel	filtration.a		
Entry	 Chelator	conditions	
TADH	
sample	
Protein	
conc.	(%)	
Specific	
activity	(%)	
Zn	content	
(%)	
	 Control	 secTADH	 2.1	mg	/	mL	 3.2	U	/	mg	 Protein	:	Zn	1	:	1.5	
1	 10	mM	OPA	 Apo-TADH	 66	 22	 73	
2	 10	mM	OPA	 Zn-TADH	 75	 21	 120	
3	 10	mM	OPA	+	20	mM	EDTA	 Apo-TADH	 61	 47	 20	
4	 10	mM	OPA	+	20	mM	EDTA	 Zn-TADH	 82	 21	 7	
a	Apo-TADH	was	prepared	by	stirring	secTADH	in	20	mM	MES	pH	6.0	containing	chelating	agents	for							
2	h,	followed	by	2	x	buffer	exchange	using	Sephadex	G-25	PD-10	columns;	Zn-TADH	was	prepared	by	
stirring	secTADH	in	20	mM	MES	pH	6.5	containing	20	μM	zinc	acetate	for	2	h,	followed	by	2	x	buffer	
exchange	using	Sephadex	G-25	PD-10	column.	The	control	sample	was	secTADH	that	underwent	1	x	
buffer	exchange	using	PD-10	against	20	mM	MES	pH	6.0,	and	a	second	buffer	exchange	using	PD-10	
against	20	mM	MES	pH	6.5.	The	control	showed	100	%	protein	concentration,	43	%	specific	activity	and	
zinc	content	not	checked,	compared	to	the	non-dialysed	protein	at	the	beginning	of	the	experiment.	
Experiments	were	performed	on	a	 scale	of	2.5	mL	sample.	 	Percentages	are	given	compared	 to	 the	
control.		
This	 method	 resulted	 in	 significant	 protein	 loss	 occurring	 upon	 treatment	 with	
chelators.	Moreover,	whilst	protein	activity	was	 lost,	as	expected,	upon	removal	of	
zinc,	 the	reinsertion	was	 less	successful,	and	no	activity	was	recovered.	When	OPA	
was	used,	some	zinc	appeared	to	be	reinserted	which,	corroborated	with	the	lack	of	
activity,	suggested	the	removal	of	structural	zinc	using	this	method.	When	the	OPA	+	
EDTA	mixture	 was	 used,	 most	 of	 the	 zinc	 was	 lost	 and	 was	 not	 reinserted,	 again	
suggesting	that	direct	contact	with	these	chelators	removed	a	significant	proportion	
of	catalytic	zinc,	and	that	the	protein	could	not	be	reactivated	by	direct	contact	with	
the	zinc.	It	was	hypothesised,	at	this	stage,	that	these	conditions	were	too	harsh	and	
denatured	the	protein.	
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Despite	some	encouraging	results	obtained	using	dialysis	against	specific	chelators,	
and	zinc	or	cobalt	reinsertion,	a	robust	method	for	the	creation	of	apo-TADH	has	yet	
to	be	developed.	For	HLADH,	Maret	et	al.	reported	selective	removal	of	the	catalytic	
zinc	ions	with	10	mM	DA	and	a	partially	crystallised	HLADH	in	a	solution	of	tert-butanol	
(25%	v/v)	 in	TES	buffer.117	Equilibrium	dialysis	at	pH	5.5	against	a	Co(II)-containing	
buffer	was	also	reported.16	Selective	removal	of	the	catalytic	zinc	in	HLADH	seems	to	
be	more	successful	in	this	crystallised	form	of	HLADH,	where	the	structural	zinc	ions	
are	 less	 accessible	 to	 the	 chelator.	Conditions	 for	 the	 crystallisation	of	 TADH	were	
published	during	the	course	of	this	thesis	by	Man	et	al.,18	and	employed	0.1	M	Bis-Tris	
buffer	pH	6.5	containing	1	M	sodium	chloride	and	1.5	M	ammonium	sulphate.	Moving	
forward,	 further	 attempts	 at	 the	 creation	 of	 apo-TADH	 could	 be	 made,	 with	 a	
crystallised	 solution	 of	 TADH	 and	 a	 range	 of	 selected	 chelators.	 A	 column	
chromatography	method	was	also	employed	by	Maret	et	al.,	 in	which	the	zinc	was	
replaced	by	cobalt	on	a	gel	filtration	(Sephadex	G-25)	column	pre-equilibrated	with	a	
Co(II)-containing	buffer,	thus	avoiding	direct	chelator	treatment.	The	exchange	was	
performed	at	55	oC	during	8	h.	The	increase	in	temperature	was	shown	to	favour	the	
exchange	 of	 catalytic	 zinc	 over	 the	 structural	 one,	 presumably	 by	 inducing	 more	
flexibility	in	the	tertiary	structure.	It	is	possible	that	this	method	could	be	applied	to	
TADH,	as	inspection	of	the	structure	suggests	that	the	structural	binding	site	resides	
closer	to	the	protein	surface.		
4.3.6 Rhodium	reinsertion	into	purified	secTADH	and	imine	reduction	assays	
Given	the	partial	removal	of	catalytic	zinc	observed	with	the	above	methods,	rhodium	
insertion	was	attempted	using	both	dialysis	and	gel	filtration.	The	resulting	Rh-TADH	
was	assayed	for	both	ketone	and	imine	reduction.		
Rhodium	insertion	was	first	attempted	by	dialysis	of	the	apo-TADH	against	a	20	µM	
Rh(I)	solution	in	20mM	MES	buffer	pH	6.5.	Rh(acac)(CO)2	was	used	as	the	Rh(I)	source	
as	the	acetylacetonate	group	is	relatively	small	to	fit	within	the	active	site.	It	is	stable	
in	 air	 and	 fairly	water	 soluble.	Nonetheless,	 the	 buffer	 solution	was	 degassed	 and	
dialysis	performed	under	nitrogen	to	prevent	any	oxidation.	Apo-TADH	samples	were	
prepared	by	dialysis	against	chelators	OPA	and	OPA	+	EDTA,	as	described	in	section	
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4.3.5.	In	both	cases	the	activity	diminished	further	upon	Rh(I)	insertion,	from	44	%	and	
74	%	for	the	apo-TADH	samples,	to	15	%	and	26	%	for	Rh-TADH,	for	the	OPA	and	OPA	
+	EDTA	treatments,	respectively	(Table	4.23,	entries	1-4).	The	ICP-MS	data	not	only	
showed	an	excess	of	rhodium	binding	(rhodium	:	protein	ratios	of	6.5	and	24.0),	but	
also,	more	surprisingly,	the	reintroduction	of	zinc	after	dialysis	against	the	rhodium	
solution.	This	result	suggested	that	residual	zinc	was	present	in	the	metal	salt.	To	avoid	
this	 issue,	 the	 rhodium	 solution	was	 submitted	 to	 treatment	 with	 Chelex®100	 for	
removal	of	residual	zinc,	and	the	rhodium	reinsertion	experiment	was	repeated.	
Table	4.23.	Zinc	removal	and	rhodium	reinsertion	into	secTADH	by	dialysis.a	
Entryb	 Chelator	 TADH	sample	
Protein	
conc.	(%)	
Specific	
activity	
(%)	
Zn	
content	
(%)	
Ratio	
TADH	:	Zn	:	Rh	
	 Controlc	 secTADH	 0.34		mg	/	mL	
8.3		
U	/	mg	 	 1	:	1.6	:	0	
1	 OPA	 Apo-TADH	 100	 44	 38	 1	:	0.6	:	0	
2	 OPA	 Rh-TADH	 100	 15	 88	 1	:	1.4	:	6.5	
3	 OPA	+	EDTA	 Apo-TADH	 94	 74	 50	 1	:	0.8	:	0	
4	 OPA	+	EDTA	 Rh-TADH	 83	 26	 156	 1	:	2.5	:	24.0	
	 Controld	 secTADH	 0.58		mg	/	mL	
4.4		
U	/	mg	 	 1	:	1.5	:	0	
5	 OPA	 Apo-TADH	 72	 6	 60	 1	:	0.9	:	0	
6	 OPA	 Rh-TADH	 82	 2	 80	 1	:	1.2	:	1.7	
7	 OPA	+	EDTA	 Apo-TADH	 92	 1	 13	 1	:	0.2	:	0	
8	 OPA	+	EDTA	 Rh-TADH	 63	 32	 27	 1	:	0.4	:	2.6	
a	Apo-TADH	was	prepared	by	dialysing	secTADH	against	20	mM	MES	pH	6.0	containing	chelating	agents;	
excess	 chelators	were	 removed	 by	 dialysis	 against	 20	mM	MES	 pH	 6.5.	 Rh-TADH	was	 prepared	 by	
dialysing	 apo-TADH	 against	 20	mM	MES	 pH	 6.5	 containing	 20	 μM	Rh(I)(acac)(CO)2,	excess	 zinc	was	
removed	by	dialysis	against	20	mM	MES	pH	6.5.	All	dialyses	were	performed	at	4	oC.	The	control	sample	
was	 secTADH	dialysed	against	20	mM	MES	pH	6.5	at	4	 oC	 throughout	 the	experiment	 (96	h).	 c	The	
control	showed	57	%	protein	concentration,	99	%	specific	activity	and	94	%	zinc	compared;	d	The	control	
showed	66	%	protein	concentration,	88	%	specific	activity	and	no	loss	in	zinc	content;	compared	to	the	
non-dialysed	protein	at	the	beginning	of	the	experiment.	Experiments	were	performed	on	a	scale	of	2	
mL	sample.		Percentages	are	given	compared	to	the	control.	Analyses	of	protein	concentration,	specific	
activity	 and	 Zn	 concentration	 were	 performed	 after	 centrifugation	 of	 the	 samples;	 b	 Samples	 1-4:	
buffers	were	used	as	such;	samples	5-8:	buffers	were	treated	with	Chelex®.	
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Upon	“purification”	of	the	Rh(I)-containing	buffer	from	divalent	metal	ions	such	as	Zn	
by	treatment	with	Chelex,	rhodium	insertion	into	apo-secTADH	formed	by	treatment	
with	 the	OPA	+	 EDTA	mixture	 presented	 a	 somewhat	 encouraging	 result.	 The	 zinc	
content	was	still	observed	to	increase	from	1	:	0.2	to	1	:	0.4	protein	:	Zn	content,	which	
was	much	 less	 than	 previously	 observed	 (Table	 4.23,	 entry	 4	 vs.	 8).	 The	 protein	 :	
rhodium	 content	 was	 determined	 to	 be	 1	 :	 2.6,	 suggesting	 the	 existence	 of	 non-
specific	binding	sites	within	TADH.	Some	activity	was	recovered	as	well,	higher	than	
expected	from	the	zinc	content.	This	suggested	that	some	of	the	activity	might	be	due	
to	the	presence	of	rhodium.	It	was	impossible	to	ascertain,	at	this	stage,	whether	the	
activity	was	due	to	the	presence	of	rhodium	at	the	active	site,	or	elsewhere	 in	the	
protein.	
On	 the	 contrary,	 the	 insertion	 of	 rhodium	 into	 the	 apo-TADH	prepared	 by	 dialysis	
against	 OPA	 did	 not	 result	 in	 active	 protein.	 Again,	 zinc	 content	 was	 observed	 to	
increase	in	the	apo-TADH	from	1	:	0.9	to	1	:	1.2	protein	:	zinc	ratio,	despite	treatment	
of	buffers	with	Chelex.	Rhodium	content	was	also	seen	to	increase	to	1	:	1.7	protein	:	
Rh	ratio	(Table	4.23,	entries	5-6).	Again,	some	unspecific	binding	was	observed	when	
rhodium	was	used.		
Finally,	 rhodium	 was	 also	 reinserted	 in	 the	 apo-TADH	 samples	 prepared	 by	 gel	
filtration	(Table	4.24).	Interestingly,	when	OPA	was	used	as	chelator,	the	zinc	content	
in	the	apo-TADH	was	reduced	from	1	:	1.5	in	secTADH	to	1	:	1.1	in	apo-TADH,	and	was	
further	reduced	to	1	:	0.9	 in	Rh-TADH.	On	the	other	hand,	Rh	content	 increased	to								
1	:	0.9,	yielding	the	expected	metal	content	within	this	protein.	Activity	also	increased	
compared	to	apo-TADH,	suggesting	that	the	bound	Rh	was	active.	However,	at	this	
stage	 it	was	 impossible	to	ascertain	whether	the	Rh	was	present	at	 the	active	site.	
When	OPA	+	EDTA	were	used	as	chelating	agents,	little	Rh	binding	and	little	activity	
were	observed.	These	results	were	treated	with	caution,	because	of	the	poor	results	
obtained	 for	 zinc	 reinsertion	 suggesting	 that	 this	 method	 was	 not	 suitable	 for	
reconstitution.		
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Table	4.24.	Zinc	removal	and	rhodium	reinsertion	into	secTADH	by	gel	filtration.a	
Entry	 Chelator	 TADH	sample	
Protein	
conc.	(%)	
Specific	
activity	
(%)	
Zn	
content	
(%)	
Ratio	
TADH	:	Zn	:	Rh	
	 Control	 secTADH	 2.1		mg	/	mL	
3.2		
U	/	mg	 	 1	:	1.5	:	0	
1	 OPA	 Apo-TADH	 66	 22	 73	 1	:	1.1	:	0	
2	 OPA	 Rh-TADH	 91	 36	 60	 1	:	0.9	:	0.9	
3	 OPA+EDTA	 Apo-TADH	 61	 47	 20	 1	:	0.3	:	0	
4	 OPA+EDTA	 Rh-TADH	 23	 8	 7	 1	:	0.1	:	0.3	
a	Apo-TADH	was	prepared	by	stirring	secTADH	in	20	mM	MES	pH	6.0	containing	chelating	agents	for	2	
h,	 followed	by	2x	buffer	exchange	using	Sephadex	G-25	PD-10	 columns;	Rh-TADH	was	prepared	by	
stirring	secTADH	in	20	mM	MES	pH	6.5	containing	20	μM	Rh(I)(acac)(CO)2	for	2	h,	followed	by	2x	buffer	
exchange	using	Sephadex	G-25	PD-10	column.	The	control	 sample	was	secTADH	that	underwent	1x	
buffer	exchange	using	PD-10	against	20	mM	MES	pH	6.0,	and	a	second	buffer	exchange	using	PD-10	
against	20	mM	MES	pH	6.5.	The	control	showed	100	%	protein	concentration,	43	%	specific	activity	and	
zinc	content	not	checked,	compared	to	the	non-dialysed	protein	at	the	beginning	of	the	experiment.		
Experiments	were	performed	on	a	 scale	of	2.5	mL	sample.	 	Percentages	are	given	compared	 to	 the	
control.	
All	Rh-TADH	samples	prepared	above	were	investigated	for	imine	reductase	activity	
with	2-methyl-1-pyrroline	1	as	substrate,	but	no	activity	was	observed.	 Increase	of	
enzyme	 concentration,	 and	 thus	 of	 rhodium,	 was	 unsuccessful	 as	 well.	 Without	
further	 investigations	on	the	localisation	of	Rh	within	TADH,	 it	 is	difficult	to	predict	
how	 to	 optimise	 this	 result.	 Before	 engaging	 in	 any	 further	 investigations	 it	 is	
important	 to	have	a	well-defined	coordination	environment	 in	 the	Rh-TADH.	Given	
the	difficulties	to	obtain	a	robust	method	for	the	preparation	of	both	apo-TADH	and	
metal-TADH,	whether	with	 Zn,	 Co	 or	 Rh,	 no	 further	work	 has	 been	 performed	 on	
developing	an	artificial	metalloenzyme	using	 this	 route.	 	Other	possible	ways	were	
envisaged	to	incorporate	rhodium	into	the	TADH	scaffold,	which	are	investigated	and	
discussed	in	detail	in	Section	4.4.		
4.3.7 Conclusions	
The	removal	of	the	catalytic	zinc(II)	ion	and	its	re-insertion	via	dialysis	were	studied	
using	 the	 thermostable	 TADH.	 The	 analysis	 was	 complicated	 by	 the	 fact	 that	 the	
proteins	 contains	 two	 zinc	 ions	 per	 monomer:	 one	 catalytic,	 and	 one	 structural.	
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Protein	precipitation	during	zinc	removal	was	minimised	by	using	appropriate	buffers.	
The	best	conditions	for	zinc	removal	were	observed	at	pH	6.0	and	4	oC,	with	chelating	
agent	OPA	(10	mM)	or	a	mixture	of	OPA	+	EDTA	(10	mM	+	20	mM,	respectively).	These	
resulted	in	almost	complete	loss	of	specific	activity,	and	partial	 loss	of	zinc.	Protein	
loss	was	also	observed	during	these	experiments.	Activity,	zinc	content	and	protein	
concentration	all	increased	upon	zinc	reinsertion	by	dialysis	against	a	buffer	solution	
containing	zinc	acetate	(20	µM)	at	pH	6.5	and	4	oC.		
Previous	literature	results	suggested	that	the	HLADH	structural	zinc	was	more	difficult	
to	remove	in	the	presence	of	chelators,117	and	highlighted	its	role	in	maintaining	the	
overall	 protein	 structure.84	 The	 fact	 that	 the	 protein	 could	 be	 recovered	 upon	
treatment	of	apo-TADH	with	zinc	suggested	that	most	of	the	zinc	removed,	and	thus	
reinserted,	was	from	the	catalytic	site.	However,	protein	precipitation	and	variability	
of	the	repeats	suggested	that	this	was	not	a	robust	method	for	zinc	replacement.	
Cobalt(II)	was	also	 inserted	 into	apo-TADH	and	 resulted	 in	 recovery	of	 the	 specific	
activity	to	82	%	of	the	initial	zinc-containing	protein.	However,	metal	content	analysis	
showed	 that	both	 the	 zinc	 and	 the	 cobalt	 content	of	 the	protein	were	 lower	 than	
expected.	This	was	assumed	to	be	due	to	the	presence	of	zinc-devoid	protein	in	the	
initial	sample,	which	also	had	a	lower	zinc	content	than	expected.	Purification	of	the	
TADH	sample	by	size	exclusion	chromatography	increased	the	zinc	content.	However,	
zinc	 removal	 and	 re-insertion	 experiments	 into	 the	 purified	 secTADH	 also	 led	 to	
variable	amounts	of	protein	precipitation,	and	a	lack	of	correlation	between	activity	
and	amount	of	remaining	zinc.	
Binding	of	Rh(I)	to	apo-TADH	was	observed	to	occur	in	2.6-fold	molar	excess	in	the	
best	of	the	studies	conditions.	Some	residual	alcohol	oxidation	was	observed	possibly	
due	to	bound	Rh	but	it	is	difficult	to	ascertain.	However,	no	imine	reductase	activity	
was	observed	for	the	reduction	of	2-methylpyrroline.	Given	the	difficulty	in	developing	
a	 robust	method	 for	 zinc	 replacement	 in	 TADH,	 a	 different	 strategy	was	 adopted,	
consisting	in	introducing	an	artificial	binding	site	into	the	protein.	
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4.4 Synthesis	of	an	artificial	metal-binding	site	for	TADH	
4.4.1 	Introduction	and	highlights	
Introduction	of	a	rhodium	catalyst	by	direct	and	specific	binding	to	the	amino	acids	
forming	the	TADH	native	metal-binding	site	was	difficult	to	assess,	and	could	not	be	
applied	 to	 imine	 reduction.	 A	 second	 strategy	 was	 adopted,	 which	 consisted	 in	
designing	and	synthesising	a	non-native	binding	site,	to	be	incorporated	into	TADH.	
Two	methods	 have	 been	 described	 for	 the	 bioconjugation	 of	 a	 non-native	metal-
binding	 site	 to	 a	 protein:	 direct	 covalent	 attachment	 to	 a	 reactive	 side-chain,	 e.g.	
cysteine	thiol	group;	and	attachment	to	a	molecule	with	high	affinity	for	the	protein,	
e.g.	an	inhibitor	or	a	cofactor,	which	can	be	inserted	into	a	defined	binding	pocket	by	
supramolecular	 anchoring.	 Using	 this	 strategy,	 Ward	 et	 al.	 designed	 biotinylated	
iridium	 catalysts,	 which	 performed	 imine	 reduction	 upon	 incorporation	 into	
streptavidin	using	biotin	as	an	anchor.		
The	aim	of	this	section	was	to	exploit	the	affinity	of	the	NAD+	cofactor	and	of	its	mimics	
for	ADH,	in	order	to	use	it	as	an	anchor	for	the	introduction	of	metal	catalysts	 into	
TADH.	Therefore,	the	design	and	synthesis	of	a	metal-containing	NAD+	analogue	was	
performed.	The	NAD+	mimic	would	ensure	the	positioning	of	the	metal	complex	within	
TADH.	 The	 metal	 complex181	 would	 act	 as	 the	 hydrogen	 transfer	 catalyst,	 in	 the	
presence	 of	 a	 stoichiometric	 hydrogen	 source,	 similar	 to	 chemical	 transfer	
hydrogenation	catalysis.	
Highlights	
• A	 novel	 iridium(III)	 complex,	 containing	 a	 nicotinamide-functionalised	 N-
heterocyclic	carbene	(NHC)	ligand,	was	synthesised	and	characterised.	
• The	nicotinamide-functionalised	Ir-NHC	was	shown	to	be	active	in	the	transfer	
hydrogenation	of	ketone	and	imine	substrates,	both	in	organic	solvents	with	
isopropanol	and	in	buffer	with	sodium	formate	as	hydride	donor.	
• Inhibition	 kinetics	 and	 controls	 in	 the	 presence	 of	 NADH	 suggested	 some	
interactions	of	the	Ir-catalyst	with	the	protein,	but	not	at	the	cofactor-binding	
site	
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4.4.2 Design	of	nicotinamide-functionalised	metal	complexes			
Previous	work	by	Fish	and	co-workers	showed	that	1-benzylnicotinamide	triflate	(9,	
Figure	4.30)	and	b-nicotinamide-5’-ribose	methyl	phosphate	(10,	Figure	4.30)	could	
perform	the	enantioselective	reduction	of	ketones	inside	HLADH,	in	the	presence	of	a	
rhodium	 catalyst	 and	 of	 a	 hydride	 donor.115-116	 These	 nicotinamide	 derivatives,	
possessing	benzyl	or	ribose-5’-methylphosphate	substituents	on	the	pyridinium	ring	
were	demonstrated	to	yield	similar	turnover	numbers	and	enantioselectivities	to	the	
native	cofactor	NADH,	suggesting	that	they	replaced	NADH	during	catalysis.	Control	
experiments	 excluded	 the	 presence	 of	 residual	 native	 cofactor	 performing	 the	
catalysis.	 Therefore,	 the	 authors	 proposed	 that	 the	 pyridinium	 ring	 substituents	
played	a	role	in	the	binding	to	the	NAD+-binding	pocket	of	HLADH,	and	in	positioning	
the	 key	 nicotinamide	 motif	 in	 proximity	 of	 the	 substrate-binding	 pocket,	 where	
enantioselective	hydride	transfer	takes	place.	
	
Figure	4.30.	NAD+	analogues	with	the	nicotinamide	moiety	highlighted	in	red.		
The	binding	of	NAD+	mimics	to	the	ADH	cofactor	site	suggested	that	the	pyridinium-
substituted	 nicotinamide	 ring	 could	 act	 as	 an	 anchor,	 for	 the	 attachment	 and	
introduction	 of	 metal	 complexes	 within	 TADH.	 TADH	 and	 HLADH	 have	 a	 similar	
cofactor-binding	pocket,	 and	 it	was	 therefore	hypothesised	 that	 similar	 affinity	 for	
NAD+	mimics	would	be	observed.	The	1-benzylnicotinamide	analogue	was	selected,	as	
it	was	 simple	enough	 to	be	 synthesised.	To	 select	a	position	 for	 the	connection	of	
appropriate	 metal	 complexes,	 the	 ease	 of	 nicotinamide	 modification	 and	 the	
proximity	of	the	metal	attachment	to	the	substrate-binding	pocket	were	considered.		
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Figure	4.31.	Active	site	of	TADH	(PDB	4CPD),	showing	bound	NAD+	(orange	sticks),	the	catalytic	zinc	
(grey	sphere)	and	the	substrate-binding	site.	
Figure	 4.31	 shows	 the	 NAD+-binding	 pocket	 and	 the	 active	 site	 in	 TADH.	 The	
orientation	of	the	cofactor	is	such	that	position	4	of	the	nicotinamide	ring	is	positioned	
towards	the	substrate-binding	pocket,	whilst	position	5	is	oriented	towards	the	active	
site	zinc	ion.	Assuming	that	the	nicotinamide	ring	of	the	NAD+	analogues	was	similar	
to	that	of	NAD+	upon	TADH	binding,	these	two	positions	were	selected	for	anchoring	
of	the	catalyst,	because	space	was	available	 in	their	proximity.	The	general	designs	
chosen	for	the	metal	complexes	connected	to	the	nicotinamide	anchors	are	presented	
in	Figure	4.32.	
	
Figure	4.32.	Design	of	metal	 complexes	connected	 to	nicotinamide	mimics,	 for	 incorporation	 into	
TADH.	The	benzylnicotinamide	anchor	is	represented	in	red.	
The	choice	of	the	metal	catalyst	was	based	on	reported	 literature	results	 for	 imine	
reduction	 by	 transfer	 hydrogenation.182,183	 The	 majority	 of	 reported	 catalysts	
contained	 iridium,	 rhodium	and	ruthenium	with	a	variety	of	chiral	 ligands,	and	the	
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best	 conversions	were	 generally	 obtained	with	 iridium	catalysts.184	 Concerning	 the	
ligand,	 small	N-heterocyclic	 carbenes	 (NHCs)	were	 selected,	 to	minimise	 the	 space	
occupied	by	 the	metal	 complex	 inside	 the	protein.	From	a	 synthetic	point	of	view,	
NHCs	can	be	directly	connected	to	the	nicotinamide	ring,	without	the	need	of	a	linker	
(see	 later),	 thus	 enhancing	 the	 possibility	 to	 position	 the	 metal	 catalyst	 in	 close	
proximity	 to	 the	 nicotinamide	 ring,	 and	 thus	 to	 the	 substrate-binding	 pocket.	
Additionally,	NHC	ligands	have	the	advantage	of	high	thermal	stability,	and	the	ability	
to	tune	the	electronic	properties	of	the	metal	complex.185	Rh(III),	Ir(I	or	III)-	and	Ru(II)-	
N-heterocyclic	 carbenes	 were	 previously	 demonstrated	 to	 perform	 transfer	
hydrogenation	 with	 imine	 substrates	 (Figure	 4.33).186-190	 Out	 of	 these,	 iridium	
catalysts	were	the	most	efficient	for	this	transformation.	
	
Figure	4.33.	Rh,	Ru	and	Ir	chemical	catalysts	capable	of	performing	transfer	hydrogenation	on	imine	
substrates	containing	one	or	more	N-heterocyclic	carbene.		
Additionally,	 the	 synthesis	and	characterisation	of	a	Rh(I)-NHC	complex	 linked	 to	a	
nicotinamide	 derivative	 was	 recently	 reported	 (12,	 Figure	 4.34).	 The	 report	 also	
demonstrated	 the	 ability	 of	 such	 complexes	 to	 act	 as	 hydride	 ion	 carriers,	 by	
transferring	a	hydride	 to	 the	4	position	of	 the	nicotinamide	 ring.158	 	A	 substituted,	
tertiary	diisopropyl	amide	was	used,	due	to	ease	of	synthesis	and	handling,	and	both	
the	pyridinium	ring	and	the	NHC	possessed	a	methyl	substitution.	
	
Figure	4.34.	Hydride	transfer	ability	of	a	Rh(I)-NHC	complex	linked	to	nicotinamide.	Modified	from	
the	report	of	Colbran	and	co-workers.158	
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In	conclusion,	following	the	literature	research,	four	novel	structures	were	proposed	
to	introduce	a	non-native	metal-binding	site	into	TADH	(Figure	4.35,	13a	to	14b).	The	
structural	variations	included	the	connection	point	between	the	metal-NHC	complex	
and	the	nicotinamide	anchor	(position	4	or	5	of	the	nicotinamide	ring),	and	the	type	
of	metal	catalyst	used	for	complexation	(Ir(I)	or	Ir(III)).		
	
Figure	4.35.	Proposed	structures	of	nicotinamide-functionalised	Ir-NHC	catalysts.		
Despite	 published	 work	 suggesting	 easier	 handling	 of	 the	 tertiary,	 diisopropyl-
substituted	 nicotinamide,	 this	 substitution	was	 reasoned	 to	 add	 steric	 bulk	 to	 the	
nicotinamide	 anchor,	 and	 the	 primary	 amide	 was	 used	 instead.	Moreover,	 at	 the	
difference	 from	 the	 previously	 published	 methyl-substituted	 Rh-NHC	 11,	 a	 benzyl	
group	was	thought	necessary	for	the	recognition	of	the	substituted	nicotinamide	by	
ADH.	Since	the	selective	N-alkylation	of	the	nicotinamide	vs.	the	imidazole	ring	was	
deemed	difficult,	 benzyl	was	 used	 both	 as	 the	 pyridinium	 functionality	 and	 as	 the	
second	 substituent	of	 the	NHC,	despite	 its	 increased	bulk.	 Functionalisation	of	 the	
nicotinamide	with	 a	metal-NHC	 complex	 at	 the	4-position	has	not	been	previously	
reported	 and	 was	 therefore	 investigated.	 The	 synthesis	 of	 these	 structures	 was	
studied	in	the	following	section.	
4.4.3 Synthesis	 of	 a	 nicotinamide-functionalised	 iridium	 N-heterocyclic	 carbene	
complex		
The	synthesis	of	the	4-	and	5-functionalised	benzyl	nicotinamide	was	adapted	from	
the	procedure	previously	published	by	Colbran	and	co-workers	(Figure	4.36).158	The	
reported	synthesis158	relied	on	an	Ullmann	coupling	reaction	between	a	nicotinamide	
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halide	derivative	and	imidazole,	in	the	presence	of	a	copper	(I)	catalyst.	Derivatisation	
with	benzyl	iodide	at	both	the	pyridine	and	the	imidazole	nucleophilic	nitrogen	atoms	
afforded	the	corresponding	pyridinium	and	imidazolium	functionalities,	respectively.	
Formation	of	the	NHC	metal	complex	from	the	imidazolium	derivatives	was	relatively	
straightforward.	This	synthetic	scheme	was	adapted	to	the	synthesis	of	ligandss	17a	+	
b	and	18	a	+	b	(Figure	4.38).	
	
Figure	4.36.	Retrosynthetic	scheme	for	the	synthesis	of	nicotinamide	derivatives	linked	to	metal-NHC	
complexes.	The	synthesis	was	based	on	the	procedure	published	by	Colbran	and	co-workers.		
Ullmann	 coupling	 is	 a	 cross-coupling	 reaction	 between	 aryl	 halides	 a	 nucleophile,	
leading	 to	 C-C,	 C-N	 and	 C-O	 bond	 formation.191-196	 It	 is	 essentially	 an	 aromatic	
nucleophilic	 substitution,	 mediated	 by	 Cu(I).	 The	 generally	 accepted	 mechanism	
involves	 Cu(I)	 undergoing	 oxidative	 addition,	 followed	 by	 co-ordination	 to	 the	
nucleophile	and	reductive	elimination	(Figure	4.37,	route	A).	Mechanisms	proposed	
up	until	the	end	of	the	last	century	largely	suggested	the	nucleophile	to	co-ordinate	
first	 (Figure	 4.37,	 route	 B),	 increasing	 the	 electrophilicity	 on	 the	 aromatic	 and	
subsequently	the	susceptibility	to	oxidative	addition.	From	a	recent	review	on	copper-
catalysed	Ullmann	chemistry,	 it	 is	apparent	that	 the	mechanism	depends	upon	the	
specific	substrates	and	reaction	conditions	employed.195		
In	the	reported	synthesis	of	12,	the	use	of	a	“protected”	tertiary	nicotinamide	avoided	
the	 amide	 group	 acting	 as	 a	 nucleophile	 during	 the	 coupling.197,198	Moreover,	 the	
authors	 justified	 substitution	 of	 the	 primary	 amide	 to	 the	 tertiary	 amide	 by	 an	
increased	solubility,	avoidance	of	deprotonation	due	to	the	excess	base,	as	well	as	of	
co-ordination	to	the	copper	catalyst.	To	compare	the	influence	of	amide	protection	
on	the	Ullmann	coupling,	both	the	tertiary,	diisopropyl	nicotinamide	and	the	primary,	
“free”	nicotinamide	halide	derivatives	were	used	as	coupling	partners	with	imidazole.	
155	
	
	
Figure	 4.37.	 Reported	 catalytic	 cycles	 of	 copper-catalysed	 Ullmann	 coupling.	 Modified	 from	
Beletskaya	et	al.	(2004).199		
Substitution	of	position	4	of	the	nicotinamide	ring	by	N-arylation	of	the	imidazole	was	
not	previously	published.	Only	a	 few	examples	of	N-arylation	of	 imidazole	using	4-
substituted	pyridine	exist,	at	high	temperatures	and	long	reaction	times.200	Similar	to	
all	oxidative	additions,	the	reactivity	of	the	substituted	pyridine	halides	varies	in	the	
order	I	>	Br	>	Cl	>	F,	and	both	4-chloro-	and	4-bromopyridine	were	shown	to	give	high	
yields	when	coupled	to	imidazole	using	Ullmann	chemistry	(Figure	4.37).199	Based	on	
these	 results,	 both	 bromo-	 and	 chloro-substituted	 nicotinamide	 derivatives	 were	
tested	for	the	coupling	with	imidazole.	The	following	two	sub-sections	describe	the	
syntheses	of	the	metal-NHC	complexes	linked	to	tertiary	and	to	primary	nicotinamide	
derivatives,	respectively.	
4.4.3.1 Synthesis	of	4-	and	5-imidazolyl-diisopropylnicotinamide	ligands	
The	 method	 published	 by	 Colbran	 and	 co-workers	 for	 the	 synthesis	 of	 a	 tertiary	
nicotinamide	derivative	functionalised	with	imidazolium	at	position	5	was	reproduced,	
but	using	benzyl	group	substitutions	instead	of	methyl.	Additionally,	the	same	method	
was	tested	for	the	synthesis	of	the	4-substituted	nicotinamide	derivative	(Figure	4.38).		
Initially,	 the	 tertiary	 amide	 16a	 was	 synthesised	 according	 to	 Marsais	 from	
commercially	available	5-bromonicotinic	acid	15a,	in	79	%	yield	after	purification	by	
silica	 gel	 chromatography.157	 Attempts	 to	 synthesise	 4-bromonicotinamide	 from	
CuIY
CuI NuCuIII X
Y
Ar
HNu + base
base HX
HNu + base
base HY
ArX
CuIX
Ar Nu Ar X
A B
CuIII X
Nu
Ar
156	
	
commercial	 4-bromonicotinic	 acid	 resulted	 in	 substitution	 of	 the	 4-bromide	 by	
chloride,	during	treatment	with	SOCl2,	probably	due	to	the	higher	reactivity	of	the	4-
position	towards	nucleophilic	substitution.	To	avoid	this	issue,	4-chloronicotinic	acid	
15b	was	used	as	starting	material,	although	it	was	anticipated	that	Ullmann	coupling	
would	be	easier	with	the	Br	substituent.	Amide	synthesis	yielded	the	4-substituted	
compound	16b,	in	71	%	yield.		
	
Figure	4.38.	Proposed	synthesis	of	4-	and	5-imidazolyl-diisopropylnicotinamide	compounds.		
Both	the	4-chloro	and	the	5-bromo	substituted	nicotinamide	derivatives	were	further	
subjected	to	Ullmann	coupling	with	imidazole,	using	Cu(I)	catalyst	in	the	presence	of	
caesium	carbonate.	Products	5-(1H-imidazol-1-yl)-N,N-	diisopropylrnicotinamide	17a	
and	 4-(1H-imidazol-1-yl)-N,N-diisopropylnicotinamide	 17b	 were	 synthesised	
successfully	 in	 40	 %	 and	 68	 %	 yield,	 respectively.	 The	 yield	 for	 the	 5-imidazolyl	
compound	 17a	 was	 as	 expected	 when	 compared	 to	 the	 literature	 (70%).158	 	 The	
synthesis	 of	 the	 4-imidazolyl	 product	 17b	 demonstrated	 that	 imidazole	 could	
successfully	be	introduced	at	the	4-position	of	the	diisopropylnicotinamide.	However,	
the	lower	yield	suggested	that	coupling	at	the	4-position	was	challenging.		
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Benzylation	of	4-	and	5-	imidazolyl	coupled	products	17a	and	17b	with	two	equivalents	
of	benzyl	bromide	resulted	 in	benzyl	addition	at	both	the	nucleophilic	nitrogens	of	
imidazole	and	pyridine,	yielding	the	double-benzylated	products	18a	and	18b	in	30	%	
and	62	%	yield,	respectively.	These	results	confirmed	the	feasibility	of	introducing	an	
imidazolium	substitution	at	the	4	position	of	a	benzylnicotinamide	derivative,	starting	
from	a	4-chloro	substituted	starting	material.	
4.4.3.2 Synthesis	of	4-	and	5-imidazolyl-nicotinamide	ligands	21a	and	21b	
The	 synthesis	 of	 the	 4-	 and	 5-imidazolyl	 substituted	 benzylnicotinamide	 bearing	 a	
“free”,	non-substituted	primary	amide	was	attempted	following	a	similar	procedure	
as	above.	The	synthetic	scheme	is	outlined	in	Figure	4.39.	
	
	
Figure	4.39.	Proposed	synthesis	of	4-	and	5-imidazolyl-nicotinamide	compounds	21a	and	21b.		
5-(1H-Imidazol-1-yl)nicotinamide	 20a	 was	 successfully	 synthesised	 using	 Colbran’s	
reported	 procedure	 and	 obtained	 in	 78	 %	 yield	 after	 purification	 by	 silica	 gel	
chromatography	with	DCM	/	MeOH	(80	/	20)	as	the	eluting	agent.	This	demonstrated	
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the	successful	use	of	non-protected	5-bromo	substituted	nicotinamide	as	a	coupling	
partner	with	imidazole	under	Ullmann	reaction	conditions.	However,	the	purification	
of	the	primary	nicotinamide	did	prove	more	difficult	compared	to	the	corresponding	
tertiary	nicotinamide,	due	to	the	occurrence	of	minor	side-products	which	migrated	
close	together.		
On	the	other	hand,	the	synthesis	of	4-(1H-imidazol-1-yl)nicotinamide	20b	by	imidazole	
coupling	 to	 the	4-chloronicotinamide	19b	was	unsuccessful.	Several	attempts	were	
made	 to	 improve	 this	 result,	 including	 increased	 reaction	 time,	 temperature	 and	
reagent	equivalents	(Table	4.25).	However,	the	outcome	remained	the	same	in	most	
cases,	 i.e.	unreacted	starting	materials	observed	by	both	TLC	and	NMR,	along	with	
minor	side	products	that	could	not	be	isolated.	A	minor	amount	of	product	could	be	
observed	 by	 1H	 NMR;	 however,	 purification	 by	 silica	 gel	 chromatography	 proved	
difficult	and	the	desired	product	could	not	be	isolated.		
Table	 4.25.	 Summary	 of	 reaction	 conditions	 tested	 for	 the	 Ullmann	 coupling	 between	 4-
chloronicotinamide	19b	and	imidazole.	
Entry	 Reaction	Conditions	a	 Outcome	
1	 Imidazole	(1.6	eqv.),	CsCO3	(2	eqv.),	CuI	(0.2	eqv.),	in	DMF	at	110-120	oC,	24	h	
Presence	of	starting	material,	
minor	side	products	and	minor	
amount	of	desired	product	
2	 Temperature	increased	to	150	oC	 Degradation	and	minor	side	products	present.	
3	 Reaction	time	increased	to	36	h	 Same	as	model	reaction	
4	 Equivalents	of	reagents	increased	1.5	times	 Same	as	model	reaction	
5	 Equivalents	of	reagents	increased	1.5	times,	reaction	time	increased	to	36	h	 Same	as	model	reaction	
	a	Reaction	conditions	as	compared	to	the	model	reaction;	entry	1.	
There	were	two	main	differences	between	the	successful	and	unsuccessful	starting	
materials	 for	 the	Ullmann	 coupling:	 the	nicotinamide	 substitution	pattern	 (4	vs.	5-
halide)	and	the	nature	of	the	halide.	To	assess	whether	the	substitution	pattern	had	
159	
	
an	influence	on	the	reaction,	the	use	of	4-bromonicotinamide	was	envisaged,	in	order	
to	 compare	 the	 outcome	 with	 the	 5-bromonicotinamide	 use	 presented	 above.	
However,	 4-bromonicotinamide	 was	 not	 commercially	 available	 and	 attempts	 to	
prepare	 it	 from	4-bromonicotinic	 acid	were	not	 straightforward.	 The	 reaction	with	
thionyl	chloride	followed	by	ammonium	hydroxide	resulted	in	very	low	yields	(<25	%)	
of	a	non-separable	mixture	of	4-Br	and	4-Cl	products,	as	 identified	by	1H	NMR	and	
mass	spectrometry.		
	
Figure	4.40.	Ullmann	coupling	of	imidazole	with	4-bromonicotinic	acid.	
When	4-bromonicotinic	acid	was	directly	used	as	a	coupling	partner	with	imidazole,	
4-(1H-imidazol-1-yl)nicotinic	acid	23	was	successfully	synthesised	in	67	%	yield	after	
purification	by	silica	gel	chromatography	(Figure	4.40).	Therefore,	it	was	hypothesised	
that	the	bromo	substitution	was	required	for	the	reaction	to	proceed.	Aryl	chlorides	
are	 known	 to	 be	 less	 reactive	 substrates	 than	 aryl	 bromides	 in	 Ullman	 coupling	
reactions.	 However,	 oxidative	 addition	 of	 the	 “protected”	 4-chloronicotinamide	
derivative	 17b	 to	 Cu(I)	 and	 further	 coupling	 to	 imidazole	 was	 successfully	
demonstrated	 in	 the	 previous	 section.	 It	 was	 unlikely	 that	 the	 tertiary	 amide	
substitution	 had	 such	 a	 dramatic	 effect	 on	 the	 reactivity	 of	 the	 aryl	 halide	 during	
oxidative	addition.		
Considering	these	results,	it	was	hypothesised	that	the	presence	of	the	primary	amide	
was	 not	 compatible	 with	 performing	 the	 Ullmann	 coupling	 at	 position	 4	 of	 the	
nicotinamide.	The	primary	amide	from	a	second	nicotinamide	molecule	could	act	as	a	
nucleophile	at	the	place	of	 imidazole;	however,	this	was	not	observed	in	the	crude	
NMR.	 On	 the	 other	 hand,	 intramolecular	 coordination	 of	 the	 amide	 group	 to	 the	
adduct	 formed	 from	 oxidative	 addition	 to	 Cu(I)	 could	 occur,	 thus	 blocking	
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coordination	of	the	imidazole	coupling	partner.	When	the	amide	was	protected	by	the	
bulky	diisopropyl	groups,	this	coordination	might	have	been	hindered	(Figure	4.42).	
	
Figure	 4.41.	 Suggested	 mechanism	 for	 the	 inhibition	 of	 Ullman	 coupling	 by	 intramolecular	
coordination	of	the	Cu	adduct	to	the	primary	nicotinamide	functionality.	
Benzylation	of	 the	5-substituted	compound	20a	was	successfully	performed	with	4	
equivalents	of	benzyl	bromide	to	yield	compound	21a	in	87	%,	after	precipitation	and	
washing	 with	 diethyl	 ether.	 Given	 the	 difficulty	 in	 obtaining	 the	 4-substituted	
compound	20b,	the	synthesis	of	metal-complexes	was	only	investigated	starting	from	
21a.	
4.4.3.3 	Metalation	of	5-imidazolyl-nicotinamide	ligand	21a	
The	synthesis	of	benzylated	NHC	complexes	of	Rh	/	Ru	/	Ir	is	reported	in	the	literature	
using	two	different	methods.201,25	The	most	effective	route	is	the	initial	formation	of	
the	 silver	 carbenoid	 (Ag(I)-NHC)	 by	 reaction	 with	 silver	 oxide,	 followed	 by	
transmetalation	 with	 the	 desired	 metal	 complex	 to	 achieve	 the	 final	 metal-NHC	
compound	 (Figure	4.42).202	Advantages	of	 this	method	are	 the	selective	binding	of	
Ag(I)	 to	 the	 -N-CH-N-	 carbon	 of	 the	 imidazolium	 salt,	 the	 lack	 of	 additional	 base	
required	 to	 deprotonate	 the	 imidazolium	 and	 the	 broad	 tolerance	 for	 sensitive	
substituents,	avoiding	any	unwanted	side	reactions	or	decomposition	of	the	ligand.203	
An	alternative	method	for	NHC	formation	is	the	addition	of	a	base	to	deprotonate	the	
–N-CH-N-	carbon.203,204		
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Figure	4.42.	General	outline	for	the	synthesis	of	metal-NHC	complexes	via	transmetalation	with	silver	
(I)	oxide	
Initial	efforts	focused	on	the	metalation	of	ligand	21a	with	[Rh(COD)Cl2],	in	an	attempt	
to	 reproduce	 the	 result	 previously	 reported	 by	 Colbran	 and	 co-workers	 for	 the	
synthesis	 of	 nicotinamide-NHC-metal	 complexes.	 The	 method	 used	 is	 outlined	 in	
Figure	4.42,	with	dichloromethane	as	the	solvent.	No	reaction	was	observed	when	the	
progress	 of	 the	 reaction	 was	 monitored	 by	 TLC.	 Addition	 of	 the	 ligand	 to	
dichloromethane	resulted	in	a	cloudy	suspension,	suggesting	its	poor	solubility.	Before	
moving	forward,	the	solubilities	of	the	ligand	and	the	metal	precursor	were	assessed	
in	various	solvents	(Table	4.26)	The	only	solvent	observed	to	fully	dissolve	both	the	
ligand	and	Rh(I)	complex	was	dimethylformamide	(DMF).	However,	the	reaction	did	
not	proceed	in	DMF.	It	was	then	decided	to	perform	a	thorough	assessment	of	NHC	
formation	and	metalation	reaction,	using	iridium	catalysts.	The	choice	of	Ir	precursors	
was	due	to	their	reported	ability	to	catalyse	imine	reduction	earlier.		
Table	 4.26.	 Qualitative	 solubility	 assessment	 of	 ligand	 21a	 and	 of	 metal	 precursors	 in	 selected	
solvents.a	
Solvents	 Ligand	21a	 [Rh(COD)Cl]2	
H2O	 soluble	 not	soluble	
MeOH	 soluble	 partially	soluble	
CH2Cl2	 partially	soluble	 soluble	
Acetonitrile	 not	soluble	 soluble	
Acetone	 not	soluble	 soluble	
DMF	 soluble	 soluble	
DMSO	 soluble	 not	soluble	
a	5mg	of	Rh(I)	precursor	was	added	to	0.5	mL	solvent	with	stirring	and	further	sonication	(2	min)	if	ppt	
was	observed.	Solubility	was	observed	by	visual	inspection.	
N
C
N
R
R
H
I-
+ Ag2O
N
C
N
R
R
Ag I
(0.5 eqv.)
-H2O
N
C
N
R
R
MLX
metal complex
-AgI
162	
	
Metalation	was	 assessed	with	 both	 Ir(III)	 and	 Ir(I)	 precursors.	 [IrCp*Cl2]2	 was	 fully	
soluble	in	MeOH,	whereas	[Ir(COD)Cl]2	was	only	partially	soluble,	whilst	the	reverse	
was	observed	with	CH2Cl2	as	the	solvent.	Both	the	transmetalation	with	silver	oxide	
and	the	base	treatment	and	deprotonation	were	investigated	by	TLC	throughout	and	
NMR	analysis	of	the	final	adduct,	without	intermediate	isolation	of	the	Ag(I)	carbene,	
and	the	results	are	presented	in	Table	4.27.		
Table	4.27.	Summary	of	reaction	conditions	and	outcomes	of	the	metalation	attempts	of	ligand	21a	
with	Ir(I)	and	Ir(III)	precursors.		
Entry	 Basea	 Metal	complex	 Solvent	 Outcome	
1	 Ag2O	 [IrCp*Cl2]2	 MeOH	 No	reaction	
2	 Ag2O	 [IrCp*Cl2]2	 CH2Cl2	 No	reaction	
3	 Ag2O	 [IrCp*Cl2]2	
CH2Cl2	/	MeOH	
(5:1)	
No	reaction	
4	 Ag2O	 [Ir(COD)Cl]2	 MeOH	 No	reaction	
5	 Ag2O	 [Ir(COD)Cl]2	 CH2Cl2	 No	reaction	
6	 Ag2O	 [Ir(COD)Cl]2	
CH2Cl2	/	MeOH	
(5:1)	
No	reaction	
7	 Ag2O	 [Ir(COD)Cl]2	 CH2Cl2	(in	situ)b	 No	reaction	
8	 NaOAc	 [IrCp*Cl2]2	 MeOH	 Product	present	
9	 tBuOAc	 [IrCp*Cl2]2	 MeOH	 Product	present	
10	 NaOAc	 [Ir(COD)Cl]2	 MeOH	 No	reaction	
11	 tBuOAc	 [Ir(COD)Cl]2	 MeOH	 No	reaction	
a	Reaction	conditions	when	Ag2O	was	used:	Ag2O	(0.5	eqv.),	ligand	21a	(1.0	eqv.),	metal	complex	(0.5	
eqv.);	 when	 base	 was	 used:	 NaOAc/NaOtBu	 (1.0	 eqv.),	 KCl	 (6.7	 eqv.),	 ligand	 21a	 (1.0	 eqv.),	 metal	
complex	 (0.5	 eqv.):	All	 solvents	were	degassed.	 Entries	 1-6:	 Ligand	21a	 and	Ag2O	added	 to	desired	
solvent,	suspension	stirred	r.t.,	2	h	under	the	exclusion	of	 light.	The	suspension	 is	 then	filtered	 into	
metal	complex	containing	solvent	and	stirred	at	r.t.,	12	h,	followed	by	filtration	and	analysis.	b	The	metal	
complex,	ligand	and	Ag2O	were	reacted	in	situ,	entry	7	same	process	as	above	without	the	1st	filtration	
step,	instead	the	metal	complex	was	added	to	the	reaction	mixture	after	2	h.	Entries	8:	Metal	complex,	
base,	KCl,	ligand	21a	were	stirred	in	MeOH	at	reflux,	16	h.	Suspension	then	filtered	on	celite	and	purified	
by	column	chromatography.		
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No	metalation	was	achieved	with	the	silver	oxide	method.	The	poor	solubility	of	the	
metal	 precursors	 in	 the	 reaction	 solvents	 could	 explain	 this.	 Previous	 literature	
suggested	 silver-induced	 oxidative	 degradation	 of	 the	 imidazolium	 precursor	 in	
certain	cases,205	which	was	also	suggested	by	inspection	of	the	crude	1H	NMR	of	the	
reaction	mixtures	containing	the	Ag(I)-NHC	intermediate,	and	after	transmetalation.	
A	complete	characterisation	of	the	crude	mixtures	was	difficult	to	perform,	however	
most	analyses	showed	a	large	amount	of	unreacted	metal	precursor.	
On	 the	 other	 hand,	 the	 use	 of	 either	 NaOAc	 or	 NatOBu	 for	 deprotonation	 were	
successful	for	metalation	with	IrCp*,	with	the	presence	of	an	identical	Ir(III)Cp*-ligand	
complex	 obtained	 in	 both	 cases,	 confirmed	 by	 NMR	 and	 mass	 spectrometry.	 No	
metalation	was	 observed	with	 the	 [Ir(COD)Cl]2	precursor,	 probably	 due	 to	 its	 poor	
solubility	 in	 MeOH.	 Both	 the	 successful	 IrCp*	 metalation	 methods	 contained	
impurities	and	required	purification	by	silica	gel	chromatography.	Isolation	was	only	
performed	on	the	reaction	mixture	from	Table	4.27,	entry	9,	because	it	contained	less	
impurities.	The	final	product	was	obtained	in	28	%	yield	after	purification.	
Analysis	of	the	[Ir(Cp*)21a]	complex	was	performed	by	1H	and	13C	NMR	and	by	ESI-
MS.	Successful	formation	of	the	Ir-NHC	complex	was	confirmed	by	the	removal	of	the	
imidazolium	proton	(N-CH-N)	at	9.68	ppm,	and	by	the	shift	of	the	NHC	carbon	from	
146.4	 ppm	 in	 the	 imidazolium	 ligand,	 towards	 165-170	 ppm	 in	 the	 Ir-complex.	
However,	 the	presence	of	 two	13C	signals	 in	 the	 Ir-C	 region	 (167.6	and	170.7	ppm)	
suggested	the	 formation	of	a	second	C-Ir	bond.	Cyclometallation	by	 intramolecular						
C-H	activation	has	previously	been	reported	for	NHC	complexes	in	the	presence	of	a	
tBuO-	 base.	 Four	 aromatic	 C-H	 positions	were	 available	 for	 cyclometalation	 in	 the	
complexation	of	Ir(Cp*)	with	21a:	two	of	these	are	on	the	nicotinamide	ring,	whilst	
the	other	two	on	the	N-benzyl	functionality	of	the	NHC	(Figure	4.43).	
Careful	 inspection	 of	 the	 NMR	 data	 suggested	 that	 C-H	 insertion	 occurred	 at	 the	
nicotinamide	 ring,	 as	 suggested	 by	 the	 removal	 of	 one	 of	 the	 corresponding	
pyridinium	protons	at	10.1	ppm,	as	well	as	by	the	reduced	multiplicity	of	the	remaining	
protons,	from	multiplets	to	doublets.	The	remaining	pyridinium	signals	shifted	upfield,	
from	10.1	and	9.51,	to	9.09	and	8.55,	respectively,	consistent	with	an	Ir-C	bond	in	the	
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meta	position.	This	is	supported	by	the	fact	that	the	aromatic	C-H	bond	in	the	ortho	
or	para	position	of	the	protonated	nitrogen	atom	is	more	activated	than	the	aromatic	
C-H	bond	on	the	benzyl	group.	
	
Figure	4.43.	C-H	activation	of	Ir-complex	21a		
It	 was	 difficult	 to	 assert	 unambiguously,	 from	 this	 NMR	 structure,	 whether	 the	
insertion	occurred	at	position	2	or	6	of	the	pyridinium	ring.	However,	the	13C	signal	at	
position	 6	 seems	 to	 be	 the	 same	when	 comparing	 the	 ligand	 and	 the	 Ir-complex,	
suggesting	 cyclometallation	 at	 position	 2,	 thus	 yielding	 24a.	 Interestingly,	 the	 CH2	
protons	corresponding	to	the	NHC	N-benzyl	group	are	diastereotopic,	presenting	two	
doublets	at	5.53	and	5.47	ppm,	consistent	with	previous	work.	
	
Figure	4.44.	1H	NMR	analysis	of	cyclometallated	complex	24a.	
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In	 conclusion,	 an	 NHC	 carbene	 precursor	 was	 introduced	 at	 the	 5-position	 of	
benzylnicotinamide,	to	yield	21a	in	reasonable	yields.	Substitution	at	the	4-position	of	
benzylnicotinamide	proved	difficult	under	the	conditions	tested.	On	the	other	hand,	
metalation	 of	 the	 5-substituted	 ligand	21a	 resulted	 in	 a	 new	 Ir-NHC	 complex	24a,	
which	underwent	cyclometalation	at	position	6,	it	is	thought.	Whilst	this	structure	was	
less	 flexible	 than	 the	 initially	designed	complexes,	 it	was	decided	 to	 investigate	 its	
activity	towards	ketone	and	imine	reduction,	in	the	presence	and	in	the	absence	of	
TADH.		
4.4.4 	Transfer	hydrogenation	of	ketones	and	of	imines	by	an	iridium	complex	of	a	
nicotinamide-functionalised	N-heterocyclic	carbene		
Preliminary	 investigations	 into	 the	 ability	 of	 24a	 to	 catalyse	 ketone	 and	 imine	
reduction	were	performed	under	both	organic	and	aqueous	transfer	hydrogenation	
conditions.	Isopropanol	was	employed	as	the	solvent	and	source	of	hydrogen	in	the	
organic	 reaction,	 while	 a	 buffer	 solution	 containing	 sodium	 formate	 provide	 the	
hydride	in	aqueous	reactions.	Model	ketone	and	imine	substrates	were	acetophenone	
25,	 3,4-dihydroisoquinoline	 2,	 and	 2-methyl-1-pyrroline	 1.	 The	 conversions	 were	
approximated	by	1H	NMR	analysis	of	the	final	reaction	mixtures	as	a	result	of	the	ratio	
of	integration	of	the	starting	material	to	the	product.		
	
Figure	4.45.	 Transfer	hydrogenation	 reactions	of	 acetophenone	 (25),	 2-methyl-1-pyrroline	 (1)	 and	
2,3-dihydroisoquinoline	(2)	catalysed	by	24a	in	organic	and	aqueous	media.		
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4.4.4.1 Transfer	hydrogenation	of	ketones	and	imines	using	24a	in	organic	solvent		
Complex	24a	was	investigated	for	the	transfer	hydrogenation	of	acetophenone	using	
standard	conditions	found	in	literature	reports	with	an	isopropanol	/	NatOBu	mixture.	
The	reaction	proceeded	with	76	%	conversion	(Table	4.28,	entry	1).	No	side	products	
were	 observed	 by	 1H	 NMR.	 When	 the	 substrates	 and	 reagents	 were	 diluted,	 to	
increase	compatibility	with	enzyme	presence	in	subsequent	experiments,	conversion	
decreased	 to	 21	 %	 (Table	 4.28,	 entry	 2).	 Transfer	 hydrogenation	 of	 3,4-
dihydroisoquinoline	2	at	low	concentration	yielded	a	similar	conversion	of	24	%	(Table	
4.28,	 entry	 3).	 On	 the	 other	 hand,	 no	 reaction	 was	 observed	 when	 2-methyl-1-
pyrroline	1	was	used.	These	results	demonstrated	that	the	new	Ir-NHC	complex	was	
active	for	transfer	hydrogenation	reactions	to	ketones	and	imines.	No	attempts	were	
made	 to	optimise	 the	conversions.	 Instead,	 the	activity	of	 the	complex	 in	aqueous	
conditions	was	tested.		
Table	4.28.	Transfer	hydrogenation	of	acetophenone	(25),	3,4-dihydroisoquinoline	(2)	and	2-methyl-
1-pyyroline	(1)	with	the	nicotinamide-functionalised	Ir-NHC	complex	24a	in	organic	solvent.	
Entry	 Substrate	 Substrate	concentration	 Conversion	(%)
a	
1	 acetophenone	 3	M	 76b	
2	 acetophenone	 0.3	M	 21	
3	 3,4-dihydroisoquinoline	 0.3	M	 24	
4	 2-methyl-1-pyrroline	 0.3	M	 0	
The	reaction	was	performed	at	reflux,	under	N2	for	24	h	containing	substrate	(0.15	mmol,	300	mM),	10	
mol	%	NaOtBu	(0.015	mmol),	1	mol	%	 Ir	complex	24a	 (0.3	mM,	final	conc.)	 in	 iPrOH	(0.5	mL).	After	
completion	 solvent	 removed	 and	 products	 sent	 for	 NMR	 analysis.	 a	 Conversions	 calculated	 as	 a	
percentage	 of	 products	 :	 oxidised	 /	 reduced	 substrate	 ratio	 based	 upon	 the	 integration	 of	 specific	
signals	in	1H-NMR.	b	reaction	containing	substrate	(1.5	mmol,	3	M),	10	mol	%	NaOtBu	(0.015	mmol),							
1	mol	%	Ir	complex	24a	(3	mM,	final	conc.)	in	iPrOH	(3	mL).	
4.4.4.2	Transfer	hydrogenation	of	ketones	and	imines	using	24a	in	aqueous	solvent	
Following	 from	 the	 encouraging	 results	 observed	 for	 hydrogen	 transfer	 in	 organic	
conditions,	 complex	 24a	 was	 investigated	 as	 a	 catalyst	 for	 the	 same	 reactions	 in	
aqueous	 conditions.	 To	 enhance	 solubility	 of	 both	 24a	 and	 the	 substrates	 in	 the	
aqueous	 reaction	 solvent,	 stock	 solutions	 were	 prepared	 in	 DMF,	 at	 a	 final	
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concentration	 of	 the	 organic	 solvent	 in	 the	 reaction	 of	 4-7	%	 (v	 /	 v).	 Under	 these	
conditions,	 reduction	of	ketone	to	the	corresponding	alcohol	occurred	with	a	19	%	
conversion,	 similar	 to	 the	 result	 obtained	 in	 organic	 solvent	 (Table	 4.29,	 entry	 1).	
Encouragingly,	100	%	conversion	was	observed	with	 imine	substrate	2	 (Table	4.29,	
entry	2).	On	the	other	hand,	no	conversion	was	seen	with	2-methyl-1-pyrroline	1.	
Table	4.29.	Transfer	hydrogenation	of	acetophenone	(25),	3,4-dihydroisoquinoline	(2)	and	2-methyl-
1-pyrroline	(1)	with	the	nicotinamide-functionalised	Ir-NHC	complex	24a	in	aqueous	solvent.	
Entry	 Substrate	
Organic	solvent	
(%	v	/	v)	
Conversion	(%)a	
1	 acetophenone	 4	%	DMF	 19	
2	 3,4-dihydroisoquinoline	 7	%	DMF	 100	
3	 2-methyl-1-pyrroline	 4	%	DMF	 0	
4	 acetophenone	 4	%	ACN	 0	
5	 3,4-dihydroisoquinoline	 5	%	ACN	 100	
6	 2-methyl-1-pyrroline	 4	%	ACN	 0	
The	reaction	was	performed	at	55	oC,	under	N2	for	24	h:	entries	1-3	containing	substrate	(0.15	mmol,	
300	mM),	1	mol	%	Ir	complex	24a	(0.3	mM,	final	conc.)	in	1.2	M	MOPS	containing	3	M	sodium	formate	
(0.5	mL)	and	entries	4-6	containing	substrate	(1.25	µmol,	2.5	mM),	1	mol	%	Ir	complex	24a	(0.0025	mM,	
final	conc.)	in	0.4	M	MOPS	containing	1	M	sodium	formate	(1	mL).	After	completion	products	extracted	
with	CHCl3	 (4	x	3	mL),	dried	and	sent	 for	NMR	analysis.	 a	Conversions	calculated	as	a	percentage	of	
products	:	oxidised	/	reduced	substrate	ratio	based	upon	the	integration	of	specific	signals	in	1H-NMR.	
The	substrate	concentrations	used	for	these	reactions	were	too	high	to	be	used	in	the	
presence	of	the	enzyme,	which	was	objective	of	this	section.	Moreover,	acetonitrile	
was	 highlighted	 in	 an	 earlier	 section	 as	 the	 solvent	with	 the	 least	 effect	 on	 TADH	
activity,	in	contrast	to	DMF,	which	inhibited	the	reaction.		Therefore,	a	second	set	of	
transfer	hydrogenation	reactions	were	performed	using	ACN	as	the	co-solvent	to	aid	
substrate	solubilisation,	and	at	a	substrate	concentration	>100	times	lower	compared	
to	the	initial	experiments.	Under	these	conditions,	no	conversion	was	obtained	with	
acetophenone	(This	was	thought	to	occur	because	of	the	low	solubility	of	the	ketone	
substrate	in	acetonitrile,	which	resulted	in	a	cloudy	reaction	mixture	throughout.	On	
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the	other	hand,	the	imine	substrate	2	was	observed	to	undergo	full	conversion.)	It	is	
possible	that	the	difference	between	the	results	was	due	to	the	higher	reactivity	of	
the	Ir-catalyst	for	 imine	reduction,	compared	to	the	ketone	counterpart.	The	result	
obtained	with	 the	 imine	was	most	 encouraging,	 as	 for	 the	 purposes	 of	 this	 study,	
catalyst	24a	was	required	to	react	efficiently	in	mild	conditions	in	order	to	be	used	in	
conjunction	with	TADH.	
4.4.4.3	Transfer	hydrogenation	of	 ketones	and	 imines	using	24a	 in	 the	presence	of	
TADH	
Next,	 investigations	 into	 hydrogen	 transfer	 reactions	 catalysed	 by	 24a	 were	
performed	in	the	presence	of	TADH	(Table	4.30).		Reactions	were	performed	with	the	
addition	 of	 ACN	 (4-5	 %)	 as	 co-solvent.	 Again,	 no	 reaction	 was	 observed	 with	
acetophenone	25	or	2-methyl-1-pyrroline	1	as	substrates	whilst	full	conversion	was	
observed	for	the	transfer	hydrogenation	of	3,4-dihydroisoquinoline	2.	This	suggested	
that	TADH	did	not	act	as	an	inhibitor	of	the	reaction	under	these	concentrations.	This	
was	an	interesting	result,	given	that	previous	reports	suggested	mutual	inactivation	
between	TADH	and	[Cp*Rh(bipyridine)Cl]	catalyst.111		
Table	4.30.	Transfer	hydrogenation	of	acetophenone	(25),	3,4-dihydroisoquinoline	(2)	and	2-methyl-
1-pyrroline	(1)	with	the	nicotinamide-functionalised	Ir-NHC	complex	24a	in	the	presence	of	TADH.	
Entry	 Substrate	 Organic	solvent	(%	v	/	v)	 Conversion	(%)a	
1	 acetophenone		 4	%	ACN	 0	
2	 3,4-dihydroisoquinoline	 5	%	ACN	 100	
3	 3,4-dihydroisoquinoline	 5	%	ACN	 100b	
4	 2-methyl-1-pyrroline	 4	%	ACN	 0	
5	 2-methyl-1-pyrroline	 4	%	ACN	 0b	
The	 reaction	was	performed	at	55	 oC,	under	N2	 for	24	h	containing	substrate	 (1.25	µmol,	2.5	mM),													
1	mol	%	Ir	complex	24a	 (0.0025	mM,	final	conc.)	and	TADH	(0.0025	mM	final	conc.)	 in	0.4	M	MOPS	
containing	1	M	sodium	formate	(1	mL).	After	completion	products	extracted	with	CHCl3	(4	x	3mL),	dried	
and	sent	for	NMR	analysis.	a	Conversions	calculated	as	a	percentage	of	products	:	oxidised	/	reduced	
substrate	ratio	based	upon	the	integration	of	specific	signals	in	1H-NMR.	b	additionally	containing	NADH	
(2.5	mM	final	conc.)		
169	
	
In	conclusion,	a	novel	iridium	complex,	24a	was	shown	to	catalyse	hydrogen	transfer	
of	acetophenone	25	and	3,4-dihydroiisoquinoline	2	under	both	organic	and	aqueous	
conditions.	The	imine	was	preferred	as	a	substrate,	yielding	quantitative	conversions	
even	 at	 low	 substrate	 concentrations	 catalyst.	 However,	 the	 5-membered	 ring	
aliphatic	imine,	2-methyl-1-pyrroline	1	was	not	converted.	The	catalyst	was	shown	to	
perform	 effectively	 in	 the	 presence	 of	 TADH,	 however	 the	 performance	 was	
unaffected	in	the	presence	of	NADH,	suggesting	no	affinity	for	the	co-factor	binding	
pocket.		
To	 investigate	 the	 affinity	 of	 the	 iridium	 complex	 for	 TADH,	 kinetic	 studies	 were	
performed,	where	the	inhibition	of	TADH	activity	was	determined	with	both	the	Ir-
complex	24a	and	the	corresponding	ligand	21a.		
4.4.5	 Inhibition	 studies	of	 TADH	by	nicotinamide-functionalised	 ligand	and	metal	
complex	
Preliminary	 studies	 were	 performed,	 where	 Michaelis-Menten	 kinetics	 were	
determined	 with	 varying	 cofactor	 concentrations	 in	 the	 presence	 of	 the	 metal	
complex	24a	or	of	the	ligand	21a,	in	order	to	assess	whether	inhibition	occurs.	Binding	
of	 the	 modified	 nicotinamide	 mimics	 to	 the	 cofactor-binding	 site	 would	 lead	 to	
reversible	competitive	inhibition	that	would	increase	KM,	thus	lowering	the	affinity	for	
the	 cofactor,	 but	 would	 not	 affect	 Vmax.	 Investigations	 were	 performed	 in	 the	
reduction	direction	with	cyclohexanone	(500	mM)	and	NADH	(0.5-12.5	mM)	as	the	
substrates,	 and	 with	 21a	 or	 24a	 (0.05-0.25	mM)	 as	 inhibitors.	 A	 control	 was	 also	
performed	 in	 the	 absence	 of	 NADH	 to	 confirm	 21a	 and	 24a	 had	 no	 interfering	
absorbances	at	340	nm.		
4.4.5.1	Inhibition	studies	with	nicotinamide-functionalised	ligand	21a	
Given	the	poor	solubility	of	ligand	21a,	these	experiments	were	performed	with	the	
addition	of	2	%	DMSO	in	the	reaction	mixture,	which	was	required	in	order	to	solubilise	
the	ligand.	DMSO	was	reported	to	act	as	an	inhibitor	for	HLADH	and	TbADH.	(Section	
4.2.2.1),	However	the	impact	of	2	%	(v	/	v)	DMSO	was	relatively	low,	with	42	%	of	the	
activity	retained.	Michaelis-Menten	kinetics	was	performed	in	the	absence	and	in	the	
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presence	of	ligand	21a	as	an	inhibitor	at	concentrations	of	0.1	mM	and	0.25	mM,	and	
the	 results	 were	 used	 to	 produce	 a	 Lineweaver-Burk	 (Figure	 4.46)	 and	Michaelis-
Menten	plot	 (Appendix	7),	 from	which	the	KM	and	Vmax	values	were	calculated	and	
compared	(Table	4.31).			
	
Figure	 4.46.	 Lineweaver-Burk	 plot	 illustrating	 the	 inhibitory	 effect	 of	 nicotinamide-functionalised	
ligand	21a	in	the	reductive	direction	using	NADH	and	cyclohexanone	as	substrates.	Specific	activities	
were	determined	 in	 the	 reductive	direction	at	60	 oC,	using	TADH	(5.6	µg),	NADH	(0.01,	0.025,	0.05,	
0.075,	0.1,	0.25	mM)	as	substrate,	cyclohexanone	(20	mM)	as	secondary	substrate,	in	50	mM	Bis-Tris	
buffer	 pH	 6.0	 containing	 2	 %	 v/v	 DMF	with	 nicotinamide-functionalised	 ligand,	 21a	 as	 inhibitor	 at	
concentration:	(l)	0	mM	,	()	0.1	mM,	(¾)	0.25	mM.	
The	 data	 from	 Table	 4.31	 showed	 irregular	 trends	 for	 these	 inhibition	 studies,	
although	 relatively	 low	 errors	were	 obtained	 from	 triplicate	 experiments,	 showing	
that	 the	 results	 were	 reproducible.	 The	 typical	 trends	 expected	 for	 competitive	
inhibition	were	not	observed.	From	the	KM	and	Vmax	calculated	values	(Table	4.31),	it	
appeared	 that	 Vmax	 remained	 relatively	 unchanged	 irrespective	 of	 the	 inhibitor	
concentration,	 while	 KM	 was	 observed	 to	 increase	 as	 the	 ligand	 concentration	
increased.	 This	 hinted	 towards	 possible	 competitive	 binding	 of	 the	 ligand	 at	 the	
cofactor	binding	site.	To	explain	the	irregular	trends	observed	during	the	kinetics,	it	
was	hypothesised	that	the	low	solubility	of	the	ligand	in	the	reaction	mixture	may	have	
skewed	the	results.		
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Table	4.31.	Comparison	of	Vmax	and	KM	obtained	for	NADH	in	the	presence	of	different	concentrations	
of	21a.	
Inhibitor	concentration	
(mM)	
Vmax	
(µM	/	min)	
KM	
(mM)	
0	 2.36	±	0.034	 0.00232	±	0.00042	
0.1	 2.62	±	0.064	 0.00497	±	0.00093	
0.25	 2.17	±	0.078	 0.00617	±	0.0015	
Specific	activities	were	determined	in	the	reductive	direction	at	60	oC,	using	TADH	(5.6	µg),	NADH	(0.01,	
0.025,	 0.05,	 0.075,	 0.1,	 0.25	mM)	 as	 substrate,	 cyclohexanone	 (20	mM)	 as	 secondary	 substrate,	 in												
50	mM	Bis-Tris	buffer	pH	6.0	containing	2	%	v	/	v	DMF	with	nicotinamide-functionalised	ligand,	21a	as	
inhibitor	(0,	0.1,	0.25	mM.)	Michaelis-Menten	plot	is	present	in	Appendix	7.	
4.4.5.2	Inhibition	studies	with	nicotinamide-functionalised	Ir-NHC	catalyst	24a		
The	 same	 inhibition	 experiments	 performed	with	 the	 ligand	were	 repeated	 in	 the	
presence	of	the	Ir-NHC	complex	24a.	Inhibition	was	observed	at	lower	concentrations	
of	 the	 Ir-NHC	 complex,	 and	 experiments	 were	 performed	 at	 the	 lower	 inhibitor	
concentrations	 of	 0.1	mM	 and	 0.05	mM.	 The	 solubility	 of	 24a	 in	 acetonitrile	 was	
higher,	 allowing	 the	use	of	 this	 solvent	 in	 the	 reaction	mixture	 at	 5	%	 (v	 /	 v).	 The	
kinetics	 results	 were	 used	 to	 produce	 a	 Lineweaver-Burk	 plot	 (Figure	 4.47),	 and	
Michaelis-Menten	 plot	 (Appendix	 8),	 from	 which	 the	 KM	 and	 Vmax	 values	 were	
calculated	and	compared	(Table	4.32).	
In	comparison	to	the	results	obtained	with	ligand	21a,	inhibition	studies	with	the	Ir-
NHC	 complex	 24a	 showed	 clear	 and	 reproducible	 trends	 corresponding	 to	 mixed	
inhibition.	 The	 KM	 was	 observed	 to	 increase,	 whereas	 the	 Vmax	 decreased	 with	
increasing	 concentration	 of	 Ir-NHC.	 This	 type	 of	 inhibition	 suggests	 binding	 of	 the	
inhibitor	at	a	different	site	from	the	cofactor	binding	site.	
The	 increased	KM	suggested	that	 the	 Ir	complex	 inhibited	the	binding	of	 the	NADH	
cofactor,	 because	 more	 NADH	 was	 required	 to	 reach	 half	 Vmax.	 However,	 the	
decreased	Vmax	suggested	that	NADH	could	not	outcompete	the	inhibitor	binding	at	
high	concentrations.	In	contrast	to	competitive	binding,	where	the	inhibitor	occupies	
the	 substrate-binding	 pocket	 and	 does	 not	 allow	 it	 to	 bind,	 the	 observed	 mixed	
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inhibition	suggested	that	NADH	could	still	bind	to	the	enzyme-inhibitor	complex,	but	
the	conversion	to	product	was	inhibited.	This	was	possibly	as	a	result	of	the	Ir-catalyst	
binding	elsewhere	to	the	enzyme,	such	as	in	the	proximity	of	the	ketone-binding	site.		
	
Figure	4.47.	 Lineweaver-Burk	 illustrating	 the	 inhibitory	effect	of	 Ir	 complex	 (24a)	 in	 the	 reductive	
direction	using	NADH	and	 cyclohexanone	as	 substrates.	Specific	 activities	were	determined	 in	 the	
reductive	direction	at	60	oC,	using	TADH	(5.6	µg),	NADH	(0.01,	0.025,	0.05,	0.075,	0.1,	0.25	mM)	as	
substrate,	cyclohexanone	(20	mM)	as	secondary	substrate,	in	50	mM	Bis-Tris	buffer	pH	6.0	containing	
5	%	v/v	ACN	with	Ir	complex,	24a	as	inhibitor	at	concentration:	(l)	0	mM	,	()	0.05	mM,	(¾)	0.1	mM.		
This	 study	 showed	 that	 both	 the	 ligand	 and	 Ir	 catalyst	 interacted	 with	 TADH	 to	
decrease	 its	 natural	 activity.	 However,	 they	 also	 suggested	 that	 binding	 of	 the	
nicotinamide-functionalised	Ir-NHC	complex	24a	does	not	occur	at	the	NADH	binding	
site.	
Table	4.32.	Comparison	of	Vmax	and	KM	obtained	for	NADH	in	the	presence	of	different	concentrations	
of	(24a)	
Inhibitor	
concentration	(mM)	
Vmax	
(µM	/	min)	
KM	
(mM)	
0	 1.98	±	0.059	 0.00484	±	0.0011	
0.05	 1.49	±	0.083	 0.0311	±	0.0059	
0.1	 1.47	±	0.11	 0.0785	±	0.013	
Specific	activities	were	determined	in	the	reductive	direction	at	60	oC,	using	TADH	(5.6	µg),	NADH	(0.01,	
0.025,	 0.05,	 0.075,	 0.1,	 0.25	mM)	 as	 substrate,	 cyclohexanone	 (20	mM)	 as	 secondary	 substrate,	 in										
50	mM	Bis-Tris	buffer	pH	6.0	containing	5	%	v	/	v	ACN	with	Ir	complex,	24a	as	inhibitor	at	(0,	0.05,	0.1	
mM.);	Michaelis-Menten	plot	is	present	in	Appendix	8.		
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4.4.5 Conclusions	
Two	 nicotinamide-functionalised	 N-heterocyclic	 ligand	 scaffolds	 were	 designed	 as	
precursors	 to	 Ir-complexes	 to	 be	 introduced	 in	 TADH.	 In	 these	 scaffolds,	 benzyl	
nicotinamide	was	used	as	an	anchor	with	affinity	for	ADH,	and	connection	with	the	
NHC	was	envisaged	at	positions	4	and	5	of	the	nicotinamide	ring,	to	allow	orientation	
of	the	resulting	complex	towards	the	substrate-binding	pocket	in	TADH.		
Synthesis	 of	 the	 5-imidazoyl-functionalised	 benzylated	 nicotinamide	 ring	 was	
successfully	 achieved,	 and	 the	 resulting	 [(Cp*)Ir(NHC)]	 complex	 was	 formed.	
Cyclometalation	was	observed	at	position	6	of	the	nicotinamide	ring,	and	the	resulting	
Ir-complex	structure	was	elucidated	by	NMR	and	MS	studies.	On	the	other	hand,	the	
functionalisation	 at	 position	 4	 of	 the	 nicotinamide	 ring	with	 a	 NHC	 precursor	was	
unsuccessful,	due	to	the	inefficiency	of	the	key	Ullmann	coupling	step.	Intramolecular	
coordination	of	the	non-protected	nicotinamide	to	the	Cu	catalyst	was	suggested	to	
be	responsible	for	this	result.		
The	nicotinamide-functionalised	 [(Cp*)Ir(NHC)]	complex	was	shown	to	be	an	active	
catalyst	in	the	transfer	hydrogenation	of	aryl	ketones	(acetophenone)	and	imines	(3,4-
dihydroisoquinoline).	 Similar	 conversions	 (~20	 %)	 were	 obtained	 for	 the	 two	
substrates	in	organic	solvent,	using	isopropanol	as	hydride	donor.	On	the	other	hand,	
the	activity	 towards	 the	 imine	substrate	was	much	higher	 in	aqueous	buffer,	using	
sodium	formate.		
Inhibition	 studies	 showed	 that	 the	 Ir-catalyst	 interfered	with	 the	 enzyme	 kinetics,	
acting	 as	 a	mixed	 inhibitor	 for	 the	 enzyme	when	NADH	 concentration	was	 varied.	
Whilst	 the	 catalyst	 remained	 active	 in	 the	 presence	 of	 TADH,	 no	 decrease	 in	
conversion	 was	 observed	 upon	 NADH	 addition.	 Taken	 together,	 these	 results	
suggested	that	the	nicotinamide-functionalised	catalyst	did	not	bind	at	the	cofactor-
binding	site.		
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Chapter	5 Conclusions	and	perspectives	
This	 thesis	presents	the	attempts	at	both	genetic	and	chemical	modification	of	 the	
active	 site	 of	 a	 thermostable	 alcohol	 dehydrogenase,	 to	 introduce	 reaction	
promiscuity	towards	imine	reduction.	The	results	obtained	allowed	an	increase	in	the	
understanding	of	how	imines	interact	with	the	active	site	of	alcohol	dehydrogenases.	
Variants	 of	 TADH	 containing	 protic	 residues	 in	 the	 active	 site	 were	 successfully	
designed.	 Rh-containing	 TADH	 variants	 were	 also	 prepared,	 however	 the	 precise	
localisation	of	 the	Rh	 at	 the	place	of	 the	 catalytic	 zinc	was	not	 determined.	 Imine	
reduction	 activity	 was	 not	 identified	 in	 any	 of	 the	 modified	 enzymes,	 under	 the	
conditions	employed.	In	a	different	approach,	a	novel	iridium(III)	complex	bearing	a	
nicotinamide	 anchor	was	 designed	 for	 introduction	 into	 TADH,	 and	 showed	 imine	
reduction	 activity	 in	 the	 presence	 of	 the	 enzyme.	 However,	 based	 on	 inhibition	
studies,	 it	was	suggested	that	this	complex	was	not	 incorporated	into	the	cofactor-
binding	site	of	TADH.		
Preliminary	experiments,	outlined	in	Chapter	4.1,	were	concerned	with	the	choice	of	
a	thermostable	protein	as	a	starting	point	for	this	work,	and	with	the	development	of	
expression	and	purification	methods,	based	on	literature	reports.	ADH	from	Thermus	
sp.	ATN1	was	selected	based	on	its	stability	and	broad	substrate	range.	Some	issues	
were	 observed	 with	 reproducing	 the	 TADH	 preparation	 as	 characterised	 in	 the	
literature.	 Expression	of	 TADH	was	 successfully	 achieved	 in	E.	 coli,	after	 growth	at							
30	oC	and	induction	with	0.4	mM	IPTG	at	30	oC.	A	heat	purification	step	was	applied	at	
80	oC	for	20	min,	yielding	relatively	pure	protein,	as	estimated	by	SDS-PAGE.	The	zinc	
content	 of	 this	 protein	 was	 observed	 to	 be	 lower	 than	 expected	 by	 ICP-MS.	 Size	
exclusion	 purification	 did	 not	 replicate	 the	 increased	 activity	 observed	 in	 the	
literature,	although	the	zinc	content	was	seen	to	increase	to	1	:	1.6,	still	lower	than	
the	expected	1	:	2	protein	:	zinc	ratio.	The	resulting	TADH	showed	kinetic	parameters	
similar	to	the	ones	reported	in	the	literature.	
In	Chapter	4.2,	the	interaction	of	TADH	with	two	selected	cyclic	imines,	5-membered	
ring	 2-methyl-1-pyrroline	 1	 and	 6-membered	 ring	 3,4-dihydroisoquinoline	 2,	 was	
characterised	 by	 inhibition	 studies	 and	 by	 computational	 (docking)	methods.	 First,	
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TADH	was	observed	to	maintain	activity	with	the	ketone	/	aldehyde	precursors	of	the	
two	imines.	Despite	the	reduced	activities	observed	with	both	2-ethylbenzaldehyde	
and	2-pentanone	(4-5	%	remaining	activity	compared	to	cyclohexanone),	the	results	
demonstrated	that	architectures	similar	to	the	cyclic	 imine	substrates	could	fit	 into	
the	active	site.	Preliminary	 inhibition	studies	with	 imines	and	their	reduced	amines	
illustrated	complete	 inhibition	of	TADH	by	the	6-membered	structures	 (2	and	4)	at	
concentrations	equal	to	the	substrate.	Inhibition	kinetics	with	the	5-membered	cyclic	
imine	 1	 and	 reduced	 amine	 3	 showed	 mixed	 inhibition	 for	 these	 compounds,	
suggesting	 that	 inhibitor	 and	 substrate-binding	 sites	 were	 different.	 For	 example,	
imines	might	bind	at	the	place	of	NADH,	and	/	or	at	another	position	within	the	active	
site.	 The	 amine	 compound	 was	 shown	 to	 have	 inhibitory	 effect	 at	 lower	
concentrations	compared	to	the	imine,	thus	suggesting	a	possible	interaction	with	the	
catalytic	zinc.		
Furthermore,	 docking	 studies	 of	 imines	 1	 and	 3	 inside	 cofactor-bound	 TADH	
confirmed	 the	 possibility	 of	 their	 acceptance	 in	 the	 active	 site.	 Their	 preferred	
orientation	was	similar	to	that	of	a	docked	model	ketone,	within	range	for	both	proton	
and	hydride	 transfer,	while	 the	 imine	nitrogen	atom	pointed	 towards	 the	 catalytic	
zinc.	In	the	presence	of	the	ketone,	imines	docked	in	a	separate	cavity,	adjacent	to	the	
substrate-binding	pocket.	In	the	absence	of	NADH,	imine	2	was	bound	in	the	cofactor-
binding	site,	whereas	imine	1	was	bound	at	the	active	site,	in	proximity	of	zinc.		For	a	
better	understanding	of	imine	interaction	within	ADHs,	further	inhibition	studies	with	
NADH	 as	 substrate	 should	 also	 be	 performed,	 to	 assess	 whether	 imines	 act	 as	
inhibitors	 of	 the	 cofactor-binding.	 Additionally,	 a	 crystal	 structure	 with	 a	 bound	
inhibitor	would	give	a	clear	idea	of	the	interaction	of	imines	and	amines	with	TADH.	
Also	in	chapter	4.2,	the	active	site	of	TADH	was	engineered	to	remove	the	catalytic	
zinc,	and	to	introduce	a	protic	acid	at	various	positions,	in	an	effort	to	replicate	the	
imine	 reductase	 active	 site.	 While	 the	 mutants	 were	 successfully	 expressed	 and	
purified,	 no	 imine	 reduction	 was	 observed.	 It	 was	 thought	 that	 site-directed	
mutagenesis	was	not	suited	for	introduction	of	imine	activation,	because	it	could	not	
reconstitute	 the	 interplay	 between	 parameters	 that	 can	 affect	 reactivity,	 such	 as	
substrate	 orientation,	 active	 residue	 pKa	 and	 pH	 of	 the	 system.	 An	 alternative	
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approach	would	be	a	semi-directed	evolution,	simultaneously	targeting	the	active	site	
residues.	 Perhaps	 a	 more	 successful	 approach	 would	 be	 to	 target	 short	 chain	
dehydrogenase	/	reductases	as	a	starting	point	for	engineering,	which	instead	of	zinc	
show	the	critical	presence	of	a	catalytic	triad,	thus	enabling	acid	/	base	catalysis.	In	
particular,	the	presence	of	this	triad	hints	that	not	only	the	acidic	residue	is	important	
at	the	correct	position	for	substrate	activation,	but	also	the	environment	around	this	
residue,	which	promotes	proton	transfer	by	modulating	the	pKa.	In	support	of	this,	
recent	studies	of	IRED	mechanism206,73	have	discovered	non-protic	residues	such	as	
alanine,	phenylalanine	and	asparagine	in	the	key	position	for	substrate	activation	to	
possess	activity.		
Investigations	into	rhodium(I)	replacement	of	the	catalytic	zinc(II)	could	not	identify	a	
robust	and	reproducible	method,	as	highlighted	in	Chapter	4.3.	The	limiting	factor	was	
identified	as	the	zinc	removal	step,	which	was	complicated	by	the	presence	of	two	zinc	
ions,	one	catalytic	and	one	structural.	The	best	conditions	for	zinc	removal	were	by	
dialysis	against	1,2-phenantroline	or	a	mixture	of	1,2-phenantroline	and	EDTA,	at	pH	
6.0.	These	resulted	in	almost	complete	loss	of	specific	activity,	and	partial	loss	of	zinc.	
Protein	loss	was	also	observed	during	these	experiments,	and	might	have	been	due	to	
the	 instability	 of	 the	 protein	 in	 the	 absence	 of	 zinc.	 Encouragingly,	 activity,	 zinc	
content	 and	 protein	 concentration	 all	 increased	 upon	 zinc	 reinsertion	 by	 dialysis	
against	 a	 buffer	 solution	 containing	 zinc	 acetate	 (20	µM)	 at	 pH	 6.5	 and	 4	 oC.	 This	
suggested	that	most	of	the	zinc	removed,	and	thus	reinserted,	was	from	the	catalytic	
site.	Cobalt(II)	was	 inserted	 into	apo-TADH	and	resulted	 in	recovery	of	82	%	of	 the	
initial	activity.		Binding	of	Rh(I)	was	also	observed	to	occur,	however	unspecific	binding	
was	seen	by	the	presence	of	excess	(2.6-fold)	protein,	and	the	binding	of	Rh	at	the	
catalytic	site	was	not	confirmed.	Some	residual	alcohol	oxidation	was	observed	with	
the	Rh-protein,	but	no	imine	reductase	activity	was	observed	for	the	reduction	of	2-
methyl-1-pyyroline	1.		
To	 improve	these	results,	metal	replacement	 investigations	could	be	performed	on	
single	zinc-containing	thermophilic	ADHs	such	as	TbADH,	which	does	not	possess	a	
structural	zinc	and	where	successful	zinc	removal	and	metal	reinsertion	methods	have	
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also	been	reported.	Alternatively,	selective	removal	of	the	catalytic	zinc	ions	could	be	
further	attempted	using	a	 crystallised	version	of	TADH,	as	previously	 suggested	by	
others	for	HLADH.	Conditions	for	the	crystallisation	of	TADH	were	published	during	
the	course	of	this	thesis,	and	could	be	adapted	to	this	effect.	
The	design	of	transition	metal	complexes	bound	to	an	NAD+	mimic	was	presented	in	
Chapter	4.4,	and	was	based	upon	the	observed	ADH	recognition	of	NAD+	analogues.116	
Two	nicotinamide-functionalised	N-heterocyclic	bound	 Ir	 complexes	were	designed	
for	introduction	into	TADH,	differing	at	the	point	of	attachment	between	the	NHC	and	
nicotinamide	ring.	Positions	4	and	5	(relative	to	the	nitrogen	atom)	of	the	nicotinamide	
ring	were	investigated	for	NHC	connection,	envisioning	that	the	resulting	orientation	
would	 present	 the	metal	 complex	 towards	 the	 substrate-binding	 pocket	 in	 TADH.	
Synthesis	 of	 the	 5-imidazoyl-functionalised	 benzylated	 nicotinamide	 ring	 was	
successfully	achieved,	whereas	the	functionalisation	at	position	4	of	the	nicotinamide	
ring	with	a	NHC	precursor	was	unsuccessful	as	a	result	of	the	inefficiency	of	Ullmann	
coupling	 at	 this	 position.	 This	 was	 suggested	 to	 be	 a	 result	 of	 intramolecular	
coordination	of	the	primary	nicotinamide	to	the	Cu	catalyst.	Future	investigations	into	
Ullmann	 coupling	 at	 this	 position	 could	 focus	 on	 using	 an	 amide	 protecting	 group	
during	 the	coupling,	which	would	complicate	 the	synthesis,	but	might	 improve	 the	
coupling	results.	
Complexation	 of	 the	 [Cp*Ir(III)Cl2]2	 precursor	 to	 the	 5-imidazoyl-functionalised	
benzylated	 nicotinamide	 ring	 was	 successfully	 achieved,	 however	 low	 yields	 were	
recovered	 after	 purification.	 The	 isolated	 compound	 was	 observed	 to	 undergo	
cyclometalation,	which	was	suggested	to	occur	at	position	6	of	the	nicotinamide	ring.	
The	nicotinamide-functionalised	 [(Cp*)Ir(NHC)]	complex	was	shown	to	be	an	active	
catalyst	in	the	transfer	hydrogenation	of	aryl	ketones	(acetophenone)	and	imines	(3,4-
dihydroisoquinoline)	 in	 both	 organic	 and	 aqueous	 media.	 The	 imine	 3,4-
dihydroisoquinoline	outperformed	acetophenone	in	aqueous	conditions.	The	catalyst	
was	active	in	the	presence	of	TADH,	however	the	addition	of	NADH	did	not	show	any	
inhibition,	suggesting	that	the	complex	was	not	found	in	the	cofactor-binding	pocket.	
Inhibition	studies	also	showed	that	the	complex	was	not	likely	to	bind	at	the	cofactor-
binding	site,	although	it	did	act	as	a	mixed	inhibitor.	Further	studies	are	required	to	
178	
	
confirm	 this	 lack	of	 interaction.	 In	particular,	 the	enantioselectivity	of	 the	 reaction	
should	be	determined,	in	order	to	assess	whether	TADH	has	any	effect	on	the	catalysis.	
Additionally,	 the	 interaction	 of	 the	 Ir-NHC	 catalyst	 with	 NADH	 should	 also	 be	
investigated.	Hydride	 transfer	 from	NADH	 to	 an	 Ir(III)	 cyclometalated	 complex	 has	
previously	been	reported,	and	might	be	responsible	for	the	inhibition	results	obtained	
with	the	Ir-complex.		
The	 affinity	 of	 benzyl	 nicotinamide	mimics	 is	 currently	 a	 subject	 of	 debate	 in	 the	
scientific	community,	with	two	research	groups	reporting	contradicting	results	with	
respect	 to	 their	 activity	 towards	 ADHs.	 Affinity	 studies	 should	 be	 performed	with	
benzyl	nicotinamide	and	TADH,	to	ascertain	the	 interaction	of	 this	anchor	with	the	
enzyme.	 The	 use	 of	 other	 pyridinium	 substituents,	 such	 as	 ribose,	 might	 prove	
beneficial	to	increase	this	affinity.	The	group	of	Hollmann	reported	micromolar	affinity	
of	 substituted	 nicotinamide	 for	 enoate	 reductases,	 and	 these	 could	 constitute	 an	
alternative	starting	point	to	engineer	imine	reduction	promiscuity	inside	a	reductase	
with	a	different	functionality.	
In	 conclusion,	 this	 thesis	 provided	 an	 insight	 into	 the	 chemical	 and	 genetic	
modification	of	TADH	for	promiscuity	 towards	 imines.	Continued	efforts	 in	enzyme	
engineering	will	 provide	 a	 better	 understanding	 on	 the	 IRED	 activity,	 to	 provide	 a	
robust	and	efficient	method	for	the	synthesis	of	chiral	secondary	amines.		
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Chapter	7 Appendices	
Appendix	1	-	Thermus	sp	ADH	(TADH)	Constructs	
The	TADH	gene	inserted	into	a	derivative	of	the	pET-11a	vector	was	obtained	from	Dr.	
Frank	Hollmann.	The	plasmid	was	constructed	by	inserting	the	TADH	gene	between	
the	EcoRIand	the	BamHI	sites	of	the	pET11aEco	vector.	pET11aEco	is	a	derivative	of	
pET-11a	from	Novagen,	containing	an	additional	EcoRI	site	between	the	NdeI	and	the	
RBS	sites.		
CCTCTAGAATAATTTTGTTTAACTTTAAGAAGGAGAATTCCTATGCGCGCAGTGGTTTTTGA
AAACAAAGAGCGCGTCGCCGTCAAGGAGGTCAATGCCCCTCGCCTACAACATCCCCTAGAT
GCCCTCGTGCGCGTGCACCTGGCCGGCATATGTGGCTCGGACTTGCACCTTTACCACGGCA
AAATACCTGTTCTCCCCGGAAGTGTACTGGGCCACGAGTTCGTGGGCCAAGTGGAAGCCGT
GGGCGAAGGTATCCAAGATCTTCAGCCAGGGGACTGGGTTGTTGGACCGTTCCACATCGCC
TGTGGCACCTGCCCCTACTGCCGAAGGCACCAGTACAACCTGTGTGAACGGGGAGGCGTCT
ACGGTTATGGCCCCATGTTTGGCAATCTCCAAGGAGCCCAGGCGGAAATCCTTCGGGTTCC
CTTCAGCAACGTCAATCTCCGGAAACTGCCTCCAAACCTAAGCCCAGAACGGGCCATCTTTG
CCGGCGATATCCTCTCCACAGCCTATGGAGGACTCATCCAGGGCCAGCTCCGGCCCGGTGA
TAGCGTGGCTGTCATCGGAGCGGGGCCCGTGGGATTGATGGCCATTGAAGTAGCCCAGGT
ATTGGGTGCGAGCAAAATACTTGCCATAGATCGCATTCCTGAGCGATTGGAACGCGCCGCT
TCCCTCGGCGCCATCCCCATCAACGCCGAACAAGAAAATCCTGTCCGGCGAGTTCGCTCTGA
AACCAACGATGAGGGGCCAGATTTGGTCCTCGAGGCTGTAGGCGGAGCTGCCACCCTCAG
CTTGGCCCTGGAGATGGTACGCCCTGGGGGAAGGGTATCAGCTGTTGGGGTGGATAACGC
CCCCTCCTTTCCATTCCCTTTAGCATCGGGCCTGGTCAAGGACCTAACCTTCCGTATAGGTTT
GGCCAACGTCCACCTCTACATTGATGCGGTTCTGGCCCTTTTGGCTAGCGGCCGTTTGCAAC
CGGAGCGGATTGTTTCCCACTATCTCCCCTTGGAGGAAGCTCCTCGAGGGTATGAGCTTTTT
GACCGGAAAGAAGCGCTAAAAGTCCTTTTGGTTGTCAGGGGGTGATGAAAGGTGTTAAGG
GAAGGGTTCCAAACAGCGCGGGTAGGCCTGAAGGACTCGTTTCCTCTCCAACTTTACCACA
AGGCAAAGAAGTACTTCTGGGATCCGGCTGCTAACAAAGCCCGAAAGAA	
The	 TADH	 primary	 sequence	 is	 shown	 below	 (the	 five	 cysteines	 are	 highlighted	 in	
yellow.).	Predicted	properties:	MW	=	37194;	pI	=	6.32.		
MRAVVFENKERVAVKEVNAPRLQHPLDALVRVHLAGICGSDLHLYHGKIPVLPGSVLGHEFVG
QVEAVGEGIQDLQPGDWVVGPFHIACGTCPYCRRHQYNLCERGGVYGYGPMFGNLQGAQAE
ILRVPFSNVNLRKLPPNLSPERAIFAGDILSTAYGGLIQGQLRPGDSVAVIGAGPVGLMAIEVAQV
LGASKILAIDRIPERLERAASLGAIPINAEQENPVRRVRSETNDEGPDLVLEAVGGAATLSLALEM
VRPGGRVSAVGVDNAPSFPFPLASGLVKDLTFRIGLANVHLYIDAVLALLASGRLQPERIVSHYLP
LEEAPRGYELFDRKEALKVLLVVRG	
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Appendix	2	-	Primer	sequences	of	forward	and	reverse	primers	for	introduction	of	desired	mutations	
(shown	in	red),	continued	over	the	page.	
Starting	
protein	
Mutation	 Primer	name	 Primer	Sequence	(5’	to	3’)	
W
T_
TA
DH
	
C38A	 t112g_g113c	
5'-gtccgagccagctatgccggccaggtgcacg-3'	
5'-cgtgcacctggccggcatagctggctcggac-3'	
W
T_
TA
DH
	
H59A	 c175g_a176c	
5'-ggcccacgaactcggcgcccagtacacttc-3'	
5'-gaagtgtactgggcgccgagttcgtgggcc-3'	
W
T_
TA
DH
	
D152A	 a455c	
5'-gctgtggagaggatagcgccggcaaagatgg-3'	
5'-ccatctttgccggcgctatcctctccacagc-3'	
D1
52
A_
TA
DH
	
C38Y	 g113a	
5'-tccgagccatatatgccggccaggtgc-3'	
5'-gcacctggccggcatatatggctcgga-3'	
C3
8A
_T
AD
H	
H59Y	 c175t_c177t	
5'-cttggcccacgaactcatagcccagtacacttccg-3'	
5'-cggaagtgtactgggctatgagttcgtgggccaag-3'	
C3
8A
_T
AD
H	
D152Y	 g454t	
5'-ctgtggagaggatatagccggcaaagatggc-3'	
5'-gccatctttgccggctatatcctctccacag-3'	
C3
8A
_T
AD
H	
S40Y	
t112g_g113c	
c119a_g120t	
5'-tggtaaaggtgcaagtcatagccagctatgccggccaggtgcac-3'	
5'-gtgcacctggccggcatagctggctatgacttgcacctttacca-3'	
C3
8A
_T
AD
H	
F85Y	 t254a_c255t	
5'-gccacaggcgatgtgatacggtccaacaaccc-3'	
5'-gggttgttggaccgtatcacatcgcctgtggc-3'	
C3
8A
_T
AD
H	
V108Y	 g322t_t323a_c324t	
5'-catggggccataaccgtaatagcctccccgttcacacag-3'	
5'-ctgtgtgaacggggaggctattacggttatggccccatg-3'	
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C3
8A
_T
AD
H	
V268Y	 g802t_t803a_g804t	
5'-gaaaggagggggcgttatcatacccaacagctgataccctt-3'	
5'-aagggtatcagctgttgggtatgataacgccccctcctttc-3'	
D1
52
A_
TA
DH
	
C38D	 t112g_g113a	
5'-gtccgagccatctatgccggccaggtgcacg-3'	
5'-cgtgcacctggccggcatagatggctcggac-3'	
C3
8A
_T
AD
H	
H59D	 c175g_c177t	
5'-ttggcccacgaactcatcgcccagtacacttcc-3'	
5'-ggaagtgtactgggcgatgagttcgtgggccaa-3'	
C3
8A
_T
AD
H	
S40D	
t112g_g113c_t118g	
c119a_g120t	
5'-gtggtaaaggtgcaagtcatcgccagctatgccggccaggtgcacg-3'	
5'-cgtgcacctggccggcatagctggcgatgacttgcacctttaccac-3'	
C3
8A
_T
AD
H	
F85D	 t253g_t245a_c255t	
5'-actgggttgttggaccggatcacatcgcctgtggcac-3'	
5'-gtgccacaggcgatgtgatccggtccaacaacccagt-3'	
C3
8A
_T
AD
H	
V108D	 t323a_c324t	
5'-ggggccataaccgtaatcgcctccccgttcac-3'	
5'-gtgaacggggaggcgattacggttatggcccc-3'	
C3
8A
_T
AD
H	
V268D	 t803a_g804t	
5'-aggagggggcgttatcatccccaacagctgatac-3'	
5'-gtatcagctgttggggatgataacgccccctcct-3'	
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Appendix	3	-	Michaelis-Menten	kinetics	of	cyclohexanol		
	
Oxidation	assays	were	performed	at	60	oC,	using	TADH	(3	µg)	cyclohexanol	(0.5,	1,	1.5,	2,	3,	5,	7.5	and	
10	mM)	as	substrate,	NAD+	(1	mM)	as	cofactor,	 in	50	mM	Glycine-NaOH	buffer	pH	9.0.	The	specific	
activities	were	determined	from	the	slope	calculated	in	the	first	250	seconds	of	enzymatic	activity	plots	
and	enzyme	concentration.	These	values	were	used	to	plot	the	Michaelis-Menten	graph.	Assays	were	
performed	in	triplicate	with	error	bars	shown	over	1	%	error.	
	
Appendix	4	-	Michaelis-Menten	kinetics	of	cyclohexanone		
	
Reduction	was	performed	at	60	oC,	using	TADH	(1	µg),	cyclohexanone	(1,	2.5,	7.5	15,	25	and	50	mM)	as	
substrate,	NADH	 (0.1	mM)	as	cofactor,	 in	50	mM	Bis-Tris	buffer	pH	6.0.	The	specific	activities	were	
determined	from	the	slope	calculated	in	the	first	250	seconds	of	enzymatic	activity	plots	and	enzyme	
concentration.	These	values	were	used	to	plot	the	Michaelis-Menten	graph.	Assays	were	performed	in	
triplicate	with	error	bars	shown	over	1	%	error.	
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Appendix	 5	 -	 Michaelis-Menten	 kinetics	 for	 cyclohexanone	 in	 the	 presence	 of	 different	
concentrations	of	2-methyl-1-pyrroline,	(1).	
	
Reduction	was	performed	at	60	oC,	using	TADH	(1	µg),	cyclohexanone	(1,	2.5,	7.5	15,	25	and	50	mM)	as	
substrate,	NADH	(0.1	mM)	as	cofactor,	in	50	mM	Bis-Tris	buffer	pH	6.0	Containing	2	%	v	/	v	ACN	with	
containing	2-methyl-1-pyrroline,	1	as	inhibitor	at	concentration:	(l)	0	mM,	()	10	mM,	(¾)	25	mM,	
(¿)	50	mM.	The	specific	activities	were	determined	from	the	slope	calculated	in	the	first	250	seconds	
of	enzymatic	activity	plots	and	enzyme	concentration.	Assays	were	performed	in	triplicate	with	error	
bars	shown	over	1	%	error.	
	
Appendix	6	-	Michaelis-Menten	kinetics	for	cyclohexanol	in	the	presence	of	different	concentrations	
of	1-methylpyrrolidine,	(3).	
	
Oxidation	assays	were	performed	at	60	oC,	using	TADH	(3	µg)	cyclohexanol	(0.5,	1,	2,	4,	8	and	12	mM)	
as	substrate,	NAD+	(1	mM)	as	cofactor,	in	50	mM	Glycine-	NaOH	buffer	pH	9.0	containing	5	%	v	/	v	ACN	
with	2-methylpyrrolidine,	3	as	inhibitor	at	concentration:	(l)	0	mM,	()	1	mM,	(¾)	5	mM,	(¿)	10	mM.	
The	specific	activities	were	determined	from	the	slope	calculated	in	the	first	250	seconds	of	enzymatic	
activity	plots	and	enzyme	concentration.	These	values	were	used	to	plot	the	Michaelis-Menten	graph.	
Assays	were	performed	in	triplicate	with	error	bars	shown	over	1	%	error.	
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Appendix	7	-	Michaelis-Menten	illustrating	the	inhibitory	effect	of	nicotinamide-functionalised	ligand	
21a	in	the	reductive	direction	using	NADH	and	cyclohexanone	as	substrates	
	
Specific	activities	were	determined	in	the	reductive	direction	at	60	oC,	using	TADH	(5.6	µg),	NADH	(0.01,	
0.025,	0.05,	0.075,	0.1,	0.25	mM)	as	substrate,	cyclohexanone	(20	mM)	as	secondary	substrate,	in	50	
mM	Bis-Tris	buffer	pH	6.0	containing	2	%	v	/	v	DMF	with	nicotinamide-functionalised	 ligand,	21a	as	
inhibitor	at	concentration:	(l)	0	mM,	()	0.1	mM,	(¾)	0.25	mM.	
	
Appendix	8	-	Michaelis-Menten	illustrating	the	inhibitory	effect	of	Ir	complex	24a	in	the	reductive	
direction	using	NADH	and	cyclohexanone	as	substrates	
	
Specific	activities	were	determined	in	the	reductive	direction	at	60	oC,	using	TADH	(5.6	µg),	NADH	(0.01,	
0.025,	0.05,	0.075,	0.1,	0.25	mM)	as	substrate,	cyclohexanone	(20	mM)	as	secondary	substrate,	in	50	
mM	Bis-Tris	buffer	pH	6.0	containing	5	%	v	/	v	ACN	with	Ir	complex,	24a	as	inhibitor	at	concentration:	
(l)	0	mM,	()	0.05	mM,	(¾)	0.1	mM.	
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Appendix	9	-	1H	and	13C	NMRs	from	section	3.7.	synthesis	of	nicotinamide	NHC	functionalised	iridium	
complexes	
1H-NMR	5-chloro-N,N-diisopropylnicotinamide,	16a
		 					
	
13C-NMR	5-chloro-N,N-diisopropylnicotinamide,	16a	
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1H-NMR	4-chloro-N,N-diisopropylnicotinamide,	16b	
	
	
13C-NMR	4-chloro-N,N-diisopropylnicotinamide,	16b	
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1H-NMR	5-(1	H-imidazol-1-yl)-N,N-diisopropylnicotinamide,	17a		
	
	
13C-NMR	5-(1	H-imidazol-1-yl)-N,N-diisopropylnicotinamide,	17a		
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1H-NMR	4-(1H-imidazol-1-yl)-N,N-diisopropylnicotinamide,	17b	
	
	
13C-NMR	4-(1H-imidazol-1-yl)-N,N-diisopropylnicotinamide,	17b	
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1H-NMR	5-(1H-imidazol-1-yl)nicotinamide,	20a	
	
	
13C-NMR	5-(1H-imidazol-1-yl)nicotinamide,	20a	
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1H-NMR	4-(1H-imidazol-1-yl)nicotinic	acid,	23	
	
	
13C-NMR	4-(1H-imidazol-1-yl)nicotinic	acid,	23	
	
	
202	
	
1H-NMR	 1-benzyl-3-(N-benzylimidazol-1-yl)-5-(diisopropylcarbamoyl)pyridinium									
bromide,	18a	
	
	
13C-NMR	1-benzyl-3-(N-benzylimidazol-1-yl)-5-(diisopropylcarbamoyl)pyridinium									
bromide,	18a	
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1H-NMR	 1-benzyl-4-(N-benzylimidazol-1-yl)-3-(diisopropylcarbamoyl)pyridinium								
bromide,	18b	
	
	
13C-NMR	1-benzyl-4-(N-benzylimidazol-1-yl)-3-(diisopropylcarbamoyl)pyridinium				
bromide,	18b		
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1H-NMR	 1-benzyl-3-(N-benzylimidazol-1-yl)-5-carbamoylpyridinium	 bromide,	 21a:	
(or	Ligand	21a)	
	
	
13C-NMR	1-benzyl-3-(N-benzylimidazol-1-yl)-5-carbamoylpyridinium	bromide,	 21a:	
(or	Ligand	21a)	
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1H-NMR	iridium	NHC	functionalised	complex,	24a	(or	Ir	complex	24a)		
	
	
13C-NMR	iridium	NHC	functionalised	complex,	24a	(or	Ir	complex	24a)	
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Appendix	10	–	1H	NMRs	of	Ir	complex	24a	catalysed	transfer	hydrogenation	with	a	selected	ketone	
and	imine	with	(see	Section	3.8.1)	
1H-NMR	 Transfer	 hydrogenation	 reaction	 with	 24a	 showing	 conversion	 of	
acetophenone	to	1-phenylethanol	
	
1H-NMR	 Transfer	 hydrogenation	 reaction	 with	 24a	 showing	 conversion	 of	 3,4-
dihydroquinoline	to	1,2,3,4-tetrahydroisoquinoline	
	
